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Abstract 
Type 2 diabetes, as a complex disease, has a range of genetic and environmental factors that 
underpin its aetiology.  It is hoped that the emerging study of epigenetic processes will provide 
the necessary mechanistic insight into the genetic and environmental interactions that, to 
date, are poorly understood.  This thesis considers the role of DNA methylation, an epigenetic 
modification, in the aetiology of type 2 diabetes.   A range of different genome-wide and 
whole genome techniques are applied to a study of established type 2 diabetes and 
experimental models (human and animal) of fetal programming.   
Samples from a recent genome-wide association study of type 2 diabetes were used to identify 
DNA methylation patterns at areas of genetic variation associated with disease risk.  Analysis 
of data from methylated DNA immunoprecipitation and microarray identified a genetic-
epigenetic interaction in the FTO gene.  At this locus, the presence or absence of a SNP created 
or abrogated a CpG site capable of methylation and further analyses highlighted possible 
functional relevance via enhancer activity. 
Models of fetal programming were then used to identify whether variation in DNA methylation 
may underlie the ‘programmed’ phenotype of diabetes and related cardiometabolic disease.   
Pre-existing human models of programming via maternal vitamin B12 deficiency and maternal 
famine exposure have been used to generate exploratory evidence of such mechanisms.  
Whole genome-based techniques (Medip-seq and Illumina 450k methylation array) were used 
to profile DNA methylation in whole blood samples from the offspring born to each of these 
studies.  Custom bioinformatic analysis was performed to identify differences in methylation 
between offspring exposed versus unexposed to the in utero environmental insult.  Technical 
replication and validation studies are ongoing to confirm or refute the presence of regions of 
differential methylation. 
Finally, this thesis considers whether a state of ‘over nutrition’ gestational diabetes, may play a 
role in fetal programming.  This condition is of increasing prevalence across the world and is 
characterised by maternal hyperglycaemia and insulin resistance, often resulting in fetal 
overgrowth.  A mouse model using an inbred strain (Lepr) of mice induced a programmed 
phenotype of glucose intolerance and obesity in aged offspring born to mothers with 
gestational diabetes.  Medip-seq performed on the livers of late gestation mouse embryos 
identified differential methylation in cases vs. controls, located at genomic regions with 
potential functional relevance.  A human cohort of women with gestational diabetes was 
collected to develop further hypothesis around the multiple environmental factors that could 
interact in pregnancy.  Prevalent nutritional deficiencies of vitamin D, iron and one-carbon 
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metabolites were found in women with and without gestational diabetes recruited from a 
local antenatal clinic.    
This thesis presents preliminary findings that variation in DNA methylation may be involved in 
the genetic and environmental risk of type 2 diabetes.  The work presented highlights how 
future studies must incorporate integrated genetic, epigenetic and functional analysis with 
sufficient sample size if their results are to be translatable to diverse populations at risk of 
diabetes. 
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Chapter 1.  General introduction 
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The notion that both genetic and environmental factors are important factors in the 
susceptibility to type 2 diabetes is long known, yet poorly understood.  Over recent years, the 
advent of molecular techniques to study epigenetic modifications, the chemical changes 
around DNA that affect gene activity, have provided an exciting insight into the processes that 
may underlie these gene-environment interactions.  Epigenetic signatures set down in early 
developmental life and modified by a range of stochastic and programmed processes 
throughout the lifecourse are thought to have an important role in an individual’s 
susceptibility to complex disease. 
This thesis attempts to use epigenetic discovery to yield insights into the aetiology of type 2 
diabetes, and related ‘cardiometabolic’ conditions such as obesity.  The application of 
epigenetic studies to the understanding of complex disease is a recent molecular approach 
that is being used to elucidate mechanisms by which genetic and environmental factors 
interact and in how genetic susceptibility variants may exert a functional effect.  The 
experiments set out in this thesis will use epigenomic techniques to assay and profile 
epigenome-wide DNA methylation in human and animal models of type 2 diabetes, to 
understand (i) genetic-epigenetic interactions in established type 2 diabetes and (ii) 
environment-epigenetic interactions in fetal programming. 
 
1.1 Type 2 diabetes 
 
1.1.1 Epidemiology 
The increasing global prevalence of Type 2 diabetes and obesity is well-characterised, and is 
known to be increasing across the world, with age-standardised diabetes prevalence of 9.8% 
(men) and 9.2% (women) in 2008, compared to 8.3 and 7.5% in 1980 (1).  The rise in diabetes 
prevalence is particularly apparent in certain global contexts, including the high-income 
populations of Australasia, North America and Western Europe, but also countries in South 
Asia under rapid population transition (see Figure 1a).  The vascular complications associated 
with type 2 diabetes are the predominant reason why the disease burden is associated with 
excess morbidity and mortality.  The recent Global Burden of Disease report (2) estimated that 
the ‘years of life lost’ due to ischaemic heart disease and stroke have increased by 17-28% 
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across the world between 1990 and 2010.
 
Figure 1a. Global patterns of diabetes prevalence.  The figure shows diabetes prevalence (%) 
over the last 3 decades, with 95% confidence intervals (shaded area). (adapted from (1)) 
 
1.1.2 Complex disease aetiology  
Complex diseases, such as type 2 diabetes, are thought to have a combination of genetic and 
environmental risk factors underlying their onset.   The genetic basis of these conditions is 
known to be polygenic, rather than monogenic, and the advent of genome-wide association 
studies (GWAS) has provided significant insight into understanding these multiple influences 
though gene discovery.  Despite these advances in the detection of the multiple disease-
associated genetic variants in type 2 diabetes, little is known about their role in aetiology and 
how they interact with other factors that play a role in disease susceptibility. 
Over 40 genetic variants have now been associated with Type 2 diabetes but, even when taken 
in combination, account for only a small excess in disease risk on an individual level.  
Furthermore, the majority of these genetic variants identified relate the pancreatic beta-cell 
dysfunction in type 2 diabetes pathogenesis, leaving the mechanisms of insulin resistance 
underrepresented.  The small effect size of the genetic polymorphisms associated with type 2 
diabetes have led researchers to conceptualise a ‘missing heritability’ of Type 2 diabetes and 
to seek alternative mechanisms to explain it, e.g. via the identification of rare or structural 
variants or interactions between genetic variants (3)(4).  Despite this focus on genetic factors 
in disease causation, there are numerous other factors that may predispose an individual to 
developing type 2 diabetes.  Environmental determinants are well characterised in 
epidemiological literature, but little is known about their mechanistic roles in disease 
causation (5) (6).  The potential for genetic and environmental influences to interact is 
significant and indeed could account for the supposed ‘missing heritability’ concept.  
‘Heritability’ of disease may be affected by non-genetic factors, such as shared environmental 
susceptibility within families or populations. 
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For many years, the existence of ‘gene-environment interactions’ has been supposed through 
study of genetically-susceptible populations in increasingly ‘diabetogenic’ environments, 
however, only recently have plausible ‘epigenetic’ mechanisms underlying these interactions 
been described (7). Epigenetic modifications, including DNA methylation, post-translational 
modification of histones, or other chromatin modifying factors, are highly variable and plastic 
features of the genome.  These modifications may influence phenotype through downstream 
or bi-directional influences over gene expression (8).  The epigenetic ‘landscape’ of an 
organism is reflected by the functional diversity of the genome despite its predetermined 
genetic state.  A range of processes, both normal and aberrant, may alter the epigenetic state 
of an organism, and it is expected that an increased understanding of them may shed light on 
aetiology of complex phenotype and disease.  These epigenetic processes will be discussed 
further in section 1.3. 
 
1.1.3 Pathogenesis of type 2 diabetes 
Type 2 diabetes is a disorder of glucose homeostasis, characterised by insulin resistance in 
peripheral tissues including liver, muscle and adipocytes; disturbances in insulin secretion from 
the pancreatic beta cell; and abnormalities in uptake and metabolism of glucose in the gut, via 
incretin hormones and the splanchnic circulation (9). 
Insulin resistance occurs in peripheral tissues such as liver, muscle and adipocytes and is the 
harbinger of overt type 2 diabetes.  Insulin resistance is usually asymptomatic and is manifest 
by impaired glucose tolerance (IGT) or impaired fasting glycaemia (IFG) during oral glucose 
tolerance testing or fasting glucose measurement.  IGT and IFG are more common in 
individuals with central adiposity, but usually have no sensitive or specific clinical features 
associated with them, except sometimes the development of acanthosis nigricans, a skin 
manifestation of insulin resistance.  Peripheral insulin resistance is a complex and poorly 
understood phenomenon, contributed to by a failure of the suppression of hepatic glucose 
production, and reduced uptake of glucose by peripheral tissues (mostly muscle).  Recent 
insights into defective insulin intracellular signalling pathways have been gained, identifying 
defects at phosphorylation of the insulin receptor subunit and downstream phosphorylation 
cascades including the phosphatidylinositol 3-kinase pathway and its downstream targets 
including AKT and the insulin-dependent glucose transporter, GLUT4 (10). 
Beta cell failure occurs progressively in response to the increasing demands on the pancreas to 
produce sufficient insulin to overcome peripheral insulin resistance.  A range of factors are 
involved in beta cell failure, including the effects of glucolipotoxicity, where elevated glucose 
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and free fatty acids are thought to lead to an acquired defect in insulin secretion.  In addition, 
a blunting of the incretin response, whereby gut peptides such as gastric inhibitory 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) increase the insulin response to glucose 
ingestion, is thought to impair insulin secretion.  Specific genetic polymorphisms, identified 
through GWAS and candidate gene studies (11), and include genes such as TCF7L2, a 
transcription factor with a role in glucose-stimulated insulin secretion in the pancreatic beta 
cell (12). 
 
1.1.4 Related cardiometabolic diseases and complications 
Vascular complications are the predominant cause of morbidity and mortality in individuals 
with type 2 diabetes.  The seminal work performed by the UKPDS study groups identified the 
risks of increasing glycaemia on macrovascular (e.g. ischaemic heart disease and stroke) and 
microvascular (e.g. retinopathy and nephropathy) complications of diabetes (13).  Recently, 
this data has been challenged in long-term outcome studies of individuals with type 2 diabetes 
suggesting an increased risk of death from macrovascular disease in those who have been 
intensively treated with regard to glycaemia in the ACCORD trial and others (reviewed in (14)).  
However, the risks of glycaemia in respect to microvascular outcomes remain, and the concept 
of an early ‘metabolic memory’ has emerged suggesting that the reduction in macrovascular 
complications is restricted to those individuals who have achieved tight glycaemic control in 
the early stages of disease (15).  Hyperglycaemia is not the sole mediator of long-term 
cardiometabolic complications in individuals with type 2 diabetes; the effects of advanced 
glycation end products and systemic inflammation contribute to tissue damage, as do the 
commonly coexisting conditions of dyslipidaemia and hypertension (16).   
 
1.1.5 Treatment 
Treatment of type 2 diabetes follows a stepwise approach, starting with lifestyle advice and 
then incorporating drugs targeted to treat insulin resistance (e.g. metformin) or overcome 
reduced insulin secretion from the beta cell (sulphonylureas, insulin).  Newer therapies (e.g. 
liraglutide) have been developed to augment the defective incretin response in people with 
diabetes, thus aiding the insulin response to oral glucose. 
A personalised approach is taken to treatment of type 2 diabetes, but factors affecting 
individual responsiveness to treatment are not known.  Pharmacogenomics has identified a 
genetic variant in the ATM gene that affects the glycaemic response to metformin, but as yet, 
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there is no direct translational benefit of this discovery.  A greater understanding of 
functionally relevant epigenetic processes in diabetes pathogenesis may enable tailored drug 
design and personalised therapy to be developed in the future. 
 
1.1.6 Prevention 
Prevention strategies use a broad-brush approach to reduce diabetes risk and are based on 
population-based studies.  Whilst such studies have shown the effectiveness of lifestyle-based 
prevention strategies, e.g. the Finnish Diabetes Prevention Study, which reduced relative risk 
of progression from impaired glucose tolerance to type 2 diabetes by 43% over 7 years 
through intensive diet and exercise (17), they are considered to have had minimal impact on 
wider populations.  The ‘one size fits all’ approach to lifestyle and health promotion advice, 
based around achieving weight loss and increased physical activity is often considered to be 
ineffective, particularly in populations where societal and personal barriers to these changes 
exist. 
 
1.2 Fetal programming 
The concept of fetal programming, or the developmental origins of disease (DoHAD), has 
become increasingly described and studied over the last two decades.  Fetal programming 
refers to the hypothesis that adverse environmental factors in utero can have lasting effects 
on the physiological development of the fetus that can influence, and increase, its propensity 
to develop certain diseases in later life, such as type 2 diabetes.  This theory is gaining 
increasing recognition from a multidisciplinary perspective, combining basic scientists with 
clinicians, epidemiologists and social scientists.  Hales and Barker (18), were the first to 
describe the phenomenon of fetal programming in routinely collected clinical data from 
Hertfordshire, UK.  These researchers used birth records collected by midwives in the 1920s 
and 30s, and were able to follow up 463 of men for whom these records existed in late 
adulthood.  In doing so, Barker and Hales noted that there was an inverse relationship 
between birth weight and risk of adult diseases, including type 2 diabetes and cardiovascular 
disease (18) (19).    
The contrasting thrifty phenotype and fetal insulin hypotheses are two concepts that seek to 
understand fetal programming in greater detail and will now be discussed.  In addition, the 
range of different environmental insults that can give rise to fetal programming, notably 
gestational diabetes and nutritional insults, will be considered. 
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1.2.1 Thrifty phenotype hypothesis 
Barker and Hales described the ‘thrifty phenotype hypothesis’ to try and conceptualise their 
observations (18).  They explained that a fetus that develops in an adverse pregnancy 
environment may be born small and in later life be ‘programmed’ to function in a similarly 
restricted environment.  These adaptations allow the human to exist through continued 
‘thrift’, perhaps with limited growth potential, but in a state of health.  For those individuals 
whose environment changes into one of nutritional excess, a mismatch can occur between 
their thrifty design and the challenges that their body is put under.  Type 2 diabetes, obesity, 
and related disorders can ensue from this mismatch and the inability for the human to cope 
with the extra demands on it due to reduced plasticity that was programmed in its early 
development. 
Proponents of this hypothesis see the potential for this phenomenon to underlie the changing 
global patterns of diabetes and obesity and put fetal programming at the heart of the putative 
gene-environment interactions underlying their aetiology.  In particular, it has been noted that 
the ‘thrifty phenotype’ hypothesis has the potential to explain the increasing prevalence of 
these diseases in Asia, as many people moved from rural, undernourished environments, to 
urban areas with calorific excess and reduced physical activity.     
 
1.2.2 Fetal insulin hypothesis  
Other researchers have proposed a contrasting theory to explain the fetal origins of type 2 
diabetes and obesity: the fetal insulin hypothesis (20).  This hypothesis explains that 
interacting genetic influences between a mother and her developing child can regulate both 
birth weight, and future risk of diabetes.  These important genetic determinants of birth 
weight are located around insulin control genes, e.g. glucokinase, which have a combined 
effect on birth weight, through insulin’s actions as a growth factor, and their role in future type 
2 diabetes risk, e.g. ADCY5 (21).  However, these genetic variants contribute only a small 
amount to birth weight variation, e.g. for the 9% of Europeans estimated to carry 4 birth 
weight-lowering alleles, there is 113g reduction in birth weight, compared to those carrying 
zero or one allele.  This suggests the potential for multiple additional regulators of birth 
weight, including both genetic and environmental factors that may also play a role in the long-
term risk of cardiometabolic diseases.   
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1.2.4 Gestational diabetes 
1.2.4.1 Epidemiology 
Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy, manifest 
by maternal impaired glucose tolerance in mothers in the late 2nd trimester of pregnancy and 
onwards.  The prevalence of GDM is not well described, and as it is usually asymptomatic in its 
early stages, diagnosis relies on biochemical screening policies.   The National Institute of 
Clinical Excellence guidance on diabetes in pregnancy in 2008 
(www.nice.org.uk/nicemedia/pdf/CG063Guidance.pdf) has suggested that the prevalence of 
GDM in England and Wales is 3.5%, but the American Diabetes Association report an average 
of 7% prevalence across studies.  Estimates from a local audit study (N. Tomkins, unpublished) 
at the Royal London Hospital suggests that GDM affected 11.9% of the 4612 receiving 
antenatal care during 2011, highlighting the excessive prevalence of the disorder in at-risk 
groups, such as women of South Asian origin (predominantly Bangladeshi), which comprise 
49% of the pregnant population at the Royal London Hospital.  Other risk factors for 
gestational diabetes have been described by the American Diabetes Association include 
obesity, previous gestational diabetes, a first degree family history of diabetes, and South 
Asian, black Caribbean, or Middle-Eastern ethnic origin, and identification of these triggers oral 
glucose tolerance tests (OGTT) screening at 24-28 weeks gestation (22).  One of the reasons 
that GDM prevalence estimates vary is due to differences in diagnostic criteria for the 
condition defined by various researchers and advisory committees, including the International 
Association of Diabetes and Pregnancy Study Groups (23) and the UK-based NICE guidance 
(described above) (see table 1a).   The IADPSG criteria have been based on more recent data 
from the HAPO Study (to be discussed later) suggesting a linear association between maternal 
glycaemia and adverse pregnancy outcomes.  However, many have questioned whether the 
criteria for fasting and 1 hour post-challenge glucose were too stringent and lead to over-
diagnosis and whether the 2 hour post-glucose challenge cutoff is too lax, especially for 
women of Asian origin who are known to exhibit greater post-prandial hyperglycaemia (24). 
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Oral glucose 
challenge 
Fasting 
glucose 
1 hour glucose 
post-challenge 
2 hour glucose 
post- challenge 
Carpenter and Coustan 
(25)  
100g 5.3 8.7 7.8 
WHO criteria (26) 75g 7.0 Not used 7.8 
NICE guidelines (2008) 75g 7.0 Not used 7.8 
IADPSG (23) 75g 5.1 10.0 8.5 
Royal London Hospital 
(current practice) 
75g 5.8 Not used 7.8 
Table 1a.  Diagnostic criteria for gestational diabetes based on different clinical guidelines.  Glucose 
cutoffs are all greater than or equal to the value presented and units are mmol/l 
 
1.2.4.2 Aetiology 
Gestational diabetes is thought to have a similar aetiological basis to that of type 2 diabetes.  
Risk factors for GDM include ethnicity (women of Asian, Middle-Eastern and African origin are 
particularly at risk), maternal obesity, increasing age and parity, and a family history of GDM 
and type 2 diabetes.  The genetic basis of gestational diabetes is not well characterised, but it 
is thought to overlap with that of type 2 diabetes.  Only one genome-wide association study 
has been performed GDM (in Korean women) and identifies CDKAL1 and MTNR1B as genetic 
variants associated with the condition, at genome-wide significance (27).  The CDKAL1 and 
MTNR1B variants have also been identified as risk variants in type 2 diabetes; it is believed 
that they play a role in beta cell functioning and control of fasting glucose levels.   Other 
studies have tested for commonality of the known type 2 diabetes GWAS hits with GDM and 
have found considerable overlap, but this approach does not fully address the question of 
whether they are associated with GDM or later T2DM risk, or both, in the individuals tested.   
 
1.2.4.3 Pathogenesis 
During normal pregnancy, alterations to glucose and insulin metabolism occur to provide extra 
fuel for developing fetus.  During the first trimester, a pregnant woman becomes leptin 
resistant, enabling the accumulation of fat stores as fuel deposits for later pregnancy and 
lactation.  Increasing maternal insulin resistance and gluconeogenesis during gestation results 
in increased glucose transit to the fetus.  Maternal pancreatic beta cell expansion occurs to 
cope with increased demands for insulin due to this change in maternal glucose metabolism, 
but as maternal insulin does not cross the placenta, the maternal hyperinsulinaemia does not 
prevent the transit of sufficient glucose across to the fetus.  Placental glucose transfer is 
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mediated by specific members of the glucose transporter (GLUT) family, e.g. GLUT1 and 
GLUT3.  Recent evidence suggests that the GLUT genes may be dynamically regulated by 
epigenetic processes (28).  Fetal glucose metabolism is regulated by its own insulin production, 
in addition to other hormones, e.g. thyroid hormone, IGF1, cortisol, with a role in glucose 
homeostasis.  Transfer of lipids across the placenta also requires complex metabolic pathways 
to supply the correct lipid substances (predominantly free fatty acids) to the developing fetus 
for development of white fat stores towards the end of gestation.  Amino acid transport across 
the placenta enables the increasing demands of the fetus for a positive protein and nitrogen 
balance to support its growth.  Amino acid transfer is dependent on the physiological increase 
in placental perfusion to assist active exchange across trophoblast membranes.  The 
complexities of these normal physiological processes of placento-fetal nutrient transfer are 
great and, furthermore, their disruption in pathological conditions of pregnancy, such as 
gestational diabetes, are poorly understood and can have significant consequences on fetal 
growth. 
Gestational diabetes is manifest by glucose intolerance in the late 2nd trimester due to a failure 
of the required beta-cell expansion to cope with increased requirements for insulin production 
as well as increased peripheral insulin resistance.  The resulting maternal glucose intolerance is 
manifest as maternal hyperglycaemia and results in increased glucose transit to the developing 
fetus.  Maternal hyperinsulinaemia ensues in response to hyperglycaemia but as maternal 
insulin does not cross the placental interface, the fetal environment is hyperglycaemic and 
results in the fetus producing its own insulin in excess to try and maintain normoglycaemia.  
Fetal hyperinsulinism results in accelerated fetal growth, leading to macrosomia and 
organomegaly, as well as the risk of neonatal hypoglycaemia when the neonate has to adapt 
rapidly to its own normoglycaemic environment post-partum after a prolonged state of 
hyperinsulinism during gestation. 
The triggers to these abnormal homeostatic and metabolic processes in GDM are poorly 
understood.  The hormones prolactin and human placental lactogen are thought to play a role 
in the beta cell expansion required in pregnancy and a recent study has shown that serotonin 
has an important role downstream of these which, if disrupted, may lead to failure of beta cell 
expansion and ensuing glucose intolerance (29).  Leptin resistance is known to occur in normal 
pregnancy and is thought to be mediated centrally through hypothalamic pathways.  Increased 
leptin resistance has been found in women with gestational diabetes and may play a role in 
reducing insulin sensitivity in pregnant women and inhibiting insulin secretion (reviewed in 
(30)).  Yamashita et al (31) have used these insights to understand the role of leptin in 
gestational diabetes and adiposity using a leptin receptor mutant inbred mouse strain (see 
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Chapter 6) and suggest that leptin administration in pregnancy may improve maternal insulin 
resistance via reducing adiposity.  Finally, specific cytokine members of inflammatory 
pathways, e.g. adiponectin and TNFa, may also play a role in the metabolic phenotypes of 
pregnancy and tendency towards gestational diabetes (32). 
 
1.2.4.4 Clinical features 
There are few specific clinical features of gestational diabetes in mothers, other than those 
associated with risk of developing the condition, including obesity, ethnicity and increasing 
age.  The maternal risks associated with gestational diabetes include pregnancy-associated 
complications e.g. preterm birth, increased rate of Caesarean section and instrumental 
delivery, and are predominantly related to fetal macrosomia (33).  In the longer-term, women 
with gestational diabetes are known to have an accelerated progression to type 2 diabetes 
(T2D), compared to those with and equivalent degree of impaired glucose tolerance unrelated 
to pregnancy.  This observation, and the understanding that the fasting glucose level post-
GDM pregnancy is predictive of T2D onset, suggests either a common genetic susceptibility to 
both GDM and T2D mediated by beta cell genes, or that having a GDM pregnancy in some way 
‘exhausts’ beta cell function and therefore accelerates the progression to type 2 diabetes.  
Long-term follow up of the ALSPAC cohort has also shown an increase in 10 year 
cardiovascular disease risk in women who have had a pregnancy complicated by gestational 
diabetes (34).  Further studies to address the exact mechanisms behind these observations are 
important and should yield insights into the aetiology and pathogenesis of GDM and T2DM.   
The short-term risks of gestational diabetes to the developing fetus relate mostly to the 
complications of excessive fetal growth to specific organs, e.g. cardiac malformations, as well 
as overall macrosomia, which is known to leading to delivery-related complications such as 
shoulder dystocia.  After delivery, fetal hypoglycaemia from beta cell hypertrophy in response 
to maternal glucose levels can occur and is associated with neonatal morbidity and mortality. 
 
1.2.4.5 Role of GDM in fetal programming 
The long-term risks to offspring exposed to gestational diabetes are increasingly recognised 
and considered to be a mode of fetal programming of adult disease.  Multiple cross-sectional 
studies have identified an association between maternal gestational diabetes and a 
programmed phenotype of diabetes and obesity in offspring.  Studies in mothers with 
gestational diabetes in the Pima Indian population of the USA provided early insights into this 
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model, showing that offspring born to these women had fasting hyperglycaemia, higher rates 
of abnormal glucose tolerance and obesity, compared to controls (35).  Early criticisms of this 
data suggested that this observation could be explained by the inheritance from mother to 
child of genetic risk towards all of these phenotypes.  A rat model performed by Gauguier (36) 
in which continuous intravenous infusion of glucose to dams in the third trimester of 
pregnancy rendered them hyperglycaemic and induced programmed glucose intolerance and 
impaired insulin secretion in F1 offspring.  When female offspring were mated with unexposed 
rats, they exhibited further glucose intolerance in pregnancy and the programmed effects 
were transmitted to the F2 generation who were macrosomic and displayed abnormal glucose 
and insulin metabolism from birth and into adulthood.  Since this seminal study, further animal 
evidence of the programming effects of maternal hyperglycaemia have been published (37) 
and more detailed human studies have been performed.  However, a series of studies refines 
this hypothesis, identifying that exposure to varied maternal hyperglycaemia in utero does 
indeed ‘programme’ offspring to developing type 2 diabetes and obesity, independent of 
genetic influences.  Another study of the Pima Indian population used siblings born to mothers 
in subsequent pregnancies when one had been exposed to diabetes and the other had not 
(38).  The offspring exposed to maternal diabetes showed a 3.7 times greater risk of having 
diabetes and at follow-up than their unexposed (age-matched) sibling, with similar differences 
in obesity, thereby identifying a risk in excess of that explainable by genetic influence.  
Additional evidence for the non-genetic basis of this programming model comes from Lindsay 
et al (39) who have shown an increased propensity to overweight and obesity in offspring born 
to mothers with type 1 diabetes, and they hypothesise that this may be regulated by higher 
cord leptin.   
The mechanisms underlying these programming events are not clear, but it seems likely that 
they have the potential to occur late in gestation, during the period of maximal fetal growth.  
Further studies are required to understand the precise mechanisms by which this 
programming can occur and whether it is induced through one environmental factor or many.  
Additional understanding of the contributory genetic factors (from mother, father and child) in 
modulating this programming is important, as highlighted by the observation that paternal 
insulin resistance can affect fetal growth in the Parthenon studies in Mysore, India (40).   
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1.2.5 Nutritional deficiency in pregnancy 
1.2.5.1 Micronutrient deficiency – vitamin B12 and folate 
Over recent years, human and animal studies have shown the potential for maternal deficiency 
of one-carbon cycle nutrients to programme a phenotype of diabetes and obesity in offspring, 
and have suggested that this programming occurs via epigenetic variation.  Vitamin B12 and 
folate are two key components of the one carbon metabolic cycle: folate (from dietary 
tetrahydrofolate) exists as a substrate and B12 as a cofactor to methionine synthase for the 
efficient cycling of methionine to homocysteine (see figure 7a).  Crucially, when this one-
carbon cycle is working effectively, it produces methyl groups from the conversion of the 
substrate, S-adenosyl-methionine (SAM), to its product, S-adenosyl-homocysteine (SAH), using 
methyltransferase enzymes.   Researchers have described the ratio of SAM:SAH as marker of 
‘cellular methylation capacity’ and several studies have suggested that it has a direct impact on 
DNA methylation (41).  The studies described use a range of different tissue types, including 
lymphocytes and solid organ tissue as well as cell lines to highlight how methyl donor 
deficiency results in reduced SAM:SAH and consequent disruption in DNA methylation.  
However, the techniques that have been used are now out-dated and rely on quantitative 
global estimates of DNA methylation (e.g. (42)) that do not provide genomic detail. 
The role of B12 and folate in human fetal programming has been described elegantly in the 
Pune Maternal Nutrition Study (43).  In this study, Yajnik and colleagues have performed a 
prospective study of young women and their children from pre-conception, through pregnancy 
and beyond.  Thus far, the study has followed these children until their early teens with 
published studies on the childhood outcomes of different in utero influences.  The most 
notable finding from this study is that women who were B12 deficient in early pregnancy (a 
common problem in India due to the predominant lacto-vegetarian diet) have children who 
are more insulin resistant and obese than children born to mothers who were B12 replete in 
pregnancy.  These differences, measured using detailed anthropometry measurements and 
biochemical indices of glucose and insulin homeostasis, were observed in several hundred 6 
year-old children born to the study.  The possible role of altered DNA methylation in this 
example of fetal programming will be explored in Chapter 4. 
A model of periconceptual methyl group deprivation in ewes has also been described and 
provides further support to the role of one-carbon metabolites in a programmed 
‘cardiometabolic’ offspring phenotype (44).  In this model, ewes were deprived of a range of 
methyl donors in their diet, including vitamin B12 and folate as well as methionine, pre-
conceptually and at the time of conception   The ewes receiving the deprived diet showed 
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biochemical deficiency of B12, folate and methionine with an expected rise in homocysteine.  
Blastocysts from these donor ewes were then transferred to normally fed surrogate ewes for 
the remainder of pregnancy, as well as weaning.  Granulosa cell lysates were collected at the 
time of embryo transfer and these showed a reduced SAM:SAH ratio. The phenotype of 
offspring exposed to periconceptual maternal methyl deficiency was consistent with 
programming towards cardiometabolic disease.  All methyl-deficient exposed offspring were 
heavier at birth and exhibited higher growth rates into their adulthood, and male offspring 
exhibited higher fat mass (judged by CT scan) at 12 months of age compared to controls.  Male 
offspring also showed insulin resistance, independent of differences in adiposity, with similar, 
but smaller, differences seen in female offspring.  By 23 months of age, male offspring showed 
elevated body fat-adjusted blood pressure in the exposed group vs. controls.  These convincing 
phenotypic changes were associated with reported variation in DNA methylation.  The 
researchers used methylation-sensitive restriction enzymes to characterise DNA methylation 
at 1400 CpG sites, mostly at promoter sequences of genes in the fetal livers of 18 control and 
16 methyl deficient animals.  In their analysis, they found that 57 loci (4% of the CpG sites 
studied) exhibited altered methylation in two or more animals in methyl-deficient offspring 
and suggest that this is more than would be expected by chance.   Furthermore, the authors 
report that hypomethylation was more common than hypermethylation, as could be expected 
from methyl deficiency, and that the differences were more common in males than females, 
consistent with the phenotypic outcome.   Although this method of studying DNA methylation 
provides only a limited perspective of the potential complex epigenomic phenomena, and has 
now been superseded by genome-wide technologies, this paper has given an early, and much-
needed support of the potential mechanisms underlying this fetal programming hypothesis. 
Other researchers have shown small methylation differences in target genes in association 
with maternal and infant one-carbon status and folic acid supplementation in healthy 
populations in the UK and USA (45) (46).  These studies used bisulphite-pyrosequencing assays 
and detected small methylation differences (of up to 8%) and weak correlations in association 
with parameters of one-carbon status.  More importantly, McKay and colleagues have 
provided evidence in their paper that epigenetic-genetic interactions may be important in 
determining methylation status.  In their study, analysis of common genetic variants that 
regulate folate metabolism, such as the methyltetrahydrofolate (MTHFR) gene, identified an 
association between maternal and infant genotype with infant methylation.  Although only 
preliminary findings, these highlight the complexity of interacting influences of gene and 
environment that regulate methylation patterns across the genome. 
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1.2.5.2 Exposure to famine 
Several large studies based on periods of severe and widespread famine have refined the 
evidence that a restricted in utero environment can predispose to diabetes in later life. The 
Dutch Winter Hunger was a period of extreme famine in the 1940s in Holland.  A combination 
of the after-effects of the Second World War and harsh weather conditions leading to crop 
failure meant that a large proportion of the Dutch population were exposed to extreme 
nutritional deprivation for a 5-month period.  Epidemiological studies (47) have compared 
those offspring exposed to famine around the time of conception (periconceptual) or in fetal 
development, with their younger siblings who were not exposed to famine.  Those offspring 
who were exposed to famine in utero were more likely to develop type 2 diabetes, obesity and 
other disorders such as schizophrenia, in later life, compared to their unexposed siblings.   The 
individuals studied included those born before famine (n = 202), those exposed in early 
gestation (n = 63), mid-gestation (n = 100), late gestation (n = 116), and born after (n = 221).  
At follow-up, the mean age of participants was 50 years, mean BMI was 27kg/m2 and there 
was a background risk of type 2 diabetes of 16% (in the conceived after famine group).  This 
study did not identify significant differences in those with and without T2DM between groups, 
but 2 hours post-challenge glucose and insulin were higher in those exposed to famine, with 
an increase in 2 hour plasma glucose of 2.4% per kg/m2 of BMI (95% CI 1.9-2.9).  When 
adjusted for BMI and sex, was greatest in those exposed in late gestation, followed by mid- 
gestation exposure, with early exposure conferring the smallest excess risk of post-challenge 
hyperglycaemia.  The glucose intolerance of offspring was inversely associated with maternal 
weight and birth weight, and those offspring who had the lowest birth weight but the highest 
adult BMI had the highest 120 minute glucose values.  The authors have tried to elucidate 
whether the programmed offspring display insulin resistance and/or a beta cell secretory 
defect by measuring pro-insulin, split pro-insulin and insulin levels in the dynamic glucose 
studies performed.  The fasting pro-insulin levels of offspring exposed to famine were 
elevated, however there was no other evidence of a beta-cell secretory defect from these 
fasting measures nor their incremental response to glucose, therefore the results are more 
consistent with an insulin resistant pathogenesis. 
Subsequent studies on a smaller group of offspring born to the Dutch Winter Hunger model 
used more complex dynamic studies to assess the mechanism of glucose intolerance, 
calculating a disposition index from an intravenous glucose tolerance test as a measure of 
beta-cell secretion, adjusted for insulin resistance.   In this study, the researchers studied 97 
individuals with normal glucose tolerance, excluding anyone with impaired glucose tolerance 
or type 2 diabetes.  Similar to the original study, there was no difference in the fasting glucose 
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and insulin parameters of famine-exposed and unexposed, however the glucose intolerance of 
the former group was reproduced in this study.  The disposition index was lower in the group 
exposed to famine exposure in mid-gestation to a statistically significant level, however this 
was not seen in the groups exposed early or late in gestation.  The authors of this study 
conclude that maternal famine exposure in mid-gestation induces glucose intolerance via 
insulin secretory defect (48).  This is consistent with the theory of fuel-mediated teratogenesis 
(49), however the exclusion of individuals with established dysglycaemia is a significant 
omission in understanding the mechanisms across this group as a whole.  The finding of beta-
cell dysfunction is also in conflict with animal studies that suggest insulin resistance is the 
more common result of prenatal famine exposure (50).   
Similar data comes from studies of offspring born during the severe Chinese famine in 1958-
1961 (51).  This famine occurred at the time of the ‘Great Leap Forward’, when widespread 
political and economic change across China is said to have caused a severe famine and millions 
of deaths.  As with the Dutch Winter Hunger Study, population-based follow up studies have 
been performed on the offspring born before and after this famine, with n=1005 exposed and 
1974 unexposed offspring studied at age 38-42 years.  In this study, the severely famine-
exposed (n=503) had a four-fold increased risk of hyperglycaemia (>6.1mmol/l fasting or 
>7.8mmol/l 2 hours post glucose load) at age compared to those in rural areas unaffected by 
famine (OR=3.92, 95% CI 1.64 – 9.39, p=0.002).  Importantly, for those exposed to severe 
famine who followed a Western/affluent diet in later life, the increased risk of diabetes was 
even greater (OR = 7.63, 95% CI 2.41-24.1, p=0.0005), with a similar increase in risk seen in 
individuals who had a higher socioeconomic status in later life.  Interestingly, mean BMI across 
both exposed and unexposed offspring was no different and within the normal weight range at 
23kg/m2 in both groups.  This study has not examined trimester-specific effects on later 
diabetes risk. 
A study (unpublished) in Bangladesh looking at individuals exposed to famine during the 1970s 
shows a higher rate of impaired glucose tolerance in young adults exposed to famine in utero, 
compared to those born either before, or after.  This study was performed in a rural 
population at high genetic risk of type 2 diabetes, but where under-nutrition and low birth 
weight are still common and will be discussed in Chapter 4. 
In contrast to these two studies, the Siege of Leningrad study, which followed up individuals 
following their exposure to famine, found no real differences in their risk of diabetes and 
obesity in later life compared to a matched group of individuals that were not exposed to the 
famine (52).  This may be due to the continued poverty of this group of individuals that made 
the ‘famine’ expose less defined and more chronic, lasting well into postnatal and later life.  
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Criticisms of these studies have been levelled at the epidemiological assumption that an 
association between famine exposure and diabetes implies causation.  A range of other factors 
may influence the increased risk of diabetes in these studies, including differences in the 
external environment and behaviours of these offspring from their postnatal life into 
adulthood.  In such population-based cohorts and with retrospective methods of data 
collection, it is difficult to define these postnatal influences and to characterise the exact 
exposure in terms of nutritional deficits, accompanying diseases, social deprivation or stress.   
Famine may involve exposure to multiple micronutrient and macronutrient deficiencies and its 
precise nutritional manifestation has not been characterised in detail in the studies above.  
Data from animal models have supported the role of specific micronutrient deficiencies (44), 
protein deficiency and vascular compromise in programming (reviewed in (53)).  
The molecular basis of these models of fetal programming is poorly understood.  Recent 
advances in the field of epigenetics suggests that the environmental susceptibility of the 
developing fetal epigenome, and predisposing genetic factors, are an important means of 
elucidating these molecular mechanisms and determining the aetiological and pathogenic 
influences on complex disease phenotype.  This putative epigenetic process will be discussed 
in the next section. 
 
 
1.3 Epigenetic variation 
 
In recent years, numerous collaborative GWAS studies using large cohorts have yielded some 
insight into the genetic control of phenotypic diversity (3) (54). Similar studies of the epiallelic 
contribution to complex traits have so far been limited by technological and economic factors 
as well as the analytical complexity required. However, insight has been gained from the 
characterisation of epiallelically-induced phenotypic variation in monozygotic twins (55)  and 
the identification of pleiotropic quantitative loci which account for phenotypic variance in mice 
(56). Large-scale ‘epigenomic’ initiatives, such as the NIH International Human Epigenomic 
Consortium, are being created to study the range of epigenetic modifications in normal and 
diseased states, and a variety of tissues.  Open access data from such studies is increasingly 
displayed on standard genome browsers will foster further developments in this area.  DNA 
methylation, as a stable epigenetic modification, lends itself to detailed study through a range 
of experimental platforms.  Epigenomic patterns of methylation are now well characterised, 
and show a relationship between CpG density and genomic location, described Figure 1b.  
 36 
Much focus has been placed on CpG islands (CGIs), regions where the observed density of CpG 
dinucleotides is higher than that expected from the background genome (defined by the 
Ensembl gene browser as >400 bp long and with a CpGo/e density of >0.6).  Typically, CGIs 
overlie gene promoters and are relatively under-methylated compared to regions of lower CpG 
density.  A detailed human epigenomic profile comes from Lister (57) who used a technique 
that couples bisulphite conversion with Next Generation Sequencing (called BS-seq) to study 
DNA methylation in a human cell line and embryonic stem cells.  Using this approach, 1.16-
1.18 billion reads were generated, providing coverage of over 86% of both strands of the 
3.08Gb human reference sequence. This extensive profiling confirmed previous epigenomic 
observations, but also highlights the existence of non-CpG site methylation in embryonic stem 
cells.  The role of non-CpG methylation is unclear, but it seems likely to play a role in cellular 
differentiation. 
 
Figure 1b. Analysis of somatic DNA methylation profiles, using MeDIP-chip.  Data were categorised into 
unmethylated (yellow: <40%), intermediate (green: 40-60%) and methylated (blue: >60%) regions, and 
included non-promoter CpG islands.  X axis = CpG observed/expected ratio and Y axis = frequency 
Reproduced from Rakyan et al (58).  
 
 
Techniques for studying protein-DNA binding, such as ChIP-seq, have been used to profile the 
range of histone modifications that contribute to the variable epigenetic landscape in humans, 
and their interaction with DNA methylation.  High-resolution maps for up to 20 chromatin 
modifications have now been produced (59) (60), and these have also provided an insight into 
the possible role of epigenetic mechanisms in transcriptional regulation.  A range of ‘active’ 
and ‘repressive’ histone modifications have now been well characterised, and these seem to 
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have predictable relationships with DNA methylation patterns, nucleosome positioning and 
gene expression (59) (61) (62) (Figure 1c). 
 
 
 
Figure 1c.  Characteristic histone methylation profiles of active and silent genes.  Y axis represents 
enrichment and X axis the genomic location. From Barski et al (59).  
 
 
The characterisation of epigenetic modifications on their own gives a limited insight into their 
interactions with other factors, e.g. genetic variants, their acquisition and maintenance, and 
their functional role.  Like genetic variants, or alleles, epigenetic variants are increasingly seen 
as stable and penetrant entities and have thus been defined as ‘epialleles’ by some (63).  In 
defining an epiallele, they can be conceptualised first as regions where genetic, environmental 
and stochastic events converge to form clear ‘signatures’, and second, as having a defined 
outcome such as variable gene expression or phenotype.  Richards has defined these epialleles 
as obligatory, facilitated and pure (summarised in Figure 1d), a classification that is helpful in 
understanding how to detect and understand their putative role in complex disease aetiology, 
especially with respect to their interaction with genetic and environmental factors. 
 
 
1.3.1 Epialleles 
1.3.1.1 Obligatory epialleles.  
These are generated as a direct consequence of genetic polymorphism and are independent of 
environmental or stochastic influences (Figure 1d). Epialleles of this type may be associated 
with a specific haplotype, in which case they are said to occur in cis.  Single-locus studies have 
identified obligatory epialleles for DNA methylation, where a single nucleotide polymorphism 
(SNP) is responsible for the creation, or deletion of a CpG site (64) (65). Genome-wide 
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approaches have identified further examples of SNP associated, allele-specific methylation 
that is more widespread (66) (67). Another recent study has mapped differentially methylated 
regions (DMRs) in the F1 generation from crosses of unique, inbred mouse strains, and reports 
that the majority of differentially methylated regions (DMRs) coincided with the underlying 
genotype (68). Similarly, it has been reported that local histone modifications may also 
segregate in a Mendelian manner, although the statistical power of this finding was weak (69).  
Allele-specific chromatin marks have recently been identified through the study of CTCF-
binding sites across the genome; these commonly occurring trans-acting transcription and 
chromatin regulatory factors act as insulators, blocking enhancer activity.  McDaniell and 
colleagues (70) have identified allele-specificity of CTCF-binding sites on a genomic level in 
humans, and a potential complex regulatory role in X inactivation.  
 
When an epiallele results from a polymorphism at a distant genomic location, it is termed 
trans-obligatory (Figure 1d). Epialleles of this nature are less easy to identify, however, the 
mutagenesis screen utilised by Whitelaw and colleagues (71) (72) identified several chromatin 
modifiers using this principle. Mutations identified in their screen included core regulators of 
epigenetic phenomena, e.g. DNA methyl-transferase 1 (DNMT1), and unsurprisingly, were 
associated with severe phenotypes, many being homozygous embryonically lethal (72).  
 
Although obligatory epialleles influence phenotype through introducing epigenetic variation, 
they exist purely as a direct result of genetic variation. Whether alleles of this nature should be 
considered as epialleles is subject to ongoing debate.  
 
 
1.3.1.2 Facilitated epialleles  
In other cases, genetic polymorphism may predispose to the formation of an epiallele without 
determining the epigenotype.  Epialleles of this nature are termed ‘facilitated’, and their 
occurrence has been further defined as a severance in the direct link between genetic and 
epigenetic variation (63).  Facilitated epialleles, although mitotically stable, do not conform to 
Mendelian segregation.  Some of the best examples of facilitated epialleles include the agouti 
viable yellow (Avy) (73) and axin-fused (74) alleles, both of which are associated with the 
insertion of an intracisternal-A particle (IAP) retrotransposon into a non-translated region of 
the endogenous gene.  Promoters associated with these retrotransposons are capable of 
directing production of an aberrant transcript and are epigenetically regulated, potentially 
existing in a transcriptionally silent or active state.  By contrast, in the absence of the IAP 
insertion, the endogenous gene does not exist as an epiallele, and thus the genetic event is 
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seen to be a necessary substrate for its creation.  These epialleles have been studied in 
isogenic mice, eliminating confounding effects of trans-modifiers and revealing that the 
epigenetic state of the introduced IAP promoter is stochastically established early in 
development.   
 
In humans, a possible example of a facilitated epiallele is observed in fragile-X syndrome, a 
condition associated with expansion of a repetitive CGG sequence in the 5’ untranslated region 
of the X-linked FMR1 gene.  This expansion predisposes to aberrant methylation and reduced 
FMR1 expression, producing the Fragile X phenotype.  Furthermore, in a family of 5 brothers 
all carrying the same predisposing X allele, methylation and FMR1 expression are mosaic and 
variably expressed amongst the brothers, producing phenotypes ranging from silent to fully 
penetrant (75). 
 
1.3.1.3 Pure epialleles 
These epialleles arise independently of genetic variation.  In such cases it is thought that 
environmental or ‘stochastic’ factors act to induce epigenetic variance, subsequently 
producing phenotypic plasticity (55) (76)  (Figure 1e).  A range of specific environmental 
factors have been implicated, including diet and drug/toxin exposure, whilst in many cases, the 
inducer remains ill defined.  The concept that environment can induce epiallelic variance, with 
mitotic and/or meiotic stability, seems particularly relevant to elucidating the mechanisms of 
fetal programming. Animal models in which maternal low protein programmes a 
cardiometabolic phenotype in offspring have been used to identify epigenetic differences 
associated with this programming.  One such study has identified hypomethylation at the 
glucocorticoid receptor (GR) and peroxisome proliferator-activated receptor alpha (PPARα) 
gene promoters in offspring exposed to the programmable insult and, if stable, may be 
examples of pure epialleles resulting from the in utero environmental insult (77).  Further 
evidence for the epigenetic role in programming comes from the finding that supplementation 
with the methyl donor, folate, prevents the hypomethylation in response to low protein (78). 
The phenotypic consequence of exposure to low protein diet is an insulin resistant phenotype 
in offspring (79), replicating the observation from human cohorts of maternal famine exposure 
leading to excess risk of type 2 diabetes in offspring (47).  These comparisons raise a tempting 
possibility that human epigenomic studies may also enable the identification of pure epialleles, 
and indeed a recent study of fetal programming has identified stable epigenetic variants 
associated with in utero nutritional supply (80).  This notable study will be discussed in further 
detail in section 1.5.2 and Chapter 5. 
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Figure 1d.  Types of epialleles.  1. Obligatory epialleles. A genetic mutation (green star) either occurring 
at the site of the epiallele (red) (in cis), or at a distinct genomic location (in trans) is directly causative of 
epiallele formation. 2. Facilitated epialleles. A genetic mutation (green star) is a necessary substrate for 
epiallele (red) formation, but additional stochastic (blue bolt) factors are also required for epiallele 
formation. 3. Pure epialleles. Exist in the absence of any underlying genetic change and are derived as a 
result of stochastic factors (blue bolt) alone. Reproduced from Finer et al, (81). 
 
1.4 Epigenetic changes during the mammalian life course 
 
During the mammalian life course, the epigenetic profile of an organism undergoes a series of 
developmental changes and processes by which it maintains itself.  Waddington (1951) 
originally proposed the concept that multiple stochastic influences during the lifecourse of an 
organism determines its fate (Figures 1e and 1f).   
With further understanding of both the normal and aberrant processes that influence the 
epigenetic state of an organism, it is possible to understand the relative importance of 
different developmental time periods in determining its phenotypic fate.  This knowledge is 
likely to be of particular importance in understanding the aetiology of type 2 diabetes and 
determining mechanisms underlying environmental and genetic susceptibility, rather than just 
epidemiological association. 
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Figure 1e.   The varied fate of an organism, determined by its genotype and its phenotypic development 
through its exposure to multiple stochastic influences during its lifecourse, represented by a ball 
(genotype) travelling through a varied environment (landscape) reproduced from Mitchell (82).  This 
indirect relationship of genotype to phenotype is mediated by epigenetic influences. The diagrams 
represent two “runs” of the developmental process in two individuals (A and B) with the same starting 
genotype (as in monozygotic twins, for example). These two individuals therefore inherit the same 
probability of developing a certain phenotype but may have different actual phenotypic end points, 
determined by stochastic factors and environmental effects, especially at critical points. 
 
Figure 1f. The origins of epialleles. The developmental period at which an epiallele originates will 
determine how it might influence phenotype, as well as the potential for it to be meiotically heritable.  
Reproduced from Finer S et al (81). 
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1.4.1 Gametogenesis, embryogenesis and fetal development 
In mammalian development, two periods of genome-wide epigenetic reprogramming occur, 
during which time development-specific epigenetic marks are established (figure 1g).  The first 
event is timed during the formation of germ cells (gametogenesis) and is required for the 
establishment of a unique germ-cell specific gene expression signature, including the erasure 
and re-establishment of parental imprints and reactivation of the inactive X chromosome in 
preparation for meiosis (83).  The second event occurs post-fertilisation, when maternally and 
paternally contributed genomes are processed differently; the male genome sees rapid 
replacement of its protamines with histones, and DNA methylation patterns are erased across 
male and female genomes by active and passive mechanisms, respectively (84). 
 
 
 
 
Figure 1g. Changes in methylation status during gametogenesis and early embryogenesis, reproduced 
from Jirtle (7) 
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Incomplete erasure or variation in the re-establishment of epigenetic marks in either of these 
two rounds of reprogramming has the potential to give rise to epialleles.  The creation of these 
epialleles during gametogenesis or early embryogenesis results in their penetrance through all 
somatic lineages, exemplified by the human soma-wide epigenetic silencing of the mismatch 
repair gene, MLH1 (85).  The potential for disruption of these complex processes by external 
influences is great.  Adverse environmental factors, such as gestational diet and toxin 
exposure, have been found to induce epialleles during these susceptible developmental 
windows.  For example, when pregnant dams carrying Avy/a offspring are fed a methyl donor 
supplemented diet mid-gestation, not only the F1 show a shift in phenotype towards increased 
silencing of the Avy epiallele, but also the F2, indicating that exposure of the developing germ 
cells in F1 to methyl donors influences the Avy epigenotype in a manner that survives post-
fertilisation reprogramming (86).  
 
The key role of the placenta in fetal development is well understood at a physiological level.  
Recently, patterns of placenta-specific methylation have been identified, for example in the 
regulation of vitamin D-responsive genes (87).  The functional consequences of these unique 
mechanisms of epigenetic regulation at the materno-placental-fetal interface are not clear, but 
evidence is emerging for their role in fetal growth (88). 
 
Furthermore, the application of epigenetic studies to models of fetal programming has yielded 
substantial insights into their possible role in the developmental origins of adult disease.  DNA 
methylation changes have been identified at candidate loci in offspring exposed to the Dutch 
Hunger Winter in utero (89).  These methylation changes are small and, to date, no association 
with gene expression or phenotypic outcome has been described.  However, more direct 
evidence for the involvement of epigenetics in the establishment of lifelong gene expression 
profiles in response to environmental factors has been provided by animal studies of both 
nutritional and behavioural models (90) (91).  
 
1.4.2 Adult life and ageing 
Studies have suggested that perturbation of the epigenome can occur from stochastic 
environmental influences during the lifecourse, characterised most notably in the epigenome 
of monozygotic twins that become more dissimilar as twins age (76).  In eliminating genetic 
differences, twin study design is able to identify potential stochastically-induced epigenetic 
variation, and recent studies have identified age-associated differences at bivalent chromatin 
domains, regions with important epigenetic regulatory potential (92).  However, to date, no 
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such studies have been able to associate conclusively a link between methylation variation 
with phenotype.  Larger-scale genome-wide studies of twins are likely to be able to uncover 
some of these associations, as well as the possible role of other genomic differences such as 
structural variation. 
 
 
 
 
1.5 Role of epigenetic variation in aetiology and pathogenesis of Type 2 diabetes 
 
Whilst epigenetic variation provides a tantalising means of studying type 2 diabetes aetiology, 
it is crucial to consider the potential interacting genetic, environmental influences on complex 
disease phenotypes and these should be taken into account when designing studies to 
determine its molecular basis.   Complementary to this is to consider how and where these 
interactions occur and whether there are particular susceptible periods in the life course.  
Consideration must also be given to whether these interactions affect the organism as a 
whole, or induce tissue-specific effects with localised effects on gene expression and function. 
 
1.5.1 Genetic-epigenetic interactions 
The role of aberrant epigenetic marks is well established at single gene loci with rare imprinted 
disorders (93) and as well in cancer genomes with global hypomethylation and locus 
hypermethylation (94). Recent investigations in other complex diseases, such as type 1 
diabetes (95) have been successful at identifying some preliminary insights into genetic-
epigenetic interactions on a genomic scale.   However, the relationship between epigenetic 
modifications and genetic variation across the genome is poorly understood.  In complex 
diseases such as type 2 diabetes, genetic risk is influenced by polygenic influences and could 
therefore also be modulated by a myriad of interacting epigenetic modifications.  It is 
hypothesised that such epigenetic variation could underlie the missing heritability of complex 
disease, but to date, there is only limited evidence to support this notion.  
The first suggested evidence for direct genetic-epigenetic interactions in type 2 diabetes came 
from the identification of parent-of-origin specific associations of genetic susceptibility 
variants, putatively due to the occurrence of imprinting (65), whereby allelic expression occurs 
in a parent-of-origin specific manner.   Since this observation, only one study identifies a 
 45 
possible functional role of an imprinted locus in the aetiology of type 2 diabetes; Small et al 
(96) show that variants in KLF14, a maternally-expressed transcription factor can modulate 
adipose tissue gene expression via trans effects in relevant metabolic pathways.   Currently, 
there is no other evidence for imprinting playing a role in the aetiology of type 2 diabetes, 
although related phenotypes can arise from rare single-gene imprinting disorders such as 
Silver-Russell and Beckwith-Wiedemann syndromes (97), and transient neonatal diabetes (98).  
Interestingly, despite their common role in developmental processes, imprinted genes are not 
thought to be susceptible to environmentally induced fetal programming (99). 
More recently, many studies have identified epigenetic variation at genes with a known role in 
diabetes pathogenesis, e.g. increased DNA methylation associated with decreased PDX1 
expression in human pancreatic islets from individuals with type 2 diabetes (100).  However, 
such studies do not define whether these epigenetic variants are in fact stable epialleles, and 
whether they are induced stochastically, through environmental variation (e.g. pure epialleles) 
or in association with genetic variation (obligatory and facilitated epialleles).  The association 
between genetic and epigenetic variation is an important consideration given their potential 
dual role in the development of complex disease phenotypes.  Studies that integrate assays of 
genetic variants, e.g. single nucleotide polymorphisms, copy number variants etc, and 
epigenetic variants are required to understand these interactions in more detail.  
 
1.5.2 Environment-epigenetic interactions 
The notion of a pure epiallele, described above, suggests that environmental and/or stochastic 
factors can alone induce metastable epigenetic variants with secondary effects on gene 
function.  To date, evidence for pure environmental-epigenetic interactions that occur 
independently of genetic variation and have a phenotypic consequence in humans is limited.  
In contrast, a range of studies using inbred mouse and rat strains have identified stable 
epigenetic variants induced through stimuli in the maternal environment, and the examples of 
these have been discussed in section 1.3.1.3.  
Whilst many studies attempt to show evidence that pure epialleles exist in humans, most do 
not answer the difficult questions that are crucial to their definition: are these truly metastable 
changes that could be inherited through subsequent generations, do they predate disease 
onset and therefore have an aetiological role, and/or do they arise with complete 
independence from genetic risk variants?   Secondly, most studies identifying methylation 
variation induced through environmental stimuli have not addressed whether these variants 
have an effect on gene function.   
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A study of epigenetic variation in type 1 diabetes has provided some evidence that epigenetic 
variants can predate the onset of type 1 diabetes, using longitudinal sampling from individuals 
before and after the onset of disease (101).  This study also used disease-discordant 
monozygotic twins as the primary study group and can therefore conclude that the variation in 
DNA methylation they identify is occurring independently of genetic variation.  No single 
environmental precipitant is identified as the cause of these epigenetic changes, nor are they 
proved to be metastable, however this is an important study in understanding the nature of 
environment-epigenetic interactions and their role in the onset of complex diseases. 
Waterland and colleagues have performed a study that goes further towards identifying 
environmentally induced metastable epialleles in humans (80).  The authors designed their 
study using an important principle of murine metastable epialleles, that they show inter-
individual variation and are present across germ layers.  A methylation-specific microarray was 
used to identify regions of the genome exhibiting inter-individual variation in DNA methylation 
that were present across mesodermal (peripheral leucocytes) and ectodermal (hair follicles) 
cell lineages.  Of the 107 loci fulfilling these criteria, 34 were associated with SNPs, a further 35 
were associated with probable copy number variation in sub-telomeric regions, and of the 
remaining loci, only 8 were technically validated by bisulphite-pyrosequencing.   Further 
support of these candidate regions being stochastic or environmentally mediated, rather than 
genetically induced was provided by the observation that the majority of them showed inter-
twin variation across 23 monozygotic twin pairs.  Finally, the methylation state of these 
candidate regions was assayed in Gambian offspring where season of birth is associated 
different birth phenotypes and developmental programming.  The authors found a statistically 
significant association (p<0.05) between season of birth and methylation at 5 of their selected 
candidate regions, with an increase in methylation of around 5% associated with birth during 
the nutritionally replete rainy season.  The authors conclude that their findings provide 
evidence of metastable epialleles that have occurred independently of genetic variation and 
are induced through the environment at specific regions of methylation variation. 
Beyond these issues, what remains is how to interpret the studies showing the direct influence 
of environmental perturbations on epigenetic marks where the study design does not seek to 
identify them as stable epialleles.  Whilst the identification of a stable epiallele is key to 
understanding potential trans-generational inheritance of epigenetic marks, it is not 
necessarily crucial to understanding the role of the environment in inducing epigenetic 
variation and complex disease phenotype in a single generation.  There is a wealth of studies 
that identify epigenetic variants in association with complex disease phenotypes; for example, 
small-scale targeted studies have identified an association between insulin resistance in elderly 
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subjects and promoter methylation at NDUFB6 (102) and methylation differences at 
PPARGC1A in human islets from twins with and without type 2 diabetes (103).  These findings, 
at small numbers of CpG sites in gene candidates, do not provide sufficient evidence of their 
existence as stable epialleles but do provide insights into their association with environmental 
factors rather than genetic variation.  The key question to ask of the observed environmental-
epigenetic interactions and their association with disease phenotype is whether this is a 
primary and causative association or a secondary consequence of disease pathology.  Away 
from the difficult question of whether or not an epigenetic variant is an epiallele, the 
differentiation between primary and secondary epigenetic variation is crucial if trying to 
understand their role in disease risk.  Other studies have already shown in detail how 
epigenetic variants can be part of disease pathology, rather than being causative, in diabetes.  
El-Osta and colleagues (104) (105) (106) have identified histone modifications induced through 
transient hyperglycaemia at the promoter of the NF-kB subunit p65 in vascular cells with 
consequences on gene expression.  These studies do not look at DNA methylation changes but 
provide a fascinating insight into how specific cellular environments associated with diabetes 
can induce long-standing changes to gene function that may underlie metabolic and vascular 
complications of diabetes and molecular memory of early glycaemic control.   Other studies 
have shown variable DNA methylation in the leptin gene of women with gestational diabetes 
(107) and the existence of genome-wide DNA methylation variation in diabetic nephropathy 
(108).  These studies contribute to a wider body of animal experiments, but all identify 
epigenetic variation that is likely to be a secondary phenomenon to the disease itself. 
 
1.5.3 Gene and environment interacting through the epigenome  
The difficulty in understanding genetic-epigenetic and environmental-epigenetic interactions 
as separate entities may be due to the fact that the majority of epigenetic variation occurs in 
tandem with genetic variation and is modulated through the environment.  In addition, these 
dichotomous interactions are difficult to elucidate experimentally; the identification of pure 
epialleles necessitates complex study design that includes monozygotic twins and/or inbred 
animal strains.  Identification of functional genetic-epigenetic variants requires large sample 
sizes, allele-specific functional studies and complex computational methods to identify cis and 
trans effects.  The majority of published research on the role of epigenetic variation in complex 
disease aetiology is not designed to address the exact nature of these interactions at this level 
of detail and the conclusions of most published epigenomic studies at this time suggest 
putative roles of both environment and genetic variation.  Furthermore, it could be argued 
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that the lack of evidence of pure epialleles in the many epigenomic studies performed to date 
may in fact reflect the fact that they are a rare occurrence.   
As discussed earlier, the aetiology of type 2 diabetes and related disorders is thought to 
incorporate complex interactions between gene and environment and that early 
developmental life may be particularly susceptible to disruption of either, e.g. via 
polymorphisms or an aberrant environmental factor.  Studies of fetal programming provide 
crucial insight into these convergent factors, and the impact of inherited genetic risk and 
environmental perturbations in utero can provide exciting insights into the nature of these 
interactions and their role in complex disease aetiology.    
The body of evidence supporting the notion that an adverse maternal environment can 
predispose the developing fetus to adult disease in later life assumes a combined role of 
genetic and environmental influence.  The potential for epigenetic regulatory mechanisms to 
lie at the interface between parental genotype, in utero environment and the developing 
offspring is strong.  Identification of defined environmental insults in pregnancy has provided a 
useful starting point with which to explore the molecular mechanisms underlying fetal 
programming and there is now a wealth of preliminary data that is starting to elucidate these 
environmental-genetic-epigenetic interactions.  The maternal low protein model, described 
above, is particularly well studied and multiple studies have shown that exposed offspring 
have a predictable phenotype of insulin resistance.  Complementary molecular studies in this 
model have identified small methylation differences in relevant genes that have a role in 
insulin resistance (77), highlighting the convergence of genetic and environmental risk through 
epigenetic modifications.  The low protein mouse model have lent support to human cohorts 
in which growth-restricted offspring born during periods of famine were found to have small 
methylation differences in IGF2, GNASAS and IL-10 and other genes, several of which are 
already implicated in the aetiology of diabetes.  These changes occur in a time- and sex-
specific manner, implicating gametogenesis as the period most susceptible to the 
environmental exposure (89) (109).  However, these studies do not elucidate the functional 
consequences of the small methylation differences observed, nor do they address the 
important concern that the end phenotype associated with the programmed event may in fact 
be the cause of the epigenetic differences.  Few studies can identify a true aetiological role for 
these interactions and sub-clinical phenotypes in human studies may further obscure the 
difference between primary and secondary changes.  Indeed a robust study that detected 
stable epigenetic variants in Gambian offspring according to season of birth (as a surrogate for 
maternal nutrition) did not find any differences in DNA methylation at IGF2, GNASAS or IL-10 
(80).  Serial sampling from human cohorts could help to overcome these difficult issues with 
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the ability to identify the temporal relationship of epigenetic changes with phenotypic 
outcome.  Recent work using Guthrie cards as a means with which to generate epigenomic 
insights of DNA methylation may provide a feasible and practical platform to address these 
important questions in the future (101). 
One study that does identify the functional effects of epigenetic variants has been performed 
by the researchers who identified promoter methylation differences at NDUFB6 and 
PPARGCIA, described earlier (110).  Muscle biopsies were taken from men in their 20s who had 
been born either at an extreme of low birth weight (LBW), or normal birth weight.  Those who 
had had a low birth weight had convincing signs of early insulin resistance and obesity and 
differences in methylation at 2 CpG sites in the PPARGC1A promoter compared to those who 
had been born at normal birth weight.  After high-fat feeding, the normal birth weight group 
showed increased methylation at the same CpG sites in association with increased expression 
of PPARG1CA, whereas those with LBW did not.  Mouse studies of intrauterine growth 
restriction also support a true causative role through epigenetic silencing of a gene involved in 
pancreatic development prior to the onset of any programmed phenotype (111).   A tissue-
specific view of epigenetic variation in diabetes is also important in detecting its functional 
role, and this has been highlighted by Bhandare et al (112) in their genome-wide profiling of 
DNA methylation and histone modifications of human islets.  They find, surprisingly, the 
absence of ‘active’ histone marks (H3K4me3) associated with transcriptionally active genes, 
such as those encoding the hormones insulin and glucagon, suggesting the need for detailed 
functional models to understand how epigenetic modifications, as well as their interaction 
with genetic and environmental factors, relate to disease aetiology and pathology. 
 
In trying to characterise the role of genetic and environmental factors in epigenetic 
mechanisms of fetal programming, care must also be taken in the study design to address 
variables that may confound environmental and/or genetic risk factors and, in turn, influence 
outcome.  The maternal low protein experiments offer a useful model of programming where 
the exposure is itself independent of genetic risk.  In contrast, other models, such as that of 
programming through maternal hyperglycaemia may be prone to confounding by common 
genetic risk of diabetes inherited from the mother (with gestational diabetes) to the child, and 
studies also show a high prevalence of vitamin D deficiency in mothers with gestational 
diabetes (113).  The ‘adverse environments’ described in human models of fetal programming 
may also include confounding variables and need careful thought to determine the nature of 
the complex nutritional and/or metabolic insults so that these can be elucidated.  For example, 
the ability for famine exposure to induce developmental programming may in fact be due to 
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single nutrient deficiencies such as protein deficiency, or multiple factors related to the dietary 
insult itself or other factors associated with famine exposure such as recurrent infections or 
reduced physical activity.  These complex factors are important to consider when comparing 
similar human studies and also when using animal models to simulate the human exposure. 
 
 
1.6 Application of epigenomic studies to understanding the aetiology of type 2 diabetes 
 
Much of the current research being performed to understand the role of epigenetics in the 
fetal origins of and gene-environment interactions in complex disease aetiology employs a 
gene-specific or targeted approach.  Targeted studies offer a useful insight into specific 
molecular mechanisms or regions of interest within the epigenome, chosen using a priori 
hypotheses.  Whilst this approach may be useful to complement existing candidate-based 
studies, it cannot be used to generate the unbiased insights into gene-epigenetic-environment 
interactions that are required in these early stages of understanding complex disease aetiology 
on this level.  The approach of the work presented in this thesis is to use genome-scale and 
genome-wide approaches to generate novel insights into the aetiology of type 2 diabetes, and 
to generate insights for downstream hypothesis-driven studies.   
 
1.6.1 Genome-scale genetic-epigenetic studies 
Genome-scale studies implement genomic technologies to identify molecular events at 
multiple pre-defined areas of the genome and commonly use custom-designable arrays.  These 
technologies have mostly been superseded by array-based and whole-genome-based 
approaches of recent years, but have been used in the study of type 2 diabetes presented in 
Chapter 3.   
 
1.6.2 Genome-wide and whole genome studies of gene-environment-epigenome 
Just as the unbiased genomic techniques have yielded an in depth understanding of candidate 
gene disease associations in recent years, whole ‘epigenome’ study is now being used to 
characterise the epigenetic mechanisms underlying complex phenotype and disease.  
Characterising and profiling the epigenomic state (including its variety of epigenetic marks, 
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their plasticity and interaction) brings significant technical challenges on top of those 
encountered in pure genomic investigation.  DNA methylation is the best-studied epigenetic 
profile due to its relatively predictable interaction with the underlying DNA sequence and 
effects on gene expression, and several affordable and robust techniques now exist with which 
to do this.  An optimal technical platform to study DNA methylation on an epigenomic scale is 
one in which methylation status can be identified quantitatively and at high resolution across 
whole genome, and one that is combined with simultaneous identification of the underlying 
genetic sequence. 
MeDIP-seq has been used as an experimental platform that has been applied to the study of 
DNA methylation across mammalian genomes (114).  The technique involves methylated DNA 
immunoprecipitation of short DNA fragments using a monoclonal antibody specific to 5-
methylcytosine - enriched methylated DNA fragments are isolated for use in the sequencing 
stage of this process.  Next Generation Sequencing (NGS) platforms are used to sequence 
methylated DNA fragments, having undergone the appropriate library preparation, and can 
produce 10s of millions of sequence reads in a few days that can be aligned to a reference 
genome and provide extensive coverage of methylated regions.  Detection of the efficiency of 
MeDIP enrichment across overlapping genomic fragments allows the quantitative estimation 
of methylation across the genome and identification of ‘differentially methylated regions’ 
(DMRs); this will be discussed in more detail in Chapter 2.   
The potential applications of MeDIP-seq are wide-ranging, allowing unbiased detailed study of 
the dynamic processes of DNA methylation, its role in developmental programming and the 
characterisation of disease-associated aberrant marks.  Methylation profiles generated by 
MeDIP-seq are freely accessible via the Ensembl genome browser display.  However, 
limitations of the MeDIP-seq approach exist, notably that it does not offer the single base pair 
resolution of bisulphite conversion coupled with Next Generation Sequencing (BS-seq).  
Bisulphite treatment of single-stranded DNA causes the selective conversion of unmethylated 
cytosines to uracil, leaving methylated cytosines unchanged, and thereby allowing the 
identification of methylation status per nucleotide residue.  This gold-standard technique has 
now been successfully applied to animal (115) and human-based studies (116), but at the 
current time the sequencing requirements (i.e. cost and time) are prohibitive for many 
researchers.  Reduced representation bisulphite sequencing (RRBS) provides a more pragmatic 
approach to BS-seq, using a MspI restriction digest specific to CpG sites and therefore enriches 
for regions of DNA methylation (117).  Bisulphite conversion is then applied and after PCR, 
DNA libraries are applied to Next Generation Sequencing (NGS).  This approach provides single 
nucleotide resolution, however by limiting itself to CpG dense regions, it has less extensive 
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coverage MeDIP-seq, and may miss DMRs in CpG-poor regions such as gene bodies, the 
functional relevance of which is not fully determined at this time.  Another potential bias for 
RRBS- and BS-seq is the possibility of incomplete bisulphite conversion which may occur when 
double-stranded DNA is not fully denatured or has re-annealed, and is therefore not subject to 
the conversion that single-stranded DNA undergoes.  If this occurs, unmethylated cytosines 
may represent experimental artefact and introduce bias into the analysis of data generated 
from this technique. 
The three epigenomic approaches described above are reliant on detailed and expert 
bioinformatic analysis that can be time-consuming and short in supply given the rapid 
expansion in data since the recent technical advances in molecular biology.  However, recent 
advances in the computational analysis of these techniques offer the exciting possibility of 
integration with related studies of histone modification (ChIP-seq) and functional investigation 
(RNA-seq) to build integrative maps (59).   
Array-based techniques, in combination with MeDIP or restriction digests and hybridisation of 
methylated against unmethylated DNA, may be used to identify DMRs.  These offer a cheap 
method of assessing DNA methylation at multiple genomic sites in large numbers of samples 
and generate data quickly often using relatively simple bioinformatic analytic techniques.  
Numerous examples of these platforms exist, including the Illumina HumanMethylation 450 
BeadChip, a relatively cheap and easy platform to use in studies where large numbers of 
samples are being analysed and prohibit the use of BS-seq, RRBS-seq or Medip-seq. 
Identification of regions of epigenetic variation, e.g. DMRs, can be validated using a targeted 
approach in a larger sample size using standard genetic sequencing of bisulphite-treated DNA 
and can be processed in a cost- and time-efficient manner.   
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1.7 Determining the functional role of epigenetic variants 
 
To date, epiallelic variation is functionally characterised in terms of its influence over gene 
transcription.  However, it is important to establish a deterministic link between an epiallele 
and altered gene expression, which could be influenced by unlinked genetic modifiers.  Inbred 
mouse models provide a useful resource in which large numbers of genetically similar 
individuals can be simultaneously assessed for both the presence of the epiallele and its 
putative functional effect.  An integrative approach, combining several genome-scale data 
sets, offers the most powerful strategy to detect epialleles that, in addition to cis effects, may 
exist mono-allelically, or act by influencing distant enhancers.  The power of combining 
epigenomic and transcriptomic mapping to detect epialleles with functional and phenotypic 
outcome is huge, and is likely to yield considerable data resources that could be made 
accessible publicly though browsers such as Ensembl.  However, at present, cost and analytical 
barriers limit the potential to scale up these experimental approaches to the sample sizes that 
have given insight into complex disease pathogenesis from the detection of genetic variants.  
 
As previously discussed, the acquisition of an epiallele may be determined by the interaction 
of genetic and/or environmental factors. When designing an experimental approach to not 
only identify the presence of an epiallele, but also determine the factors that have led to its 
existence, appropriate study design is vital.  Facilitated epialleles must be identified in the 
context of both genetic and epigenetic variation.  Obligatory epialleles, which are induced 
solely through the existence of a genetic variant, may be detected by identifying the genetic 
variant or its functional consequence in the first instance and the epigenetic event second 
(118).  To study pure epialleles, an isogenic environment offers a means with which to increase 
the power to detect non-genetic events, and this has been successfully performed in inbred 
mouse strains (119) and studies of disease-discordant monozygotic twins (95).  Identification 
of environmentally-induced epialleles in human cohorts should also take careful note of 
potential confounding factors when considering their aetiological role (120).   
 
Fetal programming of adult disease via environmentally determined epigenetic variants, with 
or without the association of genetic susceptibility, has been discussed earlier.  To date, 
studies are limited and focus on individuals exposed to extreme environmental insults or 
animal models.  Larger-scale human studies encompassing milder environmental insults or 
behavioural patterns will increase our understanding of the complex interaction of epigenetic 
marks, genetic risk and environment, and how they predispose to disease during an 
individual’s lifetime.  This knowledge is particularly pertinent given the increasing global 
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prevalence of complex diseases and furthermore, may provide insight into how environmental 
factors may be modified as a means of disease prevention.  The identification of disease-
associated epialleles either associated with disease induction, or pathogenesis, has the 
potential to translate into screening, diagnosis and identification of biomarkers (121).  An 
understanding of the epiallelic contribution to disease pathogenesis will also provide a 
platform for the development of targeted drug treatments.  
 
In all studies identifying epigenetic variants in association with disease, it is imperative to 
determine a causal role if trying to understand the aetiology of disease.  This may be 
determined with functional experiments, however the ability to identify changes in gene 
expression due to epigenetic variation is complex and requires a careful experimental 
approach that is likely to incorporate the complexity of allele-specific expression and tissue-
specificity (122) (123). 
 
 
 
  
 55 
1.8 Objectives  
 
This introduction has highlighted how the study of epigenetic variation may yield insights into 
the aetiology and pathogenesis of type 2 diabetes and related cardiometabolic conditions such 
as obesity.  The application of discovery-based studies to understand how multiple interacting 
genetic and environmental factors influence type 2 diabetes risk through the epigenome has 
been introduced and will contribute to the main objectives of this thesis.  In addition, the 
importance of the developing epigenome in fetal programming of cardiometabolic diseases, 
and its apparent susceptibility to environmental perturbations has been highlighted and will 
form the later objectives of this thesis.  The broad objectives of this thesis are as follows: 
 To identify epigenetic factors involved in susceptibility to Type 2 diabetes as a route to 
understand disease aetiology and pathogenesis. 
 To apply animal and human models to elucidate the role of epigenetic mechanisms in fetal 
programming of Type 2 diabetes and related cardiometabolic conditions. 
 To use ‘discovery-based’ techniques to determine interactions between genetic, epigenetic 
and environmental influences, on an epigenomic scale. 
 
More specifically, these objectives will be applied to the following questions and contexts: 
 Chapter 3:  Type 2 diabetes study.  This study will identify epigenetic variation at specific 
regions of genetic susceptibility to Type 2 diabetes to characterise putative regions of 
genetic-epigenetic interactions.  A Medip-chip approach will be used to profile DNA 
methylation on a genome-wide scale and methylation profiles will be built across 
susceptibility haplotypes. 
 Chapter 4: Pune Maternal Nutrition Study:  Epigenomic techniques will be used to identify 
differentially methylated regions in whole blood from offspring from this cohort in which 
maternal one-carbon cycle defects have been shown to induce a programmed phenotype 
of insulin resistance and obesity in offspring. 
 Chapter 5:  Matlab Famine Study:  Genome-wide techniques will be used to identify 
differentially methylated regions in offspring exposed to famine in utero or early childhood 
or unexposed. 
 Chapter 6:  Mouse model of gestational diabetes:  A mouse model, analogous to human 
gestational diabetes, will be used to simulate fetal programming from exposure to 
hyperglycaemia in utero. The primary aim of this model will be to study epigenomic 
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variation in offspring to identify the consequences of exposure to hyperglycaemia, and 
hence elucidate mechanisms of fetal programming.  The secondary aims of this model will 
be to investigate the role of tissue-, age- and sex-specific epigenetic factors and functional 
outcomes.   
 Chapter 7:  Human model of gestational diabetes:  A human cohort of women with and 
without gestational diabetes will be developed with which to characterise the combined 
metabolic and nutritional influences of pregnant women of Asian origin living in London.  
This cohort will then be used to identify epigenetic variation associated with these 
pregnancy environments in cord blood and placenta.  Results from this study and Chapter 6 
will be used to complement each other.   
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Chapter 2:  Methods 
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2.1 Materials 
 
2.1.1 Chemicals and reagents  
Agarose for routine use, Sigma-Aldrich 
Ethidium bromide, Sigma-Aldrich 
Triton X-100, Sigma-Aldrich 
Tris-HCL, BioChemika Fluka 
Ethylenediaminetetraacetic acid disodium dehydrate (EDTA), Sigma-Aldrich 
Phenol Solution, Sigma-Aldrich 
Phenol:Chloroform:Isoamyl alcohol 25:24:1, Sigma-Aldrich 
Chloroform 99% minimum, Sigma-Aldrich 
Orange G, Sigma-Aldrich 
 
2.1.2 Buffers and Solution 
All buffers and solutions were made with milli-Q water unless otherwise stated 
TE Buffer: TricHCl 10mM, EDTA 1mM, pH 8.0 
Proteinase K Buffer: TrisHCl , EDTA 10mM, SDS 0.5%, pH 8.0 
2x IP buffer: 20mM sodium phosphate buffer pH7, 280mM sodium chloride, 0.1% Triton X-100 
1x TBE: tris-borate, EDTA 
DNA loading dye: 1x Orange G  
D-glucose, diluted to 100mg/ml in sterile water 
 
2.1.3 Enzymes, antibodies and kits 
5-methyl cytidine antibody 500μg/50μl, Diagenode 
Dynabeads – sheep anti-mouse IgG, Invitrogen 
GenomePlex® Whole Genome Amplification Kit, Sigma-Aldrich 
Klenow Fragment (3’-5’ exo-), NEB 
T4 Polynuclotide kinase, NEB 
Quick Ligation kit, NEB 
Proteinase K, PCR grade, Roche 
Ribonuclease A solution from bovine pancreas, Sigma-Aldrich 
Phusion HotStart DNA polymerase, NEB 
Platinum Taq Polymerase, Invitrogen 
Amplitaq Gold, Applied Biosystems  
qPCR MasterMix Plus w/o Ung for sYBR Assay Low Rox, Eurogentec 
QIAquick PCR purification kit, QIAGEN 
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QIAquick Gel extraction kit, QIAGEN 
QIAamp DNA mini blood and tissue kit, QIAGEN 
QIAamp DNA maxi blood and tissue kit, QIAGEN 
Zymo DNA clean and concentrator kit, Cambridge Bioscience 
Bisulphite conversion kits - EZ Methylation-Gold and EZ Methylation in single column and 96-
well plate formats, (Zymo research) 
Sybr green Low ROX, Eurogentec 
RP1 purified 0.05µmol lyophilised primers (Sigma Genosys)ABI optical PCR plates 
Primers were ordered from SIGMA (Desalted, scale:0.2) 
Adhesive PCR film (cat# AB 0558) 
MESA Blue qPCR Master Mix Plus for SYBR Assay (cat#  RT-SY2X-03+WOUB 600rs)  
 
 
2.1.4 Specific laboratory equipment 
Accuchek aviva blood glucose monitor 
Diagenode Bioruptor 
Agilent 2100 Bioanalyser and DNA 1000 and HS kits 
7500HT Real time PCR system        
Nanodrop spectrophotometer 
Quant-iT Pico green fluorometer and ds DNA BR assay kit (Invitrogen) 
Dark Reader transilluminator  
 
2.1.5 Genomic and sequencing-based equipment 
Nimblegen custom-designed microarray, Nimblegen 
Illumina GAIIx Genome Analyzer, UCL Genomics, Babraham Institute and Barts and the London 
Genome Centre 
Illumina HumanMethylation 450 BeadChip, UCL Genomics and Barts and the London Genome 
Centre 
Illumina HiScan, UCL Genomics and Barts and the London Genome Centre 
Biotage PSQ HS96 instrument, UCL Genomics  
 
2.1.6 Bioinformatic software, scripts and statistical packages 
UCSC genome browser 
Ensembl genome browser 
Maq (Mapping and Assembly with Quality) – mapping software 
BWA 
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BATMAN (T. Down) 
USeq 
Perl and JAVA scripts (written by C. Mathews, T. Down, G. Carbajosa, D. Van Heel) 
R Statistical package (Ihaka R, Gentleman R, 1996. R: A Language for Data Analysis and 
Graphics. Journal of Computational and Graphical Statistics Vol 5: 299-314) 
Bioconductor packages:  Limma 
GraphPad Prism, USA 
SPSS, USA 
  
 61 
2.2  Common Experimental methods 
 
2.2.1 DNA extraction and purification 
2.2.1.1 Phenol:chloroform extraction 
Frozen tissue for DNA extraction was stored at -80o.  One 5mm piece of tissue was added to 
750uL PK buffer and 5uL proteinase K enzyme and incubated together at 55o overnight.  The 
following morning, 5uL RNAse was added and the sample incubated at 37o for 60mins. 
Phenol (from lower phase) was added in a 1:1 volume of phenol to sample, shaken together 
for 5mins and then spun at high speed for 5mins.  The upper phase was removed and and put 
in new Eppendorf and these same steps were repeated with phenol:chloroform and then 
chloroform. 
One-tenth of the total volume of the remaining sample (approximately 50uL) of sodium 
acetate was added, followed by 2.5x the total volume (usu 1.25ml) 100% ethanol.  The sample 
was then shaken carefully until DNA became visible.  The sample was then placed in a -20o 
freezer for 1 hour and then spun at full speed for 10 minutes.  The ethanol was decanted out 
and the DNA pellet was spun again for 10 minutes.  The remaining ethanol was then removed 
carefully using a pipette.  The tube containing the DNA pellet was covered lightly until any 
remaining ethanol had evaporated, but without the DNA pellet drying out.   
Finally, 200uL TE buffer was added to the DNA pellet and together were heated gently at 50o 
for 60 minutes with regular vortexing.  Following this, the concentration and quality of the 
DNA were checked (see below). 
 
2.2.1.2 DNA extraction and purification kits 
Manufacturer’s instructions were followed when using kits for DNA extraction and purification.  
Unless stated otherwise, an RNAase digestion was performed with all DNA extractions.  DNA 
purification was performed using Qiagen QIAquick PCR purification kits (where elution 
volumes >14uL were required) or Zymo Clean and Concentrator kits (where elution volumes of 
<14uL were required). 
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2.2.2 Checking DNA concentration and quality 
2.2.2.1 Agarose gels 
Unless otherwise specified, 80ml agarose gels were prepared using 2% agarose with TBE and 
5µL ethidium bromide for all gels to check nucleic acid integrity, size and distribution.  Gels 
were visualised under UV light.   
 
2.2.1.2 Checking DNA concentration  
DNA concentrations were checked using a nanodrop spectrophotometer that uses UV 
absorbance to estimate DNA concentration.  DNA samples extracted using phenol: chloroform 
with a salt-based precipitation method, or those with RNA contamination, were also quantified 
using Qubit as this fluorometry-based system is able to distinguish between DNA and other 
contaminants. 
DNA concentration and fragment size distribution of individual samples was checked using a 
Bioanalyser, during MeDIP-seq library preparation. 
 
2.2.3  Sonication 
DNA was sonicated using a Diagenode Bioruptor, in 100µL H20, with varying starting 
concentrations according to the experimental protocol.  Sonication was performed using the 
‘high’ setting, in 30 second on/off cycles, with ice bath changes every 10 minutes.  Sonication 
duration varied according to the experimental protocol, and fragment size checked using an 
agarose gel with 100bp ladder and/or bioanalyser.  Sonication was followed by DNA 
purification using a Qiagen kit. 
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2.3 Enrichment-based DNA methylation experiments 
 
In this section, the Medip (methylated DNA immunoprecipitation) experiment will be 
discussed.  This enrichment-based experiment, first described by Weber et al. (107), allows the 
isolation of a pool of methylated DNA (in <1000bp fragments) using a recombinant antibody 
specific to 5-methylcytosine.  Coupled with a genomic platform, e.g. microarray or Next 
Generation Sequencing, Medip enrichment can be used to identify quantitative methylation 
patterns on a genome-wide of whole genome level.  Two experimental approaches, Medip-
chip and Medip-seq will be discussed after a description of the Medip protocol. 
 
2.3.1 Medip 
1.5µg DNA was sonicated to produce 200-700bp fragments.  50ng DNA was set aside as the 
‘input’ control and the remaining 1.0µg was made up to 97µL in H2O, denatured at 100
oC for 
10 minutes and then cooled on ice.  Subsequently, 2.5µL 5MeC-mAb was added to the DNA 
solution with 100µL 2xIP buffer and incubated at 4oC on rotator at 8rpm for 2 hours.  
Dynabeads (10µL) were washed in 500µL 1xIP buffer, collected in a magnetic rack, and 
resuspended in 500µL fresh 1xIP buffer.  The DNA solution was added to the beads and then 
incubated at 4oC on a rotator at 8rpm for 2 hours.  After this incubation, a further 3 complete 
washes in 500µL 1xIP buffer were performed, and finally the beads were resuspended in 100µL 
PK buffer.  1 µL proteinase K was added to each sample and then incubated at 50 oC, 20rpm.  
After this digestion, DNA in solution was separated from beads in a magnetic rack, and purified 
using a Zymo kit, eluting in 25µL H2O.   
 
2.3.1.1 qPCR to determine Medip efficiency 
A test to determine the efficiency of MeDIP enrichment in all MeDIP-based experiments (i.e. 
MeDIP-chip and MeDIP-seq) was performed by qPCR.  Quantitative amplification of known 
methylated/unmethylated regions of the genome, as determined by the Human Epigenome 
Project, was used on Medip and input samples.  Primer sequences targeted to these regions 
were used, as in table 2a.   
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Species Methylation enrichment status Primer name Primer sequence 
Human enriched 
6583_F CACTCACCGTCCAGCTATCA 
6583_R CTCCCTGACCTCCATCTTCA 
Human enriched 
11851_F CCAAGAGGGCTCCCTAGAAG 
11851_R ATTTGGAAGGGACCTTGCTT 
Human enriched 
4994_F GGGAATATAAGGAGCGCACA 
4994_R TCGGTTAAAACGGTCAGGTC 
Human unenriched 
8804_F CGAGGCGTGAGTTATTCCTG 
8804_R CTCTTGTGGCTGAGCTCCTT 
Mouse enriched 
IAP-R CCCCGTCCCTTTTTTAGGAGA 
IAP-F CTCCATGTGCTCTGCCTTCC 
Mouse unenriched 
CSA-R GCAACATGGCAACTGGAAACA 
CSA-F TGGTTGGCATTTTATCCCTAG 
Mouse enriched 
H19-R TGGCCCTTGGACATTGTCAT 
H19-F TGCCAGAAAGCACAAAAGCC 
Mouse unenriched 
APRT-R AGATCCCCGAGGCTGCCTAC 
APRT-F 
 
TGCTGTTCAGGTGCGGTCAC 
 
Table 2a.  qPCR primers used to test success of Medip enrichment 
 
 
A mastermix was made for qPCR reactions, containing 3.5μl H20 (PCR grade), 10ng DNA in 
1.0μl, 6.5μl SYBR green mix and 2.5μl primer mix per reaction.  Reactions were performed in 
duplicate, per primer pair, and mean Ct values were plotted for Medip versus input DNA.  A 
standard qPCR cycle was used on an Agilent 7500HT realtime PCR machine, as follows: 
(1) 50C for 2 minutes 
(2) 95C for 10 minutes 
 (3) 40 cycles of:  95C for 15 seconds and 60C for 1 minute 
(4) 95 for 15 seconds 
(5) 60 for 15 seconds 
 
Successful MeDIP enrichment was determined by a higher relative Ct value for Medip versus 
input sample at the unmethylated locus. 
 
2.3.2 Medip-chip 
This experimental approach combines the standard Medip protocol outlined above with a 
microarray-based genomic platform to yield quantitative methylation profiling on a genomic 
scale. 
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2.3.2.1 Amplification of Medip and input DNA 
Medip and input fractions of DNA from the Medip experiment described in 2.3.1 were 
amplified using Sigma Whole Genome Amplification GenomePlex kits.  The initial library 
preparation used 10ng sonicated ‘input’ DNA in 10µl H2O, and 10µL ‘Medip’ solution, both in 
duplicate.  To each of the 4 reactions, 2µl 1x Library preparation buffer and 1µl library 
stabilization solution were added, and after vortexing were denatured at 95oC for 2 minutes, 
cooled and spun down.  Subsequently, 1µl Library preparation enzyme was added, and the 
samples incubated in a thermal cycler at 16oC for 20 minutes, 24 oC for 20 minutes, 37 oC for20 
minutes and 75 oC for 5 minutes before being cooled.  A mastermix was prepared, containing 
7.5µl 10x Amplification Master Mix, 47.5µl nuclease-free H2O, 5µl WGA DNA polymerase per 
reaction.  60µl Master Mix was added to each sample, and then the PCR incubation was 
performed as follows:  incubation at 95 oC for 3 minutes, followed by 14 cycles of 94 oC for 15 
seconds and 65 oC for 5 minutes.  The amplified samples were purified using a QIAquick PCR 
Purification Kit, and eluted in 53µL H2O.   
2.3.2.2 Custom-designed targeted sequencing arrays for Medip-chip  
A Nimblegen custom-designed microarray was used in Medip-chip experiments.  The details of 
the array design, hybridisation, normalisation and analysis will be discussed in chapter 3.   
 
2.3.3 Medip-seq  
The experimental approach for Medip-seq library preparation is summarised in figure 2a. 
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Figure 2a.  Summary diagram of Medip-Seq experimental approach. 
 
 
2.3.3.1 Medip-seq library preparation 
Library preparation for Medip-seq experiments includes preparation of samples for Illumina 
GAIIx sequencing, as well as a modified Medip protocol.  Compared to the Medip-chip 
protocol, a larger starting quantity of DNA is used to allow incorporation of sequencing 
adapters and careful size selection of fragments prior to sequencing.  A multiplexing strategy 
allows a maximum of 12 samples to be combined in one library and DNA fragments to be 
pooled prior to size selection, thus ensuring careful size-matching of biological replicates.  This 
strategy also allows for pooled sequencing across more than one flowcell from the same 
sample pool with subsequent analysis of individual or grouped samples.  
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Sonication:  Three micrograms of genomic DNA were suspended in 100μl water and sonicated 
to median size of 150bp.  Sonicated samples were purified using QIAquick PCR Purification Kit, 
eluting in 40μl of elution buffer (EB). 
 
Perform end repair:  blunt ends of the DNA fragments (introduced through sonication) were 
repaired by incubating the DNA sample (approximately 2ug DNA) with Klenow DNA 
polymerase (0.5μl), T4 DNA polymerase (2.5μl) and T4 PNK (2.5μl) in T4 DNA ligase buffer with 
10mM ATP (5μl) and dNTP mix (2μl, 10mM) at 20C for 30 minutes.  The 3’ to 5’ exonuclease 
activity of the three enzymes removes the 3’ overhangs, and the polymerase activity fills in 5’ 
overhangs.  Purification was then performed using a QIAquick PCR Purification Kit, eluting in 
32μl of EB. 
 
Add ‘A’ bases to 3’ ends:  an ‘A’ base is needed at the blunt 3’ends of the phosphorylated DNA 
fragments for subsequent ligation of the sequencing adapters, which have a single ‘T’ 
overhang at their 3’ end.  The DNA sample is incubated for 30 minutes at 37°C with Klenow 
exo 3’ to 5’ exo minus (3μl) and dATP (10μl 1mM) in NEB2 buffer (5μl ) to create these A bases.  
The samples were purified using Zymo DNA Clean and Concentrator-5 kit, eluting in 12 μl of 
EB. 
 
Ligate adapters to DNA fragments:  paired-end sample adapter oligos (2.5μl) were ligated to 
the DNA samples using DNA ligase (2.0μl) in DNA ligase buffer (13.5μl) with a 15 minute 
incubation at room temperature.  Purification was performed using the QIAquick PCR 
Purification Kit, eluting in 50μl of water.  
 
After these steps, the concentrations of individual samples were checked using a Nanodrop 
and run on gel to ensure that no leftover adapters were present (these would form short 
complexes and be identified as a band of <100bp fragments).   
 
At this stage, 50ng of DNA is set aside as an ‘input’ fraction, for later comparison with the 
‘MeDIP’ fraction.   
 
MeDIP:  A modified protocol is used in the preparation of a MeDIP-seq library, and I optimised 
this to be able to use reduced (2ug) starting quantity of DNA.  The DNA sample is suspended in 
125μl water, denatured at 100 °C for 10 minutes and cooled immediately on ice for 5 minutes.  
125μl of 2xIP buffer is added to the sample with 5mC Ab  (4μl), followed by incubation 2 hours 
at 4°C with slow rotation. The sample is then added to 20µl of pre-washed Dynabeads and 
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incubated for 2 hours at 4°C with slow rotation. After this incubation, 300µl 1xIP buffer is 
added to the sample and the beads are washed in a magnetic rack in 3 cycles with 500µl 1x IP 
buffer, discarding the supernatant each time.  After the final wash, the beads are resuspended 
in 100µl Proteinase K digestion buffer, proteinase K is added (2µl of 20mg/ml stock) and 
incubated for 2 hours at 55°C (using rotation or shaking to prevent sedimentation of the 
beads).  The samples are purified with Zymo DNA Clean and Concentrator-5 kit and eluted in 
20 µl of water.  
 
Amplification of adapter-modified DNA fragments and introduction of multiplex tag sequences 
using PCR:  both Medip and input fractions are amplified using a PCR reaction with primers 
designed to paired-end sample adapters.  In designing the PCR in this way, amplification occurs 
selectively in those DNA fragments with ligated adapters.  A third PCR primer is used, 
containing a multiplexed sequence tag that is incorporated into the DNA fragment as 
amplification takes place.  Separate PCR reactions using one of twelve multiplex sequence tags 
are performed for each sample, allowing for later identification sequence data from individual 
samples.   
 
The PCR reaction mix for each individual sample was as follows: 
  DNA (20μl of MeDIP and 50ng for input)  
10μl 5X HF buffer 
1μl dNTPs (10mM) 
0.5μl Phusion HotStart DNA polymerase 
1.0μl Index (25μM of index 1-12) 
1μl PCR primer F (25μM of indexPE primer 1.0) 
1μl PCR primer R (0.5μM of indexPE primer 2.0) 
  + Water to 50 μl total volume. 
 
Cycling conditions were:  
  (1)  30 seconds at 98°C  
(2) 18 cycles of: 10 seconds at 98°C, 30 seconds at 65°C, 30 seconds at 72°C  
(3) 5 minutes at 72°C  
(4) Hold at 4 – 10°C  
 
PCR products were purified using a Qiagen purification kit, eluting in 30μl of water.  The 
success of amplification was determined by nanodrop concentration and gel visualisation to 
ensure that no primer-dimers had formed. 
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2.3.3.2 Multiplexing Medip-seq samples 
The use of a multiplexed strategy restricts the number of samples that can be analysed to 12 in 
one library.  Without multiplexing, individual samples can be run in individual lanes on the 
Illumina GAIIx flowcell, enabling sequencing of a larger sample number across more than one 
flowcell.  Individual Medip-seq libraries are prepared per sample, as for multiplexed library 
preparation.  During the PCR amplification of Medip products, the index solution was omitted, 
and an extra 1uL of water is added to the PCR mix.  After PCR, size selection of DNA fragments 
for sequencing must be performed individually for each sample, with careful size matching of 
case and control samples in pairs to achieve a similar distribution between groups.   
 
2.3.3.3 Size selection of finished libraries 
Gel excision:  Multiplexed MeDIP-seq DNA libraries were pooled and 15 μl samples were run 
on a 2% agarose gel (with ethidium bromide) against a 50 bp ladder.  The gel was viewed using 
a Dark Reader transilluminator and a gel slice in the 250–300 bp range (i.e. insert size of ~ 120 
– 170 bp) was excised.  A Qiagen Gel Extraction Kit was used to extract the size-selected DNA 
fragments and purify them, eluting in 30 μl water.   At this stage, the MeDIP-seq library is 
ready to be quantified and sequenced, provided the MeDIP efficiency has already been 
determined by qPCR. 
 
2.3.3.4 qPCR to determine Medip library efficiency 
This test of Medip enrichment was performed as described above in 2.3.1.1.  
 
2.3.3.5 Illumina GAIIx sequencing 
Illumina GAIIx sequencing was performed in all Medip-seq experiments by three service 
laboratories at the Barts and the London Genome Centre, UCL Genomics and the Babraham 
Research Institute.  Standard methods and protocols were used at all three sites, and the 
choice of different sites was determined by cost and turnaround time.   
This Next-Generation Sequencing platform uses a sequencing-by-synthesis approach, coupled 
with massive parallel read detection to generate a large quantity of high quality sequence 
data.   The sequencing methods are as follows: 
(a) Library preparation for sequencing: specific Illumina adapters are joined at each end of 
the DNA fragments to be sequenced.  These adapters are incorporated during the 
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library preparation steps described above.  Library preparation may also include 
ligation of multiplex adapters where this approach is being used. 
(b) Attaching DNA to the sequencing flowcell:  single-stranded DNA is added to the 
sequencing flowcell via capillary tubes running across each of its 8 channels.  
(c) Bridge amplification:  The DNA fragments join to the flowcell at each end using the 
adapter sequences.  These ‘bridges’ are then amplified by the addition of nucleotides 
to form double-stranded DNA, and then denatured to leave single-stranded templates 
anchored at one end to the flowcell surface. 
(d) Cluster generation:  the single-stranded DNA templates are amplified to form dense 
clusters of DNA ready for sequencing. 
(e) Sequencing cycles:  the DNA template is read one base at a time in repetitive cycles.  
The first cycle is initiated by the addition of DNA polymerase, primers and labelled 
reversible terminators that recognise each of the 4 bases in the sequence.  The first 
base is identified by the joining of the labelled terminators that emit a fluorescent 
signal that is captured by a laser.  The reversible binding of terminators allows these to 
be detached from the first base to join the second, with each base being detected by 
another cycle of laser-identification.  Sequence data is captured as image files 
generated from these multiple cycles. 
All DNA samples were sequenced using 36bp paired-end reads, with multiplexing.  Standard 
sequencing chemistry and protocols were used.  Sequence data output files (.txt format) were 
accessed via the Genome Centre or remote access servers. 
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Paired end sequencing involves the addition of paired sequencing primers at each end of the 
DNA fragment.  Sequencing of the paired primers occurs from either end, sequentially.  By 
detecting the sequence from either end of the DNA fragment, the sequence of a longer insert 
between the two primers can be inferred by mapping the two end reads to the genome.  
Paired-end sequencing also enables the detection of structural variation, e.g. copy number 
variation, within the sequenced fragment.  All sequencing performed in the experiments 
described used paired-end sequencing, however the short sequence read length (36 base 
pairs) facilitated relatively rapid sequencing and generation of a large number of reads. The 
addition of an index sequence for multiplexing is performed at the PCR amplification step of 
library preparation.  This inserts an index sequence between the adapter and sequencing 
primers that can be read during the sequencing protocol.  These steps are summarised in 
Figure 2b. 
 
Figure 2b.  Method of Illumina GAIIx paired-end sequencing using adapter fragments.   Adapter 
fragments (A1 and A2) are ligated onto DNA fragments with sequencing primers (SP1 and SP2).  DNA 
template multiplies into clusters using bridge amplification, and then undergoes sequencing by 
synthesis starting at the sequencing primers.  Diagram from Illumina product brochure. 
 72 
Each sequencing flowcell incorporated a PHiX control samples, derived from a bacteriophage 
genome.  The PHiX library is a standard addition to Illumina GAIIx sequencing and is used to 
validate the quality of each run.  Data from the PHiX control is used to generate a matrix file 
that is used in analysis to calculate the relative proportion of different bases in the sequenced 
libraries as a test of sequencing quality.  PHiX control may be run in a single lane of a flowcell, 
or may be added as a 0.5% ‘spike-in’ to experimental samples; the latter obviates the need to 
use up a full lane of the flowcell and is therefore cheaper. 
 
 
2.4 Methylation array-based experiments 
 
2.4.1 Illumina HumanMethylation 450 BeadChip array 
The Illumina HumanMethylation450 BeadChip (to be summarised hereafter as the ‘450k 
array’) is a bead array-based platform designed for genome-wide DNA methylation studies in 
humans.  This platform is recently developed and became available to researchers in 2011, and 
it has therefore been possible to use it to generate data from samples in the Matlab famine 
and Human GDM studies (chapters 5 and 7).   
The 450k array is based on Illumina’s Infinium assay which allows single base resolution 
detection of DNA methylation at pre-defined loci.  Genomic DNA is first treated with sodium 
bisulphite, a reaction which converts unmethylated cytosines to uracil but leaves methylated 
cytosines intact.  Following this standard conversion reaction (using Zymo EZ-methylation kits), 
DNA is incubated with probes, targeted to specific sites within the genome), and in two forms: 
one complementary to methylated DNA (M bead type), and one complementary to 
unmethylated DNA (U bead type).  Following hybridisation, single base-pair extension of the 
probes occurs and a labelled ddNTP is incorporated and stained by fluorescent reagents that 
match either the methylated or unmethylated probes.  The ratio of fluorescence from each 
probe is detected and used to generate a quantitative score of methylation at each probe. 
Coverage of the 450k array incorporates the following genomic locations: 
 All designable (approximately 99%) RefSeq genes, including promoter, 5' UTR, first 
exon, gene body and 3' UTR regions, without bias against those genes lacking CpG 
islands.  
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 CpG islands (approximately 96% of the total) in addition to multiple targets around 
these regions to incorporate CpG shores and flanking regions  
 CpG sites outside of CpG islands 
 Non-CpG methylated sites identified in human stem cells 
 Differentially methylated sites identified in tumour versus normal (multiple forms of 
cancer) and across several tissue types 
 miRNA promoter regions 
 DNase hypersensitive sites 
 Disease-associated regions identified through GWAS 
 
Approximately 90% of the regions targeted by the 450k array were covered by its predecessor, 
the Illumina Human 27k Methylation array.  The 27k array has been well used and results from 
it have been widely published (92).  
Limitations of the 450k array include the lack of comprehensive coverage of Imprinting control 
regions (unless included in the list above) and its inability to detect hydroxymethylation due to 
its reliance on bisulphite conversion.  In addition to these limitations, many of the array probes 
overlap SNPs and these can affect the efficiency of probe binding.  Furthermore, the presence 
of SNPs in many of the probe targets could cause variable methylation patterns according to 
the conformation of the SNP, according to whether it creates or abrogates a CpG site.  It is not 
yet clear how this phenomenon can be analysed in conjunction with the probes that do not 
include genetic variants. 
 
2.4.1.1 Bisulphite conversion 
Bisulphite conversion is the first step in the 450k array experimental protocol (see figure 2c).  
The bisulphite conversion reaction enables single-base discrimination of methylation status at 
CpG dinucleotides.  In this reaction, DNA is treated with sodium bisulphite resulting in 
preferential deamination of unmethylated cytosines to uracil, via sulphonation, hydrolytic 
deamination, and desulphonation.  Methylated cytosines are not converted by this reaction, 
and therefore a single base difference following bisulphite treatment can be detected using 
standard genetic sequencing to discriminate between a methylated and unmethylated CpG.  
This reaction is exploited in a range of targeted and epigenomic platforms designed to 
characterise DNA methylation status and will be discussed here in relation to the 450k 
methylation array and bisulphite-pyrosequencing.   
 
 
 74 
 
Figure 2c.  Bisulphite conversion of methylated and unmethylated cytosines.  Addition of sodium 
bisulphite (HSO
-
3) to genomic DNA enables the conversion of unmethylated cytosine to uracil through 
sulphonation, deamination and desulphonation.  Methylated cytosines are resistant to this sulphonation 
and therefore do not convert to uracil, enabling downstream sequencing-based experiments to 
differentiate between methylated and unmethylated cytosines.  
 
Bisulphite kits, manufactured by Zymo, have been used in the various experimental protocols 
to be discussed and have included both single-column and 96-well plate formats.  Illumina 
have developed their protocol for bisulphite conversion prior to 450k array hybridisation using 
the standard Zymo EZ methylation kit, rather than the EZ methylation gold kit which is more 
routinely used (due to its considerably shorter incubation times) and has been used in later 
validation experiments.  
The EZ methylation kit protocol requires the preparation of CT conversion reagent with 750µL 
water and 210 µL  M-dilution buffer.  DNA (200ng – 2µg) is then diluted with 5µL M-dilution 
buffer and water to achieve a volume of 50µL.  After a short incubation at 37oC for 15 minutes, 
100µL of CT conversion reagent and is combined with the DNA sample incubated at 50oC for 
12-16 hours, for the bisulphite reaction to take place, followed by cooling to 4oC for 10 
minutes. The sample was then added to 400µL M-Binding buffer in a spin column, inverted 
several times, and centrifuged at full speed for 30 seconds.  100µL wash buffer was added, and 
the column spun again, followed by the addition of 200µL desulphonation buffer which was 
allowed to wait for 15 minutes, and then spun again.  A final 2 washes with 200µL wash buffer 
were performed, and then the sample was eluted in 10 µL of elution buffer.  All samples were 
stored at -20oC for a maximum of 72 hours in this state or for up to 6 months at -80oC. 
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In experiments where large numbers of samples were being handled, the Zymo EZ methylation 
deep well kits for 96-well plates were used.  The protocol for the plate conversion has minor 
differences to the single column kit, including the use of a larger volume of wash buffer 
(400µL) at all wash steps.  The final elution step is performed in a total volume of 15µL made 
up with elution buffer.  All centrifugation steps in this protocol were performed at 3000g for 5 
minutes. 
The efficiency of the bisulphite conversion using these kits is thought to be >99% when the 
protocol is followed correctly.  At least 75% of the original DNA is recovered by the end of the 
conversion and cleanup.  If the starting DNA concentration is low, i.e. less than the 25ng/µL 
required, then the difference from the required 20µL volume was made up with water. 
 
2.4.1.1.1 Testing bisulphite conversion efficiency 
Early experiments using the 450k array showed that the efficiency of the initial bisulphite 
conversion is crucial to the quality of the data output.  As samples are processed for this array 
in large batches and without the use of robotics, small errors in the bisulphite conversion can 
easily occur and have significant consequences.  Therefore, for some 450k array experiments, 
a QC of the bisulphite conversion was performed prior to array hybridisation.  This qPCR-based 
QC was developed by the UCL Genomics group and was performed by Melissa Smart.   
The qPCR reactions were designed against parts of the MLH and GAPDH genes (see Table 2b 
for primer design).  The MLH primer pair is designed against the expected sequence of a region 
of the gene after the genetic changes brought about by successful bisulphite conversion.  The 
GAPDH primer pair is designed to normal genomic sequence.  Thus, if conversion is successful 
a product from the MLH1 primer pair should be seen and if it is not successful the template 
will not match the primer sequence and no product can result.  Conversely the GAPDH primers 
should only produce product when conversion is NOT successful as this is when the primer 
sequences will properly match the template.  The ratio of each of these products in a given 
sample can then be used to determine the conversion efficiency. 
Gene Target Primer Primer sequence 
MLH1 Bisulphite converted sequence 
F (5'>3') GGAGTGAAGGAGGTTACGGGTAAGT 
R (5'>3') AAAAACGATAAAACCCTATACCTAATCTATC 
GAPDH Unconverted sequence 
F (5'>3') CGCCCCCGGTTTCTATAAAT 
R (5'>3') CAAAAGAAGATGCGGCTGAC 
Table 2b. Primer Sequences for bisulphite conversion efficiency experiments 
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The bisulphite conversion has a yield of 11-13μl of converted DNA.  A 2μl of this DNA is taken 
and diluted in 8μl water for the qPCR and the remaining DNA is set aside for the subsequent 
array hybridisation.  A mastermix was made for qPCR reactions, containing 3.75μl H20 (PCR 
grade), 1.25μl of diluted DNA, 6.5μl SYBR green mix and 1.25μl primer mix per reaction.  
Reactions were performed in triplicate, per primer pair, and incorporating blank wells and 
negative controls using unconverted DNA.  A standard qPCR cycle program plus dissociation 
curve was used, as per that described in section 2.3.1.1. 
The results of the qPCR were analysed qualitatively using the mean of triplicate Ct values for 
each amplicon.  Where bisulphite conversion has been successful, the Ct value for GAPDH is 
high (reflecting a low quantity of unconverted DNA and therefore many cycles needed to 
amplify it) and the Ct value for MLH1 is low (as there is plenty of bisulphite converted DNA for 
amplification).  Samples that showed less than 95% bisulphite conversion (calculated using a 
standard delta delta Ct calculation) were not used in array hybridisation.  
 
2.4.1.2 Array hybridisation 
The Illumina 450k methylation array uses two types of 50mer probe assays, developed using 
their Infinium technology.  The Infinium I assay, also used by the 27k array, incorporates two 
beads per probe, one designed to bind to an unmethylated locus, the other to a methylated 
locus.  In contrast, the Infinium II beadtype uses only one bead per locus, employing a single 
base extension step after hybridisation to differentiate converted (unmethylated) from 
unconverted (methylated) DNA.  Where possible, Infinium II probes were used in the array 
design in order to maximise the possible coverage of the array.   
The Infinium II chemistry uses degenerate oligonucleotides (a group of oligonucleotides 
designed to bind to the same genomic location but allowing for specific single base 
differences) designed to all possible combinations of methylation status across up to 3 CpG 
sites that fall within a single a probe sequence, in contrast to the Infinium I assay which 
assumes that all CpG sites within a single probe have the same methylation status. 
Hybridisation of bisulphite-treated DNA was performed by the Genome Centre, Barts and the 
London, or UCL Genomics using standard protocols, and involved the following steps (also 
shown in figure 2d): 
 Denaturation and neutralisation of bisulphite-converted DNA 
 Isothermal amplification in an overnight incubation 
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 Enzyme-fragmentation of DNA 
 DNA precipitation using isopropanol and centrifugation 
 Re-suspension of DNA in hybridisation buffer and application on BeadChips (twelve 
samples each) 
 Overnight incubation in hybridisation oven allowing for annealing to probes 
 Washing of BeadChip to remove unhybridised and non-specifically bound DNA 
 Single base extension of oligos using the hybridised DNA as a template, and 
incorporation of fluorophore labels in capillary flow-through chambers.  Labels stain in 
one of two channels: red or green. 
 Illumina HiScan detection of fluorophore labels by laser excitement of the single base 
extension product on each bead.  The scanner collects high-resolution images of the 
coloured light emitted from the fluorophores as the data output. 
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Figure 2d.  Schematic of the Illumina HumanMethylation 450 BeadChip, showing the Infinium I and II 
bead chemistry, from Bibikova (124).  The Infinium I bead chemistry is shown in (A), and show that two 
beads are required to differentiate between methylated and unmethylated DNA.  DNA (green strands, 
read from 5’) is hybridised to the beadchip and allows differentiation of unconverted cytosines (C) and 
converted cytosines (T) by the failure of single base extension beyond the mismatched primer sequence.  
The Infinium II bead chemistry is shown in (B) and it is seen that a single bead with a degenerate base is 
used to differentiate the methylation status of each individual CpG site to bind to the genomic DNA.  In 
both beadtypes, it is the incorporation of a fluorophobe-labelled base, using single base extension that 
allows a colour-based detection of sequence using laser excitement from the Illumina HiScan. 
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2.4.1.3 Data output 
Illumina-designed software is used to convert bead-level image data (.tiff files) into processed 
data suitable for analysis.  A .idat file is produced by Illumina software and contains data from 
every bead on each BeadChip, summarising the data by sample, and colour channel.  
Conversion of raw data into .idat files incorporates some background adjustment determined 
by the performance of the samples in the negative and non-polymorphic array controls.  These 
processing steps will be discussed in more detail in section 2.5.4.1. The summary data includes 
the number of beads (CpG sites), the mean methylation and standard deviation.  The .idat files 
are converted into project files that can be opened in the Illumina software, GenomeStudio, or 
Bioconductor analysis packages, e.g. minfi, for normalisation and analysis.  
 
 
2.5 Data analysis of epigenomic datasets 
 
The broad principles underlying analysis of epigenomic data sets will be discussed here.  
Methods and specific details of data analysis from these epigenomic experiments will be 
discussed in the relevant results chapters.  
 
2.5.1 Important considerations in the analysis of epigenomic datasets 
2.5.1.1 Epigenomic profiling – what is normal? 
One of the challenges in studying DNA methylation (and other epigenetic marks) on an 
epigenomic scale is a lack of knowledge of the basic architecture of the epigenome.   General 
features of epigenetic marks, such as the non-random distribution of DNA methylation across 
the genome and its association with CpG density, are well characterised (125).  However, 
beyond these general principles, epigenetic marks vary significantly according to many 
different factors, notably the tissue in which they are studied (58).  Additional factors that may 
influence the detection of epigenetic variation include their potentially dynamic nature in 
different environmental conditions, relationship to gene activity and the influence of long-
range genetic and structural variation that is not easily detected through standard epigenomic 
profiling. 
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Several global projects, e.g. the International Human Epigenome Consortium and NIH 
Epigenomics Roadmap Intitiative, have been set up in an attempt to focus resources on 
mapping of normal epigenomic profiles in a range of primary cell types and cell lines.  It is 
hoped that these studies will provide important resources for researchers with which to 
compare their own epigenomic datasets.  Such initiatives are analogous to genomic mapping 
projects e.g. HapMap and the 1000 Genomes Project, but also address the greater complexity 
of the epigenomic profile of an organism above and beyond its relatively straightforward 
genetic architecture. 
 
2.5.1.2 Sample size and power calculations 
The sample size required to detect epigenetic differences depends on many factors, including 
the size of difference expected, the amount of variation from other sources (e.g. genetic 
variation), and the performance of the experiment and analytic tools used to detect 
differences.  At the current time, there is insufficient knowledge to account for all of these 
uncertainties and to generate accurate sample size and power calculations for study design.  
The majority of literature using human models to identify epigenetic variation associated with 
environmental exposures and/or complex phenotypes have used targeted, gene-specific 
epigenetic methods and the sample size calculations for these are unlikely to be able to inform 
discovery-based genome-wide analyses.  Those genome-wide epigenomic studies that have 
been performed and published are mainly in the field of cancer biology where the epigenetic 
differences identified are often large and associated with genetic and structural variation.   
 
2.5.1.3 Description of methylation values 
Quantitative methylation values are generated by different means according to the 
experimental approach to their measurement.  Enrichment-based methylation detection does 
not produce individual CpG-level quantification of methylation values.  To generate a 
methylation level from enrichment-based experiments, it can either be estimated by 
computation using bioinformatic tools such as Batman, or it can be presented as ‘differential 
methylation’ in a statistical comparison of enrichment peak heights (e.g. using USeq). 
The use of methylation arrays, such as the Illumina 450k array, allows direct quantification of 
DNA methylation at individual CpG sites.  The proportion of total fluorescent signal intensity 
from the red and green beads in the 450k array can be converted into a beta-value to reflect 
 81 
methylation.  Targeted assays of methylation also give quantitative measures of DNA 
methylation via their PCR and sequencing-based assays.   
 
2.5.1.4 Quality control  
Early quality control of data generated from epigenomic studies is vital for subsequent 
analysis.  One of the risks associated with handling such datasets is that their size makes it 
difficult to ‘eyeball’ data to ensure that it makes biological sense and does not introduce 
significant technical bias into analysis.  Many genomic and epigenomic platforms incorporate 
control dashboards and quality control checks to enable the researcher to visualise their 
datasets and ensure that the technical processes have gone to plan.  For example, the 
GenomeStudio software provided by Illumina for use with their 450k methylation array 
provides an inbuilt control panel dashboard where it is possible to identify technical problems 
with bisulphite conversion, array hybridisation and dye intensity at an early stage in analysis 
and using a selection of Illumina-designed control probes identical across arrays.  Using such 
means, the researcher can make ‘sanity checks’ of their data prior to detailed analysis.  These 
quality control checks include checking for expected dye intensities in array data, measures of 
bisulphite conversion efficiency, and read counts generated per flowcell lane during Next 
Generation Sequencing.  Such quality control checks and potential technical biases will be 
discussed in more detail in due course. 
 
2.5.1.5 Normalisation strategies 
When creating large datasets from different experimental processes, e.g. different arrays or 
flowcells, it is important to consider how technical biases may affect the distribution of data 
values and downstream analysis.  Normalisation uses statistical techniques to make the 
distribution of data from two different datasets the same.  Normalisation therefore makes the 
assumption that different data distributions are due to technical effects, e.g. between-array 
differences.  Using normalisation without first understanding any quality control issues could 
therefore mask any true differences due to technical problems and result in drawing incorrect 
conclusions from a dataset. 
The normalisation strategies that are commonly used in analysing genomic data include 
quantile and Loess normalisation.  Quantile normalisation uses a reference or standard 
distribution (the latter being based on the appropriate distribution for the data, e.g. Gaussian 
or Poisson) to compare the distribution of test data.  Differences between the standard and 
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test distributions are ranked and used to correct towards the standard distribution.  Loess 
normalisation uses multiple regression to fit multiple regression lines to  a dataset.  Overlap 
between these regression lines are then smoothed out across the entire dataset to produce a 
normalised set of values.   
 
2.5.1.6 Problems of multiple testing 
Another important consideration when analysing epigenomic datasets is the potential 
problems that arise from multiple hypothesis testing.  This important statistical consideration 
relates to the increasing number of inferences and assumptions that are made within a dataset 
as more data points are compared with each other.  For example, the more genomic regions 
that are included within an epigenomic study comparing cases and controls, the more likely 
the study is to show a difference between cases and controls.  This incorrect assertion occurs 
as the more statistical comparisons that take place, the more likely they are to fall outside of 
the standard 95% confidence intervals or accepted hypothesis test cut-offs. (e.g. p<0.05).   
Failure to account for these factors when analysing large datasets will result in false positives 
being accepted. 
These statistical concerns necessitate a more stringent approach to analysing epigenomic 
datasets.  One widely accepted approach in both epigenomic and genomic studies is to use a 
false discovery rate (FDR, and also known as the Benjamini and Hochberg FDR) as a means of 
controlling and defining the expected proportion of false positives (i.e. incorrectly rejected null 
hypotheses or type I errors).  The FDR states the proportion of false positives in a series of 
multiple comparisons is determined by the observed p value distribution of these 
comparisons, itself determined by the consistency of the dataset (126).  An adjusted p value 
(or q value) is generated from the distribution of p values in an experiment, and defines the 
expected proportion of significant tests that will result in false positives.  For example, a p 
value of 0.05 explains that 5% of all tests will result in false positives, but a q value describes 
that 5% of significant tests will occur due to false positives.  An FDR threshold can be set from 
the q value, according to what is deemed appropriate.  Unlike p values, there is no one single 
accepted FDR threshold in studies that incorporate multiple comparisons.   
4 factors determine the FDR characteristics: 
- The proportion of differentially methylated regions (DMRs) in relation to those 
regions that are not differentially methylated (this proportion usually increases, 
the more probes you have) 
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- The size of true differences 
- Measurement of variability 
- Sample size 
An FDR of 0.1 means that of 100 DMRs detected, a maximum of 10 of them would be 
expected to be false positives.  If too stringent an FDR is set, e.g. 0.05, it may reduce the false 
positives, but it will also reduce the ability to identify true differences (i.e. reduce the 
sensitivity).  This is avoided by understanding the sensitivity (or false negative rate) of the 
dataset. 
The FDR is a less conservative means of controlling for multiple comparisons than the more 
stringent approach using a Bonferroni correction (127).  The latter is a good means of reducing 
false positives, but at the risk of losing true discoveries in a dataset.  For this reason, the FDR is 
now a widely accepted tool to control for multiple hypothesis testing in epigenomic studies. 
 
2.5.1.7 Identification of methylation variation 
The amount of methylation difference that is ‘significant’ is commonly discussed amongst 
epigenetic researchers.  Studies of cancer show large epigenetic differences associated with 
genomic rearrangements (128).  However, epigenetic studies looking at environmentally 
induced epigenetic variation, with or without genetic susceptibility, identify methylation 
differences that are far smaller (89).  Quantitative differences in methylation may exert their 
significance not only by order of magnitude, rather by the conformational changes in higher 
order DNA and protein structure exerted by DNA methylation.   In contrast, SNP-associated 
variation will reflect the presence or absence of a CpG site and therefore the ability or inability 
to methylate, resulting in variation of 0, 50 and 100% according to the conformation of the 
SNP. 
Identification of variants in DNA methylation between study groups are defined as either 
differentially methylated regions (“DMRs”) or methylation variable positions (“MVPs”).  The 
description of a DMR is applied to experiments such as Medip-chip or Medip-seq where 
quantitative methylation estimates are made across small regions (e.g. bioinformatically 
generated windows) but do not have single base resolution.  In contrast, experiments that 
identify single base methylation differences, such as targeted bisulphite PCR or 
pyrosequencing, or methylation array experiments, allow the definition of an MVP as the 
genomic position is defined.  
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2.5.1.8 Integration of epigenetic and genetic data 
Epigenomic datasets can be aligned to genomic data via sequence alignment to a reference 
genome.  This epigenomic and genomic integration is performed early in data analysis 
pipelines and makes use of single- or paired-end sequencing methods to facilitate alignment.  
In contrast, array-based methylation experiments (e.g. Medip-chip, methylation arrays) have 
defined genomic targets incorporated into their probe design, enabling easy integration of the 
epigenetic and genetic data.   
Custom scripts used in analysis incorporate annotation of genetic regions, including genomic 
position, gene names and local architecture.  Scripts also allow integration of additional data 
sources, such as that from dbSNP. 
Characterisation of DMRs and MVPs is complemented by their addition to custom views of 
commonly used genome browsers, such as Ensembl and UCSC.  Unless otherwise specified, the 
Ensembl genome browser is used in the experiments presented, and the latest human genome 
assembly (GRCh37/hg19) was used in all analyses. 
 
2.5.1.9 Validation and replication 
It is imperative that the findings of epigenomic studies are well validated and replicated.  
Technical validation (repeating an experiment using a different experimental platform) is an 
important means by which experimental biases are excluded.  Replication of studies in a larger 
sample size is a useful determinant of biological plausibility and can also be used to address 
wider questions such as the effects of sample heterogeneity, epigenetic-phenotypic 
associations and the influence of genetic factors.  Validation and replication may be best 
achieved through high-throughput targeted experimental approaches.  This will be discussed 
in more detail in the relevant chapters. 
 
2.5.2 Analysis of Medip-chip 
The principles of analysing Medip-chip data (after normalisation) include the use of a custom 
bioinformatic algorithm to address the potential confounding effects of CpG density on Medip 
enrichment, and therefore methylation estimates.  Different bioinformatic algorithms exist to 
overcome this potential confounding; Batman is the most widely used and was developed by 
Rakyan and Down (58), and MEDME (129) is an alternative. Batman uses Bayesian statistics to 
make an estimation of absolute methylation across the genome, according to knowledge of 
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CpG density across the genome.  The algorithm calculates a coupling factor between the CpG 
sites within the targeted array probe and the fraction of DNA molecules that hybridise to it.  
The sum of coupling factors within a probe gives the local CpG density, and this in turn is put 
into a statistical model that uses Bayesian probabilities to estimate the likelihood of a given 
methylation score (as determined by a normalised log2-array signal).  To reduce the amount of 
computation required, the model makes an assumption that the methylation of adjacent CpGs 
is highly correlated across several hundred base pairs.  In this paper, Down and Rakyan 
validated the Batman algorithm against bisulphite-PCR based quantitative methylation analysis 
from the Human Epigenome Project. 
 The estimates of absolute methylation across the targeted regions in different samples were 
compared using a ‘sliding window’ approach.  Standard statistical tests, e.g. Kruskal Wallis, 
were then applied to identify differences in absolute methylation estimates between the 
experimental groups.  The statistical analysis of Medip-chip data that has gone through the 
Batman algorithm, will be discussed in more detail in Chapter 3.  
 
2.5.3 Analysis of Medip-seq 
Similar principles were applied to the analysis of Medip-seq data and these will be discussed in 
more detail in Chapter 4.  As with Medip-chip experiments, custom bioinformatic algorithms 
were used to analyse data, this time coming from Next Generation Sequencing.  The volume of 
data generated from these experiments makes it imperative to have detailed and careful 
quality control, normalisation and sanity checking of data before analysis, and this will be 
explained in detail in the relevant chapter.  
Quantitative methylation estimates are generated by mapping the sequence reads (i.e. 
methylated DNA) to the genome and counting the read density at different areas using size 
windows.  The greater the read density, the higher the methylation level is estimated to be.  In 
contrast, if a region is not methylated, it will not be contained in the enriched Medip-fraction 
of DNA and it will therefore not be sequenced and counted as a sequence read.   
 
2.5.3.1 Quality control 
Quality control of sequenced Medip-seq libraries takes several steps.  Either side of each step, 
a read count is calculated per sample or multiplex tag.  This read count is used to check the 
quality of data through the pipeline by following the predicted read loss per step that is similar 
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to other experiments and is similar between samples.  The following steps (using custom and 
standard scripts) were included in the bioinformatic pipeline by way of quality control:   
1. Paired end read formation:  the reads from libraries that have sequenced using paired 
end chemistry are paired up using  
2. Mapping of reads:  reads were mapped to the reference genome using BWA, a 
standard mapping algorithm that converts reads into SAM files.  This file format is 
common to many next generation sequencing analysis pipelines and is suitable for the 
subsequent steps in the QC and bioinformatic processes. 
3. Removal of duplicate reads:  this was performed to remove polyclonal reads which 
occasionally arise due to the PCR amplification step in library preparation, 
4. Q10 filter:  this removes reads that map poorly to the genome, using a standard Maq 
quality score of <10% as a cutoff. 
5. Calibration plots:  Custom bioinformatic scripts designed as part of the Batman 
algorithm are used to generate plots of read density against methylation to identify 
whether there is appropriate genomic coverage of the mapped reads. 
 
2.5.3.2 DMR calling strategies 
Several different approaches exist to identify regions of differential methylation from Medip-
seq data.  These approaches have not been extensively used nor compared and a combination 
of different strategies was applied to analysis of Medip-seq datasets. 
 
2.5.3.2.1 Batman algorithm   
Batman has been used to generate a ‘methylome’ map from Medip-seq data.  However, since 
this data was published, concern has been raised (personal communication by T Down and V 
Rakyan) that the adjustments for CpG density that Batman makes may not be sufficient to 
represent accurately methylation differences in whole genome experiments.  Batman employs 
a coupling factor to account for variation in CpG density corrects for CpG density but, in 
combination the enrichment bias of Medip (in which regions of low CpG density are over-
represented), there may be over-correction of regions of low CpG density and under-
correction of regions of high CpG density.  Instead, it was advised that Medip-seq data should 
be analysed with algorithms that do not correct for CpG density.   
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2.5.3.2.2 Thomas Down DMR caller 
Following the criticism of the Batman DMR caller, it was decided that a more simplistic 
approach should be taken to analysing Medip-seq data.  Thomas Down therefore developed a 
simple and unbiased method of detecting methylation variation using minimal computation 
that could also offer the ability to perform pair-wise and group-wise comparisons.   This 
algorithm uses Java-based custom scripts written by Thomas Down in Perl. 
Following standard quality control checks on Medip-seq data, the ‘Thomas Down DMR caller’ 
implements size selection of fragments and fragment size normalisation in the analysis.  This 
cautious approach reduces the chance of fragment size affecting the amount of Medip 
enrichment.  Subsequently, calibration plots are generated (using Java-based scripts) in the 
Batman algorithm to identify patterns of enrichment between samples.   Following this data 
processing, custom Java-based scripts, are used to move rolling windows across the genomic 
datasets and compare read counts between each other, in a group-wise or pair-wise 
arrangement, using simple t-test based statistics to identify regions of differential methylation 
enrichment.   Group-wise analyses can be performed between experimental groups, e.g. cases 
and controls.  Pair-wise analysis using this DMR caller can be applied to case-control pairs, and 
can allow further normalisation of data, e.g. by matching sample pairs according to Medip-
enrichment efficiency.   
The simplistic nature of this analytical approach confers a high chance of detecting false 
positive results and sensitivity being low.  It can be discussed that the approach, with minimal 
computation based on assumptions of normal and abnormal methylation architecture, has a 
high specificity, or ability to detect true negative results. 
 
2.5.3.2.3 USeq 
Useq is a custom Java and R-based bioinformatic algorithm, originally designed to analyse 
RNA-seq and ChIP-seq data, which calculates the statistical significance of differential 
enrichment from RNA-seq and ChIP-seq experiments (130).  USeq uses the principles of a 
binomial distribution to minimise the potential biases when deriving robust estimates of 
difference when enrichment-based experiments are coupled with Next Generation 
Sequencing.  In their paper, Nix and Boucher discuss that the process of mapping multiple 
short sequence reads of unenriched DNA to the genome does not produce a random 
distribution of alignment (due to many technical biases in the generation of sequencing 
libraries).  They describe that existing bioinformatic algorithms do not account for localised 
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systematic bias when calling differences in ChIP-seq peaks and proposed a new model to 
address this.  This bias, as well as the difficulty of multiple hypothesis testing when handling 
any genomic datasets, led the authors to test a range of methods with which to identify 
differences in ChIP-seq peaks.  Peak identification methods were compared using a control 
dataset and a defined sliding window approach to interrogate genomic regions.  The true 
positive rate (TPR) and FDR were calculated with the presence of spike-in data to enable 
subsequent comparison of peak identification methods.  Four methods of peak identification 
were compared, using simple comparisons of peak heights and more complex statistical 
interpretations.  The performance of each method was evaluated using their TPR and FDR and 
it was concluded that the calculation of a binomial p value for binding peaks outperformed 
other methods.   
A binomial test is used when trying to differentiate between the likelihood of two 
dichotomous variables occurring in an experiment with multiple testing.  It is commonly 
applied to a situation where one variable is more or less likely to occur than the other.  
Examples of where this distribution could be applied are in experiments that are trying to 
differentiate between success and failure, or observed versus expected in a series of repeated 
measurements or settings.  This statistical test allows for multiple observations to be 
compared and this can incorporate an experimental design where biological replicates are 
used, such as in the experiments to be presented in subsequent chapters.  A negative binomial 
test is used in similar experimental contexts, but when trying to decide the number of tests 
that would be required to differentiate the two dichotomous variables.   
The binomial test p values generated by USeq are calculated in 500bp windows that are 
applied to the mid-point of each paired-end read.  The USeq algorithm also generates a ‘best 
window’ of x bp within each 500 bp window to further localise the region that is driving the 
most differential enrichment.  At each window, an FDR is generated using Storey’s q value 
(131).  The q value is a measure of significance in terms of a false discovery rate, in contrast to 
the p value, a measure of significance in relation to false positive rates.  The use of the q value 
enables more stringency in the selection of differential enrichment and reduces the number of 
false positive results.   
The conversion of window p values to q values assumes that input DNA (i.e. unenriched) p-
values would be distributed uniformly across analysis windows; as input DNA is not used in 
most experiments (including the ones presented here), the potential bias from this assumption 
controlled by filtering out windows with a low read density (<10 reads).  In doing filtering out 
these windows, the FDR can be overestimated and therefore the sensitivity of small datasets 
can be reduced.   
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Although designed for ChIP-seq and RNA-seq, this peak detection method can be applied to 
other enrichment-based experiments.  Researchers, e.g. Vining et al, have begun to use this 
statistical approach (132) to determine statistical significance of differences in peak 
distributions derived from Medip-seq.   
 
2.5.3.2.4 Combined Thomas Down + USeq DMR callers 
As discussed, the principles behind the Thomas Down and USeq DMR callers suggest that they 
offer a more robust means of calling differential methylation in Medip-seq datasets compared 
to Batman.  In the absence of a bioinformatic algorithm for Medip-seq datasets that has been 
validated, the results from any of the current analytic tools should be interpreted with caution.  
The simple means by which the Thomas Down caller identifies differential methylation in 
groups or pairs with no preceding probabilistic judgment about the likelihood of differential 
methylation results in a low sensitivity and the over-calling of DMRs.  In contrast, USeq takes 
an approach to identifying differential methylation in which correction for multiple testing is 
incorporated using binomial tests of probability.  This approach is also better suited to 
experiments that incorporate biological replicates.  FDR and p-value based statistics are 
generated in USeq and whilst this makes it a more stringent approach than the Thomas Down 
caller, it does increase the likelihood of rejecting true positives.  It was therefore decided that 
both the Thomas Down and USeq DMR callers should be used in Medip-seq analysis, with the 
first used as a crude test of differential methylation with no a priori hypothesis, and the 
second to control for false discovery.  By then collating a list of DMRs that are identified in 
both DMR callers, the chances of over-computation and false discovery would be minimised 
and provide a list of ‘top hits’ for validation. 
 
2.5.3.3 Gene ontology analysis 
Identification of gene ontology (GO) (133) was performed using the GOStats package.  The list 
of Medip-seq DMRs used to generate GO terms will be described in the relevant results 
chapters.   
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2.5.4 Analysis of 450k methylation array 
The projects using the 450k methylation array were analysed using the same pipeline, 
explained in this methods section.  The custom methods described have been developed by R. 
Lowe, C. Mathews, G. Carbajosa with V. Rakyan.   
 
2.5.4.1 Quality control checks 
As described earlier, the data from the different bead types (Infinium I and II) in the 450k 
platform are summarised in .idat files generated by Illumina’s custom software, 
GenomeStudio.   Genome Studio and the minfi R package for analysis of 450k data perform a 
series of quality control checks on each step of the array processing using specially designed 
probes.  These steps include sample-independent QCs: bead-staining with biotin (green) and 
DNP (red) of DNA; extension efficiency of nucleotide sequences to the probes; hybridisation 
efficiency and subsequent target removal.  Sample dependent QCs include a test of the 
bisulphite conversion efficiency and the specificity of probe binding and primer extension.  
Due to the different functionality of the two Infinium probes (I and II), these QCs are 
performed with each probe type separately.  Negative control probes are also included in the 
array design to define the background signal from non-specific primer extension and cross 
hybridisation, subsequently incorporated into data processing from raw signal to .idat files.  
Finally, non-polymorphic regions of the bisulphite-converted genome are used as a control to 
test assay performance by designing A, C, T and G probes within these non-polymorphic 
regions that can be compared across different samples. 
 
2.5.4.2 Normalisation 
Data is normalised using standard quantile normalisation methods.  Where samples have been 
run in different batches, quantile normalisation is performed per batch. 
 
2.5.4.3 Data filtering 
Probes are filtered as follows: 
(a) X and Y chromosome probes were removed in all studies to prevent differential 
methylation being called from different numbers of X and Y chromosomes in mixed sex 
experimental groups.   
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(b) Cross-hybridising probes were removed.  Cross hybridisation can occur on all bead 
arrays due to regions of sequence homology. Specific probes susceptible to this cross 
hybridisation have been identified and are easily filtered out of downstream analysis. 
(c) Detection P value.  A p value is generated for each probe on the beadarray, describing 
the variance in intensity generated from the beads per probe.  A high level of intensity 
variation implies that there is signal noise and the only probes with a p value of <0.01 
are included in analysis. 
(d) SNP-containing probes.  40,484 of the probes on the 450k array overlap SNPs, and it is 
unclear to many researchers whether this may affect the binding and therefore 
intensity generated by these probes, or whether they may be used to describe 
methylation variation in association with SNPs.  In our analyses, SNP-containing probes 
have been identified from the 1000 genomes project data.  Our analyses have been 
performed with and without SNP-containing probes, and this will be discussed in more 
detail in the relevant sections. 
 
2.5.4.4 Methylation values 
Methylation is quantified by the dye intensity emitted by methylated vs. unmethylated beads 
in the 450k array and is converted into beta-values of 0 (unmethylated) to 1 (fully methylated).  
Beta values are the most commonly used means of quantifying methylation and are used in a 
range of plots to start characterising data from the 450k array.  Plots of beta values can also be 
used to sanity check data from the array to ensure that data is following the appropriate 
distribution of methylation values at different genomic locations. 
Unsupervised cluster plots or multi-dimensional scaling (MDS) plots are frequently used to 
identify whether samples differ from each other in terms of beta values generated from the 
450k array.  The dimensions on these plots (shown on the X and Y axes) represent a calculation 
based on the number of probes examined and the number of samples; comparison of MDS 
plots require both of these variables to be constant if a quantitative estimate of difference 
between plots is going to be made   However, clustering of samples in such hierarchical models 
can identify technical differences, e.g. in the case of a batch effect which clusters out from 
other samples, and also biological differences, and qualitative and visual assessment of these 
differences are usually sufficient.   
Transforming beta values into an ‘M value’ is thought to be a more statistically sound means of 
representing methylation values than the beta value (134) (see figure 2e).  The M value 
equates to the log2 ratio of the intensities of the methylated vs unmethylated probes and is 
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thought to account for the bimodal distribution of methylation across the genome more 
accurately.  The variability, or so-called ‘heteroscedasticity’, of beta values outside of the 0.2-
0.8 range prevents the appropriate use of statistical tests that rely on a Gaussian distribution 
of data, e.g. the t-test.  In contrast, the logit transformation of beta values into M values, 
allows the application of statistical tests that rely on a Gaussian distribution and therefore 
makes the identification of differential methylation more robust. 
 
 
Figure 2e. Frequency histograms of beta-value (left) and M-value (right) derived from interrogating 
27578 CpG sites using the Illumina 27k array.  From Du et al (134). 
 
 
2.5.4.5 MVP calls 
Numerous techniques for analysing differences in methylation from 450k array data, mostly 
relying on standard statistical tests for comparing differences in mean levels of methylation at 
single CpG probes.  The R-based Limma package was used to determine differential 
methylation from the 450k array, after the steps above had been carried out using Minfi. 
Methylation variable positions (MVPs) are identified from comparing the methylation values 
(Beta- or M-values) different experimental groups and are the primary outcome from the 450k 
array studies presented.  Parametric statistical tests that rely on normally distributed data can 
be used to identify MVPs after the careful processing of data outlined above.   
When comparing two study groups, a t-test can be used to identify MVPs, and when 
comparing more than two groups, an F-test has been used.  The F-test is a type of ANOVA 
(analysis of variance) that can identify differences between several groups without any pre-
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conceived expectation of how the groups relate to each other.  This test has been used to 
detect variation in gene expression resulting from different environmental conditions (135).   
T-test and F-based statistics generate p values that are used, in the standard way, to 
determine the degree of significance between means.  However, as these array experiments 
incorporate multiple testing (i.e. interrogation of each array probe is one test), a standard p 
value is not sufficient to control for the likelihood of false positives.  A correction for multiple 
testing should be performed, either as an FDR-adjusted p value (or q value), or by the use of a 
Bonferroni correction, as described in section 2.5.1.6. 
 
2.5.4.6 Sensitivity analysis 
Sensitivity analyses are used to assess how one variable (e.g. sample within a batch of 
samples) controls the results of a multivariate model.  Application of a sensitivity analysis to 
the MVPs produced in a 450k dataset allows the identification of MVPs that are driven by 
differential methylation in just one sample in its experimental group.  Such MVPs are likely to 
be false positives and by excluding them from the analysis, it is possible to have greater 
confidence in the remaining MVPs being true positives.  Although not as robust as using 
methods such as a false discovery rate, this approach can be useful in datasets that are not 
powered well enough for FDR correction. 
The leave-one-out-cross-validation (LOOCV) analysis can be used as a means of performing a 
sensitivity analysis.  In LOOCV, the dataset is re-analysed in multiple different iterations and 
each re-analysis leaves one successive sample out of the analysis.  This identifies the MVPs 
driven by a large difference in methylation in just one sample, thereby allowing their exclusion 
from further analyses.   
 
2.5.4.7 Identification of SNP-associated methylation variation 
At this stage of analysis, it is feasible to visualise the MVPs generated from the MVP call with a 
simple histogram of methylation level (beta value) per sample at specific probes.  Some MVPs 
display beta values of around 0%, 50% or 100% in different samples, consistent with the 
presence of zero, one or two copies of a SNP that creates or abrogates a CpG site capable of 
methylation.  Although not conclusive, this pattern of methylation is a strong indication that 
this is one of the 40,000 probes overlying SNPs (in which case it can be identified from Illumina 
software) or that it may overlie an unknown SNP or be in cis with a nearby SNP. 
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2.5.4.8 Gene ontology analysis 
Identification of gene ontology was performed using GO analysis tools that interface directly 
with the Limma R package.  The GOstats package enables the creation of a list of GO terms 
from the MVPs identified in analysis.  In all cases, the MVP list after sensitivity analysis was 
used to generate GO terms.   
 
 
2.6 Validation experiments 
 
2.6.1 Bisulphite pyrosequencing 
2.6.1.1 Bisulphite conversion 
Bisulphite conversion of whole blood samples was performed by C. Bell at UCL, and 
hypothalamus/brain samples by S. Finer.  A standard bisulphite conversion kit (Zymo EZ 
Methylation Gold) was used in which 130µL of CT conversion reagent was combined with 20 
µL DNA sample and incubated at 98oC for 10 minutes, 64oC for 2.5hours and then held at 4oC.  
The sample was then added to 600µL M-Binding buffer in a spin column, inverted several 
times, and centrifuged at full speed for 30 seconds.  100µL wash buffer was added, and the 
column spun again, followed by the addition of 200µL desulphonation buffer that was allowed 
to wait for 15 minutes, and then spun again.  A final 2 washes with 200µL wash buffer were 
performed, and then the sample was eluted in 10µL of elution buffer.  This conversion reaction 
was performed for all samples individually, and the DNA was subsequently amplified using 
primers targeted to the Batman-derived windows of interest designed using Biotage PSQ assay 
design software 1.06 (© Biotage). Primer sequences are described in table 2c.  Each sample 
was run on a 2% agarose gel to ensure amplification, using a PCR ladder to check the product 
size.   
  Window 9, position 11-15: Window 9, position 12-15 Window 12 
Forward GTAGATTAGGTGGGTTAAATGATA AAATAATTCAATATCTTTAA GGTAGGAGAATTGTTTGAAT 
Reverse TAAATTTACTCTTCCATAAACCA AATATATGAGAAAGAAGGTAAATG GGAGGTTGAGGTAGGAGAATTGT 
Sequence GATATTATAGTTAAATTAAG CTAAATTTACTCTTCCATAAACCA ATCCACACTCTTTATCATAACTTT 
 
Table 2c.  Pyrosequencing primers used to validate FTO 900bp window 
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2.6.1.2 Pyrosequencing  
Pyrosequencing was performed on the amplified DNA, using the additional sequencing primer, 
using a Biotage PSQ HS96 instrument at UCL and at the Genome Centre, as per manufacturers 
instructions. SNPs within the regions sequenced were represented by their IUPAC code to 
enable sequencing and estimation of methylation at genetic variants. 
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Chapter 3.  Type 2 Diabetes Study 
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3.1 Introduction 
 
Recent genetic advances in the study of type 2 diabetes and related disorders have uncovered 
many susceptibility loci using a genome-wide association study (GWAS) approach.  Despite 
these important advances, the common genetic variants identified explain <10% of the 
heritable component of disease, and little is known about their contribution to aetiology.  A 
range of different molecular approaches is now attempting to explain the ‘missing heritability’ 
in complex diseases and address the mechanisms whereby genetic variants exert their 
influence in disease aetiology and pathogenesis.  Some researchers are trying to identify rare 
and structural gene variants as well as how discovery SNPs and causal variants interact (136).  
Complimentary to this approach is to identify whether stable epigenetic modifications interact 
with genetic variants and whether they may, together, confer additional risk or pinpoint those 
genetic variants with functional relevance.    This study has been designed to identify whether 
these genetic-epigenetic interactions exist at regions of known genetic susceptibility to type 2 
diabetes.  It incorporates contemporary knowledge of genetic susceptibility variants identified 
through GWAS, to a targeted study of DNA methylation.  At the time this study was designed, 
around 30 common variant loci had been associated with T2D (137)(138).  Preliminary 
evidence implicates epigenetic factors in the aetiology and pathogenesis of diabetes, and in 
some studies has shown an association with genetic susceptibility variants (103)(102). 
However, a genome-wide approach to identifying epigenetic-genetic interactions had not 
previously been taken in Type 2 diabetes when this study was performed.  Given the 
complexity of the epigenomic landscape and its variable association with genetic features 
(described above), a genome-wide approach offers an unbiased means with which to 
interrogate the genome and identify these possible genetic-epigenetic potential.   
 
With this broad principle in mind, this study has been designed to test the following 
hypotheses.   
a) Variation in DNA methylation occurs at regions of genetic susceptibility to Type 2 
diabetes and can be detected via a Medip-chip approach 
b) Detection of epigenetic variants, and their tissue-specificity, may provide a route to 
identify aetiological variants identified through GWAS.  
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3.2 Methods 
 
3.2.1 Sample identification and preparation 
Whole blood genomic DNA from two pre-existing population studies was used. Forty UK 
Warren 2 T2D female participants selected from trios and had a diagnosis of Type 2 diabetes 
made by either current prescription of a diabetes-specific medication or laboratory evidence 
of hyperglycemia (World Health Organization definition).  Forty female participants without 
diabetes were selected from the Exeter Family Study of Childhood Health and had normal 
fasting glucose and/or HbA1c levels. Informed consent was obtained from all participants. 
Hypothalamus and prefrontal cortex samples were selected from ‘normal brain’ post-mortem 
tissues from the MRC London Brainbank for Neurodegenerative Diseases, and DNA was 
extracted using standard phenol:chloroform techniques.  Hypothalamus and prefrontal cortex 
tissue was selected as relevant tissues to obesity pathogenesis as well as tissues where a 
target gene identified in this study (see section 3.3.4) is highly expressed. 
 Warren 2 T2D 
Exeter Family Study of 
Childhood Health 
MRC London Brainbank for 
Neurodegenerative Diseases 
Number of samples 40 40 14 
Disease status 
Type 2 
diabetes 
No diabetes ‘Healthy brain’ 
DNA source Whole blood Whole blood 
4 hypothalamus, 10 prefrontal 
cortex 
Mean age (range) 41 (27-56) 36 (24-44) 55 (25-96) 
Sex All female All female 8 male, 6 female 
Mean body mass 
index (kg/m
2
) (range) 
34 (23-49) 22 (15-36) Not known 
Table 3a.  Source of samples and participant characteristics 
 
Whole blood DNA, previously extracted and stored was used.  Each sample was sonicated 
individually for 30 minutes in the first instance, using the same starting concentration and 
volume of DNA in solution (1.5µg in 100 µL) to minimise variation in sonication.  Each 
sonicated sample was visualised on an agarose gel to ensure that the fragment size was 
between 200 and 700bp, and further sonication (in 5 minute cycles) was performed where 
necessary.  These steps were important to achieve similar Medip efficiency between samples, 
and therefore to eliminate bias that could be introduced through variation in antibody 
enrichment between samples.  Samples were cleaned up after sonication using a Qiagen 
QIAquick PCR purification kit. 
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3.2.2 Medip and whole genome amplification 
The Medip protocol was optimised using test samples of DNA and different concentrations of 
5-methylcytidine antibody.  The quantity of antibody for optimal Medip enrichment, as 
determined by qPCR, was found to be 2.5ug.  DNA concentrations were checked after Medip 
(usually between 5-10ng/uL) and after whole genome amplification (60-80ng/uL) as a 
preliminary means of determining their success.  Whole genome amplification (WGA) was 
performed on Medip samples in duplicate, in order to obtain sufficient DNA quantity, but this 
was not required for input samples.  Duplicate amplified Medip samples were pooled for all 
subsequent analyses. 
 
3.2.3 qPCR 
After whole genome amplification, Medip and input samples underwent a qPCR analysis to 
determine the success of Medip enrichment (see 2.3.1.1).   Successful MeDIP enrichment was 
determined by a higher relative Ct value for MeDIP vs input sample at the unmethylated locus.   
 
3.2.4 Array design 
The Type 2 diabetes study used a custom-designed Nimblegen array, comprising 387,835 50-
75mer probes divided into 122 regions covering 37,037,978 bases of the genome 
(080314_HG18_PA_Tiling), designed by C. Lindgren (Oxford).  At the time this study was 
designed and performed, this array offered the most accessible platform with which to assay 
DNA methylation on a genome-wide scale; it has since been superseded by several platforms 
with much greater coverage.  The genomic regions targeted on the array were all 
contemporaneously known T2D association loci (20 regions, covering the 60kb around the 
gene or LD block containing the association SNP) and monogenic obesity & diabetes (13 
genes).  In addition, the T2D chromosome 1q linkage region (1q21-24: 148.4-171.3Mb) 
comprising 22.8Mb identified in multi-continental populations and all known imprinted genes 
and imprinting control regions were covered on the array.  Imprinted genes and control 
regions were selected from Imprinted Gene and Parent-Of-Origin Effect Database 
(www.otago.ac.nz/IGC) with 108 regions containing either the gene or control region +/- 5000 
bp (139).  These 108 regions included all those described in humans as well as regions syntenic 
to mouse imprinted loci that have not yet been confirmed in humans.  Finally, a miscellaneous 
group of nine loci including Coronary Artery Disease and Stature, hyperuricaemia association 
regions and the PPARGCA1 gene (described in (110)) were included. All coordinates are for 
genome build NCBI Hs36.1/ HG18. 
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3.2.5 Array hybridisation 
Medip and input samples were labelled in a two-colour protocol, using Cy5 and Cy3 
respectively, and co-hybridised to a single array.   Colour intensity from Cy5 versus Cy3 was 
used to determine methylation levels in subsequent bioinformatic analysis. 
 
3.2.6 Array normalisation 
Intensity and Spatial Plots were drawn.  Lowess normalisation was used in order to smooth out 
variation that arises due non-linear responses during labelling, hybridisation, or scanning to 
the two different dye colours in the data. Quantile Normalisation was performed to correct for 
variation in probe level intensities between arrays.  The normalised and raw data are available 
from GEO (Gene Expression Omnibus, NCBI) under the accession number GSE20553. 
 
3.2.7 Medip-chip bioinformatic analysis 
C. Bell, G. Lewis and A. Teschendorff at University College London performed Bioinformatic 
analysis for this project.   All genome co-ordinates for this study are given for NCBI Build 
Hs36.1/UCSC hg18. Scripts for analysis were written in Perl. 
 
3.2.7.1 Estimation of Absolute Methylation 
It is assumed that the array Medip/input (Cy5/Cy3) intensity is proportional to the density of 
methylated CpGs.  The Bayesian algorithm, Batman, was used and has been described in 
Chapter 2 as a means of identifying differentially methylated regions (DMRs) from MeDIP-chip 
or MeDIP-seq experiments.  The algorithm uses Bayesian theory to estimate methylation in the 
context of varying CpG density across the genome (as described in (114)).  Estimation of the 
most likely methylation state is made in Batman output tiles in 100 bp windows.  The 
algorithm was run individually on each sample.  
 
3.2.7.2 Differential Methylation Calling 
Methylation values were generated for 100 bp regions, called “proxies”, within larger regions 
of interest (ROI) varying from 500 to 4000 bp in length. With the knowledge that methylation 
is generally correlated on length scales up to 500 or 1000 bp, DMR calling was performed 
across entire ROIs.  However, it was observed that proxies within ROIs sometimes exhibited 
significant variation in methylation suggesting that averaging methylation states over these 
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proxies was not appropriate.  Therefore, an algorithm was designed that would call DMRs at 
the length scale of ROIs, but using the methylation values of the individual proxies within a 
ROI, using an adapted empirical Bayesian method (140).  To correct for multiple testing, the 
estimated the False Discovery Rate (FDR) using two approaches: the q-value approach and a 
permutation-based approach whereby sample labels were permuted a large number of times 
(>1000). 
 
3.2.7.3 LD Block Methylation and Sliding Windows Analysis 
Linkage Disequilibrium blocks around genotyped susceptibility genes were defined as per 
Gabriel (141), as implemented in HAPLOVIEW v.4.1 For each block, subjects were grouped by 
genotype, without reference to case or control status, for each T2D susceptibility SNP.  
Average methylation scores per block were calculated by summating the methylation scores 
for all BATMAN windows across each block and dividing by the number of windows.  Analysis 
was then performed by non-parametric (Kruskal-Wallis) and parametric (Linear Regression) 
means for methylation score with respect to genotype status these groupings.  Permutation 
empirical p-values were calculated by retaining observed methylation scores and shuffling 
genotype assignment 10,000 times.  
A sliding window analysis was performed across these LD blocks by utilising 100 bp BATMAN 
methylation output windows.  This is similar in concept to sliding windows analysis performed 
with contiguous SNP haplotypes. Starting with a window size of one and moving one window 
along per calculation across the entire block, Kruskal–Wallis and Linear Regression analyses 
were performed for the genotype groups with respect to methylation scores.  Window size 
was then increased by one on each pass and the analysis repeated, until the window size 
equalled the entire LD block.  Resultant p-values were outputted and plotted at the midway 
point for each window.  Compared to linear regression, the more conservative Kruskal–Wallis 
analysis can still be significant when there is a non-linear relation between genotype and 
methylation status (which is more difficult to assign biological interpretation) so the mirroring 
pattern of the linear regression analysis gives further robust support to the significant 
relationship between methylation and genotype for the FTO LD block.  Sliding windows 
analysis, statistical calculation, and permutation scripts were written with the R package. 
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3.2.8 Chromatin studies  
Chromatin studies were performed alongside this study of DNA methylation to identify 
common histone modifications, including H3K4me1, H3K4me2, H3K4me3, CTCF, H3K9me1 and 
H3K9me2, to inform the interaction between epigenetic modification and gene function.  
Chromatin immunoprecipitation was performed on the same T2D designed arrays (ChIP-chip) 
in normal human skeletal muscle cells, by P. Akan (Sanger Institute) as part of a larger 
experiment using a standard protocol (142) and detection of ChIP peaks using MPeak 
software.  Duplicates were performed for all, with 90-95% agreement between replicates for 
all antibodies. 
 
3.2.9 Gene expression  
RNA-Seq data generated by an Illumina Genome Analyser from RNA derived from post-
mortem cerebellum tissue samples, collected within 24 hours of death, of six anonymous 
unrelated donor males was available from Wang et al (143).  C. Bell and G. Lewis aligned these 
data using TopHat 1.0, which incorporates the Bowtie aligner and additionally generates splice 
junction reads.  SAM output files were visualised with the Integrative Genomics Viewer 
(version 1.4.01, http://www.broadinstitute.org/igv).  
 
 
3.3 Results 
 
3.3.1 Sample preparation 
Sonication of genomic DNA was successful and produced DNA fragments of a uniform size 
distribution (see fig 3a).   
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Figure 3a.  Sonicated DNA run on an agarose gel showing size range of DNA fragments 
 
After optimising the amplification of Medip DNA, the qPCR quality control check showed 
uniformly successfully Medip enrichment in all samples (see figure 3b).  Figure 3b 
demonstrates that the Ct (cycle threshold) values of the Medip samples are similar across the 
amplicons targeted at known methylated regions (6583, 11851, 4994).  In the reaction using an 
amplicon targeted to a known unmethylated region (8804), amplification of the Medip DNA 
has a much greater Ct value, reflecting a greater number of cycles to amplify the DNA that has 
been successfully enriched for methylation by Medip.  This Ct value, and the fold change 
between it and the 3 previous targets, provides evidence that the Medip enrichment has been 
successful.  Furthermore, the input DNA (i.e. total DNA) shows equivalent Ct values across all 4 
amplicons as it has not been enriched for DNA methylation and therefore amplification of 
methylated and unmethylated regions are equally possible.    
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Figure 3b.  Plot of qPCR analyses from 2 samples demonstrating good Medip enrichment.  Successful 
enrichment is determined by the visible fold change required to amplify the MeDIP DNA fraction using 
an unmethylated primer (8804), compared to methylated primers (6583, 11851, 4994). 
 
 
The integrity of amplified Medip and input samples was checked on an agarose gel and with a 
nanodrop concentration, and confirmed that all samples had reached the target amplification 
to a concentration of 60ng/uL.  Subsequently, the 60 amplified samples (30 Warren 2 T2D and 
30 EFSOCH) were labelled with barcodes and sent for hybridisation to Nimblegen arrays.   
 
3.3.2 Nimblegen array 
Array hybridisation was performed on samples and standard QC checks performed by 
Nimblegen did not identify any problems. 
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3.3.3 DNA Methylation Analysis within T2D Association SNP LD Blocks 
Bioinformatic analysis for this study was performed by C. Bell and G. Wilson, UCL.  Array data 
underwent Lowess normalisation to smooth out any variation arising from differences in 
colour labelling.  Using the Batman algorithm DNA methylation from individual samples that 
had passed through this MeDIP-chip approach was quantified.  Whilst the exact methylation 
states of individual CpGs are not measured with the MeDIP technique, an estimate of the 
relationship between genetic haplotypes and DNA methylation was made.  BATMAN window 
methylation estimate scores across each T2D association SNP LD block were summated and 
averaged; in doing so, an average ‘methylation load’ was calculated for all 60 individuals, for 
each LD block.  Individuals then were grouped into three genotypic sets, by their respective 
genotype for each T2D-association SNP (or tagging SNP in perfect LD with association SNP) and 
Kruskal-Wallis and Linear Regression analyses were performed.  Average methylation scores 
for each genotype group and uncorrected p-values for the Linear Regression analysis are 
shown in Table 3b. 
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     Average Methylation    
Chr LD Block  Genotyped SNP Gene/ Locus 11 12 22 p-value 
1 120236149 120398430 rs2934381
a
 NOTCH2 0.496 0.495 0.502 0.187  
2 43529937 43617946 rs7578597 THADA 0.492 0.512 0.504  0.564  
3 12298413 12372392 rs1801282 PPARG 0.512 0.509 0.511 0.640  
3 64673853 64705161 rs4607103 ADAMTS9 0.477 0.472 0.481 0.760  
3 186971576 187031377 rs4402960 IGF2BP2  0.502 0.493 0.502  0.016 
4 6317902 6363877 rs10010131 WFS1 0.581 0.604 0.590 0.982  
7 28147081 28175361 rs864745 JAZF1 0.501 0.492 0.494  0.317  
8 118252732 118254914 rs13266634 SLC30A8 0.333 0.350 0.303 0.865  
9 22122209 22126489 rs10811661 CDKN2A/CDKN2B 0.543 0.512 0.512 0.389  
10 12367941 12368040
b
 rs12779790 CDC123/CAMK1D 0.611 0.590 0.671  0.913  
10 94426831 94467199 rs1111875 HHEX/IDE  0.480 0.483 0.483  0.369  
11 17350649 17365206
c
 rs5219
c
 KCNJ11 0.501 0.502 0.498 0.540  
12 69942990 69949369 rs7961581 TSPAN8 0.457 0.461 0.470  0.289  
16 52357008 52402988 rs8050136 FTO  0.497 0.510 0.531 9.397x10-4  
17 33170413 33182480 rs757210 HNF1B 0.423 0.430 0.427  0.382  
Table 3b.  Average methylation levels within each LD block, per genotype.   P-values are calculated by Linear Regression and are shown uncorrected (11 – homozygote common, 12 
– heterozygote, 22 – homozygote rare allele). a) r
2
=1 with rs10923931, b) Not in LD block – single Batman window of 100 bp utilised, c) LD block of associated SNP rs5215 used as 
rs5219 not typed in HapMap, r
2
 =0.995 with rs5219. Methylation is given as average BATMAN scores across regions (0 = unmethylated, 1 = fully methylated). 
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3.3.4 Sliding Windows & Permutation Methylation Analysis of the FTO LD Block 
In the integrated epigenomic-genomic analysis the large 46 kb LD block of the FTO gene 
(Figure 3c) was the only locus to reach nominal statistical significance by Kruskal-Wallis 
analysis (p = 0.014).  This result would not have been significant with multiple testing 
correction, so a permutation analysis was performed by shuffling genotype assignment with 
the observed methylation scores 10,000 times and achieved a significant empirical p-value of 
0.012. Subsequent analysis by Linear Regression alone was highly significant with p = 9.40 x 10-
4, and empirical p-value calculation by 10,000 permutations of 1.0 x10-3.  Age was also included 
as a factor in this later analysis, as there was variation in ages of participating subject, and this 
has been identified as an independent factor in determining methylation at certain loci (63, 
118, 119) but was excluded as a significant confounder (p = 0.676). The FTO SNP rs8050136 
risk allele A homozygotes were shown to have a higher average level of methylation of 0.531, 
with heterozygotes at an intermediate level at 0.510 and G homozygotes with 0.497 (Table 3c).  
The initial association for FTO with BMI was identified by SNP rs9939609 (144), though a 
number of subsequent studies using differing SNPs have all, with equal significance, replicated 
this finding as they are all capturing the same common haplotype (HapMap CEU frequency = 
0.425) (Figures 3c and 3d).  This LD Block encompasses just under half of the first intron, exon 
2 and the beginning of the second intron of the major FTO isoform.  
 
 
 
 
 
Table 3c. Results shown for the entire FTO LD block, the broad 7.7 kb 60-window peak (figure 3f) and 
the narrow 900 bp 9-window peak (figure 3e). Methylation is given as average BATMAN scores across 
regions (0 = unmethylated, 1 = fully methylated). 
 
 
 
 
 
FTO LD Block 
(46 kb) 
Broad Peak 
(7.7 kb) 
Narrow Peak 
(900 bp) 
Region 52,357,008-52,402,988 52,371,700-52,379,399 52,378,500-52,379,399 
AA 0.531 0.529 0.603 
AC 0.510 0.503 0.564 
CC 0.497 0.478 0.507 
p-value 0.014 8.69 x 10
-6
 5.630 x 10
-5
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Figure 3c.  Haplotypes for the FTO suscepbility LD block from HapMap CEU.  This figure summarises the 
SNPs identified in published studies of this haplotype. The SNP rs8050136 genotypes were used as the 
haplotype tagging SNP for this study’s subjects. SNP 52 (rs7202116) creates or abrogates a CpG site 
according to allele. 
 
 
To investigate whether this methylation difference was being driven by a distinct region within 
the 46 kb LD block and, if so, to isolate this location, a sliding windows analysis utilising 
BATMAN methylation scores (methylation estimates are tiled in 100 bp windows) was 
performed.  The sliding window analysis started with a window size of 1 (100 bp) and 
increased iteratively by one on each pass, up to the maximum window number of 334, moving 
across the LD block one window at a time.  A central peak of difference in methylation was 
most prominent in the 9 window (900 bp wide, at windows 161-169, chr16:52,378,500-
52,379,399) analysis with Kruskal-Wallis p = 5.630 x 10-5, empirical p = < 1 x 10-5 with 10,000 
permutations and Linear Regression analysis p = 1.94 x 10-5 (Figure 3e). Methylation averages 
were again highest for the A homozygotes (AA 0.603, AC 0.564, CC 0.507).  In addition, plotting 
the slope of linear regression analysis for the 9 window across the LD block indicates that the 
p-value peaks all co-locate with the same negative regression slope direction.  From these 
findings, it can be inferred that all of these regions could be contributing, with varying 
strength, to the increased methylation signal. 
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Figure 3d. Narrow 9 window (900bp) peak of methylation derived by sliding windows analysis across 
FTO LD block 
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Figure 3e. Broad 60 window (7.7.kb) peak of methylation 
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The most significant result was identified with a window size of 60 (7.7 kb - as repeat regions 
excluded from BATMAN analysis - windows 110-169, chr16:52,371,700-52,379,399) with 
Kruskal-Wallis p = 8.69 x 10-6, empirical p = < 1 x 10-5 with 10,000 permutations, Linear 
Regression analysis p = 1.33 x 10-7 (Figure 3f) and age p = 0.444.  This 7.7 kb window becomes 
most significant just at the point when it encapsulates the 900 bp window at its downstream 
edge.  The same trend in the average methylation scores was again identified (AA 0.529, AC 
0.503, CC 0.478).  The sliding windows analysis was in addition performed across the other T2D 
association LD blocks, but none showed any significant increasing p-values with window sizes 
greater than 10 (1 kb) (data not shown). 
The findings at the FTO LD block, using an integrated epigenomic-genomic analysis, give a 
strong estimate of the relationship between haplotype and DNA methylation level extending 
across the 7.7 kb region.  Since this approach is calculated in 100 bp windows it is unable to 
define the actual methylation state of individual CpG sites and their relationship to SNPs.  We 
therefore determined the genetic and epigenetic architecture of the 900 bp peak window in 
order to explore its contribution to the signal. 
 
3.3.5 Investigation of the Genetic Architecture Underlying the 900 bp Window Peak 
The central 9 window peak of 900 bp contains only seven CpG sites in the reference sequence, 
although of the eight common SNPs within this region, three create or abrogate additional 
CpG sites (being YpG or CpR SNPs, IUPAC: Y = C or T, R = G or A).  These SNPs (rs7206629, 
rs7202116 and rs7202296) were all included in the AFD-EUR European panel (dbSNP).  In this 
dataset, the SNPS all possess identical minor allele frequencies implying high likelihood of 
residing on the same haplotype (Table 3d).  Only rs7202116 is included in the HapMap CEU 
data set, and the methylated state allele, G of a CpG, as opposed to the A alternate allele, is 
present on the susceptibility haplotype, and is in absolute, and near perfect LD with the 
susceptibility SNPs identified (Figures 3c and 3d).  Therefore those with the obesity-
susceptibility haplotype would possess ten CpG sites capable of methylation, compared with 
seven, within this peak region.  
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     R
2
    
 SNP rs1421085 rs17817449 rs8050136 rs3751812 rs9939609 rs7202116* rs9930506 
 rs1421085  0.927 0.931 0.931 0.931 0.965 0.835 
 rs17817449 0.963  1 1 1 0.964 0.833 
D’ rs8050136 0.965 1  1 1 0.966 0.841 
 rs3751812 0.965 1 1  1 0.966 0.841 
 rs9939609 0.965 1 1 1  0.966 0.841 
 rs7202116* 1 1 1 1 1  0.871 
 rs9930506 0.963 0.962 0.964 0.964 0.964 1  
 
Table 3d. LD relationship for FTO Association SNPs and rs7202116.  Results are given for D’ and R
2 
in CEU 
HapMap population. *Indicates the methylation critical SNP within 900 bp window peak. 
 
 
3.3.6 Validation of Methylation Differences by Pyrosequencing 
To validate the methylation differences identified between the susceptibility haplotype and 
non-susceptibility haplotypes a quantitative DNA methylation pyrosequencing experiment was 
performed.  Bisulphite-pyrosequencing was performed on 80 samples, using the initial 60 plus 
an additional 20 samples from the same cohorts.  Within the 900 bp window four CpGs were 
investigated, including one of the SNP dependent CpGs (rs7202296).  An additional six CpGs 
were examined that lie directly beneath the broad 7.7 kb peak, including one SNP dependent 
CpG (rs11075988). 
Cytosine methylation levels at the CpG at rs7202296 CpR were, as expected, completely 
dependent on the presence of CpG in the genetic sequence, with average methylation levels of 
87% for A homozygotes, 55.7% for AC heterozygotes and 11.5% for C homozygotes, with 
respect to rs8050136 genotype (Table 3e and Figure 3g).  On examination of the sequence 
information from the pyrosequencing data, one individual homozygous for the A rs8050136 
allele was in fact homozygous CpA and another was heterozygote and this was due to non-
perfect LD between rs8050136 and rs7202296.  Excluding these two individuals, the 
methylation level was in fact 98.6% for those who were CpG at rs7202296.  The additional 
cytosines examined within this window though showed no significant differences that could be 
accounted for by allele-specific methylation (ASM) or evidence of a cis-methylation effect on 
the surrounding non-polymorphic CpGs (120).  Of note is the ~50% methylation values of the 
cytosine at 52,379,254, implying that whilst no evidence of ASM, there may be parent of origin 
specific methylation imprinting of this CpG, although FTO is not known to be imprinted.  The 
three in-phase CpG-creating SNPs therefore would easily account on their own for the ~10% 
difference seen in methylation levels in this 900 bp window peak region identified in the initial 
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MeDIP array experiment.  The additional CpGs investigated beneath the peak of Window 60 
showed no evidence of ASM, although there were also methylation changes associated with a 
CpR site at rs11075988.  For this SNP the allele that abrogated the ability to methylate was in 
LD with the rs8050136 susceptibility genotype A, i.e. it was on the alternate phase (Data not 
shown).  
 
 CpG Location    
rs8050136 
Genotype 
52379190* 52379221 52379251 52379254 
AA 87 95.1 96.7 49.6 
AC 55.7 95.5 97 51.6 
CC 11.5 95.1 96.6 49.9 
 
Table 3e.  Bisulphite-pyrosequencing validation assay of 900bp window quantifying cytosine 
methylation (%) at CpG sites within the 900 bp 9-Window.  *CpG-creating SNP rs7202296 dependent. 
 
Figure 3f.  Single-base pictorial representation of the whole 900bp 9-window with pyrosequenced 
region (in bold) showing CG sites (red), SNPs (blue) and SNP-CpG sites (red and blue).  Methylation at 
rs7202296 is shown (according to genotype of the tag SNP (rs8050136). 
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Fourteen healthy brain samples (4 hypothalamus and 10 prefrontal cortex) were examined 
with the same bisulphite-pyrosequencing arrays to identify whether there might be allele-
specific methylation in tissues that show high FTO expression and have a known role in central 
energy balance.  The genotype of rs7202296 was determined from pyrosequencing, and it was 
assumed that it held the same LD relationship to the tag SNP found in whole blood samples.  
The same findings at the CpG-creating SNPs described above were identified (Table 3f), and no 
allele-specific effects on the surrounding CpG sites were found. 
 
 CpG Location    
rs8050136 
Genotype (n) 
52379190* 52379221 52379251 52379254 
AA (1) 96.0 100.0 100.0 84.0 
AC (8) 53.3 97.3 100.0 80.3 
CC (5) 3.2 96.0 100.0 82.2 
Table 3f.  Bisulphite-pyrosequencing validation assay in 14 healthy brain samples, quantifying cytosine 
methylation (%) at CpG sites within the 900 bp 9-Window.  *CpG-creating SNP rs7202296 dependent. 
 
 
3.3.7 Evolutionary Analysis 
This analysis was performed by C. Bell, UCL, to elucidate possible evolutionary context in which 
these genetic-epigenetic interactions would function.  Examination of the three critical CpG-
creating SNPs within the narrow peak (rs7206629, rs7202116 & rs7202296) reveals that the 
latter two have both transitioned from CpA to CpG and gained the ability to methylate from 
their ancestral state (in Pan Troglodytes, Pongo pygmaeus and Macaca mulatta) (Table 3g).  
This particular transition is a rarer mutational event than reverse transition in which 
deamination of methylated cytosines occurs (145).   Analysis of dbSNP data (release 129) 
indicates that whilst ~60% of the set of 193,133 validated SNPs of known ancestral state on 
chromosome 16 co-occur at a CpG site, only ~12% of them have gained the ability to 
methylate since the common ancestor, and less than 0.5% lie within at least 75 bp of each 
other, as per rs7202116 and rs7202996.  One of the three CpG-creating SNPs, rs7202116, is 
located within a short 49 bp mammalian evolutionarily constrained element 
(Chr16:52,379,085-52,379,132) as identified by Genomic Evolutionary Rate Profiling (GERP) 
(146).  
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SNP  Major Minor EUR  CHN  AFR  Ancestral 
rs7206629 YpG T C 0.609 0.391 0.833 0.167 0.587 0.413 C 
rs7202116 CpR A G 0.609 0.391 0.833 0.167 0.674 0.326 A 
rs7202296 CpR A G 0.609 0.391 0.833 0.167 0.674 0.326 A 
Table 3g.  Allele frequency for CpG-creating SNPs within the 900bp window.  CpG creating alleles are 
shown in bold. EUR = European, CHN = Asian, AFR = African American from dbSNP. CpG-creating sites 
(YpG or CpR SNPs, IUPAC: Y = C or T, R = G or A). 
 
Further analysis of the haplotypes present in humans was performed using the 420 HapMap 
Phase II phased SNP haplotypes for CEU, YRI and ASN and indicated that this region comprises 
60 unique haplotypes.  An inferred ancestral haplotype included in a Median-Joining Network 
analysis (147) indicates the methylation ability of the susceptibility haplotype is close to the 
ancestral with respect to the number of mutations between them.  This suggests that the 
ability to methylate was gained early and maintained on the susceptibility haplotype, whilst 
subsequently lost in the younger haplotypes present in humans.  
  
3.3.8 Enhancer Activity Evidence within the 7.7 kb Region 
A ChIP-chip study, using the same T2D array, as part of a larger experiment performed by P 
Akan (Wellcome Trust Sanger Institute), investigated normal skeletal muscle cells and 
identified evidence of enhancer activity within the 7.7 kb window, with the classic signature of 
H3K4me1 and no other strong signal.  These findings are consistent with those of Ragvin (148) 
who have recently identified that the susceptibility locus within the first intron of FTO contains 
long range enhancers influencing the expression of the IRX3 gene located ~470 kb downstream 
of this region and that FTO expression is not affected in this process.  One of the two critical 
Highly Conserved non-coding Elements (HCNEs) implicated to affect IRX3 expression by 
enhancer activity and overlap with risk variants, designated as element 6, in Ragvin et al. is 
located at Chr16:52,377,745 - 52,378,287 and resides centrally within the broad 7.7 kb peak 
(Figure 3f).  This 542 bp element is also only 213 bps 5’ of the 900 bp window. 
Examining the Sanger GENEVAR HapMap CEU expression data identified no significant 
differences with respect to FTO haplotype status in FTO or IRX3 expression from 
lymphoblastoid cell lines in children or adults (149) and insufficient expression in untreated 
and activated CD4+ T cells (150).  We also used an available RNA-Seq dataset derived from the 
cerebellum of six male individuals, but were unable to identify allele-specific expression of 
IRX3 or FTO due to low coverage across the former, and the presence of only one common but 
uninformative SNP in the latter.  
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3.3.9 T2D-DMR Analysis 
A case-control analysis across all the assayed regions of the array (T2D and obesity related 
phenotype candidates, 1q linkage region and imprinted regions) was performed to determine 
any disease-related DMRs.  There were no disease-associated DMRs with statistical 
significance post FDR correction, indicating a lack of power in the study.  
 
 
 
3.4 Discussion 
 
In this study, the power of large-scale GWAS has been harnessed to look for genetic-epigenetic 
associations that may occur in conjunction with known genetic susceptibility variants.  A 
methylation association with the strongly replicated disease haplotype of the FTO gene, 
tagged by SNP rs8050136 has been identified using a Medip-chip approach.  This association 
was confirmed and validated at single-base resolution using bisulphite pyrosequencing and it 
was found to be a genetically-led phenomenon occurring due to the phase of three CpG-
creating SNPs in LD within a narrow 900 bp window peak, creating or abrogating sites for DNA 
methylation.  Work in murine strains supports the inference that inherited genetic variability is 
a major determinate on epigenetic variability (68) and the significant contribution of allele-
specific methylation at CpG islands has been further characterised by Zhang et al. (151).  
However, how much of this effect is driven by CpG-creating SNPs directly, or additionally their 
influence on surrounding CpG methylation, or other genetic polymorphism effects on the 
methylation machinery or a combination of all of above is not known.  The absence of allele-
specific methylation differences in CpG sites downstream of the CpG-SNPs in this study lends 
further support to these findings being a haplotype-driven effect, rather than one driven by a 
primarily epigenetic phenomenon.  Had this study been performed in a larger sample set, 
allowing sufficient power for case-control analysis, it may have been possible to define our 
methylation differences erroneously as a disease-associated ‘‘differentially-methylated region’ 
and overlook a purely genetic event.   
A recent paper by Toperoff (152) has provided some external validation of the results of this 
study in larger sample numbers (710 with T2D and 459 controls) with an assay DNA 
methylation in approximately 3 million of the 28 million CpG sites across the genome.  Using a 
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microarray-based assay, they identify a CpG site located 11bp upstream of the known 
T2D/obesity variant rs1121980 that is hypermethylated in a pooled set of samples of 
individuals carrying the risk allele A identified hypermethylation compared to those containing 
the G allele.  However, the authors present conflicting data from an analysis of cases vs. 
controls, identifying relative hypomethylation (-2.55%, p=2x105, q=0.0003) at the same CpG 
site in those with T2D.  In an independent sample cohort from a longitudinal study of diabetes, 
the authors identify hypomethylation at this same CpG site in individuals sampled prior to 
their known onset of diabetes compared to those unaffected.  They hypothesise that this gives 
support of this methylation signature being causative, however they do not rule out the 
methylation differences being due to pre-clinical phenotypes.  More importantly, they do not 
study the risk alleles in the individuals included in this study.  This is a notable omission if 
trying to examine the precise relationship between genotype and DNA methylation at this 
locus, and especially given that this was a study of relatively young individuals with diabetes 
that might therefore be expected to have a high genetic risk.  It seems likely that the 
conflicting association between the phase of the rs1121980 risk allele and the adverse 
phenotype with methylation at this particular CpG site is due to the presence of another cis-
controlling SNP that has not been characterised.  The data presented in this chapter, 
specifically the presence of a nearby SNP (rs11075988) in the alternate phase to the SNP-CpG 
of interest would support this.     
Additional support for our findings is derived from a recent paper by Almen (153) that 
identifies methylation differences associated with FTO genotype in cis- and trans.   In this 
study, a genome-wide methylation array (Illumina 27k HumanMethylation array) was used to 
identify an interaction between the FTO risk allele and the methylation state at other loci.  
Interestingly, they identify long-range control over methylation at 3 distant loci as well as two 
loci on chromosome 16 where FTO is located.  The gene loci that are associated with the FTO 
risk allele have functions in transcriptional regulation that could potentially have wide-ranging 
phenotypic effects.    
 
It is important to consider these associations of FTO epigenotype and phenotypic outcome in 
the light of uncertainty over the genetic function of FTO.  The FTO disease haplotype has been 
well studied since it was first identified as containing T2D risk variants in a GWAS.  FTO has a 
common haplotype located across intron 1, exon 2 and intron 2 captured equivalently by 
various SNPs.  Despite the initial association of the FTO risk haplotype with T2D, it has since 
been shown to be mediating its disease susceptibility effect through obesity (144) (154).  The 
effect size of this risk variant is small, with adult homozygotes displaying an increase in weight 
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of 2-3kg, but it is a common variant and its effects are seen in early life (155).  Early studies on 
FTO identified phenotypic similarities observed with mutations in the nearby Ftm gene raised 
uncertainty as to the direct role of FTO in mediating obesity and energy balance.   Human 
studies of FTO have also added complexity to these theories, and do not elucidate a clear 
functional role for FTO in the pathogenesis of obesity.  Loss-of-function mutations in the FTO 
gene have been recognised in a rare autosomal-recessive lethal syndrome accompanied by 
severe growth retardation (OMIM #612938) (156).  The ability to translate the findings of 
these loss-of-function models to the effects of the common FTO sequence variants has proved 
difficult, not least as the latter are intronic and therefore their effects are expected to be 
subtle effects on gene regulation.   Attempts to identify expression differences in FTO in 
human skeletal muscle and subcutaneous adipose tissue with respect to risk SNPs have been 
unsuccessful to date (157) and no evidence of allele-specific expression in immortalised 
lymphoblastic cell lines was able to be established (158). However, FTO heterozygous loss-of-
function mutations have been found in both obese and lean subjects, further clouding its 
causative role (159).    
Recent murine models of fto deficiency lend support to FTO having a causal role, with reduced 
body weight and fat mass observed in the fto knockout mouse from an early developmental 
stage (160).  Heterozygote fto-/- mice display presumed haploinsufficiency, with a similar 
phenotype seen in heterozygous and wildtype mice.  A similar, but lesser, obesity-protective 
effect has been observed in the hypomorphic fto missense I367F mutant (161) which is 
considered to better replicate of human models as the mutation affects intron 1, the location 
of human disease-associated SNPs.  In contrast to the knockout model, a dominant-negative 
effect of the fto1367F is suggested by the phenotypic similarity between heterozygous and 
homozygous mice.  Both animal models display an increased metabolic rate and sympathetic 
over-activity in the presence of fto-deficiency, suggesting it has a role in altering energy 
expenditure.  FTO is ubiquitously expressed, but at high levels from the hypothalamus, 
suggesting that is mechanism may be in altering central energy balance.   
The mechanisms by which FTO acts on a cellular level are being elucidated.  In vitro studies 
identify FTO as a member of the Fe(II)- and 2-oxoglutarate-dependent oxygenase 
superfamilies, which have multiple roles in oxygen sensing and fatty acid metabolism, but 
recent studies cast suspicion over this being its mechanism of action (162).  Murine studies 
suggest a role in the catalysis of nucleic acid demethylation (reviewed by (163)) and recent 
studies show that a methylated base (m6A) contained in cellular mRNA may be the target of 
FTO-mediated oxidative demethylation with potentially wide-ranging consequences (164).   
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These convincing studies of FTO function do now provide the evidence to support its direct 
functional role and are also beginning to elucidate the exact mechanisms by which it acts.  The 
identification of stable epigenetic modifications associated with genotype may help to 
elucidate the precise mechanisms of action, but also highlight another possible layer of 
complexity in that distant regulators may affect the function of FTO itself.  Recent work has 
hypothesized that the lack of evidence for FTO expression modulation by the susceptibility 
SNPs may be due to this region having effects on distal surrounding genes including IRX3.  
Ragvin et al. used comparative genomics to identify highly conserved non-coding elements 
(HCNEs) and overlying genomic regulatory blocks, and has proposed that enhancers in the first 
intron susceptibility region exert long range regulatory effects on expression of the 
developmental transcription factor gene IRX3, Iroquois Homeobox 3, located in a gene desert 
~170 kb 3’ of FTO.  Enhancers are predominately located in intergenic or intronic regions and 
may act as regulators of gene transcription over long distances (165), have an activating 
function on chromatin structure (166), are sensitive to CpG methylation (167) and have an 
important role in developmental processes.  Of two HCNE-containing elements with enhancer 
effects implicated with a metabolic role, one is located within the 7.7 kb methylation window 
(chr16:52,371,700-52,378,500).  Methylation differences, driven by SNP-CpG variation, of this 
enhancer may impede its action in terms of enhancer-specific transcription factor recruitment, 
subsequent chromatin DNA looping, enhancer-promoter interaction and enhanceosome 
formation with subsequent down-regulation of IRX3 expression.  Furthermore, this HCNE is 
just over 200 bp away from the 5’ of the 900 bp window (chr16:52,378,500-52,379,399), 
placing it within a 2 kb ‘shore’ region of this enhancer.  It may be possible that these ‘enhancer 
shores’ act in a similar fashion to ‘CpG Island shores’ (regions 2 kb either side of CGIs) which 
have been identified with a more dynamic role in regards to DNA methylation change effects 
around promoter-associated CGIs (168).  The ChIP-chip data from skeletal muscle indicates a 
H3K4me1 signature within this 7.7 kb region, as well ChIP-Seq data from cell lines confirms a 
5K block of H3K4me1 enrichment completely encapsulated here (http://bioinformatics-
renlab.ucsd.edu/enhancer) (166) and a recent examination of histone modifications in 
pancreatic islets also identified this enhancer marker 1.2 kb wide over rs8050136 within the 
region (112).  The inability to determine allele-specific expression in two different datasets 
used reflects the complexity of studying the functional sequelae of genetic and epigenetic 
differences and is likely, in part, to be due to insufficient sample size and use of tissues from 
which FTO is not highly expressed.  Earlier data presented also highlights the need to consider 
the role of the fed/fasting state, circadian clock and other environmental conditions when 
designing functional studies.  The absence of correlation between allele and gene expression in 
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this and previous studies (157) may also suggest a role via IRX3 enhancer activity rather than 
cis-effects. 
Evidence against the potential trans-acting role of IRX3 over FTO in causing the obesity 
phenotype comes from two main sources.  First, the fto knockout mouse described earlier 
targeted exon 2 and 3, only ~1 kb into intron 129), and therefore did not remove any of the 
putative enhancers. Second, the function of IRX3 is poorly understood, but a role in pancreatic 
 insulin- and  glucagon-secreting cells and increased ghrelin-producing  cells has been 
suggested through the study of orthologous irx3a in a zebrafish knockdown model.  This 
putative functional mechanism of IRX3 in pancreatic development conflicts with the 
knowledge that most obese individuals display an increase in pancreatic beta cell mass as a 
compensatory response to the peripheral insulin resistance that co-exists (169) and the finding 
that most previously-identified obesity genes are involved in neuronally-mediated central 
energy balance (170).  However the evidence of functional enhancer capability of this 
conserved non-coding region is the crucial finding, as its downstream target may have changed 
or evolved to take on a more complex role over time. It is possible that the role of IRX3 in 
mammalian posterior forebrain development, including the hypothalamus, may in fact be 
critical (171) (172) and underlie mechanisms of energy balance, or a complex interaction 
between multiple genes in the region. 
Loss or gain of CpG dinucleotides over evolutionary time leading to a genetically driven 
variation in DNA methylation and subsequent higher variance has been proposed to be a 
major driver in evolutionary adaption as well as disease susceptibility (173).   The abrogation of 
CpG-SNPs can have considerable effects on regional methylation (66) and this may underlie 
their adaptive evolutionary role (174).  The functional consequence of this deamination of 
methylated CpGs in forming of transcription factor binding sites has been noted in the study of 
p53 and its critical role in regulation of insulin resistance (175).    
In conclusion, genetically driven methylation differences have been identified in association 
with the FTO obesity susceptibility locus, driven by the creation or abrogation of SNP-CpG sites 
within the risk haplotype.  Genetic association studies have identified numerous SNPs of 
equivalent importance across this region and the difference in CpG methylation capability 
could highlight the aetiological variants within this susceptibility haplotype.  Detailed analysis 
of the methylation signal and pyrosequencing validation indicate the genetic phase of CpG-
creating SNPs are a strong influence in this finding and an understanding of this is a relevant 
consideration in large-scale studies that associate epigenetic variants with disease.  The most 
significant results in this study identifies a 7.7 kb region containing enhancer sequence and the 
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observed increased methylation ability of this enhancer region would be highly likely to reduce 
the efficiency of this regulatory element.  Thus the investigation of epigenetic variation may be 
very useful in narrowing down significant regions in large LD association blocks and proposing 
functional hypotheses for subsequent follow-up from GWA studies.  The functional relevance 
of these findings remains undetermined, and preliminary studies highlight the complexity of 
integrating genomic datasets on a sequence, epigenetic and gene expression level.    
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Chapter 4: Pune Maternal Nutrition Study 
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4.1 Introduction 
 
4.1.1 Pune Maternal Nutrition Study 
The Pune Maternal Nutrition Study (PMNS) is a prospective study of a pre-pregnant population 
in rural India, led by Ranjan Yajnik (Pune, India) (43) that offers an exciting opportunity to 
investigate the role of epigenetic factors in fetal programming of type 2 diabetes and obesity.  
PMNS recruited non-pregnant women of reproductive age from 6 villages near Pune, India in 
the early 1990s and is summarised in Figure 4a.  These women were seen regularly with 
monitoring of their body anthropometry and menstrual cycle.  This close observation enabled 
careful dating of incipient pregnancy, and when pregnancy was confirmed, women were 
followed up at 18 and 28 weeks’ gestation.  At these study visits, women underwent further 
anthropometry, questionnaire-based assessment of diet and physical activity and blood 
sampling.  Assays of circulating one-carbon cycle micronutrients (see figure 7a) were 
performed, including red cell folate (its substrate) vitamin B12 (its co-factor), as well as 
homocysteine (a one-carbon cycle intermediary) and methylmalonic acid (a marker of 
functional B12 status in tissue).  Anthropometry of offspring born to these mothers was 
performed within 72 hours of their birth.  These children were followed up at 6 years of age 
with anthropometry, body composition (using whole-body dual-energy X-ray absorptiometry, 
or DEXA), glucose tolerance testing, the HOMA-IR (homeostatic model assessment of insulin 
resistance) measure of insulin resistance  (www.dtu.ox.ac.uk/homacalculator/index.php) and 
blood sampling for nutritional and metabolic assays.  An extremely high follow-up rate was 
achieved with 700 of the 762 live births studied at 6 years.  Follow-up of offspring at 12 years 
has also recently been completed.   
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Figure 4a.  Pune Maternal Nutrition Study.  Summary of participants, recruitment and study design 
(from (43)). 
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Over 60% of women had a low concentration of vitamin B12 (<150 pmol/L) when measured at 
18 and 28 weeks’ gestation, and an inverse correlation between B12 and homocysteine and 
methylmalonic acid (MMA) provided evidence for this reflecting true deficiency.  In contrast, 
only one woman out of the 618 studied had a low red cell folate concentration.  Offspring born 
to these women were studied at 6 years of age and an association between low maternal 
vitamin B12 at 18 weeks with higher HOMA-IR in the children was found (p=0.03).  In addition, 
maternal erythrocyte folate concentrations at 28 weeks predicted higher offspring adiposity 
and higher HOMA-IR (both p<0.01) at 6 years of age (Figure 4b).  Regression modeling showed 
that the offspring of mothers with a combination of high folate and low vitamin B12 
concentrations were the most insulin resistant, even when adjusted for the child’s own fat 
mass and plasma B12 concentration.  
 
 
 
 
Figure 4b.  Relationship between maternal B12/folate status and offspring insulin resistance in the Pune 
Maternal Nutrition Study. (from (43)). 
 
 
The notable finding of this study was an association between maternal B12 deficiency with a 
phenotype of insulin resistance and obesity in offspring.  The unusual finding that normal/high 
folate concentrations were found in association with these other nutritional deficiencies was 
thought to be due to women of conceptual age being given folate supplementation from pre-
conception into their pregnancy.  This supplementation is routine throughout the world, but in 
India was being given at much higher doses than are considered necessary.  In the UK, 400mcg 
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folic acid is recommended to all women who are planning a pregnancy, but in contrast, up to 
10mg was being given routinely in India.  The ‘methylfolate trap’ has been proposed as a 
mechanism by which folate repletion can exacerbate co-existent B12 deficiency via the 
impaired conversion of homocysteine to methionine (176).  
 
 As discussed in the introduction, the one-carbon cycle uses folate as its substrate and vitamin 
B12 as cofactor to convert homocysteine to methionine; in doing so, one-carbon cycle 
regulates production of methyl groups for DNA methylation.  Preliminary evidence exists 
showing the role of one carbon cycle disorders in DNA methylation and a programmed 
phenotype, and this has been discussed in Chapter 1.  This pilot study was therefore designed 
to investigate the environmental-epigenetic interaction between disorders of maternal one-
carbon status and DNA methylation patterns in programmed offspring.  The study was 
developed in collaboration with Ranjan Yajnik and Giriraj Chandak (Hyderabad, India), to try 
and characterise differences in DNA methylation across the genome in offspring according to 
varied maternal one-carbon status.   
 
 
4.1.2 Specific objectives 
This project sought to identify whether maternal vitamin B12 and folate levels in pregnancy 
programme insulin resistance and obesity in offspring via epigenetic modifications and had the 
following objectives:  
 
a) Characterisation of epigenetic variation in offspring associated with maternal vitamin 
B12 and folate levels 
b) To use whole genome DNA methylation profiling techniques to produce an unbiased 
view of epigenetic variation, with no a priori hypothesis as to where this variation 
would be occurring (other than that determined by the presence of CpG sites capable 
of methylation).   
c) To use Medip-seq as the primary tool for methylation profiling, coupled with the 450k 
array platform as an experimental validation platform. 
d) To gain insight into the gene-environment interactions involved in fetal programming 
of insulin resistance/cardiometabolic syndrome with which to develop further 
hypothesis-driven studies. 
e) To demonstrate the feasibility of using whole blood to detect differences in DNA 
methylation associated with in utero micro-nutrient deficiencies 
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4.2 Methods – common to all experiments 
 
4.2.1 Sample selection  
Samples collected from the 6-year old offspring born to the Pune Maternal Nutrition Study 
were chosen for this project.  The following selection criteria were used: 
1. Age of offspring: It was considered better to use samples from offspring at age six rather 
than age twelve as at the offspring in the former group had not entered varied stages of 
pubertal development.  In addition, at 6 years of age, the offspring had been exposed to 
less environmental variation (and therefore potential confounding postnatal effects) than 
at 12 years of age.   
2. Maternal exposure:  the two experimental groups were selected from the extremes of 
maternal exposure, i.e. the ‘high risk’ exposure of low vitamin B12 and high folate and the 
‘low risk’ exposure of high vitamin B12 and low folate.  ‘High’ and ‘low’ were defined by 
tertiles from the whole study population. 
3. Childhood phenotype:  after selecting for maternal exposure, samples were selected 
according to the phenotype associated with exposure, i.e. for the ‘high risk’ maternal 
exposure, offspring with the highest index of insulin resistance were chosen, and vice 
versa.  This aim of enriching for phenotype was to maximize the potential to identify 
epigenetic variation in association with the programming.    
4. Sex:  after selection for extremes of maternal exposure and the programmed phenotype, it 
was possible to select 6 male offspring from each group to form the first experiment.  In 
subsequent experiments (2 and 3) where larger sample numbers were used, it not possible 
to select single sex groups for study, nor was it possible to balance the numbers of males 
and females across the groups. 
 
After defining these selection criteria, the database of study participants was searched by 
Charu Joglekar (Pune, India) to identify appropriate participants.  
 
 Cases: offspring born to mothers with low B12/high folate levels in pregnancy (in whom the 
highest risk of insulin resistance was observed). 
 Controls: offspring born to mothers with high B12/low folate levels in pregnancy (in whom 
the lowest risk of insulin resistance was observed). 
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For the first Medip-seq experiment, 6 individuals from each group were chosen to provide 
what was thought to be adequate sequencing coverage across two flowcells within the budget 
available.  Experiment 2 (also Medip-seq) used 8 individuals from each group and did not 
overlap Experiment 1 completely; the reason for this will be explained below.  For the cheaper 
array-based experiment (Experiment 3), all 20 samples were used.  Table 4a summarises the 
samples that were used in these different studies. 
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Cases = Low B12 and high folate  
 
Sample ID Sex Insulin Resistance 
Age at 
sampling 
Experiment 1: 
Medip-seq Tag 
Experiment 
2: 
Medip-seq ID 
Experiment 
3: 
450k array 
30 Male 1.88 6 Yr 
Tag 1 – 
ATCACG f_1_s_1 
Pune 5 
33 Male 1.88 6 Yr 
Tag 2 – 
CGATGT  Not used 
Not used 
161 Male 0.72 6 Yr  Not used  Not used Pune 1 
348 Female 0.51 6 Yr  Not used  Not used Pune 10 
456 Female 0.92 6 Yr  Not used f_2_s_5 Pune 8 
470 Male 0.75 6 Yr  Not used f_2_s_6 Pune 2 
533 Male 1.90 6 Yr 3 – TTAGGC f_2_s_7 Pune 6 
621 Male 1.34 6 Yr 4 – TGACCA f_1_s_6 Pune 3 
622 Female 1.98 6 Yr  Not used f_2_s_8 Pune 9 
637 Male 1.48 6 Yr 5 – ACAGTG f_1_s_7 Pune 4 
657 Male 0.69 6 Yr  Not used  Not used Pune 7 
687 Male 1.42 6 Yr 
Tag 6 – 
GCCAAT  Not used  Not used 
 
Controls = High B12 and low folate 
 
Sample ID Sex Insulin Resistance 
Age at 
sampling 
Experiment 1: 
Medip-seq Tag 
Experiment 
2: 
Medip-seq ID 
Experiment 
3: 
450k array 
25 Male 0.30 6 Yr 
Tag 7 – 
CAGATC  Not used  Not used 
43 Male 0.40 6 Yr  Not used f_2_s_1 Pune 14 
48 Female 0.34 6 Yr  Not used f_2_s_2 Pune 15 
71 Female 0.73 6 Yr  Not used Not used Pune 20 
78 Male 0.87 6 Yr  Not used f_2_s_3 Pune 13 
183 Male 0.19 6 Yr 
Tag 8 – 
ACTTGA  Not used  Not used 
205 Male 0.17 6 Yr 
Tag 9 – 
GATCAG  Not used  Not used 
211 Male 0.18 6 Yr 
Tag 10 – 
TAGCTT  Not used  Not used 
270 Male 0.19 6 Yr 
Tag 11 – 
GGCTAC  Not used  Not used 
317 Male 0.32 6 Yr  Not used f_2_s_4 Pune 12 
330 Female 0.41 6 Yr  Not used f_1_s_2 Pune 18 
410 Female 0.37 6 Yr  Not used f_1_s_8 Pune 17 
417 Female 0.37 6 Yr  Not used f_1_s_4 Pune 16 
432 Female 0.52 6 Yr  Not used Not used Pune 19 
562 Male 0.19 6 Yr 
Tag 12 – 
CTTGTA 
f_1_s_5 
Pune 11 
 
Table 4a.  Summary of case and control samples used in Pune Medip-seq and 450k experiments.  Insulin 
resistance was calculated using the HOMA-IR algorithm  (www.dtu.ox.ac.uk/homacalculator/index.php). 
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4.2.2 Sample collection and preparation 
Whole blood genomic DNA samples from the twelve participants above were used.  Genomic 
DNA (unamplified) had previously been extracted using standard phenol: chloroform 
techniques and stored in Pune, India.  The quality and concentration of the samples was 
checked with visualisation on an agarose gel and Nanodrop in India, with a repeat Nanodrop 
concentration measure performed after transit to the UK. 
 
 
 
4.3 Methods (Experiment 1) 
 
 
4.3.1 Medip-seq library preparation (multiplexed) 
Medip-seq libraries were prepared using the 12 samples, as per the protocol in section 2.3.2.  
A qPCR of Medip enrichment was performed as a quality control of enrichment efficiency.  In 
this experiment, each sample was assigned an individual index (or tag), ligated to the library 
fragments during the final PCR, allowing the preparation of a multiplexed library.  After 
indexing, the 12 libraries were pooled and nanodrop concentrations were used to achieve a 
similar quantity of each sample in the final pooled library.  The pooled library was run on an 
agarose gel in a single well, allowing a single band to be cut out at 250-300 bp therefore having 
equal fragment size distributions of each sample within the pool.  
 
4.3.2 Illumina GAIIx sequencing 
The pooled Medip-seq library underwent 36bp PE sequencing on the Illumina GAIIx at the 
Genome Centre, Barts and the London.   A total of 10 lanes of sequencing were performed, 
split across two flowcells.  A single lane of PhiX control (a control library composed from a 
small viral genome, used routinely in Illumina GAIIx sequencing), was run on each flowcell. 
 
4.3.3 Sequence read processing 
Sequence data output from sequencing runs was provided at .txt files.  Bioinformatic scripts 
used in data processing were written by Thomas Down using Perl.  The following steps were 
performed to process the sequence data for downstream analysis and identification of DMRs 
and is summarised in Figure 3: 
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1. Converting sequence files:  the Illumina GAIIx (also known as Solexa) pipeline provides 
sequence files in a .txt format unsuitable for downstream processing.  The .txt file 
format was converted to .fastq and subsequently to .sfq, a Sanger sequence format, 
which enables the counting of reads and mapping. 
2. Filters:  sequence files undergo a ‘PolyA’ filter to remove the polyA tails that are a 
technical artifact associated with the Illumina GAIIx platform. 
3. Pairing: as paired-end sequencing was performed, sequence reads were paired for 
mapping and further analysis.  
4. Mapping:  sequence reads were mapped to the reference genome using Maq software 
5. Q10:  a quality filter was applied to the mapped reads, designed to remove the worst 
10% of reads. 
6. De-multiplexing:  mapped sequence reads were filtered by multiplex tag and saved as 
individual sample files. 
7. Sanity-checking of sequence: read counts before and after each step above were 
checked and plotted to ensure that the processing was proceeding in the expected 
manner, and to determine the quality of sequence data.  After all the above steps had 
been performed, calibration plots of Medip enrichment were generated using the 
‘Batman’ algorithm, and fragment size distribution was plotted to ensure uniformity 
across the multiplexed samples. 
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Figure 4c.  Summary of bioinformatic processing steps to convert raw data into sequence data for 
analysis. 
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4.3.4 Bioinformatic analysis 
Following these quality control steps, Thomas Down’s DMR caller (as described in section 
2.5.3.2.2) was used to identify differential methylation in cases versus controls. 
  
4.3.5 Short Tandem Repeat (STR) panel analysis 
In this experiment, additional techniques were used to interpret the results of the DMR call.  
These experiments applied STR panels to the original DNA samples to try and identify whether 
there was any sample contamination.  STR panel experiments were performed by Denise 
Syndercombe-Court and David Ballard (Forensic DNA laboratory, Blizard Institute) using the 
Promega PowerPlex 16 HS System.  This system is commonly used in forensic and paternity 
testing and includes sex-specific STRs in the 16 markers it targets.  One such sex-specific 
marker is targeted to the amelogenin gene, present on both X and Y chromosomes in different 
quantity, thereby allowing distinction between males and females by the presence of one or 
two peaks (respectively).  The autosomal markers on this panel include CSF1PO, D13S317, 
D16S539, D18S51, D19S433. 
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4.4 Results (Experiment 1) 
 
 
4.4.1 Medip-seq library preparation 
Medip-seq libraries were prepared for each sample individually using the protocol described 
above and with the appropriate checks of sample concentration and quality control during the 
experiment.  DNA samples did not undergo any significant change in concentration (as tested 
by nanodrop) between India and the UK, as seen in table 4b. 
 
Sample code Group ng/ul (India) ng/ul (UK) 
30 
Case  
(low B12 and high folate) 
65.99 81.6 
33 81.37 113.5 
533 149.73 197.3 
621 94.64 102.4 
637 61.5 53.7 
687 84.92 109.5 
25 
Control 
(high B12 and low folate) 
72.71 122.9 
183 50.36 76.2 
205 93.29 97.7 
211 86.55 78.8 
270 129.58 132.0 
562 55.49 60.8 
 
Table 4b.  Summary of samples and DNA concentrations used in Medip-seq (experiment 1) 
 
 
After careful optimisation and practice of the library preparation protocol, samples were 
processed in two batches of six, containing equal numbers of cases and control selected at 
random to avoid any experimental bias.  
 
4.4.2 Test of Medip enrichment using qPCR  
As described in 2.3.1.1, a qPCR is performed to test Medip enrichment efficiency using primers 
to stable regions of the genome that are known to be either fully methylated or unmethylated.  
These regions were defined by the Human Epigenome Project and have had primers designed 
to them by V Rakyan.  Three fully methylated regions  (and therefore enriched after Medip) 
and one unmethylated region (i.e. should not enrich after Medip) were used in the qPCR 
described in detail in the methods section.  Each reaction (per sample and amplicon) is 
performed in duplicate and the mean Ct value is plotted.   
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  6583 11851 4994 8804 
  
Ct 
duplicates 
mean 
Ct 
Ct 
duplicates 
mean 
Ct 
Ct 
duplicates 
mean 
Ct 
Ct 
duplicates 
mean 
Ct 
Medip 24.2 24.4 24.3 25.2 25.3 25.25 23.7 24.4 24.05 31.1 31.1 31.1 
input 25.5 25.8 25.65 26.3 26.5 26.4 25.5 25.6 25.55 25.6 25.8 25.7 
 
Table 4c. Mean Ct values (from duplicates) for sample 5 qPCR. Methylated primers: 6583, 11851, 4994, 
unmethylated primer: 8804 
 
 
 
 
Figure 4d.  Plot of qPCR results for sample number 5, showing successful MeDIP enrichment.  Successful 
enrichment is determined by the visible fold change required to amplify the MeDIP DNA fraction using 
an unmethylated primer (8804), compared to methylated primers (6583, 11851, 4994). 
 
 
As is seen in table 4c and figure 4d, the Ct values of the Medip samples are similar across the 
amplicons targeted at known methylated regions (6583, 11851, 4994).  In the reaction using an 
amplicon targeted to a known unmethylated region (8804), amplification of the Medip DNA 
has a much greater Ct value, reflecting a greater number of cycles to amplify the DNA that has 
been successfully enriched for methylation by Medip.  This Ct value, and the fold change 
between it and the 3 previous targets, provides evidence that the Medip enrichment has been 
successful.  Furthermore, the input DNA (i.e. total DNA) shows equivalent Ct values across all 4 
amplicons as it has not been enriched for DNA methylation and therefore amplification of 
methylated and unmethylated regions are equally possible.   The final observation in this plot 
is that the input Ct values are slightly higher than those where Medip DNA is amplified with 
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primers to known methylated regions.  This is due to the presence of both methylated and 
unmethylated DNA in the input fraction and therefore the need for a greater number of qPCR 
reaction cycles to amplify just one region alone. 
This qPCR was performed for all samples prior to further steps in this experimental protocol.  
Although fold change can be calculated to ensure the success of Medip enrichment, it was 
deemed unnecessary to quantify this and inspection of the plots was sufficient to proceed to 
the next stage of the experiment.   
 
 
4.4.3 Pooling of samples 
Sample fragment size distribution and concentration was determined for individual samples 
using a bioanalyser to guide pooling of samples to ensure that equal quantities of each sample 
were used.  Pooled samples were then run in two lanes of an agarose gel, and a band 250-
300bp was cut out to size select fragments.  DNA was extracted from the gel, forming the 
completed size-selected, pooled sample ready for sequencing (figure 5).   
 
 
Figure 4e.  Agarose gel showing DNA bands cut out after size selection. 
 
4.4.4 Illumina GAIIx sequencing 
The standard sequencing protocols were followed and met all routine QC checks in the 
process.  Raw sequence read counts seemed consistent with successful sequencing and were 
interpreted in more detail during the bioinformatic workflow.   
4.4.5 Bioinformatic analysis  
Bioinformatic analysis was performed by Chris Mathews, with guidance from Guillermo 
Carbajosa and Thomas Down. 
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4.4.5.1 Sequence reads pre-processing 
Sequence reads were filtered by multiplex tag so that their relative proportions at each stage 
of the pre-processing could be determined from within the pooled sample run (table 4d).   
Tag 
Tag 
sequence 
Sample 
Raw 
reads 
Raw (% of 
total reads) 
Q10 
% reads maintained 
after Q10 filter 
Tag 1 ATCACG 30 5578823 9.6 1654321 29.7 
Tag 2 CGATGT 33 6022974 10.4 2361672 39.2 
Tag 3 TTAGGC 533 4536517 7.8 3296593 72.7 
Tag 4 TGACCA 621 5092573 8.8 2034835 40.0 
Tag 5 ACAGTG 637 3514627 6.1 2780752 79.1 
Tag 6 GCCAAT 687 4170958 7.2 2539663 60.9 
Tag 7 CAGATC 25 6445443 11.1 2507863 38.9 
Tag 8 ACTTGA 183 4210016 7.3 2100440 49.9 
Tag 9 GATCAG 205 5343653 9.2 2803444 52.5 
Tag 10 TAGCTT 211 4008342 6.9 3031010 75.6 
Tag 11 GGCTAC 270 3543938 6.1 2275514 64.2 
Tag 12 CTTGTA 562 5549317 9.6 2084369 37.6 
  Total 58017181 100 29470476 50.8 
Table 4d.  Number of Medip-seq sequence reads at each stage of processing, pre-bioinformatic analysis 
in experiment 1. 
 
As can be seen from table 4d, there is considerable variation between samples in proportion of 
reads that passed the Q10 filter stage.  The possible explanation for this is variation in Medip 
enrichment due to different fragment sizes, however there was no clear correlation between 
longer fragment sizes and higher quality mapping when comparing the bioanalyser data with 
the plot above.  Furthermore, the size distribution of fragments was consistent across all 
samples (figure 4f is an example of one of these plots and shows the same distribution as all 
other samples) as the Medip-seq libraries were pooled and cut out of the same gel.  Variation 
could occur in the relative proportion of each sample, and this could affect the proportion of 
differently sized fragments between samples.  A final explanation could be variation in 
sequencing quality, but this is unlikely in a pooled sample set such as this.   
Batman calibration plots were drawn for each sample (e.g. Figure 4g) to identify the number of 
mapped sequence reads against CpG density within the reference genome.  These plots 
(exemplified using sample 33) show that the most MeDIP enrichment (and therefore mapped 
reads) occurs at genomic regions with 20-30% CpG density.  This finding is consistent with 
published data describing that the majority of DNA methylation occurs at regions of low CpG 
density (177).  Published data on Medip-seq shows a similar pattern in calibration plots, 
further supporting this finding (58). 
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Figure 4f.  Size distribution plot of raw sequence reads for sample number 30.  The X axis shows the 
fragment size (bp) and Y axis frequency. 
 
Figure 4g.  Batman calibration plot.  This plot shows the density of sequence reads (X axis) in 
relationship to CpG density (Y axis) for sample number 30.  
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4.4.5.2 DMR calling 
DMRs were called using the Thomas Down DMR caller, and 2320 were identified.  On first 
inspection of the DMRs that were generated, it was observed that a high proportion (20%) of 
these DMRs were located on the X chromosome.  This number appeared to be 
disproportionate to other chromosomes, given our hypothesis that we would see genome-
wide effects from this potential environmentally mediated programming event. The 
methylation data tracks from Medip-seq were loaded into the Ensembl genome browser for 
visualisation and ‘sanity checking’.  On close inspection of the data tracks, uploaded per 
multiplex tag, it was evident that two samples were driving most of the X chromosome DMRs 
(Figure 4h).   
  
Figure 4h(i) and 4h(ii).  Plots of sequence read counts (Y axis) per sample (X axis).  Plot (i) shows the read 
counts from the X chromosome reads and (ii) shows read counts from autosomes. 
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These findings suggested a technical concern with the 2 samples driving these X chromosome 
differences, rather than a true biological process.  A known cause of widespread X 
chromosome methylation differences is that between female and male X chromosomes due to 
the epigenetically mediated X inactivation in females.  The most likely cause of the large and 
widespread X chromosome DMRs was thought to be from inclusion of female DNA in what was 
thought to be male DNA samples, either due to sample confusion or contamination.  The 
quantitative estimates of methylation these X chromosome DMRs were also consistent with 
the evidence that X inactivation is associated with hypermethylation at gene promoters and 
hypomethylation at gene bodies (178). 
 
4.4.6 STR panel analysis of samples 
Due to the concern of sample contamination, we performed careful analysis of all samples 
with STR panels and confirmed that samples 2 and 8 contained a mixture of male and female 
DNA, the likely cause being sample contamination.   
A summary of data from 4 STR markers applied to 4 of the experimental samples is shown in 
Table 5.  Samples 33 and 687 are male but contaminated with female DNA, shown by the high 
peak height in the X allele marker (sample 33) and the low peak heights for the Y allele 
(samples 33 and 687) compared to the other male samples.  The presence of 3 alleles in 
samples 33 and 687 with the D13S317 and D16S539 confirms the presence of DNA from a 
contaminant sample.  Marker D18S51 does not show contamination and samples 621 and 183 
did not display any evidence of contamination in these markers or the other 12 samples on the 
panel.  The remaining 10 samples were also free of contaminant DNA.  In the light of this 
confirmed sample contamination, we halted further analysis of the data from these Medip-seq 
experiments.
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Sample name Marker Allele 1 Size 1 Height 1 Peak Area 1 Allele 2 Size 2 Height 2 Peak Area 2 Allele 3 Size 3 Height 3 Peak Area 3 
33 AMELOGENIN  X 107.71 5138 31220  Y 113.22 1122 6649         
621 AMELOGENIN  X 107.66 3044 18598  Y 113.12 2976 17732         
687 AMELOGENIN  X 107.63 3072 18114  Y 113.15 1315 7996         
183 AMELOGENIN  X 107.74 3654 21707  Y 113.14 3187 18860         
positive control AMELOGENIN  X 107.66 1833 11032             
water control AMELOGENIN                         
33 D13S317 10 228.01 1293 7469 11 232.28 482 2880 13 240.58 1401 8241 
621 D13S317 9 223.72 866 5016 13 240.29 713 4370         
687 D13S317 11 232.2 333 2068 12 236.4 384 2312 13 240.49 250 1552 
183 D13S317 9 223.65 835 5068 12 236.25 550 3318         
positive control D13S317 11 232.08 5148 29821 11 232.08 5148 29821         
water control D13S317                         
33 D16S539 11 278.62 1099 6717 12 282.34 351 2124 13 286.06 738 4744 
621 D16S539 8 267.3 1441 9004 8 267.3 1441 9004         
687 D16S539 9 271.06 219 1564 12 282.34 405 2720         
183 D16S539 10 274.87 716 4731 11 278.62 446 3033         
positive control D16S539 11 278.59 2515 15333 12 282.39 2883 18141         
water control D16S539                         
33 D18S51 12 285.53 464 2699 14 293.39 484 3038         
621 D18S51 13 289.39 372 2431 13 289.39 372 2431         
687 D18S51 15 297.33 84 689 25 339.52 53 231         
183 D18S51 13.3 292.35 357 2505 20 318.38 104 761         
positive control D18S51 15 297.27 2858 17466 19 314.04 2231 13927         
water control D18S51                         
 
Table 4e.  Summary of 4 STR panel markers performed on 4 samples from experiment 1.  Contaminated samples are highlighted in red. 
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4.5 Methods (Experiment 2) 
 
4.5.1 Sample selection  
New DNA samples were, taken from stored aliquots of blood that had not previously been 
used from our collaborators in India.  These samples were put through 2 STR panel analyses – 
a 10 STR panel in Hyderabad, and the 16 STR forensic panel described in Experiment 1, both of 
which confirmed that the samples were uncontaminated.   
We were unable to select single sex groups for analysis within our primary selection criteria 
(tertiles of B12 and folate; insulin resistance index) so we matched sex across groups as much 
as possible.   During the time taken to obtain new samples, it had become evident that 
Illumina GAIIx sequencing was becoming more efficient and a greater number of sequencing 
reads were being processed per flowcell, thus we were able to include a larger sample number 
(8 vs. 8) in the forthcoming experiments.  
 
 
Cases = Low B12 and high folate  
 
Sample ID Sex Insulin Resistance Age at sampling Medip-seq ID 
470 Male 0.75 6 Yr f_2_s_6 
621 Male 1.34 6 Yr f_1_s_6 
637 Male 1.48 6 Yr f_1_s_7 
30 Male 1.88 6 Yr f_1_s_1 
533 Male 1.9 6 Yr f_2_s_7 
456 Female 0.92 6 Yr f_2_s_5 
622 Female 1.98 6 Yr f_2_s_8 
348 Female 0.51 6 Yr f_1_s_3 
 
Controls = High B12 and low folate  
 
Sample ID Sex Insulin Resistance Age at sampling Medip-seq ID 
562 Male 0.19 6 Yr f_1_s_5 
317 Male 0.32 6 Yr f_2_s_4 
78 Male 0.87 6 Yr f_2_s_3 
43 Male 0.4 6 Yr f_2_s_1 
48 Female 0.34 6 Yr f_2_s_2 
417 Female 0.37 6 Yr f_1_s_4 
410 Female 0.37 6 Yr f_1_s_8 
330 Female 0.41 6 Yr f_1_s_2 
 
Table 4f.  Pune samples used in Experiment 2, including colour codes that indicate subsequent sample 
pairing according to fragment size pairing (see figure 4i). 
 144 
Sample collection and preparation was performed as per the methods in Chapter 2 and the 
colour coding of samples in table 4f relates to the fragment size pairing that will be described 
in the results section. 
 
4.5.2 Medip-seq library preparation (non-multiplexed) 
Samples were randomly assigned to one of two batches, each containing equal numbers of 
samples from group 1 and group 2 for library preparation.   Multiplexing of samples was not 
possible as the technology is only suitable for 12 samples in one batch.  It was decided that 
each samples would be run in a separate lane and that two flowcells would be used.  PhIX 
control DNA (5%) was spiked into each lane, rather than being run as a full lane per flowcell.  
Medip-seq libraries were prepared as described in the methods section, but with no multiplex 
adapter used in the PCR amplification of the Medip-enriched libraries.   
 
4.5.3 Size selection of samples 
As a multiplexing strategy was not used, it was important to perform careful size selection of 
DNA fragments between samples, to ensure no bias in downstream analysis of samples from 
different sequence read lengths.  Each completed Medip-seq library was split into two, and 
one half was run on a gel, and a band was cut out after UV-guided marking, aiming at 250-
350bp.  After DNA extraction from the gel band, samples were run on a Bioanalyser High 
Sensitivity DNA chip to determine the DNA fragment size.  Samples were matched by size in 
case-control pairs, with a mean intra-pair difference of <5bp.  In some cases, the second half of 
the Medip-seq library was run on a gel to re-extract size bands and to achieve optimal size 
matching.  
 
4.5.4 Illumina GAIIx sequencing 
Samples were re-randomised to run on 2 flowcells at the Babraham Institute, Cambridge, using 
standard reagents and protocols, running one sample per lane.  This genomics facility was 
chosen in favour of our local facilities because of time constraints.  
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4.5.5 Sequence read processing 
This was performed as per Experiment 1.  Close attention was paid to the fragment lengths 
across cases and control samples as differences could result in variable Medip enrichment 
efficiency.   
 
4.5.6 Bioinformatic analysis 
Identifying case-control sample pairs with equivalent Medip enrichment efficiency reduced the 
possible confounding role of Medip-enrichment bias.  Pairs were defined by drawing plots of 
enrichment efficiency in all possible case-control pair arrangements and then selecting the 
pairs with the most similar enrichment at low CpG densities (where the greatest read density is 
located).    
Bioinformatic analysis incorporated combined DMR calling with the Thomas Down DMR caller 
and USeq.  The Thomas Down DMR caller incorporated groupwise analyses (i.e. cases vs. 
controls) and pairwise analyses (i.e. case-control pairs matched for Medip enrichment 
efficiency). 
 
 
 
4.6 Results (Experiment 2) 
 
 
4.6.1 Library preparation 
Library preparation of the two sample batches was performed.  Case and control sample pairs 
were assigned with matched fragment sizes to one of two sequencing flowcells.  Fragment 
sizes were approximated from the bioanalyser output, shown in figure 4i. 
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Figure 4i. Bioanalyser gel pictures of finished Medip-seq libraries.  Samples were paired according to 
fragment size distribution seen in these gel pictures.  Sample pairs are highlighted by matching colours 
within each flowcell. 
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4.6.2 Illumina GAIIx sequencing 
The standard sequencing protocols were followed and met all routine QC checks in the 
process.  Raw sequence read counts seemed consistent with successful sequencing and were 
interpreted in more detail during the bioinformatic workflow. 
 
4.6.3 Bioinformatic analysis 
Chris Mathews performed the bioinformatic analyses with support from Guillermo Carbajosa 
and Thomas Down. 
 
4.6.3.1 Sequence reads pre-processing 
The standard sequence read processing steps were performed and showed predictable and 
comparable losses at each filtering step (table 4g and figure 4j).  After mapping, pairing, quality 
filters were applied, as well as removal of PCR duplicates, all but one sample showed similar 
rates of attrition with over 60% of mapped reads suitable for analysis.  Three samples (622, 
456 and 43) on flowcell 2 that did not map as well as others performed well through the 
remaining quality filters resulting in a similar number of reads suitable for subsequent analysis.  
One sample (317) seemed to perform considerably less well than others through the quality 
filter, losing proportionately more reads at each QC step than other samples, resulting in only 
50% high quality reads suitable for downstream analysis.  This sample had been processed no 
differently to others and there was no suggestion from the various library preparation QCs 
(e.g. concentration checks, gel visualisation) that there was a particular problem with it.  
Furthermore, calibration and enrichment efficiency plots involving this sample did not 
highlight a specific cause for concern and therefore it was decided that it should remain in the 
analysis. 
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  Read length statistics (pre-processing) Read processing 
Sample 
Case/ 
control 
Min 
1st 
Quartile 
Median Mean 
3rd 
Quartile 
Max 
Mapped Read 
Count 
Paired Read 
Count 
% 
Pair 
Q10 F3 
%Q1
0 
Remove 
Duplicates 
% 
Passed 
30 case 40 189 203 204 220 363 35,421,751 28,325,202 80 23,555,429 67 22,012,589 62.1 
330 control 38 168 187 189 210 384 40,723,488 34,757,501 85 28,937,958 71 27,867,336 68.4 
348 case 40 164 180 179 197 339 41,973,330 36,327,296 87 30,198,912 72 28,333,459 67.5 
417 control 39 164 181 182 201 359 37,197,975 31,139,309 84 26,088,189 70 24,090,630 64.8 
562 control 37 151 168 169 187 334 37,964,441 31,531,623 83 25,243,807 66 22,939,705 60.4 
621 case 40 152 167 167 184 319 39,806,483 33,898,716 85 27,259,823 68 24,637,453 61.9 
637 case 37 170 189 191 212 388 40,489,197 34,570,624 85 28,808,015 71 27,050,721 66.8 
410 control 39 180 195 194 212 348 38,436,470 32,306,832 84 26,810,441 70 24,846,490 64.6 
  Mean 39 167 184 184 203 354 312,013,135 262,857,103 84 
216,902,57
3 70 201,778,383 64.7 
43 control 37 153 168 168 186 327 29,113,826 27,496,959 94 22,806,397 78 19,456,002 66.8 
48 control 40 153 168 167 183 308 41,938,761 39,574,711 94 32,030,655 76 26,924,591 64.2 
78 control 40 159 175 176 194 350 41,178,009 38,150,640 93 31,305,264 76 27,235,074 66.1 
317 control 40 154 171 171 190 332 40,820,099 37,558,129 92 29,866,853 73 20,910,454 51.2 
456 case 41 149 165 165 183 327 34,460,691 28,232,679 82 27,032,753 78 23,590,031 68.5 
470 case 39 159 177 177 196 347 40,345,590 36,798,432 91 29,693,253 74 24,923,691 61.8 
533 case 37 154 168 167 182 302 39,600,334 36,637,299 93 28,799,156 73 24,506,535 61.9 
622 case 39 158 173 174 191 328 33,525,971 31,004,329 92 25,759,611 77 23,437,304 69.9 
  Mean 39 155 171 171 188 328 300,983,281 275,453,178 92 
227,293,94
0 76 190,983,680 63.5 
  Mean cases 39 162 178 178 196 339 38202918 33224322 87 27638369 72 24811473 65 
  
Mean 
controls 39 160 177 177 195 343 38421634 34064463 89 27886195 73 24283785 63 
 
Table 4g.  Medip-seq sequence read counts (n) per sample and per flowcell through each data pre-processing step.   
 149 
 
 
 
 
 
 
Figure 4j.  Medip-sequence read counts per sample and per flowcell that passed each stage of pre-
processing. 
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BATMAN calibration plots were drawn for all samples and showed appropriate patterns of 
read depth across regions of high and low CpG density.  Prior to DMR analysis, reads from the 
X and Y chromosomes were filtered out due to the mixed sample groups precluding analysis of 
them.  In addition, a final size filter was applied to remove reads that were outside the 150-
250 bp size range and case and control samples were paired according to Medip enrichment 
efficiency (figure 4j).  The read count in each size-matched pair was normalised.  Previous 
sample arrangements resulted in matched numbers of male and female samples as far as 
possible.  The result of these careful normalisation steps was that of size-matched and 
enrichment-matched case and control groups with equal numbers of reads, suitable for DMR 
calling (see table 4h).   
 
 
Figure 4k.  Medip enrichment sample matching.  This figure shows sample 30 matched to sample 330 
with equivalent enrichment of samples (estimated methylation of sample 1:sample 2 on Y axis) at 
regions that have 60% CpG density or less  (X axis).  Variable enrichment is seen at regions of the 
genome that are have high CpG density due to the fact that these are far fewer (hence the wide error 
bars) and exhibit much more variable methylation. 
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Enrichment 
matched pair Read length (bp) Normalised reads (n) Case Control Normalised reads (n) Read length(bp) 
1 204 18,052,736 30* 330* 18,052,736 189 
2 179 22,690,640 348* 78 22,690,640 176 
3 167 15,776,059 621* 317 15,776,059 171 
4 191 20,502,217 637* 410* 20,502,217 194 
5 165 15,339,645 456 43 15,339,645 168 
6 177 17,918,483 470 48 17,918,483 167 
7 167 16,205,735 533 562* 16,205,735 169 
8 174 18,518,541 622 417* 18,518,541 182 
 1424 145,004,056 Total Total 145,004,056 1416 
 178 18,125,507 Average Average 18,125,507 177 
       
 
Table 4h.  Normalised and fragment-size matched case-control pairs with read counts, ready for DMR calling.   
*= flowcell 1, and highlighted colours indicate male (blue) and female (pink). 
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4.6.3.2 DMR calling 
DMR calling of was performed in a systematic fashion using a combination of bioinformatic 
techniques that have been discussed in the methods section.     
The Thomas Down DMR caller was used to generate a long list of DMRs, first in a group-wise 
(case-control) analysis, and subsequently in a pair-wise analysis using the fragment size and 
Medip-enrichment normalised sample pairs in table 9.   Following this DMR call, USeq was 
applied to the processed and normalised data in a new DMR call. 
 
  DMR caller Method 
Size 
Normalisation 
Enrichment 
matched 
Test used 
DMRs 
Called 
Single method 
Thomas 
Down 
CaseControl 
Pairwise Caller 
(pooled case 
and control 
groups)  
Yes No T-test 30,000 
Thomas 
Down 
Pairwise 
Pairwise Caller 
(individual 
case/control 
samples paired 
using 
enrichment 
plots).  DMRs 
common to all 
pairs. 
Yes Yes T-test 16,000 
Useq Useq No No 
Negative 
Binomial 
distribution 
1800 
Combined methods 
Final 
Combination 
Thomas Down 
CaseControl + 
Pairwise + Useq 
n/a n/a n/a 48 
 
Table 4i.  DMR calling strategies and numbers of DMRs 
 
As could be predicted, the most DMRs were identified in a group-wise comparison between 
cases and controls using the Thomas Down caller, and this number (~30,000) was reduced 
considerably when differences that existed between single case-control pairs were called 
(~16,000).  The groupwise call will have picked up differences that are driven by single samples 
and has no capacity for eliminating these potentially spurious DMRs, e.g. via a sensitivity 
analysis.  The pairwise call is likely to call more differences when comparing two samples, but 
by combining the results of all pairwise calls and selecting those which are common to all, the 
number of differences is considerably reduced.  The USeq call generated the least number of 
DMRs (1800) due to its control of individual false discovery rates at each DMR.  When the 
DMRs identified by all 3 methods were compared, only 48 were common to all, and these have 
been inspected and analysed in further detail.  
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4.6.3.3 Sanity-checking of DMRs 
 
DMRs were uploaded as custom tracks to the UCSC genome browser and inspected visually 
across individual samples and are available via the following URL: http://genome.ucsc.edu/cgi-
bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=Chris%20Mathews&hgS_other
UserSessionName=Pune.  An example of this upload is shown in figure 4l with individual 
samples represented as individual tracks. This visual assessment did not suggest any technical 
issues, such as all DMRs being driven by specific samples, as had previously been noted when 
sample contamination had occurred.  The UCSC upload was then used for further 
characterisation of the Medip-seq DMRs.  
 
Figure 4l.  Example UCSC upload of Medip-seq data used for sanity checking of DMRs. 
 
 
4.6.3.4 DMR characteristics 
The 44 DMRs identified by the combined DMR call were studied in more detail using the data 
generated from the DMR callers and the UCSC upload.  Of the 48 DMRs, 27 were 
hypermethylated and 21 were hypomethylated in cases compared to controls.  The DMRs 
identified are shown in Table 4m. 
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 Thomas Down DMR caller Useq Genomic features 
Chromosome Start BP Finish BP P-Value t-stat DMR # Windows FDR Log2 Gene Location Gene details 
chr1 1596601 1597200 0.00002 4.88 hyper 2 5.97 0.84 
CDC2L1/CDK11, 
SLC35E2B and 
multiple other 
transcripts 
intron, also 
3'UTR of other 
transcripts 
Cell division cycle 2-like 1. 
p34Cdc2 kinase family  
essential for eukaryotic cell 
cycle control.  
chr1 58692501 58693500 0.00010 4.62 hyper 6 3.59 1.54 DAB1 
intron, also 
3'UTR of other 
transcripts 
Disabled homolog 1 
(drosophila) - involved in 
cerebral cortex development 
chr1 117299101 117299700 0.00001 5.18 hyper 2 5.07 1.77 CD2 intron 2 
Surface antigen of human T-
lymphocyte lineage, 
expressed on all peripheral 
blood T cells.  
chr1 149160501 149162600 0.00018 4.70 hyper 16 10.98 1.20 no 
repeat-rich 
region 
  
chr1 167704301 167705100 0.00038 3.71 hyper 4 5.89 1.64 
MPZL1, 20kb 
downstream of 
ADCY10 
intron 1 
Myelin protein zero-like 1:  
cell surface protein involved 
in signal transduction via 
tyrosine phosphorylation, 
widely expressed including 
in haematopoetic cells and 
fetal liver 
chr1 175662701 175663300 0.00004 4.64 hyper 2 11.93 1.66 TNR intron 1 
Tenascin-R: extracellular 
matrix protein expressed 
primarily in CNS and in other 
tissues in different times of 
development 
chr2 230519501 230520100 0.00016 4.06 hyper 2 4.89 1.58 
DNER, 50kb 
downstream 
ofTRIP12 
intron 1 
Delta & notch-like epidermal 
growth factor-related 
receptor: present on cell 
membrane. Mediates 
neuron-glia interaction 
chr3 77303401 77304300 0.00024 4.28 hyper 5 9.29 1.55 ROBO2 intron 2 
Roundabout axon guidance 
receptor, homolog 2: 
(immunoglobulin 
superfamily) encodes for 
protein SLIT2, functions in 
axon guidance. 
chr3 162413401 162414000 0.00012 4.12 hyper 2 9.92 1.86 no     
chr3 178411601 178412400 0.00032 3.62 hyper 4 4.18 1.18 KCNMB2 intron 1 
Potassium large 
conductance calcium-
 155 
activated channel, subfamily 
M, beta member 2: a 
voltage- & calcium-sensitive 
potassium channel used in 
smooth muscle and neuronal 
excitability 
chr3 195084601 195085600 0.00004 4.55 hyper 6 4.88 1.18 ACAP2 intron 
ArfGAP with coiled-coil, 
ankyrin repeat and PH 
domains 2: mediate diverse 
protein-protein interactions 
chr4 47741501 47742400 0.00003 4.59 hyper 5 6.16 1.76 CORIN intron 
Serine petidase: a 
transmembrane protein  
(trypsin superfamily).  
Encoded protein converts 
pro- to atrial natriuretic 
peptide – role in blood 
volume and pressure. 
chr4 105137701 105138400 0.00004 4.61 hyper 3 3.45 1.38 no     
chr5 93820001 93821000 0.00025 3.91 hyper 6 4.15 1.20 KIAA0825/C5orf36 introns + exon   
chr5 109881501 109882500 0.00027 3.72 hyper 6 3.76 1.46 TMEM232 intron Transmembrane protein 232 
chr6 9025101 9026300 0.00020 5.67 hyper 8 19.04 1.12 no     
chr6 99929001 99929900 0.00012 4.19 hyper 5 5.05 1.42 USP45 intron 
Ubiquitin-specific peptidase 
45 
chr8 3945201 3946300 0.00012 5.42 hyper 7 20.65 1.27 CSMD1 intron 
Ubiquitin-specific peptidase 
45 
chr8 36946101 36946600 0.00001 5.19 hyper 1 4.03 1.44 no     
chr8 43092301 43097700 0.00001 24.20 hyper 49 32.87 0.85 no 
repeat-rich 
region 
  
chr8 79909701 79910700 0.00017 4.40 hyper 6 8.26 1.81 no     
chr10 9780501 9781100 0.00001 4.90 hyper 2 9.92 1.86 no     
chr10 48607301 48607900 0.00003 4.58 hyper 2 5.47 1.74 no     
chr10 131119601 131120600 0.00005 4.87 hyper 6 8.11 1.00 
no, 100kb upstream 
of MGMT 
    
chr13 47344301 47345000 0.00030 3.81 hyper 3 14.66 1.97 
no, but 1kb 
upstream of ESD 
3'UTR 
  
Adjacent to ESD, a gene 
encoding a serine hydrolase 
and used as a genetic marker 
for retinoblastoma and 
Wilson's disease 
chr17 26916601 26917100 0.00003 4.55 hyper 1 3.22 1.17 SPAG5 intron 
Sperm associated antigen 5. 
This gene encodes a protein 
associated with the mitotic 
spindle apparatus. 
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chr18 60348901 60349700 0.00028 3.92 hyper 4 3.93 1.60 no     
chr1 26462301 26463200 0.00017 4.20 hypo 5 8.97 -1.32 no     
chr1 79073301 79074000 0.00018 3.87 hypo 3 6.42 -1.58 
no, 10kb upstream 
of ILI44L 
    
chr2 72486601 72487400 0.00015 4.48 hypo 4 7.09 -1.69 EXOC6B 
penultimate 
intron, 100kb 
from CYP26B1 
Exocyst complex component 
6B 
chr2 215564601 215565600 0.00009 5.16 hypo 6 20.28 -1.88 no 
likely 
hypervariable 
region 
  
chr3 36865101 36866100 0.00029 3.92 hypo 6 7.88 -1.51 
no, 1kb uptream of 
TRANK1 
    
chr3 131406201 131407300 0.00026 4.41 hypo 6 7.73 -1.75 CPNE4 intron 
Copine IV. Calcium-
dependent membrane-
binding proteins may 
regulate molecular events at 
the interface of the cell 
membrane and cytoplasm 
chr4 4265601 4266600 0.00034 3.60 hypo 6 7.58 -1.18 
no, 2kb upstream 
of LYAR 
    
chr4 47949001 47950000 0.00003 5.11 hypo 6 7.04 -1.03 CNGA1 intron 
Cyclic nucleotide gated 
channel alpha 1. The protein 
encoded is involved in 
phototransduction. Defects 
in this gene are a cause of 
retinitis pigmentosa 
autosomal recessive (ARRP) 
disease 
chr6 35316301 35317200 0.00002 4.95 hypo 5 8.21 -1.39 PPARD intron 2 
Peroxisome proliferator-
activated receptor delta. 
Potent inhibitor of ligand-
induced transcription activity 
of PPARa & PPARg gamma. 
Integrator of transcription 
repression and nuclear 
receptor signaling. 
Heterodimerises with RXR to 
regulate gene expression 
chr6 35740101 35740800 0.00004 4.69 hypo 3 3.39 -1.29 
no, 5kb upstream 
of Corf127 
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chr10 91250801 91251600 0.00019 3.86 hypo 4 5.41 -1.49 SLC16A12 intron 1 
Solute carrier family 16, 
member 12. Encodes a 
transmembrane transporter 
with a role in 
monocarboxylic acid 
transport. A mutation is 
associated with juvenile 
cataracts with microcornea 
and renal glucosuria.  
chr11 24768401 24769100 0.00010 4.04 hypo 3 3.38 -1.65 LUZP2 intron 4 Leucine zipper protein 2 
chr13 45665501 45666400 0.00035 4.46 hypo 5 8.74 -1.41 no     
chr15 31183601 31184600 0.00019 4.47 hypo 6 4.45 -1.10 
no, 10kb upstream 
of FAN1/MTMR15 
    
chr15 42095701 42096600 0.00030 3.77 hypo 5 3.12 -1.30 MAPKBP1 intron 3 
Mitogen-activated protein 
kinase binding protein 1 
chr15 102108801 102109300 0.00005 4.28 hypo 1 4.08 -1.12 no     
chr16 12739201 12740100 0.00003 4.65 hypo 5 8.19 -1.39 
no, 10kb upstream 
of CPPED1 3'UTR 
    
chr17 7758101 7758800 0.00008 4.35 hypo 3 10.56 -0.88 TMEM88  5'UTR Transmembrane protein 88 
chr17 8247301 8248000 0.00008 4.69 hypo 3 12.04 -1.27 ODF4 intron 1 
Outer dense fiber of sperm 
tails. Encodes a protein that 
is localized in the outer 
dense fibers of the tails of 
mature sperm and is 
involved in sperm structure, 
sperm movement and 
general organization of 
cellular cytoskeleton. 
chr17 80105501 80107300 0.00014 8.78 hypo 12 109.40 -2.17 CCDC57 intron 
Coiled-coil domain 
containing 57 
chr19 54727901 54728900 0.00035 3.63 hypo 4 4.46 -1.59 LILRA6/LILRB3 intron 
Leukocyte immunoglobulin-
like receptor, subfamily A 
 
Table 4k.  Summary table of Medip-seq DMRs identified using a combination of Thomas Down and USeq DMR calling methods.  The table summarises the data 
derived from the Thomas Down caller in the first 7 columns.  
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A noticeable feature of many DMRs was that they overlap contiguous windows across genomic 
regions, giving a mean size of each DMR of 650 bp.    Several DMRs crossed more than 1000bp 
and these tended to be in repeat-rich areas.  Some of the DMRs are in regions of specific 
genetic interest to the programmed phenotype, e.g. PPARD, LUZP2 (shown in figure 4m(i) and 
(ii)) and CORIN.  Several DMRs overlie genes that have role in neuronal 
development/myelination the relevance of which may be supported by the knowledge that 
vitamin B12 deficiency is associated with nerve degeneration.  However, other studies (92) 
have identified neural pathways as highly variable in their methylation status without such 
influences and therefore this may not have biological relevance.    Table 4j summarises the 
genomic features at the DMRs called.  The DMRs identified also appear to overlap some 
regulatory elements, as suggested by CTCF binding, DNase hypersensitivity, Pol2 binding sites 
and regions of enrichment of specific histone marks.  The repeat-rich nature of many DMRs is 
consistent with the findings of other studies that suggest variable DNA methylation is 
associated with repeat elements (179).   
 
Genomic features N % 
Genic 14 29 
Intergenic 34 71 
Intronic (of 14 genic DMRs) 10 71 
Conserved across species 28 58 
CpG island 2 4 
Repeat-rich 42 88 
Overlies regulatory features and/or regions of 
histone enrichment 
41 85 
 
Table 4j. Summary of genomic features of the 48 DMRs identified through the combined DMR call.
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Figure 4m(i) and (ii).  UCSC screenshots of Medip-seq DMRs at PPARD (i) and LUZP2 (ii). Individual sample methylation tracks are shown in addition to Useq-derived DMR counts 
of case (dark red) and control (green) samples.  Both DMRs are intronic, overlap repeat-rich areas, and contain SNPs within them.  LUZP2 overlaps a DNase hypersensitivity site .
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4.7 Methods (Experiment 3) 
 
4.7.1 Sample selection 
DNA from all 10 case and 10 control samples were analysed in this experiment (see table 4a), 
designed as a technical validation of the Medip-seq data from Experiment 2.  An unbalanced 
mixture of male and female samples was present across cases and controls.   
 
4.7.2 Illumina 450k methylation array 
The protocols for bisulphite conversion and qPCR test of conversion efficiency were followed.  
Array experiments were performed by UCL Genomics, within a randomised batch of containing 
samples from 2 other studies. 
 
4.7.3 Data analysis  
QC and analysis of data from the 450k array was performed in accordance with the methods 
described in the Methods Chapter.  In view of the mixed sex samples, X and Y probes were 
removed via a bioinformatic filter. 
 
 
4.7 Results (experiment 3) 
 
4.7.1 Quality control checks 
Data generated from the 450k array experiments was subjected to the standard quality control 
checks described in the methods section.  Sample-independent QC (staining, extension, 
hybridisation and target-removal) showed good performance of the array at the control 
probes (data not shown).  Sample-dependent QC (bisulphite conversion, specificity, negative 
controls and non-polymorphic controls) also showed good performance of the samples 
through the array experiments.  The bisulphite conversion QC plots are shown in figure 4n and 
4o and represent both colour channels at both Infinium bead types (I and II).  In the Infinium I 
 162 
probe QC plots (figure 4n), controls C1, C2 and C3 assess the performance of bisulphite-
converted DNA and this is monitored in the green channel.  The signal intensity produced from 
C1, C2 and C3 should be lower than their unconverted control sample counterparts (U1, U2, 
U3) due to difference in extension at the control probes.  The same pattern should be 
observed in C4/U4, C5/U5 and C6/U6 control probes in the red channel.  The Infinium II probe 
QC plots (figure 4o) are different due to the different probe design with a single probe per 
bead that hybridises both methylated and unmethylated sequence.  In these plots, a successful 
bisulphite conversion is represented by higher intensities across all control probes (II1, II2, II3 
and II4) in the red channel compared to the green channel. 
 
 
Figure 4n Infinium probe I bisulphite conversion QC plot, represented in both green and red array 
channels by control probes targeting converted sequence (C1-4) and control probes targeting 
unconverted sequence (U1-4). 
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Figure 4o Infinium probe II bisulphite conversion QC plot, represented in both green and red array 
channels by 4 control probes (II1-4) that hybridise converted and unconverted DNA. 
 
 
The .idat files generated from raw data represent the beta values following correction for 
background effects determined by the negative and non-polymorphic control probes.  Figure 
4p shows a typical bimodal distribution of beta values generated from these .idat files, 
detected at all array probes, showing that the highest density of probes detect methylation 
levels at close to 0% and 100%.   This is a feature of the array design being targeted to CpG rich 
and poor genomic regions, but this is also partly representative of methylation across the 
entire genome.  This plot shows uniformity of this distribution across all samples (both cases 
and controls) and is a useful means of detecting technical problems with individual samples. 
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Figure 4p.  Density plot of all array samples (cases = 1, controls =2) showing the density of varying beta 
values across all probes in a typical bimodal distribution 
 
 
4.7.2 Illumina 450k methylation array data 
Data filtering was performed on .idat files to remove X and Y probes and those displaying 
cross-hybridisation.  The final number of probes used for subsequent analysis was 430,975 (out 
of 485,836).  SNP-associated probes were not filtered.  A multidimensional scaling plot (MDS) 
was generated using the beta values for each sample derived from the filtered .idat files (figure 
4q).  The MDS plot did not show any significant differences that could be attributable to 
technical bias, such as clustering of samples run on different arrays, nor did it show obvious 
gross biological differences that would be represented by clustering of cases and controls. 
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Figure 4q.  MDS plot of beta values detected from 430975 probes across all samples (after removal of 
cross-hybridising probes and those failing to meet the detection p value threshold).  Group 1 = cases, 
Group 2 = control samples. 
 
 
4.7.3 MVP call 
The R-based Limma package was used to identify differential methylation between cases and 
controls using an F-test applied to transformed beta values (M values).  A total of 3963 MVPs 
were identified using this F-test, with varying statistical significance per MVP (see table 4l).  
FDR-adjustment of p values (as described in section 2.5.1.6) did not produce any statistically 
significant q values indicating that the MVPs identified in this dataset could include multiple 
false discoveries.  A sensitivity analysis was performed on the MVPs identified to try and 
reduce the false positive rate by excluding those driven by just one sample.  The sensitivity 
analysis reduced the total number of MVPs identified to 2045, 52%of the total and, as would 
be expected, these included the MVPs with stronger p values.       
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  Hypomethylated  Hypermethylated 
MVPs from basic MVP call 
N = 3963 
Number (% total MVPs) 2258 (57) 1705 (43) 
Range of Beta value differences -0.3 to -46% 0.3 to 38% 
P value (unadjusted) range 1x10
-5
 to 1x10
-2
 5x10
-6
 to 1x10
-1
 
Number of SNP-containing probe 
(%) 
484 (11) 361 (8) 
Genic (%) 1701 (76) 1307 (77) 
Promoter (% of genic MVPs) 465 (27) 434 (25) 
Intergenic (%) 547 (24) 398 (23) 
CpG Island (%) 872 (39) 705 (41) 
CpG Shore or Shelf (%) 706 (31) 495 (29) 
Enhancer (%) 424 (19) 330 (19) 
DNAse hypersensitivity site (%) 348 (15) 206 (12) 
MVPs after sensitivity 
analysis 
N = 2045 
Number (% total MVPs) 1175 (57) 870 (43) 
Range of Beta value differences -0.3 to -46% 0.3 to 38% 
P value (unadjusted) range 4x10
-5
 to 7x10
-3
 5x10
-6
 to 7x10
-3
 
Number of SNP-containing probe 
(%) 
243 (21) 194 (22) 
Genic (%) 890 (76) 657 (76) 
Promoter (% of genic MVPs) 247 (28) 434 (25) 
Intergenic (%) 285 (24) 213 (24) 
CpG Island (%) 490 (41) 387 (44) 
CpG Shore or Shelf (%) 343 (29) 237 (27) 
Enhancer (%) 241 (21) 169 (19) 
DNase hypersensitivity site (%) 184 (16) 111 (13) 
Table 4l.   Summary of MVPs from 450k dataset using Illumina annotation. 
 
Subsequent analysis and description of MVPs will now include only those that have passed 
through the sensitivity analysis.  There were more MVPs that were hypomethylated in cases 
compared to controls, and this may reflect a reduction in available methyl groups for 
methylation in the context of severe vitamin B12 deficiency.  The array design is targeted to 
CpG islands, promoters and regulatory elements (e.g. enhancers and DNase hypersensitivity 
sites), and this was reflected by the location of MVPs.  Just over 20% of MVPs identified were 
at probes known to be SNP-containing.  At these probes, SNP-CpGs create or abrogate a site 
for methylation and therefore are identified as an MVP when the genetic polymorphism is 
different in cases vs. controls.  This difference is likely to be a chance effect, and, should 
information on alleles be available, the study does not have the power to detect genetic 
association between cases and controls. 
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4.7.4 Pathway analysis 
GO terms were generated using the GOstats add-on to the Limma analysis package.    
GO: ID Pvalue 
Odd
s 
Rati
o 
Expect
ed 
count 
Observ
ed 
count 
Size Term 
GO:00325
01 
0.0000
01 1.38 356 427 4770 multicellular organismal process 
GO:00325
02 
0.0000
06 1.37 283 345 3794 developmental process 
GO:00098
87 
0.0000
18 1.74 49 79 661 organ morphogenesis 
GO:00220
08 
0.0000
20 1.60 72 107 969 neurogenesis 
GO:00301
82 
0.0000
29 1.63 63 95 844 neuron differentiation 
GO:00485
68 
0.0000
37 2.17 20 39 266 embryonic organ development 
GO:00513
36 
0.0000
47 1.67 53 82 712 regulation of hydrolase activity 
GO:00650
07 
0.0000
70 1.30 571 628 7645 biological regulation 
GO:00484
68 
0.0000
96 1.48 91 126 1224 cell development 
GO:00485
98 
0.0001
52 1.82 31 52 415 embryonic morphogenesis 
GO:00485
19 
0.0001
57 1.33 198 243 2650 negative regulation of biological process 
GO:00352
95 
0.0001
65 1.87 27 47 365 tube development 
GO:00511
79 
0.0001
72 1.29 286 336 3826 localization 
GO:00099
87 
0.0002
87 1.46 767 801 
1057
0 cellular process 
GO:00351
48 
0.0003
04 2.82 7 18 98 tube formation 
GO:00018
43 
0.0003
33 3.53 4 13 59 neural tube closure 
GO:20000
26 
0.0003
42 1.51 67 94 891 
regulation of multicellular organismal 
development 
GO:00455
96 
0.0004
07 1.86 24 42 328 negative regulation of cell differentiation 
GO:00487
04 
0.0004
19 3.24 5 14 68 embryonic skeletal system morphogenesis 
GO:00601
93 
0.0004
48 2.49 9 21 127 positive regulation of lipase activity 
 
Table 4m.  Results of a Gene Ontology analysis, summarising the top 15 pathways overrepresented by 
450k MVPs. 
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The GO analysis performed on the 450k data output shows and differential methylation 
affecting gene pathways involved in a range of developmental processes, and this could have 
functional effects via the interaction between DNA methylation and gene expression.  The 
findings of this GO analysis are non-specific and need to be corroborated by a study in larger 
sample numbers, as well as correlation in other model systems, ideally including gene 
expression data.  The representation of GO terms including neuron development and 
differentiation is similar to the GO analysis performed in the Matlab experiments (see section 
5.3.3.2) and that published previously and their inclusion may represent the normal 
methylation variation associated with ubiquitously-expressed genes in these pathways, or a 
role in relevant and common biological processes such as aging (92).  It is also interesting to 
see a pathway of neural tube closure overrepresented in this GO analysis, given the known 
effects of optimal folate and B12 status on reducing the prevalence of neural tube defects 
(180). 
 
4.7.5 Medip-seq and 450k array technical validation 
A comparison of Medip-seq DMRs and 450k array MVPs was performed by way of technical 
validation of these results.  Medip-seq experiments had been performed on 8 cases and 8 
controls and therefore, for this technical validation across experimental platforms, a new MVP 
call was performed using 450k array data using the same 8 cases vs. controls.   
First, the ‘top hit’ list of 48 Medip-seq DMRs derived from the combined analysis algorithms 
were compared to 450k array coverage.  Out of these 48 regions, only 4 had direct coverage 
with the 450k array and it was therefore decided that the entire USeq DMR list should be used 
for this technical validation.  There were only 55 450k array probes that overlap the 1800 USeq 
DMRs called, suggesting that this is a poor means of validating one platform against the other.  
However, the 55 overlapping probes covered 24 Medip-seq DMRs (i.e. some DMRs had more 
than one probe mapping within them) suggesting that both methods can identify regions of 
significant variation.  Of the 55 probes that overlapped Medip-seq DMRs, the majority (n = 32) 
showed differential methylation with the same directionality (i.e. hypomethylation or 
hypermethylation) between cases vs. controls in both datasets; this finding provides 
reassurance that the technical means of quantifying methylation are strong.  Another 14 
probes did not show statistically significant differential methylation, and only 9 showed 
conflicting directions of differential methylation between platforms.   
Co-methylation was observed in the DMRs represented by multiple array probes and provides 
some reassurance of the biological plausibility of these validated DMRs.  Co-methylation, a 
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correlation of methylation status of adjacent CpGs that has been described across <1000bp 
regions of varying CpG density (181). 
 
Of the 55 probes overlapping USeq DMRs, 24 contain annotated SNPs within the probe binding 
location and a large proportion of these are SNP CpGs.  Six of the USeq DMRs that were 
represented by 3 or more 450k probes (i.e. those that well represent the methylation level 
across the wider Medip-seq DMR) are shown in graphical format below.  Of these DMRs, 
DMR1 and DMR13 have methylation levels of near 0, 50 or 100% across the probes in all 20 
samples, due to each probe being tiled to a SNP-CpG.  This genetically driven methylation state 
is confirmed the presence of SNPs at each of the probes within these DMRs.  DMRs 5, 7, and 
10 all have at least one SNP-CpG probe within them and the beta values at non-SNP probes 
within the same DMRs appear to be in cis.  DMR24 does not have any SNP-associated probes 
within it and consequently, there is more variation in beta values than would be expected if a 
SNP or cis-effect was present.   
DMR1 
DMR5 
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Figure 4r.  DMRs represented by USeq and multiple overlapping 450k array probes.  Legends show 450k 
probe names and (*) denotes the presence of a SNP at a 450k array probe. 
 
 
 
DMR7 
DMR10  
DMR13 
DMR24 
 171 
4.8 Discussion 
 
4.8.1 Discussion points related to the PMNS clinical study 
 
a. Nature of the environmental exposure 
Maternal vitamin B12 deficiency with folate repletion was defined as the environmental 
exposure associated with the adverse childhood phenotype of insulin resistance and obesity 
and was used to examine environment-epigenetic interactions.  One of the strengths of this 
study was the careful characterisation of the maternal diet using food frequency 
questionnaires to determine macronutrient intake (i.e. protein, fat, energy and carbohydrates) 
and other dietary intake e.g. dairy products and green-leafy vegetables.  Yajnik and colleagues 
performed an analysis to identify whether there was an association between any of these 
variables and the phenotype of insulin resistance, but did not find one.  This provides 
reassurance that macronutrient status does not confound the association with maternal one-
carbon status.  The study, however, does not detail measurement of other micronutrients that 
could act as confounders in this association. 
 
b. Timing of the exposure 
In PMNS, biochemical and questionnaire data was collected at 18 and 28 weeks gestation to 
characterise maternal nutritional status in a population for whom pre-pregnancy weight, body 
mass index and physical activity had previously been characterised (182).  Data collected from 
women at 18 weeks gestation is highly likely to represent pre-pregnancy status; the 
biochemical measure of red cell folate is unlikely to change during pregnancy, and although 
serum vitamin B12 levels fall in normal pregnancy, there is not a significant change until after 
20 weeks gestation.  Other researchers have highlighted the importance of the variable timing 
of exposure on programming (109).  In the sheep model of methyl group deficiency previously 
described, the exposure was peri-conceptual, a time point that it can be assumed the PMNS 
mothers were exposed also.  One potential difficulty with interpreting the findings of PMNS 
lies in the exposure lasting throughout pregnancy and possibly also during lactation and 
postnatally and this concern has only partly been addressed by measuring vitamin B12 levels in 
6 year offspring and finding that there was no association of this with phenotypic outcome. 
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c. Genetic heterogeneity 
The genetic differences between participants in PMNS could have an impact on the parental 
and offspring phenotypes, as well as potential epigenetic differences that are detected.  
Although the participants come from a small and well-defined rural area with minimal 
population changes, there will still be considerable heterogeneity between individuals.  
Genetic differences could control the risk of developing insulin resistance and obesity, but also 
the nutritional status of the mother.  For example, vitamin B12 levels can be affected by the 
common variant FUT2 and folate status by the common allelic variation at MTHFR (183).  In 
these pilot studies proposed, it was not possible to separate the pure genetic effects on 
offspring phenotype, nor study the possible genetic-epigenetic interactions at known gene 
variants, but future studies should be designed to do so.  Finally, most of the knowledge about 
genetic susceptibility to these phenotypes are from studies of populations of European origin 
and therefore it is important to understand that the genetic variation in participants of PMNS 
may not be fully characterised or represented on genome browsers and variant databases. 
 
e. Phenotype 
PMNS showed some association between birth phenotype (e.g. weight, skinfold thickness and 
abdominal circumference) and maternal folate concentration.  However, this association did 
not extend to variation of maternal vitamin B12 status (as measured by serum B12 or 
methylmalonic acid).  These findings highlight how PMNS adds considerable new 
understanding of the phenotypic consequences of early developmental programming and that 
long-term follow up is crucial to this type of study.  The DEXA studies and oral glucose 
tolerance tests provided evidence of increased fat mass and insulin resistance in the 
programmed offspring, but these measures do not fall into the diagnostic criteria of either 
overweight, obesity or type 2 diabetes.  They can be considered to be precursors of these 
conditions, but this subclinical status does not conclusively determine a future phenotype.   
 
 
 
4.8.2 Discussion points related to the epigenomic studies 
 
The DNA methylation profiles of 16 offspring born to PMNS were characterised using Medip-
seq.  This experimental platform generated over 48 million sequencing reads suitable for 
bioinformatic analysis from DNA collected from 8 cases and 8 controls.  After careful quality 
control processes, normalisation and custom bioinformatic analysis using combined 
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algorithms, a list of 48 differentially methylated regions was generated showing variable 
methylation between cases and controls.  A significant number of reads was lost through the 
various QC filters after sequencing, but this was consistent across samples and similar to other 
Medip-seq datasets generated in the Rakyan lab.  The DMRs were located at different genomic 
regions, and some were located at repeat elements and regions of possible transcriptional 
regulation.  Technical validation using the Illumina HumanMethylation 450k array was 
attempted using the same samples but array coverage did not overlap many regions of 
differential methylation identified by Medip-seq.  Where there was overlap between 450k 
probes and Medip-seq DMRs, the 450k beta values supported most of the data generated by 
Medip-seq in terms of directionality of methylation difference.  However, the majority of these 
validated DMRs were at sites where a genetic polymorphism was regulating the epigenetic 
state, in most cases by the creation or abrogation of a SNP-CpG.  SNP-CpGs display 0, 50 or 
100% methylation and are therefore likely to be called as DMRs or MVPs in a study such as this 
with a small sample size.  The allelic variation at these SNP-CpGs is likely to be a random 
genetic event rather than anything associated with the environmental exposure of phenotypic 
outcome.  Evidence from Chapter 2 suggests that a far larger sample size is required to detect 
association between risk alleles and methylation status even within a study targeted to known 
genetic variations.  A far larger sample size (probably in the hundreds or thousands) would be 
required to detect the contribution from unknown SNPs and this is far beyond the remit and 
economics of this study.   
 
The preponderance of SNP-associated MVPs from the 450k dataset suggests that a combined 
genetic-epigenetic approach should be taken in future studies to identify the epigenomic basis 
of programming in this model.  Pure epialleles, i.e. stable epigenetic variants independent of 
genetic state, may be a feature of developmental programming in humans, but the data from 
this study suggests that a far larger study would also be required to identify these as 
preliminary evidence suggests that they may be associated with minimal variation in 
methylation of the order of 2-5% (89).   Data from the 450k array shows that the data 
generated from the 10 vs. 10 MVP call was significantly underpowered to detect such 
methylation differences between the cases and controls, despite good performance of the 
array itself with minimal data lost for technical reasons such as cross-hybridisation or poor 
quality probe binding.  The MVPs that were called were statistically too weak for control of 
multiple hypothesis testing and therefore must include a high false discovery rate.   Future 
studies must incorporate power calculations based on the knowledge generated from this 
dataset, including an understanding of the background ‘noise’ of data generated from this 
array.  However, such power calculations are difficult as the amount of DNA methylation 
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variation that is functionally relevant is not known and is likely to vary according to a complex 
range of other genetic and epigenetic phenomena.  An alternative approach to identifying the 
epigenetic differences associated with variations in one-carbon metabolism is to understand 
the consequences of direct exposure, without the transgenerational/fetal programming angle.  
Additional studies using an adipose cell line exposed to varying B12 and folate environments 
are currently underway with collaborators and will be discussed in Chapter 8.  Such model 
systems offer the opportunity to study more detailed functional effects, including integrated 
genomic, epigenomic and transcriptomic platforms.  A similar model in humans, using young 
adults in Pune before and after B12 replacement is being performed by a collaborating group 
in Southampton (Caroline Fall, Karen Lillycrop and Mark Hanson) and personal communication 
of their preliminary data suggests that studying individuals pre- and post-intervention is an 
effective way to increase power to detect differences and uncover relevant biology.  
 
The Medip-seq dataset generated in these experiments has many disadvantages compared to 
array data.  The potential experimental bias from variable fragment sizes and Medip 
enrichment, are likely to be important factors in obscuring true biological variation in DNA 
methylation.  Careful optimisation of experiments was performed to try and overcome these 
types of biases, and it is unlikely that they could be improved further.  Increased sequencing 
depth is likely to overcome some of these issues, however the financial cost and bioinformatic 
workload consequent from this could be prohibitive.  Given the findings that many DMRs and 
MVPs identified in these studies are located at SNP-CpGs or may be associated with cis or trans 
effects, the lack of single base resolution from Medip-seq is a significant disadvantage.  
Quantitative methylation estimates across the Medip-seq bioinformatic windows do not 
provide significant resolution to identify whether it is a genetic feature driving a methylation 
differences and studies using targeted BS-pyrosequencing or Sequenom are required to 
elucidate the underlying architecture of these DMRs.   
 
At the present time, a shortlist of the Medip-seq DMRs from the combined USeq and Thomas 
Down calling strategy, and super-selected by functional interest and statistical significance, are 
undergoing technical validation.  This validation is being performed using Sequenom by 
collaborators (Giriraj Chandak et al, CCMB Hyderabad, India) who have additional DNA for 
validation experiments.   In the first instance, the methylation state of these DMRs in the same 
samples used will be assessed as technical validation of the platform; this will help direct the 
methodology for future epigenomic studies.  Should these DMRs technically validate, 
replication in a larger sample may be performed and, given the control for false discovery rates 
in the USeq analysis, it may be that these are true DMRs.   
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One of the objectives of this study was that it should provide an ‘unbiased’ view of epigenetic 
variation, with no a priori hypothesis as to where this variation would be occurring (other than 
that determined by the presence of CpG sites capable of methylation).  As discussed, the 
approach and study design did unintentionally incorporate bias towards genetically driven 
methylation differences as they create large differences in methylation that are reproducible 
and widespread across the genome.  Since the design and implementation of these 
experiments, more researchers are using BS-seq as a means of studying DNA methylation 
across the genome and this now offers the gold standard approach.  BS-seq is costly and 
analytically challenging but provides an epigenomic view of DNA methylation unbiased by 
genetics and can give a single-base resolution suitable for combined detection of genetic 
variants such as SNPs.   
 
The functional relevance of DMRs and MVPs identified in these experiments has not been 
determined.  When viewed on standard genome browsers, many of the Medip-seq DMRs 
overlap regions of possible regulatory function.  These sites are represented by data tracks 
from resources such as ENCODE, and Pol2 binding, nucleosome positioning, the location of 
DNase hypersensitivity sites and CTCF binding.  These findings are of potential interest as it is 
important to consider the integrative role of DNA methylation with higher-order epigenetic 
modifications, e.g. histone modifications and chromatin packaging.  The identification of co-
methylation within some DMRs, often associated with SNP-CpGs or putative cis-acting effects, 
is important in the possible biological plausibility of these methylation changes.  Other 
important considerations in the interpretation of epigenomic data are how local (cis) or long-
range effects (trans) may exert control of DNA methylation.  These important factors will be 
discussed in more detail in Chapter 8.   
 
 Another objective of this study was to demonstrate the feasibility of using whole blood to 
detect differences in DNA methylation associated with a model of in utero programming.  
Whole blood sampling is a relatively practical, acceptable and cheap means of obtaining 
biological material for genetic studies in large clinical cohorts and has been the commonest 
tissue used in genomic studies such as GWAS.  The choice of tissue in epigenetic and 
epigenomic studies is a more complex one and will be discussed in detail in Chapter 8.  In the 
PMNS model presented here, it was felt that whole blood was a suitable tissue to use to 
generate epigenomic insights as the adverse environment that is associated with the 
programmed offspring phenotype was present in the periconceptual period.  Epigenetic 
modifications can be induced through early developmental environmental exposure (in 
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gametogenesis and early embryogenesis) and can affect all 3 developing germ layers.  For this 
reason, it is thought that whole blood may carry the molecular ‘memory’ of this programming 
and furthermore, its possible role in the inflammatory and thrombotic pathways suggest it 
may hold tissue-specific epigenetic changes that relate to the obese and insulin resistant 
phenotype observed.   However, whole blood does contain mixed cell types and therefore 
differences in cell counts may result in false positive results.  
 
These studies highlighted the importance of sample collection, storage and processing and 
that the resulting purity of samples is paramount to the data generated from these studies.  
The sample contamination identified in the first set of biological material processed in this 
study could have been misinterpreted as an experimental difference had the samples not been 
processed and analysed individually.  Larger studies in the future are going to need to address 
the sensitivity of epigenomic studies to sample contamination carefully, especially in studies 
where sample pooling strategies are used.   
 
 
Finally, it must be considered whether this epigenomic study provides any molecular support 
of the epidemiological and clinical evidence of fetal programming from alterations in maternal 
B12/folate status.  Technical validation of the Medip-seq DMRs is going to be important to 
decide whether any of these may have a biological role in this fetal programming.  The location 
of some of these DMRs at regulatory elements, should they validate and replicate, may 
suggest a functional role in transcriptional regulation that could be far-reaching and affect a 
number of biological pathways involved in insulin resistance and the development of obesity.  
It is interesting to note that both Medip-seq and 450k array analysis yielded a greater number 
of hypomethylated DMRs/MVPs that hypermethylated ones.  This finding might be expected 
given that a low B12 environment would be expected to reduce the production of methyl 
groups for DNA methylation, therefore resulting in a propensity to hypomethylation.  Further 
studies would also need to determine whether the epigenetic differences identified are 
primary phenomena or secondary to the phenotype that had already developed in the 
offspring studied in the case group.  This is particularly important as the samples selected in 
this study were enriched for the programmed and control phenotypes in order to maximise 
the potential outcome.   
 
Possible confounders in the design of this study, and the wider PMNS study, come from the 
role of postnatal environmental differences.  Although serum vitamin B12 levels were the 
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same in 6-year old offspring born to case and control mothers, the immediate postnatal 
conditions of each group of offspring were not characterised.  It is conceivable that the 
neonates born to B12 deficient mothers would remain deficient themselves during lactation 
and given that the familial environment and dietary behaviours are often similar.   
 
Since performing this study, data from a rat model has recently provided further evidence of 
the role of one-carbon metabolite deficiencies in the pathogenesis of obesity and diabetes 
(184).  This model exposed female Wistar rats to either folate, B12 or combined folate and B12 
deficiency and compared these, in the pre-pregnant state, to controls.  After 3 months of 
dietary restriction and pectin administration (to reduce intestinal absorption of these 
nutrients), nutritional deficiencies were confirmed biochemically and were said to be 
equivalent to human dietary deficiency.  Some of these female rats were examined 
phenotypically after 3 months and measures of body weight, body composition (using total 
body electrical conductivity) and fat mass (dissected fat pad weights) were calculated.  There 
were differences (p<0.05) in body weight in the folate deficient and B12 deficient rats, as well 
as altered body composition (increased fat) and increased fat mass in B12 deficient and folate 
deficient rats, respectively.  Exposure to these dietary deficiencies were continued in 48 rats 
through pregnancy, weaning and into their male F1 generation and similar phenotypic 
assessment was performed in offspring until 12 months of age.  By 12 months of age, the male 
F1 generation exposed to folate, B12 and combined deficiencies showed significantly increased 
(p<0.01) body weight, body fat and fat mass compared to controls.  In addition, all 3 groups 
showed higher plasma cholesterol, triglycerides and some features of a pro-inflammatory 
state, including elevated TNFa, IL-6, IL-1b, and reduced adiponectin in most of the exposed 
groups.  These findings provide convincing evidence of the direct effects of variable one-
carbon deficiencies on fat accumulation, and it could be inferred that there is some direct link 
via adipogenesis.   The authors develop this hypothesis by measuring fatty acid synthase and 
acetyl-CoA-carboxylase activity in the livers of the 12 month-old male offspring, finding 
increased activity of both of these adipogenic proteins in the livers of deficient animals.   To 
add to this hypothesis, other studies have shown a link between vitamin B12 deficiency and 
accumulation of liver fat (185).   Unfortunately, this model does not provide evidence of the 
potential ‘programming’ effect of maternal deficiency as the offspring have been directly 
exposed to the same dietary conditions as their mothers in their post-natal life.  It also does 
not look at the state of combined maternal B12 deficiency and folate repletion characterised in 
the PMNS data, described earlier, that conferred the highest risk of adiposity and insulin 
resistance through programming.   
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The evidence from these animal models, as well as the difficulties encountered with studying 
the epigenome of the offspring born to PMNS in this study, highlights the need for careful 
study design in the future.   Future studies should incorporate model systems in order that 
tissue-specific mechanisms can be identified in molecular studies, and this could include 
animal models or cell line experiments.  Animal models also have the advantage of being able 
to study long-term phenotypic outcomes in a manageable time window and this is also 
important in order to correlate epigenetic and expression differences with direct 
environmental exposure and outcome.  The use of inbred animal strains or cell lines also 
enables the identification of pure epigenetic phenomena, isolated from the complex genetic-
epigenetic interactions that are identified in human studies.  In human studies, intervention 
studies may provide the most useful means of differentiating primary and secondary 
epigenetic modifications, and this will be discussed in more detail in Chapter 8.    
  
 179 
Chapter 5:  Matlab Famine Study 
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5.1 Introduction 
5.1.1 Background to Matlab Study 
As discussed in chapter 1, in utero famine exposure has been characterised as a model of the 
fetal programming of adult diseases such as type 2 diabetes, hypertension and major affective 
disorders in the Dutch Winter Hunger and Chinese Great Leap Forward studies.  These studies 
complement the original observation from Barker et al that associated low birth weight with 
an increased risk of type 2 diabetes in later life.  In recent years, researchers have found 
preliminary evidence for possible epigenetic mechanisms linking the aberrant maternal 
environmental to the developing fetal genome, showing differences in DNA methylation of 
candidate genes in adults exposed to famine.  However, as yet, this data has not been 
replicated beyond the Dutch Winter Hunger Study and is limited to the study of specific 
candidate genes that are assumed to have a role in the programmed disease.  Interestingly, 
although the Dutch Winter Hunger studies have shown that famine-exposed offspring display 
insulin secretion defects (48), the candidate genes studied in recent epigenetic studies are 
focused on insulin resistance pathways.  The merits of taking an unbiased epigenomic 
approach to study complex gene-environment interactions have previously been considered 
and this discovery-based approach will be exploited in this study to generate new insights into 
the mechanisms of fetal programming. 
 
In this study, an epigenomic study of DNA methylation from offspring born to another famine 
study will be performed.  This famine study is based in Matlab, a rural area 100km from Dhaka 
in the Chandpur district of the Chittagong division of Bangladesh.  The study is run by the 
International Centre for Diarrhoea Disease Research, Bangladesh (ICDDR,B) and the Principal 
Investigator of the study is Dewan Alam, Head of the Chronic Non-Communicable Disease Unit.   
Dewan Alam and others have described the background population in Matlab in their Health 
and Demographic Surveillance System (HDSS) of 517 men and women aged 27-50 years.  This 
survey was not designed to study the famine-exposed, but by its cross-sectional nature across 
this age group will incorporate many individuals who were exposed to famine at some stage in 
their early life.  The results of the survey show that Matlab has many individuals who are 
underweight (40% of men and 27% of women) but that in addition to this, overweight and 
obesity are also prevalent, with 7% of men and 14% of women having a BMI>25 kg/m2.   Of the 
participants studied, 3% had type 2 diabetes and a further 9% had impaired glucose tolerance.  
Overweight and obesity were usually accompanied by abdominal obesity and this was strongly 
associated with glucose abnormalities.   
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The Matlab Famine Study comprises adult cohorts in this same region that were exposed to 
famine in early life, during the Bangladesh famine that occurred between 1974-1975.  The 
famine occurred 2 years after the Bangladeshi war of Independence and arose due to crop 
failure, lower purchasing power and grain imports (Alamgir, 1980).  The famine was 
responsible for several million deaths across Bangladesh due to starvation and associated 
infectious diseases such as cholera.  The specific nutritional deficits associated with famine 
exposure have not been characterised, but the severity of the famine would suggest that it 
included deficiencies of a variety of macronutrients and micronutrients.   
Two cohorts have been created in Matlab, a birth cohort of individuals exposed to famine 
before, during or soon after birth, and a second cohort of individuals exposed peri-pubertally.  
These cohorts were formed in 2000-2002 by researchers at ICDDR,B using community-wide 
recruitment of individuals that had previously been exposed to famine, as per the defined 
groups above.  At the time of sampling, the birth cohort aged 27-32 years and the peri-
pubertal exposure cohort aged 38-50 years.  The study followed standard consent procedures 
set out by ICDDR,B and the institute has a long history of successful research and engagement 
with the local community in Matlab.  Individuals within the cohorts were randomly selected 
individuals to be in a pilot study of the long-term health outcomes, focused on cardiometabolic 
diseases, of famine exposure.  Measurements of blood pressure, body mass index, and waist 
circumference were performed, as well as 75g oral glucose tolerance tests (WHO standard) 
and fasting lipid profiles on over 500 individuals.  The results of this study (unpublished) are 
summarised in table 5a. 
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 Birth cohort Peri-pubertal cohort 
Number 219 298 
Mean age (years) 29.5±1.3 43.1±4.2* 
Smokers (%) 21.9 25.5 
Owner of cultivatable land (%) 39.7 43.0 
Family size (mean number of children) 5.5±2.5 5.9±2.6 
Education (mean number of years) 5.8±5.1 3.9±4.8* 
 Male Female Male Female 
Mean BMI (kg/m2) 19.6±2.5 20.3±3.0 19.9±3.2 21.3±3.7 
BMI <18.5 (%) 40.9 33.3 39.7 22.2 
BMI ≥25 (%) 4.3 8.7 8.1 17.3 
Abdominal obesity (% >90cm in males, >80cm in females) 2.2 14.1 8.8 24.1 
Systolic hypertension (% ≥140mmHg) 1.1 0.8 4.4 8.0 
Diastolic hypertension (% ≥90mmHg) 0 2.4 5.9 8.0 
Mean fasting glucose (mmol/l) 4.8±0.5 4.7±0.5 5.1±1.1 5.2±1.7 
Impaired fasting glucose (%) 8.6 2.4 12.5 17.3 
Mean 120 mins glucose (mmol/l) 4.8±1.4 6.0±1.7 5.6±2.4 6.6±3.5 
Impaired glucose tolerance (%) 3.2 8.7 8.8 11.7 
Type 2 Diabetes (%) 0 5.1 3.2 8.1 
Metabolic syndrome (%) 2.2 4.0 5.9 14.2*~ 
Table 5a.  Summary of clinical data from participants in the Matlab famine study.  * = difference at p 
<0.05, ~ differences significant between females in each cohort and males vs. females.  Metabolic 
syndrome was diagnosed with NCEP ATP III criteria. ADA criteria used:  Impaired fasting glucose ≥5.6 to 
<7.0 mmol/l, Impaired glucose tolerance 120mins glucose ≥7.8 to <11.1 mmol/l. 
 
These data show that across the entire Matlab cohort, exposed to famine around birth or peri-
pubertally, there is a high prevalence of hypertension, impaired fasting glucose, impaired 
glucose tolerance, type 2 diabetes and metabolic syndrome in adults, in keeping with that 
described in the HDSS.  Results from the famine cohort cannot be compared to the HDSS 
directly as they are not age-matched, and also because participants in the HDSS may also have 
been exposed to famine.  However, it can be concluded that this rural population does have a 
high risk of cardiometabolic diseases despite still showing the striking features of a region that 
continues to be severely impoverished, e.g. low literacy rates, large family sizes and greater 
than one-third of individuals being underweight.  The observed diabetes prevalence in these 
cohorts falls somewhere between the estimated prevalence of 8.1% and 2.3% in urban- and 
rural-dwelling Bangladeshis (respectively) (186).  The genetic predisposition of the Bangladeshi 
population towards diabetes is not known but genetic diversity in Bangladesh is thought to be 
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similar to related ethnic subgroups in India and these are considered, but not yet proved, to 
have a higher genetic tendency towards type 2 diabetes.  
In addition to the data presented from the birth and peri-pubertal cohorts, specific data was 
collected according to timing of famine exposure in the birth cohort.  The participants formed 
three groups;  
Group A: Born before the onset of famine, and therefore exposed to famine in early 
childhood. 
Group B: Born during famine, and therefore exposed to famine in utero.  . 
Group C: Born after famine, and therefore not directly exposed to famine.   
 
Phenotypic data for each of the three groups was then collated and analysed, by researchers 
at ICDDR,B (see table 5b).  Unfortunately, there is no data on trimester-specific exposure 
within the ‘born during famine’ group.  It is also important to note that although the ‘born 
after famine’ group was not directly exposed to famine, it is likely that they were indirectly 
exposed via exposure of the parental germline.  
 
Group A Group B Group C 
Born before famine 
Exposure in early 
childhood 
Born during 
famine 
Exposure in utero 
Born after 
famine 
Unexposed 
Number 81 68 70 
Mean age (years)  30.80.35 29.00.28 27.90.31 
Male (%)  42 41 44 
Mean weight (kg) 49.77.9 47.48.6 49.46.9 
Mean height (cm) 156.47.9 155.68.1 156.98.6 
Mean BMI (kg/m
2
) 20.33.0 19.52.8 20.12.5 
BMI <18.5 (%)  32 48.5 30.0 
BMI 18.5 - 24.9  59.3 45.6 64.3 
BMI ≥25  8.6 5.9 6.8 
Fasting plasma glucose 
(mmol/l) 
4.790.53  4.760.48  4.670.57  
Impaired fasting glucose (%) 6.2  5.9  2.9  
Mean 120 mins glucose 
(mmol/l) 
5.211.38  5.761.60  5.582.02  
Impaired glucose tolerance (%) 3.7  11.8  4.3  
Table 5b.  Clinical data from Matlab famine study birth cohort, showing phenotypic outcomes in those 
exposed and unexposed to famine. 
 184 
Evidence from the Dutch Winter Hunger and Chinese Great Leap Forward studies would 
suggest that the in utero exposure group would be expected to show that famine exposure in 
utero is associated with a higher prevalence of diabetes, and specifically, that this may be 
driven by a problem with insulin secretion, manifest by a raised fasting glucose.  In these data, 
an increased tendency towards impaired glucose tolerance is observed, with an odds ratio of 
3.39 in the in utero famine exposure group (group B) compared to groups A and C.  Raw data 
from Bangladeshi has not been accessible or analysed further to identify whether any of the 
other observed phenotypic differences between exposure groups are statistically significant.  It 
can be seen that there is a higher rate of impaired fasting glucose in both group A and group B, 
compared to group C, but a statistical test has not been performed to evaluate the strength of 
these differences any further.  The odds ratio of the in utero exposed group having impaired 
glucose tolerance compared to the other two groups was 3.39 (95% confidence interval 1.02-
11.28). 
 
5.1.2 Specific aims of this study 
Hypothesis 1:  Direct famine exposure in early developmental life may be associated with 
epigenetic variation.  The timing of this direct exposure, in utero or early postnatal life, may 
influence whether programming occurs. 
On the basis of these data presented above, the primary hypothesis of this study is that group 
B (in utero famine exposure) forms our exposure group, but that group A is a second exposure 
group and that both may show the epigenetic marks of direct famine exposure in early 
developmental life.  Further, it could be assumed that the absence of direct exposure to 
famine in Group C makes this the control group with which to compare groups A and B.  
However, as there is no published data with which to support this hypothesis, the epigenetic 
studies have been designed to compare all 3 groups as distinct entities and then look for 
possible commonality across groups.  The phenotypic data and previously published work from 
the Dutch and Chinese studies will be used in support of group B as being the ‘programmed’ 
group, but the incomplete data analysis of the former and limited applicability to this study of 
the latter will not be used to make assumptions.   
 
Hypothesis 2:  Three-group analysis of those exposed to famine before, during and after in 
utero life may identify the timing at which programming occurs, but may also reflect the 
tissue-specificity of epigenetic signatures. 
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A secondary hypothesis that will be considered is that exposure to famine during different 
time windows may result in tissue-specific epigenetic consequences that are not going to be 
detectable in this study, which uses a single tissue type.  If differential methylation is seen only 
in association with famine exposure in utero, this may be a consequence of the environmental 
insult having occurred before the 3 embryonic germ layers have started on their differential 
developmental course and therefore having a detectable effect on all tissues.  In contrast, it 
could be expected that those exposed in later embryogenesis or postnatal life, may not 
develop pervasive and stable epigenetic marks in all tissues and if they do exist, they may be 
restricted to tissues with a direct functional role in aetiology such as fat, muscle or liver.   
 
Hypothesis 3:  Identification of epigenetic marks associated with famine exposure may 
characterise secondary phenotypic consequences, rather than the primary programmed event 
itself.   
This same issue has been discussed in Chapter 3, in relation to the Pune study.  The 3 group 
study design in this Matlab cohort may allow some additional insight into primary versus 
secondary epigenetic events as the strongest phenotypic outcome appears to be in group B 
but exposure to famine has occurred in group A and B.  Therefore, should the same epigenetic 
signature appear in both group A and B, it could be interpreted that this is phenotype-
independent. 
 
 
 
5.2 Methods 
 
5.2.1 Matlab Famine Study 
DNA samples collected from individuals in the Famine Study were used to investigate the 
possible long-term effects of programming on diabetes risk.  Only the birth cohort, and not the 
peri-pubertal cohort described above, was used to test the hypotheses set out above. 
Three groups of offspring born to the famine study were selected, comprising the following: 
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Group A:  Offspring born before famine exposure, i.e. exposed to famine in early 
childhood 
Group B:  Offspring born during famine exposure, i.e. exposure in utero (in whom the 
highest risk of impaired glucose tolerance was observed) 
Group C:  Offspring born after famine exposure, i.e. unexposed, but maternal exposure 
to famine before pregnancy. 
 
5.2.2 Sample collection and selection 
Whole blood genomic DNA samples from 120 (40 per group) male and female participants 
born to the Matlab Famine Study were used (see table 5c) and comprised a random selection 
of the complete collection of study samples with no selection towards phenotypic outcome or 
any other variable.  These samples had been collected previously, when the participants of this 
study were aged 27-32 years old, for the phenotypic study described above as well as for 
future use in genomic experiments.  Samples had been stored at the ICDDR,B campus in 
Matlab in a -80oC freezer since collection in 2004.  Consent had been taken at the time of 
collection for genetic studies by the local research team, but re-consenting took place by the 
same research team in order to use these same samples for epigenetic research, under 
consent procedures set out and approved by the ICDDR,B ethics board. 
 
Exposure group Dates of exposure 
Age at 
sampling 
Sample number 
Group A:  
Born before famine 
April – June 1974 27 40 
Group B:  
Born during famine 
Dec ’74 – Nov ‘75 30 40 
Group C:  
Born after famine 
April – June 1976 32 40 
Table 5c.  Details of used in Matlab famine study epigenomic experiments. 
   
The initial design for this experiment included 30 mixed sex samples per experimental group 
(i.e. total n = 90) that were randomly selected from the entire sample set (n = 120).  This 
sample size was determined by cost constraints at the time.  Following this first experiment, 
extra funds became available to put the remaining samples through the same experiments and 
therefore a second batch of samples was run as validation. 
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5.2.3 DNA extraction and preparation 
Whole blood samples were transported at 4oC to ICDDR,B, Dhaka.  Genomic DNA was 
extracted by Dr Shamim Iqbal, postdoctoral researcher at ICDDR,B, under the supervision of 
Sarah Finer, using a Qiagen QiaAmp Maxi kit using the standard protocol.  The extracted DNA 
was split into two aliquots; one was stored at ICDDR,B and the other was transported at room 
temperature by Shamim Iqbal to the Blizard Institute.  On arrival at the Blizard Institute, DNA 
quality was checked on agarose gels, and quantified using a Qubit system.   
 
5.2.4 Illumina HumanMethylation Array 
Genomic DNA samples underwent bisulphite conversion using a starting quantity of 500ng 
DNA.  Bisulphite conversion and qPCR test of conversion efficiency were performed as 
described in section 2.4.1.1 and 2.4.1.1. 
 
Samples were randomly assigned to 96-well plates with samples from another experiment that 
was running concurrently.  Batch 1 included 90 samples (30 per experimental group) as well as 
2 water controls.  A second batch included 55 samples, incorporating the 30 samples that had 
not yet been run on the 450k array as well as repeat samples (technical repeats and inter-
batch duplicates) from batch 1 and water controls.  No intra-batch sample duplicates were run. 
The samples were put through the standard protocol for 450k array hybridisation and 
processing, and this was performed by UCL Genomics. 
 
5.2.5 Data QC and analysis 
5.2.5.1 All samples 
Data QC, processing and analysis was performed according to the protocol set out in section 
2.5.4.  As the experimental samples were from a mixed sex population, X and Y probes were 
filtered out as well as the standard removal of cross-hybridising probes.  The sex of the 
offspring determined by the data sent to us from ICDDR,B was cross-validated with 
visualisation of the Y chromosome probes in all samples (a specific pattern of methylation is 
seen across these probes according to the sex of the DNA source). 
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Batch 1 samples were analysed according to standard protocols, using MDS plots and then 
MVP calling.  Batch 2 samples went through the same protocols including an MVP call, but the 
data produced from these samples was used for validation of batch 1 and therefore the data 
was also analysed as such.  The methods used in this validation strategy will be discussed as 
the results are presented but include identification of overlapping MVPs and concordant 
directionality of methylation difference between each batch.  Batch 2 also contained inter-
batch duplicate samples with which an estimate of batch difference in array performance 
could be made and incorporated into the understanding of the data output.     
 
 
5.3 Results 
 
5.3.1 DNA quality 
Some DNA samples showed degradation of the high molecular weight DNA when visualised on 
agarose gels (Figure 5a), but this did not appear to affect their performance at any of the 
quality control checks during the subsequent steps of the experimental protocol.  There did 
not appear to be significant RNA contamination.  Qubit concentrations were used to identify 
the concentration of pure DNA. 
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Figure 5a.  Agarose gels of DNA samples extracted from Matlab study participants 
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5.3.2 Illumina 450k methylation array data 
5.3.2.1 All samples 
A check of samples was performed on the Y chromosome probes to confirm that the sex of the 
samples was as expected from the participant database.  DNA from males shows a predicted 
bimodal distribution of beta values with a large peak at low CpG densities and second (smaller) 
peak at high CpG densities (see figure 5b).  Female DNA shows an erratic distribution of beta 
values across the Y probes with lower beta values due to the minimal probe binding in the 
absence of an X chromosome.  The presence of any methylation signal from female DNA at Y 
probes is thought to reflect cross-hybridisation from sequence homology between the X and Y 
chromosomes.   These cross-hybridising probes are subsequently removed from analysis by 
the QC filters.  This QC process confirmed the expected sample gender in all, and this was 
considered to be a reassurance that samples had not been swapped or mislabelled.   
 
Figure 5b.  Beta values from Y chromosome probes in a selection of samples from batch 1.  Y axis = beta 
value; X axis = CpG density.  This data shows clear and expected distinction between male DNA (e.g. 
A003) and female DNA (A097). 
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5.3.2.2 Batch 1 samples 
Standard QC checks of each step of the experimental protocol (from bisulphite conversion to 
all aspects of probe hybridisation and staining) confirmed that this had been performed 
successfully (data not shown).  Subsequently, the data was normalised and standard data 
filters were applied to remove X and Y probes as well as those that cross-hybridised. 
An MDS plot was generated for the data from batch 1 (figure 5c) and this identified 12 samples 
that had been hybridised to one complete array clustered away from the other samples.  The 
defined clustering of the randomised group of samples hybridised to this array suggested that 
this was a technical problem and one that was associated with an array or hybridisation 
problem rather than an issue with anything upstream, such as the bisulphite conversion.  The 
detailed QC plots for each step of the experimental pathway do not highlight where in the 
array processing this problem lay, but it was decided that the data indicated a chip failure and 
it was therefore excluded from subsequent analyses.  As a result, all 12 samples that had been 
hybridised to this array were removed from further analysis, leaving 78 samples (29 from 
group A, 25 from group B and 24 from group C) to be analysed in this experiment.   These 
samples were repeated in the second batch of arrays. 
 
Figure 5c. MDS plot of 90 Matlab samples from batch 1 (after normalisation).  This shows plot identifies 
12 outlying samples (circled in red) that were run on a single chip. 
 192 
A summary of the 78 samples selected for batch 1 analysis, after exclusion of the chip failure 
samples, is presented below (table 5d).  The data shows an imbalance of males and females 
across the sample groups due to the random sampling and exclusion of some samples for 
technical reasons.  The results of a Chi-squared test suggest that there is no overall difference 
at a statistically significant level across groups however, on observation of the differences, it 
does appear to be important, especially in Group C. 
 
Exposure group Number of samples Males Females 
Group A:  29 11 18 
Group B:  25 13 12 
Group C:  24 7 17 
Total 78 31 37 
Table 5d. Sample numbers used for analysis of batch 1.  Chi-Squared 2.7, df 2, p = 0.255. 
 
5.3.2.3 Batch 2 samples 
There were no concerns with the performance of the second batch of samples as they passed 
through the experimental steps and QCs.  Data from all 55 samples was normalised 
(independently of batch 1) and was used for downstream analysis.  The sample numbers are 
presented in table 5e. 
Exposure group Number of samples Males Females 
Group A:  14 9 5 
Group B:  19 7 12 
Group C:  22 8 14 
Total 55 24 31 
Table 5e. Sample numbers used for analysis of batch 2.  Chi-Squared 3.3, df 2, p = 0.20 
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5.3.2.4 Batch differences 
Samples from batch 1 and batch 2 compared using pre- and post-normalised data to examine 
overall data quality and make comparisons between them.  An MDS plot of pre-normalised 
data (after X, Y and cross-hybridising probes and chip failures were removed) showed a clear 
distinction between batch 1 and 2, however, each batch clustered well (figure 5d). 
   
Figure 5d. MDS plot of batch 1 samples (green) and batch 2 samples (orange).  The data is presented 
after X, Y and cross-hybridising probe filters have been applied, chip failures have been removed, but 
pre-normalisation of each dataset has not yet taken place.  
 
An MDS plot of the two datasets post-normalisation again shows distinct clustering between 
batch 1 and 2 but the differences are small and the clusters appear tighter (figure 5e).   
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Figure 5e.  MDS plot of batch 1 samples (green) and batch 2 samples (orange) using normalised data 
(and filters applied as per figure 5d) 
 
 
5.3.2.5 Controlling for batch effects 
With any array experiment, batch effects can introduce variation between batches due to the 
inevitable technical variability between experiments, despite standardised experimental 
protocols and the use of robotics.  The careful quality control checks that were performed in 
all experiments ensures that the batch differences are not due to a specific technical problem 
that could introduce significant bias into the datasets.  The QC plots from both batch 1 and 2, 
were analysed carefully and problem samples from batch 1 were removed and re-run with 
batch 2, along with inter-batch duplicates.  Duplicate samples allowed careful examination of 
the data QCs to ensure that the variation between them was within what would be expected 
from batch differences. 
Batch effects may be controlled through normalisation if the differences that they produce are 
linear rather than random.  Controlling batch effects that are non-linear, or random with 
 195 
normalisation introduces an artificial assumption that the data varies in the same way.  If such 
data is normalised, a bias will be introduced that may mask true differences and/or reduce the 
control of false positives.   
 
Batch effects were seen between batch 1 and 2, and these are easily visible in the MDS plots 
(figures 5d and 5e).  The nature of the batch effects, including whether the differences were 
linear or random, was examined further with an additional plot (figure 5f).  In this plot, one 
pair of sample duplicates from both batches are taken and the probes showing <1% 
methylation difference between the duplicates selected (X = 1st batch; Y = 2nd batch).  The beta 
values at these probes are then identified in 3 other sample duplicates (marked in blue, green 
and red) as a way of visualising the noise between the samples across the two batches.  The 
noise is not linear, making it difficult to correct.  There is some linearity, but only a minimal 
amount and this is unlikely to have much effect on the ability to validate MVPs across the 
arrays. 
 
 
Figure 5f.  XY plot examining the differences between batch 1 (X axis) and batch 2 (Y axis) using the 
sample duplicates run across both batches.  The beta values of three sample duplicates (green red and 
blue) at probes identified by a 4
th
 sample duplicate where there are <1% difference in beta values. 
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As a result of this plot showing non-linear inter-batch differences, no batch corrections were 
performed across both datasets as this would have introduced bias.  Both datasets had been 
normalised individually, and the benefits are clearly seen between figures 5d and 5e, but no 
further normalisation was thought appropriate given the potential risks of over-normalisation.   
 
5.3.3 Differential methylation 
5.3.3.1 Three-way MVP call 
A three-way MVP call was performed using an F-test on the 78 samples from batch 1 that had 
passed through the QC procedures.  Of the 12 samples removed due to the chip failure, there 
were 29 group A, 25 group B and 24 group C samples suitable for analysis.  The 3-way test (an 
F-test) identified 4506 MVPs with p values ranging from 4x10-6 to 1x10-2.  Methylation 
differences within these MVP calls ranged from -20 to +20%.  A sensitivity analysis using 
LOOCV reduced this list to 3441 MVPs, with p values between 8x10-6 and 1x10-2.  
As described in the objectives of this study, the hypothesis was that the direct exposure groups 
(A and B) would show methylation difference with group C (born after famine) but that no 
assumptions would be made prior to discovery-based analysis of all 3 groups and the 
differences between them.  After this 3-way MVP call, no post-hoc test was performed to 
identify what groups were driving the biggest difference, instead two-way (pairwise) calls were 
performed to localise which groups were driving the most of the methylation difference.  This 
will be discussed in the subsequent section. 
 
5.3.3.2 Two-way MVP calls 
Two-way MVP calls were performed between groups AB, AC and BC in batch 1 to determine 
which groups were driving methylation differences, and in batch 2 for the purposes of 
validation.  These MVP calls used the same procedure as for 5.3.3.1 except that they employed 
a t-test for the two-way comparison rather than an F-test.   
The two-way calls were performed on batch 1 samples and batch 2 samples, independently of 
each other.  The number of MVPs and their p-value ranges are described in table 5f.  The two-
way calls in the experimental dataset (batch 1) identifies that the largest number of MVPs 
occurs between groups A and C, i.e. those offspring born before and after famine.  The 
comparison of A and B, offspring born before and during famine, produces the second highest 
number of MVPs.  Comparison of groups B and C yielded the fewest MVPs. 
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The list of MVPs generated from batch 2 was not used in their own right as an independent 
dataset to perform further analyses, e.g. GO analysis.  The purpose of the batch 2 calls was to 
validate batch 1 MVPs, and this validation will be discussed in the next section.   
 
 
 
Batch 1 Batch 2 Batch 1 and 2 
 MVPs (n) P value range MVPs (n) P value range Validated MVPs (n) 
AB 3672 3x10
-6
 to 1x10
-2
 1467 2x10
-4
 to 1x10
-2
 2763 
AC 4039 1x10
-5
 to 1x10
-2
 2335 1x10
-6
 to 1x10
-2
 2856 
BC 2237 2x10
-6
 to 1x10
-2
 1983 2x10
-4
 to 1x10
-2
 1525 
 
Table 5f.  MVPs identified in pairwise calls in Batch 1 and Batch 2, after LOOCV, with p value ranges.  The 
MVPs highlighted in yellow indicate those identified in the first call (batch 1) that show similar 
directionality of methylation difference in batch 2, i.e. the validated MVPs. 
 
5.3.3 Validation 
The 55 samples that were processed as batch 2 were used as a validation set to see if they 
could add strength to the 3-way MVP call performed using batch 1.  It is usual to have a smaller 
sample set as the experimental group and use more samples for validation as this enables less 
false negatives to be excluded from analysis.  In this experiment, it was not clear that there 
would be funds to process all the samples at the outset and therefore the maximum number 
of samples was processed in the first round (n = 90, with 78 suitable for analysis).  
Subsequently, more funds became available and the remaining samples (n = 55, including 
repeats from batch 1) were processed and analysed.   
 
5.3.3.1 Validation of Batch 1 MVPs 
First, the MVPs identified in the 3-way call from batch 1 were compared to the MVPs called 
from batch 2.  Due to the small sample size in batch 2, there was a negligible number of MVPs 
produced from a 3-way MVP call.  The MVPs identified from the two-way calls in batch 1 and 2 
also failed to overlap significantly.  The lack of power to detect true MVPs in batch 2 was 
thought to be the reason that this approach to validation was unsuccessful, rather than and 
inappropriate rejection of the null hypothesis.  An additional contributory factor in this 
inability to validate the MVPs directly against each other was the methylation variation 
produced by technical differences, or batch effects, between the batch 1 and 2.   
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In view of this lack of power and the batch effects, it was decided that a different approach 
would be taken to validate the MVPs from the experimental group (batch 1).  The alternative 
approach used identified whether batch 1 MVPs were validated by a similar directionality of 
methylation difference across group comparisons in batch 2.  This method maximised the 
potential from the two datasets that included an experimental group that had sufficient power 
to detect MVPs and a validation set that was underpowered.  In taking this approach, it was 
seen that a high proportion of the MVPs identified from the experimental group were 
validated by the same directionality of methylation in the batch 2 dataset, provides support of 
the technical and biological validity of the MVPs identified. 
In addition to the comparison of batch 1 MVP calls with directionality in batch 2, linear 
regression modelling was performed per pairwise MVP call (i.e. AB; BC; AC).  Regression plots 
were drawn using the direction of change of beta values in the MVPs from batch 1 (X axis) and 
the data from the same probes in the same pairwise group comparisons from batch 2 (Y axis).   
In doing this, it was possible to examine the strength of the association and between the two 
datasets using the output of linear regression modelling, including the intercept of the model 
and the correlation coefficient (R2).   
 
Figure 5g. Validation of Groups A vs. B MVPs. X axis shows the direction of change in batch 1 beta values 
and the Y axis shows direction of change in beta values from batch 2. Intercept = 
-
7x10
-7
, y = 5x10
-2
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Figure 5h. Validation of Groups A vs. C MVPs. X axis shows the direction of change in batch 1 beta values 
and the Y axis shows direction of change in beta values from batch 2. Intercept = 
-
7x10
-4
, y = 0.7 
 
 
Figure 5i. Validation of Groups B vs. C MVPs.  X axis shows the direction of change in batch 1 beta values 
and the Y axis shows the direction of change in beta values from batch 2.  Intercept = 
-
2x10
-3
, y = 0.32 
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These plots (figures 5g, 5h and 5i) show that the pairwise group A vs. group C comparison 
validates best, as shown by the high correlation (R2 = 0.7) between the directionality of 
methylation variation in batch 1 MVPs and the direction of methylation difference when 
comparing the change in methylation variation between A and C at the same probes (figure 
5h).  This was the same comparison that yielded the highest number of MVPs and it is likely, 
therefore, that these are technically and biologically sound.  Group B and C comparisons also 
validated, although the weaker association (R2 0.32) probably reflects the lower number of 
MVPs called (figure 5h).  The group A and B comparison did not validate, as shown by the 
absence of a clearly positive correlation between the two datasets (figure 5g). 
The strength of association between AC and BC calls across both batches provides evidence 
that the methylation differences in these two calls is biologically sound as they have validated 
across different datasets that incorporate different samples.  The BC validation has a lower R2 
value than AC, but this could reflect the fact that there are fewer data points to compare.   The 
presence of reproducible MVPs across the datasets also provides some reassurance that the 
results of these experiments technically validate.  
Identification of a large number of MVPs in AB batch comparisons that do not correlate in the 
linear regression model suggests that these are not true differences and are likely to represent 
what could be expected to occur by chance.    
 
The validation of MVPs was further examined by identification of which overlapped the pair-
wise analyses.  The following Venn diagram (figure 5j) shows the numbers of MVPs from the 
batch 1 that have similar directionality in batch 2, i.e. the validated MVPs.  Understanding that 
the AB MVPs do not validate, the 1454 MVPs that are identified in this comparison alone can 
be considered to be that which is expected by chance.  In contrast, the AC (n=2122) and BC 
(n=958) MVPs are those that are likely to represent the true epigenetic differences in 
association with the famine exposure during pregnancy and in childhood, respectively.  The 
113 validated MVPs that overlap the AC and BC calls may therefore reflect an epigenetic 
signature that is present in famine-exposed individuals, irrespective of the timing of the insult.  
Finally, the 166 AC and 82 BC validated MVPs that overlap are likely to be the background 
‘noise’ or false positives that have arisen from these pair-wise comparisons as these are 
present in the non-validated AB group-wise comparison. 
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Figure 5j.  Venn diagram showing validated Matlab MVPs from pairwise analyses. 
 
 
5.3.3.2 Pathway analysis of validated MVPs 
Gene ontology analysis was performed on the MVPs called from the A vs. C and B vs C analyses 
using the GOstats add-on to the Limma analysis package.  The pathways over-represented in 
the MVP calls are summarised as GO terms in table 5g and 5h.   
 
GO: ID P value 
Odds 
ratio 
Expecte
d count 
Count Term 
GO:0071
363 
0.00000
514 
2.40 18 39 cellular response to growth factor stimulus 
GO:0007
173 
0.00001
105 
2.76 12 28 
epidermal growth factor receptor signaling 
pathway 
GO:0010
523 
0.00002
980 
Inf 0 4 
negative regulation of calcium ion transport 
into cytosol 
GO:0043
271 
0.00004
908 
5.34 3 11 negative regulation of ion transport 
GO:0030
154 
0.00005
879 
1.37 173 219 cell differentiation 
GO:0007
155 
0.00010
903 
1.57 64 93 cell adhesion 
GO:0042
060 
0.00012
292 
1.69 43 68 wound healing 
B-A C-A
C-B 0
958
2122
113
1454
82
166
0
 202 
GO:0009
987 
0.00017
445 
1.46 801 837 cellular process 
GO:0009
725 
0.00028
019 
1.60 49 74 response to hormone stimulus 
GO:0048
011 
0.00032
918 
2.11 16 31 nerve growth factor receptor signaling pathway 
GO:0007
399 
0.00038
618 
1.39 115 149 nervous system development 
GO:0048
856 
0.00039
149 
1.28 251 297 anatomical structure development 
GO:0014
051 
0.00039
588 
25.13 0 4 gamma-aminobutyric acid secretion 
GO:0010
628 
0.00039
821 
1.49 70 98 positive regulation of gene expression 
GO:0001
503 
0.00043
552 
1.99 19 34 ossification 
GO:0031
644 
0.00061
165 
2.14 14 27 regulation of neurological system process 
GO:0071
495 
0.00062
999 
1.65 38 58 cellular response to endogenous stimulus 
GO:0070
887 
0.00065
755 
1.39 100 131 cellular response to chemical stimulus 
GO:0000
381 
0.00067
820 
7.55 1 6 
regulation of alternative nuclear mRNA splicing, 
via spliceosome 
GO:0033
089 
0.00086
952 
16.75 1 4 
positive regulation of T cell differentiation in 
thymus 
Table 5g.  GO analysis of C vs. A validated MVPs. 
 
GO: ID P value 
Odds 
ratio 
Expecte
d count 
Count Term 
GO:0032
990 
0.00000
024 
2.44 22 48 cell part morphogenesis 
GO:0048
667 
0.00000
028 
2.56 19 43 
cell morphogenesis involved in neuron 
differentiation 
GO:0048
812 
0.00000
092 
2.46 19 42 neuron projection morphogenesis 
GO:0022
008 
0.00000
135 
2.02 36 65 neurogenesis 
GO:0030
030 
0.00000
338 
2.08 29 55 cell projection organization 
GO:0048
468 
0.00000
996 
1.87 39 67 cell development 
GO:0000
902 
0.00001
010 
2.01 29 54 cell morphogenesis 
GO:0048
731 
0.00002
467 
1.53 106 144 system development 
GO:0048
646 
0.00003
612 
2.07 23 43 
anatomical structure formation involved in 
morphogenesis 
GO:0009
887 
0.00004
974 
2.05 22 42 organ morphogenesis 
GO:0007
411 
0.00006
910 
2.45 12 27 axon guidance 
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GO:0007
268 
0.00008
687 
2.03 21 40 synaptic transmission 
GO:0050
885 
0.00009
400 
6.51 1 8 neuromuscular process controlling balance 
GO:0035
637 
0.00011
184 
1.96 24 43 multicellular organismal signaling 
GO:0051
960 
0.00016
227 
2.28 13 28 regulation of nervous system development 
GO:0033
152 
0.00017
088 
82.39 0 3 immunoglobulin V(D)J recombination 
GO:0030
182 
0.00022
028 
1.97 21 38 neuron differentiation 
GO:0007
420 
0.00026
558 
2.14 15 30 brain development 
GO:0002
009 
0.00035
023 
2.36 10 23 morphogenesis of an epithelium 
GO:0023
051 
0.00037
237 
1.54 61 87 regulation of signaling 
Table 5h.  GO analysis of A vs. B validated MVPs. 
 
These GO analyses provide a useful insight into the possible biological processes affected by 
the methylation differences.  The representation of growth factor signalling pathways in the 
AC analysis highlights a plausible functional regulatory pathway involved in the development 
of the programmed phenotype.  The representation of GO terms including nervous system 
development, neuron differentiation and neurogenesis is similar to the GO analysis performed 
in the Pune experiments (see section 4.7.4) and that published previously and their inclusion 
may represent the normal methylation variation associated with ubiquitously-expressed genes 
in these pathways, or a role in relevant and common biological processes such as aging (92). 
 
5.3.4 Cross validation of MVPs with related datasets 
It could be considered that specific genomic regions are particularly susceptible to influence by 
an aberrations in the in utero environment, e.g. under-nutrition, and therefore that there 
might be some overlap between regions of methylation variation in studies following a similar 
methodology, such as the Pune study (chapter 4) and published work on samples from the 
Dutch Winter Hunger and Gambian season of birth studies.  In addition to this, identification of 
SNP-dependent methylation at regions characterised in Chapter 3 may provide further 
technical and biological strength to the findings in this study. 
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5.3.4.1 FTO 
The 450k array does not cover the FTO SNP rs8050136 identified as a CpG-SNP in Chapter 3 
and there are no probes tiled to regions within its LD block.  Therefore it was not possible to 
identify possible commonality across these two experiments. 
  
5.3.4.2 Pune 
There was minimal overlapping coverage of Medip-seq DMRs and 450k array probes, and 
therefore these datasets were not compared.  A direct comparison of 450k data from the Pune 
study and Matlab studies has not yet been performed but will look for commonality in MVPs 
identified in both studies and whether this is more than would be expected by chance. 
 
5.3.4.3 Dutch Winter Hunger and Gambian studies 
The regions of differential methylation studied in the Dutch Winter Hunger papers were 
compared to the datasets generated from the Matlab experiments.  The two experiments are 
not directly comparable, as the Dutch study did not use a genome-wide approach, instead 
taking a selection of candidate genes for DNA methylation studies.  Table 5h shows a summary 
of the findings of this comparison.  The IGF2, IL-10, MEG3 and GNASAS loci studied in the 
Dutch studies are well represented by the 450k array. 
MVPs were identified in IGF2, GNASAS and MEG3, and these MVPs validated between batch 1 
and 2 analysis.  The GNASAS and MEG3 loci that overlap show hypermethylation in the Matlab 
exposed groups (groups A and B) compared to the unexposed (group C) and the direction of 
methylation difference is the same as in the Dutch study.  The MEG3 locus studied in the Dutch 
study is within 200bp of the 450k probe where the MVP lies (both are located within the gene 
promoter).  The GNASAS locus in the Dutch study and 450k MVP are not co-located, but both 
reside within the gene body rather than the promoter.  An MVP is located in the IGF2 locus, 
but its direction of methylation difference is opposite to that of the Dutch study locus and this 
is likely to be explained by their different location within the gene (gene body vs. promoter, 
respectively).   
The Gambian study (80) used a different experimental approach that started off genome-wide 
but honed down its MVPs into those that were present across tissue types and unaffected by 
genetic or structural variation, and thus has described stable epialleles.  The two epialleles 
from the Gambian Study that show corresponding methylation variation in Matlab are 
hypermethylated in exposed groups relative to the unexposed.  The genomic coordinates of 
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the Gambian epialleles are not published and therefore it has not been possible to identify 
whether these have a common location within the gene to the MVPs in the Matlab study. 
 
Cohort Gene 
Matlab 
MVP 
identified 
B-val difference in 
exposed vs 
control 
Direction of 
B-val 
difference 
Genomic location 
Dutch Winter 
Hunger (exposure 
= conceived 
during famine) 
IGF2 Yes Hypomethylation Opposite 
Promoter (Dutch); gene body 
(Matlab) 
IL10 No       
LEP No       
ABCA1 No       
GNASAS Yes Hypermethylation Same 
Gene body (Dutch and 
Matlab) 
MEG3 Yes Hypermethylation Same Promoter (Dutch and Matlab) 
Gambian Study 
(exposure = 
conceived during 
rainy season) 
BOLA3 No       
EXD3 Yes Hypermethylation Same Unknown 
PAX8 No       
SLITRK1 No       
ZFYVE2
8 
Yes Hypermethylation Same Unknown 
Table 5h.  Overlap between differentially methylated regions in Gambian and Dutch Winter Hunger 
Studies with Matlab. 
The identification of commonality between the regions of differential methylation identified in 
the Dutch Winter Hunger and Gambian Study and the Matlab study provide reassuring 
external validity of the results.   
 
 
5.4 Discussion 
 
5.4.1. Discussion of findings 
In this study, the long-term consequences of famine exposure during early development on 
DNA methylation patterns have been assessed.  The Matlab famine study has established that 
in utero famine exposure can increase the risk of impaired glucose tolerance in the exposed 
offspring in early adulthood.  These phenotypic findings are consistent with the Dutch Winter 
Hunger and Chinese Great Leap Forward studies and add further weight to the hypothesis that 
the developing embryo and fetus can be ‘programmed’ towards cardiometabolic disease by 
insults in the maternal environment.  Preliminary insights from the study of candidate genes 
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associated with exposure to the Dutch Winter Hunger and Gambian studies suggest that long-
standing epigenetic change from such insults can be stable and detectable from the study of 
whole blood DNA methylation patterns.  The Dutch study suggests, but does not prove, that 
these epigenetic modifications are associated with the programmed cardiometabolic 
phenotype in the adults.  Interestingly, the Dutch studies show that the strongest phenotypic 
outcome is associated with late gestational exposure but the epigenetic changes are 
associated with early gestational exposure.  This finding could be due to the fact that the 
epigenetic marks were studied in whole blood, a tissue that may only carry the signature of a 
developmental insult that has occurred before the division of the embryological germ layers.  
The Dutch Winter Hunger epigenetic studies studied 122 case-control pairs and have the 
additional strength from having sibling controls to reduce the amount of genetic heterogeneity 
between cases and controls. However, the subjects studied were considerably older than in 
the Matlab study and therefore the DNA methylation patterns in the Dutch offspring may have 
become more heterogeneous and affected by ageing-associated epigenetic variation.   
The study presented in this chapter builds on the preliminary evidence from the targeted 
Dutch and Gambian epigenetic studies and presents the first genome-wide view of 
programmed DNA methylation changes associated with early developmental famine exposure.  
The Matlab study offers additional perspective over the Dutch study by its 3 exposure groups 
that include pre-natal, in utero and postnatal exposure, as well as its targeting of a non-mobile 
community-based population in a region with a high diabetes risk in young adults.   
 
 
The findings of this study will now be discussed in relation to the experimental hypotheses set 
out in section 5.1.   
The first hypothesis suggested that direct famine exposure in early developmental life would 
be associated with epigenetic variation, and that the timing of this direct exposure, in utero or 
early postnatal life, may influence whether programming occurs.  This study has identified 
changes in DNA methylation associated with direct famine exposure by comparing the sample 
3 groups in the Matlab study.  Although it was considered likely from the outset that direct 
exposure to famine in groups A and/or B would contrast with group C offspring who were not 
directly exposed, the initial analyses did not make this presumption.  The processed data 
generated was first examined in a three-way analysis (using an F-test) to identify the most 
significant methylation differences that occurred between any of the 3 sample groups.  This 
produced a list of 3441 MVPs within the experimental dataset of 78 samples that passed a 
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sensitivity analysis.  These MVPs did not hold up to p value adjustment for genome-wide 
significance and this reflects a lack of power in the study to differentiate between true 
differences and false discoveries.   
Following the 3-way MVP call, pair-wise group MVP calls were performed to understand which 
of the sample group comparisons were driving the most variation, and with which to perform 
validation of the findings with additional samples.  These analytical steps address the second 
experimental hypothesis that suggests that the comparison of the 3 sample groups may 
identify the developmental time-points that are susceptible to programming.  The pair-wise 
MVP calls were performed between AB, AC and BC groups and generated a much higher total 
number of MVPs in batch 1 (9948) compared to that generated by the 3-way call (3441).  The 
comparison of groups B and C produced the least MVPs, and this is likely to be because of the 
smaller number of samples in these groups, compared to group A, in batch 1.  There were 
fewer MVPs produced in all 3 pair-wise comparisons in batch 2 due to the smaller number of 
samples.  The most important finding of the pair-wise analyses and comparisons is that the 
batch 1 MVPs were validated (by similar directionality of methylation difference) in batch 2 in 
AC and BC comparisons.  This finding is significant, and as the batches contain samples from 
different individuals, it suggests biological validation of the findings, and therefore support 
that direct exposure to famine in utero and in postnatal life induces DNA methylation 
differences and that these are not seen in individuals born after, and therefore not directly 
exposed to, famine. 
It is interesting to discuss the identification of DNA methylation differences in offspring 
exposed to famine postnatally.  The notion that postnatal life, and in particular nutrition, can 
programme adult disease is well founded, but the identification of these marks in whole blood 
is perhaps surprising.  Whole blood is not considered to be a tissue directly relevant to the 
pathogenesis of type 2 diabetes, unlike liver, muscle and pancreas and therefore do the MVPs 
identified have a direct role in the development of type 2 diabetes and the phenotype 
observed in this study?  It is plausible to think that these MVPs have a separate role to the 
phenotype studied, and especially given that they are identified in the postnatally exposed 
group who do not appear to have a programmed phenotype.  However, the GO analysis 
suggests that the epigenetic variants have a role in processes that could affect relevant 
homeostatic mechanisms for cardiometabolic disease, such as altered growth factor signalling.   
The second question that the use of whole blood raises in this study is whether the absence of 
a peri-conceptual insult (e.g. in group A) is further reason for whole blood not to show the 
memory of the environmental insult.  It might be expected that a peri-conceptual insult would 
result in methylation disturbances during epigenetic reprogramming that could then be 
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transmitted to all 3 germ layers that have not yet diverged resulting in detectable marks in all 
tissues including whole blood.  This argument is commonly used in to justify the need for 
relevant tissues to understand the aetiological and pathogenic role of epigenetic variation.  
However, whilst this theory can be easily applied to studies of cancer, where genetic mutations 
and aberrant epigenetic marks may accumulate within tissues, it is more difficult to 
understand in the context of environmentally determined epigenetic change.  If an organism is 
exposed to a significant environmental insult, such as famine, it is not unreasonable to think 
that the epigenetic modifications could be induced in any tissues exposed to the insult.  This is 
principle is exemplified by the ability to detect ageing-specific MVPs whole blood (92), which 
could themselves be considered as a mark of chronic environmental exposure, albeit less well-
defined.  Further work will inform whether tissue specificity is important as important in 
identifying epigenetic marks induced by the external environment of an organism as it is in 
disease models affecting specific tissues.  Functional studies and pathway prediction of the AC 
versus BC MVPs may inform this question by highlighting, for example, aetiological pathways 
with an early developmental role in the BC comparison.  It will important to consider these 
challenging questions in future study design, perhaps through the incorporation of different 
tissue types (where possible) or by sorting whole blood into cellular subtypes with relevance to 
the disease of interest.  Trimester specific information about in utero exposure is also vital to 
understand the relationship between epigenetic processes and development. 
The final hypothesis and objective of this study was to address whether famine exposure-
associated epigenetic marks characterise the primary programmed event or are secondary to 
the phenotypic outcome of it.  The identification of MVPs in offspring exposed in utero and 
postnatally, both susceptible to the cardiometabolic phenotype may indicate that the 
epigenetic events could be secondary events.  However, the phenotypic data from Matlab 
suggests that only the in utero exposed display the phenotype of impaired glucose tolerance, 
and therefore the MVPs that are common to groups A and B should not be expected to be 
purely secondary.  But the small sample number and limited analysis of the phenotypic data 
does not provide conclusive proof of the absence of a diabetic phenotype in Group A, and 
therefore it is difficult to draw a definite conclusion on this.  Larger studies using this 3-group 
approach to study programming may have the benefit of being able to differentiate primary 
from secondary epigenetic events, and a better understanding of the epigenetic signature of 
the studied phenotypes will also facilitate this understanding. 
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5.4.2 Limitations of this study  
There are several limitations of this study that need to be taken into account when 
interpreting its findings.  Importantly, the MVPs identified did not hold up to multiple 
hypothesis testing correction and therefore they must be interpreted with caution due to the 
likelihood of false discoveries.  In characterising the overlap between the non-validating AB 
group comparison, it is possible to generate an estimate of false discovery, but ultimately a 
larger sample size to validate the batch 1 MVPs is necessary.  A second, important limitation of 
this study is the imbalance of males and females in each exposure group.  Although X and Y 
chromosome probe data has been filtered out, there may still be sex-specificity in methylation 
elsewhere in the genome and it is possible that this may be driving some of the MVPs.  This 
limitation could be overcome by performing an MVP call to compare male and female samples 
at autosomal probes to see if there are any MVPs common to those generated in the exposure 
group analysis.  
The concern of all of the studies of epigenetic variation in fetal programming is that of their 
inability to prove causality over association.  This study improves on others in its 3 group 
design, and the evidence of epigenetic variation in the early childhood exposure group who do 
not have the same adverse phenotypic outcome that is evident in the exposed in utero group 
suggests that the epigenetic marks may be causal, or at least pre-date the onset of phenotype.  
Further analysis of the phenotypic data from this study is going to be important to expand on 
this observation, and future studies should incorporate longitudinal sampling so that 
epigenetic marks can be studied before, during and after the onset of the programmed 
phenotype.   Additional insights could also be gained from studying offspring in Matlab that 
have been part of the MINIMat randomised intervention study of micronutrient 
supplementation (187) and elucidating whether epigenetic changes are modifiable through 
nutritional supplementation. 
The genetic tendency towards the cardiometabolic phenotype in this population is assumed 
from background data showing a high prevalence of type 2 diabetes and related conditions.  
There is a paucity of data proving that South Asians have a higher genetic risk of type 2 
diabetes, although it is assumed that this is the case from population-wide observations of 
disease prevalence.  This is an area that needs more research, and epigenomic studies need to 
incorporate an understanding of the association of epigenetic variants with genetic risk 
variants.  This study does not incorporate any genetic insights, and is underpowered to do so in 
its own right.  The Dutch Winter Hunger study group have begun to examine these interactions 
in their work (188) and show weak, but significant, interactions between SNPs and DNA 
methylation within the IGF2/H19 locus.  These kind of studies will require much larger sample 
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numbers to elucidate this interactions in more detail and allele-specific studies of epigenetic 
modifications will be important to characterise the precise molecular changes.  Future work 
within this cohort could however include study design, such as that in Chapter 3, where risk 
haplotypes are studied in order to generate an understanding of cis control over DNA 
methylation.  
Genetic variation is unlikely to cause bias between the three exposure groups in this study.  
However, an understanding of the complex interacting factors that might predispose to a 
diabetic phenotype in offspring with a combined environmental insult are important.  Future 
studies might need to focus on whether certain parent-child genetic factors, such as 
polymorphisms in the glucokinase gene, could influence not only the genetic risk of disease 
within families, but also whether they may hold a particular susceptibility to abnormal fetal 
development in the context of environmental insult.  It is also worth considering the 
evolutionary impact of famine exposure and whether there may be any differences in the 
ability of individuals to conceive during famine.  It could be hypothesised that there is a 
selection pressure towards the ‘fittest’ individuals to reproduce during famine and that there is 
a genetic bias in the exposure groups in this kind of famine study.  Again, these are much wider 
questions that are not going to be addressed by a study of this size, but are important 
considerations in the interpretation of these studies in their wider context. 
The final important limitation of this study is how the ‘control’ group is interpreted in the 
context of famine exposure.  The control group (group C) consists of individuals born to Matlab 
families 6 months after famine exposure, and therefore there was no direct exposure to these 
offspring.  This does not, however, exclude indirect exposure to famine via the parental 
germline and the possible transgenerational transmission of epigenetic marks.  This is a 
contentious area in epigenetic research at the moment, with much focus being put on the 
notion of ‘epigenetic inheritance’ and whether it is a commonplace occurrence in humans.  
Animal studies do show that epigenetic marks, including those which have been induced 
through the environment, may be transmitted across generations, but it remains unclear 
whether this always represents stable inheritance and whether these findings are applicable to 
human models (reviewed in (81)).  Whilst research into this area is ongoing, it is important to 
consider the possibility that marks of parental exposure to famine may be transmitted to the 
offspring in group C and that this could be a limitation in the interpretation of these results.  It 
is not possible to exclude these potential transgenerational influences in the Matlab study 
design as all individuals come from the same rural cohort that was universally exposed to 
famine.  The exclusion of transgenerational epigenetic variants of famine exposure from this 
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kind of study would require the inclusion of non-famine exposed families, and in this context it 
would require a different population to be studied, itself bringing in a range of different biases.  
 
5.4.3 Potential environmental confounders 
The Matlab study did not characterise the exact nature of the famine exposure at the time and 
our data relies on post-hoc interpretation of the published studies describing the famine and 
direct experience within the community in Matlab and ICDDR,B.  It is important to consider 
what other adverse environmental factors co-existed with famine exposure to interpret the 
results of this study.  At the time of famine exposure, it can be assumed that malnutrition was 
associated with a high prevalence of diarrhoeal and other infective disease, already known to 
be common in Matlab.  Reduced physical activity may also have been associated with famine, 
in parents or offspring directly exposed.  The postnatal life of offspring born during famine may 
also have held lasting nutritional deficits, repeated infections as well as socioeconomic 
deprivation in families particularly affected by famine.  It is also important to consider whether 
‘famine exposed’ is an appropriate definition that applies equally and universally to all families 
living in Matlab at that time, or whether there was differences between and within households 
in the amount of nutrition available.  It will not be possible to characterise any of these 
possible confounders retrospectively, and therefore it is important to consider their potential 
influence on the conclusions drawn form the study.   
Another environmental influence that may confound the results of this study that has been 
characterised within Matlab is that of arsenic exposure via contaminated well water.  This 
exposure has been documented and studied in Matlab, by ICDDR,B researchers, and evidence 
exists that maternal exposure to arsenic in pregnancy can influence thymic development in 
offspring and is independent of micronutrient supplementation (189).  These observations are 
important to understand the complexities of environmental exposures and phenotypic 
outcomes, and interestingly may provide insight into new mechanisms to explain epigenetic 
variation.  Research suggests that genetic polymorphisms of one-carbon metabolism influence 
arsenic metabolism (190) and that folic acid and vitamin B12 may reduce the oxidative stress 
induced by arsenic exposure (191).  A recent study of mice exposed to arsenic in utero 
identified a range of DNA methylation differences when coupled with a high folate diet (192).  
Future plans in the Matlab study include the collation of arsenic exposure data and 
identification of any association with the programmed phenotype or epigenotype.  
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5.4.4 Applicability of this study to other fetal programming studies 
The DNA methylation variation in this study in part overlaps with that identified in other 
studies, including the Dutch Winter Hunger and Gambian Studies that have a similar focus on 
nutritional insults in early developmental life.  These findings provide support of the 
technological validity of these experiments, but also some reassurance of their biological 
validity too.  Unfortunately, the approach that these two studies took to identify epigenetic 
variation was not genome-wide and therefore it is difficult to compare the results of these 
studies directly.  The question that further research will need to answer is whether there are 
regions of the genome that are particularly susceptible to environmental insults in 
development, and if so, whether these are timing-specific and/or specific to particular 
nutritional insults.   
Given that fetal programming of cardiometabolic disease is known to occur via specific 
micronutrient deficiencies, e.g. B12 deficiency in PMNS, it is also important to consider 
whether the famine exposure in Matlab could be due to the same factors or is indeed 
reflecting the much wider nutritional insult of famine.  In the absence of specific 
characterisation of micronutrient status during famine exposure, it will not be possible to 
assess this further but must be held in consideration when drawing conclusions across these 
studies.   
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Chapter 6.  Mouse Model of Gestational Diabetes 
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6.1 Introduction 
 
Exposure to gestational diabetes has been described as a mode of fetal programming towards 
an offspring phenotype of type 2 diabetes and obesity in Chapter 1.  Epidemiological studies 
provide some evidence of this model, and carefully designed animal models of a 
hyperglycaemic environment in late pregnancy provide important data in support of these 
observations (36).   The means by which gestational diabetes may induce epigenetic change is 
poorly understood, however studies of histone modifications in a hyperglycaemic environment 
provide an important insight into possible mechanisms (104).  The developing embryo is 
exposed to maternal hyperglycaemia via maternal-placental-fetal transfer, and itself may 
become hyperinsulinaemic, resulting in accelerated growth.  Whilst these direct effects of 
gestational diabetic pregnancy are well described, the long-term outcome of these exposures 
is poorly understood.   
A mouse model of gestational diabetes can provide useful insight into these mechanisms, 
offering the ability to study tissue-specific effects as well as long-term phenotypic outcome.  
An inbred mouse strain also offers an invaluable insight into pure epigenetic phenomena, 
independent of genetic heterogeneity that is evident in human studies and that can obscure 
the maternal-child transmission of risk.   
This study has been designed to identify the potential mechanisms of fetal programming in the 
context of gestational diabetes, and uses a mouse model to replicate this disorder as much as 
possible.  Heterozygote female mice of the BKS.Cg-m+/+Leprdb/J strain (referred to in the 
simpler nomenclature, db/+), emulate human gestational diabetes in their leptin resistance 
and spontaneous glucose intolerance (due to insulin resistance) during pregnancy.  This model 
has been well studied in pregnancy, but only one study so far has looked at the potential for 
these in utero effects to programme offspring (37).  Six-month old wild-type (WT) offspring of 
db/+ mothers were found to have raised fasting plasma glucose and hyperinsulinaemia 
(female mice only) and were fatter than WT offspring of non-diabetic (+/+) mothers.  These 
researchers studied the livers of these offspring and found decreased insulin-stimulated Akt 
phosphorylation and therefore impaired insulin signaling and hypothesise that this may reduce 
insulin-dependent suppression of hepatic glucose production.  However, this study is limited in 
its phenotypic studies of these mice, and does not propose any mechanisms by which these 
insulin-signaling changes are induced.  Epigenetic mechanisms are likely to play a role in 
mediating these effects, and by comparing WT offspring from both GDM and WT mothers, it is 
possible to eliminate the potential for genetic causes.  Hyperglycaemia itself may affect the 
 215 
epigenetic state of important genes, e.g. NFkB, and therefore their expression (104) (105).  
Therefore it can be seen that the glycaemic environment (i.e. from the mother) of a developing 
fetus could modulate the developing epigenotype and produce lifelong epigenetic aberrations.  
Altered feeding patterns and changes in leptin signaling may also be associated with changes 
in DNA methylation in the melanocortin pathway, an important regulator of body weight. The 
placenta may also play a role in altered growth patterns in the fetus and the studies have 
identified altered gene expression of a range of growth factor genes that could be mediated by 
epigenetic processes and reflect long-term aberrations that could predispose to insulin 
resistance and obesity (193).  The discrepancy between maternal and neonatal levels of 
growth factors in diabetic pregnancies may highlight epigenetic dysregulation of gene 
expression in neonates in response to the maternal environment.   
 
By using this mouse model of gestational diabetes, it will be possible to test the following 
hypotheses: 
a) Does maternal gestational diabetes programme a diabetic and obese phenotype in offspring 
through non-genetic means? 
b) Do changes in DNA methylation underlie this model of fetal programming? 
c) Do these epigenetic changes occur in a tissue- or sex-specific manner, and can they be 
associated with gene expression and phenotypic outcome? 
 
 
6.2 Methods 
 
6.2.1 Mouse model  
Home office approval for the study protocol was obtained, under appropriate personal and 
project licences. 
6.2.2 Mice 
Mice were purchased from Charles River at 6 weeks of age.  A C57BL/6 background strain was 
common to all mice, and female mice were from the BKS.Cg-m+/+Leprdb/J strain.  The mice 
used are described in Table 6a.   
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Strain Genotype Number Sex 
C57BL/6  12 Males 
BKS.Cg-m+/+Lepr
db
/J db/+ (heterozygotes) 25 Females 
BKS.Cg-m+/+Lepr
db
/J +/+ (wildtypes) 24 Females 
Table 6a.  Number, sex and genotypes of mice used in mouse model 
 
All mice were housed in the Biological Services Unit (BSU), Barts and the London School of 
Medicine and Dentistry, in individually ventilated microisolator cages (IVCs), with ad libitum 
access to food (standard chow) and water, 12-hour light/dark cycles.  On arrival to the BSU, 
mice were housed in groups of 6, separated by sex and genotype. 
 
6.2.3 Breeding model 
Female heterozygotes (db/+) of the BKS.Cg-m+/+Leprdb/J strain were used as a model of 
‘gestational diabetes’, based on their pregnancy-specific hyperglycaemia previously identified 
by several researchers e.g. Friedman et al (37).  Female wildtypes (+/+) from the same strain 
were used as controls.  Dams were age-matched and in their first pregnancies.  Female mice 
were bred with male C57BL/6 animals according to the following model (Figure 6a): 
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Figure 6a.  Outline of mouse breeding model used in GDM experiments.  Wildtype (control) animals and 
their offspring are shown in blue, and GDM animals and their offspring in red. 
 
 
6.2.4 Phenotypic tests in pregnancy 
Mice were paired overnight and conception confirmed by the presence of a vaginal mucus 
plug.  Males were removed from females’ cages after overnight pairings, and only re-paired 
after an interval of 5 days to ensure the precise timing of conception.   
All female mice underwent intraperitoneal glucose tolerance testing (IPGTT) at 17.5 days post-
coitum (dpc) to determine the glycaemic response to a weight-specific intraperitoneal glucose 
load.  Mice were fasted overnight (from 6pm) and IPGTT was performed 14 hours later.  A tail 
vein bleed was performed, the first drop of blood being used to test the glucose level using a 
glucometer.  Another 20µl of blood was collected into a PCR tube and sat at room temperature 
for 1-2 hours to clot.  Intraperitoneal glucose (2g/kg, from a 100mg/ml solution) was 
administered.  Blood samples were taken 30 and 60 minutes after the administration of 
glucose.  Clotted blood samples were spun at 4o, 2000g for 15 minutes, and the serum layer 
was pipetted off into 20µl aliquots and frozen immediately at -80o. 
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6.2.5 Cull and dissection of 17.5dpc females and embryos 
After IPGTT, 8 db/+ and 8 +/+ females were culled in a CO2 chamber.  Maternal cardiac 
puncture was performed peri-mortem and blood was serum collected using the approach 
described above.  Embryos were dissected from the uterus and, after isolation from their 
embryonic sacs, placenta and umbilical cord, were weighed.  Subsequently, the liver, head, 
remaining body and placenta of each embryo were dissected and stored in individual 
Eppendorf tubes and frozen (within 15 minutes of cull) in liquid nitrogen.  Female liver, heart, 
gastrocnemius muscle and abdominal fat were dissected.  All serum and tissue samples were 
snap frozen in liquid nitrogen and transferred to -80o freezers. 
The remaining pregnant female mice were returned to their IVC cages, fed ad libitum, and 
continued their pregnancy.  On delivery of their pups, mothers were put into individual cages 
with their litters and allowed to wean normally.  Litter sizes were not standardised. 
 
6.2.6 Cull and dissection of remaining F0 generation 
After completion of breeding and weaning of all litters, all male and female F0 mice were culled 
and dissected using the same procedures described in 2.3.4. 
 
6.2.7 Genotyping and cull by genotype post-weaning of offspring 
DNA extraction was performed from embryonic mouse livers using the phenol:chloroform 
protocol described in Chapter 2.  Offspring from heterozygote mothers were genotyped in 
order to maintain only wild-type offspring in each group for later study of pure intra-uterine 
differences, rather than genetic differences.  
 
6.2.7.1 Standard PCR-restriction digest genotyping protocol 
A standard protocol from the Jackson laboratory suggests genotyping using a PCR-restriction 
digest protocol.  The mutant Lepr allele contains a G to T transversion, creating a donor splice 
site that induces alternative splicing and a 106nt insertion into the transcript. The suggested 
PCR protocol produces 135bp product from WT allele, whereas the 
G to T transversion in the mutant mice introduces an Rsa1 restriction digest site (GTA) that is 
visible as bands of 27bp and 108bp after Rsa1 treatment.  However, this reaction requires the 
reverse primer to incorporate the base substitution to provide produce a stable PCR 
amplification product.  However, this primer design is unstable and suboptimal with the 
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formation of primer dimers and low annealing temperature.  NetPrimer software calculates 
that these primers have a 69/100 rating, Tm 61o, GC 33% with multiple primer-dimers and 
hairpins formed between the two primers.  This protocol was abandoned due to its 
unreliability. 
 
6.2.7.2 Tetra-ARMS PCR protocol 
The Tetra-ARMS approach (194) has been developed for SNP genotyping, and uses two primer 
pairs to amplify the 2 different alleles of a SNP in a single PCR reaction.  Two allele-specific 
amplicons were generated using two pairs of primers, targeted to the G and A alleles 
conferred by the target SNP, designed using specific software for this technique 
(http://cedar.genetics.soton.ac.uk/public_html/primer1.html).  Mismatch between the allele 
and one of the two primer pairs (at its 3’ end) confers allele specificity when the PCR is 
performed, and a second mismatch (*) is introduced at position -2 of the 3’ end to enhance 
allelic specificity. The two outer primers are positioned at different distances from the target 
allele to allow for discrimination between the amplicons (and therefore determination of the 
allele) when the PCR product is run on a gel. 
 The primers used are longer than usual PCR primers to enhance the stability of the annealing 
to both target and non-target alleles.  This ensures that differences in allele specificity are due 
to differences in extension rate rather than differences in hybridisation efficiency.  The 
diagram below (Figure 6b) outlines the primer design around the target region in the Lepr 
gene:  
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Figure 6b.  Diagram of tetraARMS PCR designed to detect Lepr genotype 
 
 
6.2.8 Ageing of F0 offspring 
All remaining offspring were maintained until 6 months of age in cages containing 1-7 animals 
from mixed litters.  Ear marking was used to identify individual mice.  Litter sizes were not 
standardised. 
 
6.2.9 Phenotypic testing of aged offspring 
All mouse offspring for whom there was maternal phenotype data underwent phenotypic 
testing using a three-hour IPGTTs following a 14 hour fast.  The data presented shows the 
mean of the values in all mice from a single litter.  The procedure for performing these tests 
and serum collection was the same as that described in 6.2.4 except that blood glucose 
measurements were performed at 0, 15, 30, 60, 90, 120 and 180 minutes.  This change in 
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protocol was on the basis that the IPGTT results from pregnant mice were highly variable and 
therefore the incorporation of more measurements may improve the ability to detect 
differences.  Advice was also sought from a colleague (R. Batterham, UCL) with extensive 
experience of mouse models of metabolic disease as to determining the adequacy of the 
intraperitoneal injection technique during IPGTTs.  It was suggested that a 30 minute glucose 
<15mmol/l was likely to result from an inadequate or misplaced injection of glucose and that 
IPGTT results should be excluded if this criterion was not fulfilled.  The fasting glucose (i.e. pre-
injection) results from those IPGTTs deemed inadequate were still included in analysis. 
 
6.2.10 Cull of aged offspring 
After IPGTT, mice were culled and dissected.  Four mice were provided with standard chow for 
2 hours prior to cull, in order to later investigate the potential effects of fasting and stress on 
these mice in the future.  Culling and dissection was performed as previously described, but in 
addition, gonadal and retroperitoneal fat pads were dissected out and weighed, and for a 
selection of mice, kidney and brain were also harvested.   
 
6.2.11 Selection of offspring for epigenetic study 
Embryonic mouse livers were used for epigenetic studies, comparing the WT offspring of WT 
and HT mothers (n = 6 vs. 6).  The selection criteria to define the offspring for these 
experiments will be discussed in the relevant results section.  Liver was selected as the tissue 
to study as it is readily dissected out of a 17.5dpc embryo under direct vision and it has an 
important function in glucose and fat metabolism.  The study of liver in embryonic offspring 
also allows direct comparison with liver tissue in aged animals. 
 
6.2.12 DNA extraction 
As discussed above in relation to genotyping, DNA extraction from the embryonic mouse livers 
was performed using the phenol:chloroform protocol, including an RNase digest step.  This 
approach was used to maximise the DNA yield from the small amount of liver tissue.  DNA was 
extracted from all embryonic mouse livers and samples for Medip-seq analysis were selected. 
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6.2.13 Medip-seq library preparation (multiplexed) 
Medip-seq library preparation was performed using the standard protocol set out in Chapter 2.  
A multiplexed approach was used, using mouse-specific adapter sequences and primers, and 
pooling of all samples into a single library.   
 
6.2.14 Illumina GAIIx sequencing 
Medip-seq libraries were processed by UCL genomics across a 7 lanes of a single flowcell, 
leaving one lane for a PhIX control.  
 
6.2.15 Sequence read processing 
This was performed using the same protocol as described in section 4.3.3. 
 
6.2.16 Bioinformatic analysis 
Analysis of Medip-seq data was performed using the same technique set out in 4.5.6.  The 
Thomas Down DMR caller was used to generate a long list of DMRs, first in a group-wise (case 
vs. control) analysis, and subsequently in a pair-wise analysis using individual case-control 
sample pairs.   Following this DMR call, USeq was applied to the processed and normalised 
data in a new DMR call, and those DMRs that overlapped all 3 approaches were defined as the 
‘top hits’. 
 
  
 223 
6.3 Results 
 
6.3.1 Phenotypic tests in pregnancy 
Insulin and leptin resistance of mothers, and related factors such as body weight and glucose 
tolerance, were recorded during pregnancy in order to characterise maternal factors that 
could lead to ‘programming’ of the developing fetuses. 
Heterozygote mothers (db/+) were heavier than wildtype mothers before and during 
pregnancy, and they did not undergo excess weight gain as a result of pregnancy (corrected for 
litter size) (see table 6b, figures 6c and 6d).  The liver weights of GDM (db/+) mothers was 
significantly higher than in WT mothers, in those culled at 17.5dpc which would be consistent 
with excess insulin resistance (Figure 6e). 
The potential for glucose tolerance testing to have induced a stress response and 
glucocorticoid production in these animals should be considered in the light of evidence to 
suggest that this might be a cause of programming itself (195).  However, glucose tolerance 
testing was performed very late in gestation (17.5dpc) and in both study groups, and therefore 
the potential for bias is likely to be small. 
 
  
Wildtype Heterozygotes unpaired t test 
n mean +/-SEM n mean +/-SEM 
95% confidence 
interval p value 
Body weight (pre-pregnancy) 23 19.6 +/- 0.30 25 24.9 +/- 0.44 4.1-6.3 <0.0001 
Body weight (17.5dpc) 19 34.6 +/- 0.71 24 40.8 +/- 0.51 4.2-7.7 <0.0001 
Weight gain during pregnancy 19 15.1 +/- 0.72 24 15.8 +/- 0.52 1.0-2.5 0.38 
Weight gain during pregnancy (per 
embryo) 19 2.4 +/- 0.34 24 2.3 +/- 0.13 0.5-0.9 0.59 
Litter size 19 6.8 +/- 0.5 24 7.5 +/- 0.38 0.6-
-
1.9 0.32 
Liver weight at 17.5dpc 10 1.54 +/-0.06 8 1.78 +/- 0.04 0.1-0.4 0.02 
Table 6b.   Maternal and litter phenotypic characteristics. 
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Figure 6c.  Pre-pregnancy body weights of females.  Differences in means statistically significant 
(p<0.0001)  
 
Figure 6d.  Maternal body weights at 17.5dpc.  Differences in means statistically significant (p<0.0001)  
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Figure 6e. Maternal liver weights at 17.5dpc.  Differences in means statistically significant (p=0.02) 
 
A one-hour glucose tolerance test was performed on the majority of pregnant mice at 17.5dpc  
(with the exception of 4 WT females due to inaccurate timing of their conception).  The 
glucose tolerance tests identified higher basal (fasting) and post-challenge glucose levels in the 
heterozygote mothers (table 6c, figure 6f), confirming this model as one of relative maternal 
hyperglycaemia as expected from the literature.   
 
Glucose (mmol/l) post-
glucose challenge 
Wildtype Heterozygotes unpaired t test 
n 
mean +/-
SEM 
n mean +/-SEM 
95% confidence 
interval 
p val 
0 minutes 19 5.8 +/- 0.27 24 6.6 +/- 0.19 0.1-1.5 0.02 
30 minutes 19 11.3 +/- 0.66 24 14.5 +/- 0.65 1.4-5.1 0.001 
60 minutes 19 9.8 +/- 0.68 24 12.8 +/- 0.91 0.6-5.4 0.02 
Area under the curve 
(mean) 
19 572 +/- 28.7 24 726 +/- 31.7 65.2-242.3 0.001 
Table 6c.  Results from glucose tolerance tests of female mice at 17.5dpc 
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Figure 6f.  Glucose tolerance test results of 17.5dpc mice, showing mean maternal glucose with SEM and 
statistically significant differences (p<0.05) are represented by *. 
 
6.3.2 Cull and dissection of 17.5dpc females and embryos 
Embryos of heterozygote mothers were genotyped as only WT offspring will be studied.  There 
was an expected 1:1 proportion of WT (n=60) to HT (n=61) offspring.  
 
6.3.3 Cull and dissection of remaining F0 generation 
Mice from the F0 generation (i.e. parents) were culled at weaning and their tissues dissected, 
snap frozen and stored for later analysis. 
 
6.3.4 Genotyping and cull by genotype post-weaning of offspring 
Offspring of GDM (heterozygote) mothers were genotyped at weaning using tetra-ARMS PCR 
from ear snips and 61 heterozygous offspring were culled, leaving 60 WT offspring from HT 
mothers, in addition to 69 WT offspring from WT mothers.  Sex genotyping was also performed 
on WT offspring and identified 34 male and 25 female offspring from WT mothers as well as 27 
male and 33 female offspring to HT mothers.   
 
6.3.5 Ageing of F0 offspring 
Mice were kept in mixed cages in standard conditions for 6 months.   
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6.3.6 Phenotypic testing and cull of aged offspring 
In male offspring to HT mothers, increased body weight and liver weight were observed, 
relative to offspring of WT mothers (table 6d; figures 6j and 6m).  These body weight 
differences appear to be due to an increase in fat mass within the retroperitoneal fat pad.  
Offspring of HT mothers were more glucose intolerant than controls, as determined by a 
higher AUC of the 3-hour glucose tolerance test, and this effect was driven by differences from 
60 minutes onwards, indicating the role of glucose disposal mechanisms (Figure 6g and 6i). 
Following IPGTT, all animals were culled and tissues were dissected out and stored, as 
described in the methods section.  Female offspring showed the same body and liver weight 
differences (table 6e; figures 6j and 6m), and more consistent differences in both gonadal and 
retroperitoneal fat pads (table 6e, figures 6k, 6l).  Female offspring of HT mothers were also 
more glucose intolerant, as judged by the AUC of the glucose tolerance test, but the 
differences were driven by changes in the early part of the curve, including the fasting value 
(Figures 6h and 6i).  This observation supports the findings of Yamashita et al (37). 
IPGTTs from 5 offspring of WT mothers and 3 offspring of HT mothers were excluded due to 
inadequacy of the tests, judged by a 30-minute glucose of <15mmol/l.  These IPGTTs were 
performed on day 1 and 2 of experiments and were likely to reflect a lack of practice in 
performing these tests.  Exclusion of these results may have weakened the ability to detect 
phenotypic differences between offspring as more results were excluded from WT offspring 
and these would have strengthened the finding that these offspring had lower glucose levels. 
In addition, three IPGTTs (all from offspring of wildtype mothers) were also terminated early 
due to intramuscular injection of glucose at the time of testing.  This was immediately 
apparent at the time of testing due to difficulty in performing the test and a misplaced 
injection site, with the tip of the needle passing through the retroperitoneal space and hitting 
a bony structures around the posterior aspect of the pelvis or vertebral column.   
Beyond these excluded data, the variability of glucose measurements may, in part, be due to 
the stress of the animals whilst undergoing glucose tolerance testing.  The stress response, 
mediated by catecholamine and glucocorticoid production, could cause hyperglycaemia in 
these animals via gluconeogenesis.  However, the glucose tolerance testing was performed in a 
controlled fashion with optimal environmental conditions, and any bias due to these effects 
would be expected to be common to both groups and therefore should not obscure true 
differences. 
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WT offspring of 
wildtype mothers 
WT offspring of 
heterozygote mothers unpaired t test 
n mean +/-SEM n mean +/-SEM 95% CI p value 
Body weight 
34 
35.9 +/- 0.67 
27 
38.4 +/- 1.08 0.0-4.9 0.05 
Liver weight  1.28 +/- 0.03 1.51 +/- 0.06 0.1-0.3 0.0006 
Gonadal fat pad weight 1.55 +/- 0.11 1.81 +/- 0.14 0.1-0.6 0.15 
Retroperitoneal fat pad weight 0.58 +/- 0.04 0.73 +/- 0.05 0.0-0.3 0.04 
Liver weight  
(as % of body weight) 3.57 +/- 0.01 3.93 +/- 0.09 0.2-0.6 0.0008 
Gonadal fat pad weight  
(as % of body weight) 4.18 +/- 0.24 4.56 +/- 0.26 0.3-1.1 0.28 
Retroperitoneal fat pad weight  
(as % of body weight) 1.57 +/- 0.10 1.86 +/- 0.11 0.0-0.6 0.06 
Glucose (mmol/l) post-glucose 
challenge             
0 minutes 34 7.2 +/- 0.33 27 7.6 +/- 0.28 0.4-1.4 0.27 
15 minutes 21 21.7 +/- 0.75 21 21.9 +/- 0.84 2.1-2.5 0.86 
30 minutes 33 22.8 +/- 0.83 26 24.4 +/- 0.93 0.9-4.0 0.21 
60 minutes 33 21.5 +/- 1.12 26 25.1 +/- 1.16 0.4-6.9 0.028 
120 minutes 33 12.2 +/- 0.86 26 17.1 +/- 1.60 1.7-4.9 0.006 
180 minutes 33 8.1 +/- 0.36 26 9.9 +/- 0.79 0.2-3.5 0.028 
AUC (mean) 33 2777 +/- 130 26 3365 +/- 178 157-1019 0.008 
Table 6d.  Phenotypic characteristics of all male offspring at 6 months’ of age 
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Offspring of 
wildtype mothers 
Offspring of 
heterozygote mothers unpaired t test 
n mean +/-SEM n 
mean +/-
SEM 95% CI p value 
Body weight 
25 
28.3 +/- 0.91 
33 
32.7 +/- 0.65 2.1-6.5 0.0002 
Liver weight  1.08 +/- 0.03 1.21 +/- 0.02 0.0-0.1 0.0001 
Gonadal fat pad weight 1.23 +/- 0.14 1.96 +/- 0.23 0.3-1.1 0.0003 
Retroperitoneal fat pad weight 0.58 +/- 0.08 0.96 +/- 0.07 0.2-0.6 0.0006 
Liver weight  
(as % of body weight) 3.83 +/- 0.10 3.74 +/- 0.06 0.1-0.3 0.37 
Gonadal fat pad weight  
(as % of body weight) 4.05 +/- 0.37 5.83 +/- 0.29 0.8-2.7 0.0003 
Retroperitoneal fat pad weight  
(as % of body weight) 1.89 +/- 0.22 2.86 +/- 0.16 0.4-1.5 0.0006 
Glucose (mmol/l) post-glucose 
challenge             
0 minutes 25 5.8 +/- 0.25 32 6.6 +/- 0.20 0.2-1.4 0.016 
15 minutes 13 19.1 +/- 0.72 26 21.8 +/- 0.70 0.4-5.0 0.02 
30 minutes 18 21.0 +/- 0.88 30 22.8 +/- 0.69 0.4-4.1 0.1 
60 minutes 18 16.1 +/- 1.07 30 18.6 +/- 1.10 0.9-5.7 0.15 
120 minutes 18 8.3 +/- 0.74 30 8.8 +/- 0.70 1.6-2.7 0.6 
180 minutes 18 6.2+/- 0.46 30 6.5 +/- 0.37 1.0-1.4 0.69 
AUC (mean) 18 2190 +/- 100 30 2431 +/- 89 38-521 0.09 
Table 6e.  Phenotypic characteristics of all female offspring at 6 months of age 
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Figure 6g.  Glucose tolerance test results of aged male mice.  Mean maternal glucose with SEM and 
statistically significant differences (p<0.05) are represented by *. 
 
 
Figure 6h.  Glucose tolerance test results of aged female mice.  Mean maternal glucose with SEM and 
statistically significant differences (p<0.05) are represented by *. 
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Figure 6i.  AUC analysis of glucose tolerance tests with SEM and statistically significant differences 
(p<0.05) are represented by *. 
 
Figure 6j.  Mean body weight of aged mice with SEM and statistically significant differences (p<0.05) are 
represented by *. 
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Figure 6k.  Mean gonadal fat pad weights with SEM and statistically significant differences (p<0.05) are 
represented by *. 
 
Figure 6l. Mean retroperitoneal fat pad weights with SEM and statistically significant differences 
(p<0.05) are represented by *. 
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Figure 6m. Mean liver weights with SEM and statistically significant differences (p<0.05) are represented 
by *. 
 
 
6.3.7 Selection of offspring for Medip-seq experiments 
Medip-seq was performed on liver tissue from 17.5dpc female embryos.  It was decided that 
female offspring should be studied, not male, due to the stronger programmed phenotype 
evident from measurements of glucose and fat mass.   Six embryonic livers from offspring of 
WT mothers in the highest quartile of glucose tolerance and six from offspring of GDM 
mothers in the lowest quartile of glucose tolerance (i.e. most glucose intolerant) were selected 
for the initial study and identification of DMRs.  No more than one offspring per mother was 
selected and that nearest the first of a litter was selected.  Prior to library preparation, all 
samples were checked again for the correct Lepr and sex genotype and these were confirmed. 
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6.3.8 Library preparation 
All QC steps confirmed successful library preparation.  All 12 multiplexed samples were pooled 
after individual library preparation to allow gel extraction of a single, and therefore size-
matched, band. 
 
6.3.9 Illumina GAIIx sequencing 
The standard sequencing protocols were followed and met all routine QC checks in the 
process.  Raw sequence read counts (see table 6f) seemed consistent with successful 
sequencing and their quality was interpreted in more detail during the bioinformatic workflow. 
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   Read length statistics (pre-processing) Read processing 
 Tag Sample Min 
1st 
Quartile 
Median  Mean 
3rd 
Quartile 
Max    Raw    Mapped Q10 Paired 100-160bp 
Pairwise 
Normalisation 
% 
Passed 
C
as
e
s 
ATCACG 1 0 119 132 130.1 144 254 18,647,664 17,174,068 12,419,776 11,989,304 10,883,590 10,882,418 58.4 
CGATGT 2 1 119 132 130.1 144 254 24,453,337 22,970,169 17,056,904 16,715,048 14,939,453 13,270,571 54.3 
TTAGGC 3 0 121 133 131.8 145 251 28,462,599 26,025,053 15,231,579 14,850,734 13,611,688 12,466,250 43.8 
TGACCA 4 0 121 133 132.2 145 252 23,041,735 21,233,900 14,522,487 14,178,550 13,002,142 12,991,657 56.4 
ACAGTG 5 0 120 132 131 144 252 23,100,200 21,168,472 12,534,229 12,243,588 11,164,502 10,370,423 44.9 
GCCAAT 6 0 120 132 131.4 144 252 24,326,299 22,071,608 13,035,306 12,554,988 11,484,304 10,442,957 42.9 
Mean cases 0.2 120.0 132.3 131.1 144.3 252.5 23,671,972 21,773,878 14,133,380 13,755,369 12,514,280 11,737,379 50.1 
C
o
n
tr
o
ls
 
CAGATC 7 0 119 131 129.8 144 252 23,636,623 21,867,400 14,961,929 14,692,898 13,270,571 13,270,571 56.1 
ACTTGA 8 1 121 133 132.3 145 261 24,726,878 26,025,053 14,515,250 14,210,120 13,044,899 12,991,657 52.5 
GATCAG 9 0 119 132 130.1 144 255 22,116,100 20,458,933 14,021,964 13,775,088 12,470,014 12,466,250 56.4 
TAGCTT 10 0 121 133 132.2 145 251 21,481,662 19,733,557 11,923,476 11,629,054 10,442,957 10,442,957 48.6 
GGCTAC 11 1 121 133 132.2 145 252 23,882,272 19,606,799 13,924,632 13,633,844 12,463,697 10,882,418 45.6 
CTTGTA 12 0 122 134 132.8 145 252 20,296,846 18,602,289 11,590,292 11,330,660 10,404,136 10,370,423 51.1 
Mean controls 0.3 120.5 132.7 131.6 144.7 253.8 22,690,064 21,049,005 13,489,591 13,211,944 12,016,046 11,737,379 51.7 
  Total 3 1,443 1,590 1,576 1,734 3,038 278,172,215 256,937,301 165,737,824 161,803,876 147,181,953 140,848,552  50.9 
 
Table 6f.  Medip-seq sequencing read counts through before, during and after read processing.
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6.3.10 Bioinformatic analysis 
6.3.10.1 Sequence reads pre-processing 
The standard sequence read processing steps were performed and showed predictable and 
comparable losses at each filtering step (table 6f).  As all samples were from female mice, 
there was no filtering of the X and Y chromosome reads that was performed in the Pune 
experiments.  After mapping, pairing, quality filters were applied, as well as removal of PCR 
duplicates, there were similar rates of attrition across samples with a mean of 51%% of 
mapped reads suitable for analysis.  This was considerably less than when similar processing 
was performed in the Pune experiments (see 4.6.3.1), however the reduction was systematic 
across all samples and therefore was thought likely to be a difference in sequencing rather 
than anything during library preparation that could have introduced bias between individual 
samples.   
Calibration plots were drawn using case-control pairs and it was found that Medip enrichment 
across all case samples vs. control samples appeared equal (see figure 6n) and this was 
reassuring for the purposes of group-wise comparisons.  Individual Case-control pairs were 
also matched according to Medip enrichment (as described in 4.6.3.1) for pair-wise DMR 
calling using the Thomas Down algorithm. 
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Figure 6n.  Calibration plot of one case-control pair to assess Medip-seq enrichment efficiency 
 
 
6.3.10.2 DMR calling 
DMR calling was performed using fewer sequence reads per sample, compared to in the Pune 
experiments in which there was a minimum of 15 million reads per sample.  It was decided 
that a second flowcell would not be run due to cost constraints and the fact that differences in 
methylation should be more readily detectable in an isogenic mouse model. 
Chris Mathews performed DMR calling using a combination of bioinformatic algorithms, the 
Thomas Down custom DMR callers and USeq (see table 6g), combining all methods to generate 
a ‘top hit’ DMR list 
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DMR caller Method 
Size 
Normalisation 
Enrichment 
matched 
Test used 
Number 
of 
DMRs 
Single method 
Thomas 
Down 
CaseControl 
Pairwise Caller 
(pooled case and 
control groups)  
Yes No T-test 34,993 
Thomas 
Down 
Pairwise 
Pairwise Caller 
(individual 
case/control 
samples paired 
using enrichment 
plots).  DMRs 
common to all 
pairs. 
Yes Yes T-test 15,218 
Useq Useq No No 
Negative 
binomial 
distribution 
92 
Combined methods 
Final 
Combination 
Thomas Down 
CaseControl + 
Pairwise + Useq 
n/a n/a n/a 12 
Table 6g. DMR counts using different bioinformatic algorithms 
 
Despite the fewer reads per sample in this experiment, the Thomas Down calls yielded similar 
numbers of DMRs to Pune experiment 2.  This is surprising given that these samples come 
from an isogenic mouse model and therefore there are no SNP-dependent methylation 
changes that are highly variable and therefore prone to being called as DMRs.  However, USeq 
generated significantly fewer DMRs compared to the Pune experiment, and the element of 
false discovery control using this method, as well as its probabilistic approach, are well-applied 
to a dataset such as this that comprises biological replicates within each experimental group.  
Given the knowledge that inbred mouse strains may have inter-individual genetic differences 
due to the presences of structural variation, the USeq analysis was performed with varied set 
window sizes.  There was no disproportionate change in the number of DMRs identified 
according to the window size being increased or decreased.  Varied window sizes were applied 
to X chromosome reads (for ease of computation) and whilst 7 DMRs were called using 500bp 
windows, there were 48 identified with 250bp windows and no DMRs identified if 2000bp 
windows were applied.  These data make sense, as a smaller window size would be expected 
to identify DMRs that are less consistent over a genomic region, and a further assumption 
could be made that these DMRs would be less likely to be significant.  An increased window 
size would be expected to reduce the number of DMRs called (as in this example) unless a 
different form of variation, e.g. structural variation, was driving the difference.  On the basis of 
this analysis and interpretation, it was decided that the 500bp window was optimal for further 
analysis.   
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6.3.10.3 DMR characteristics 
The DMRs identified by the combined analysis are described in Table 6h and 6i.  There were 5 
DMRs hypermethylated and 7 hypomethylated in cases vs. controls.  Half of the DMRs were 
located in genes and all of these were intronic.  Four of the intergenic DMRs were at, or within 
2kb of, regions of the mouse genome with possible regulatory function determined by UCSC 
data.  The putative regulatory features denoted by UCSC tracks from Encode and ORegAnno 
included regions of enrichment for p300 (a transcriptional activator), RNA polymerase II,  (gene 
transcription), DnaseI hypersensitivity (denote active gene expression) and CTCF binding (gene 
insulation) in the samples studied by these databases.  The majority of DMRs are located in 
repeat-rich regions, something that was also found in Medip-seq DMRs in the Pune study, the 
relevance of which will be discussed later.   
The genes at which DMRs are located seem to have functional relevance to the mouse model 
and programmed phenotype in aged offspring.  DMR4 is located within the intronic sequence 
of Asxl2, a gene that has recently been described as having a role in adipogenesis in a human 
pre-adipocyte cell line.  Overexpression of the gene was shown to promote adipogenesis and 
this appeared to be mediated through modulation of PPARa and PPARg.  Interestingly, this 
DMR is hypermethylated in cases compared to controls, and the location of this DMR in a gene 
body, in which hypermethylation may be expected to increase gene expression, an observation 
that would fit with the presumed increased adipogenesis in cases.  DMR3, located within an 
intron of Npc1l1, could also have an important role in promoting adipogenesis and 
dysglycaemia through its expression in the liver and role in enhancing intestinal and biliary 
cholesterol absorption (196).  Again, the expected result of the hypermethylation seen in cases 
at the Npc1l1 intron would fit with overexpression of the gene and the end phenotype of 
increased fat mass and hyperglycaemia.   
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DMR 
Cases 
vs. 
controls 
Genomic location 
Useq (data from 'best 
windows') 
Thomas Down Genomic features 
Chro
m 
Start Stop #Window FDR Diff* 
Case 
reads 
Control 
reads 
Reads 
difference 
Repea
t 
CpG 
island 
Gene 
Genic 
region 
1 
H
yp
e
rm
e
th
yl
at
e
d
 
D
M
R
s 
chr1 192505673 192506174 1 14.3 1.3 138 65 73 no yes no intergenic 
2 chr4 148931475 148932010 3 11.8 1.8 74 31 43 yes no Ctnnbip1 intron 4 
3 chr11 6119659 6120284 4 12.0 1.8 58 27 31 yes no Npc1l1 intron 10 
4 chr12 3481927 3482454 2 10.5 2.1 47 18 29 yes no Asxl2 intron 5 
5 chr16 24056029 24056530 1 10.9 1.6 89 53 36 no no no Intergenic 
6 
H
yp
o
m
e
th
yl
at
e
d
 D
M
R
s 
chr4 48066275 48066775 1 8.7 -2.0 6 35 29 no near Nr4a3 intron 1 
7 chr4 86370153 86370836 3 9.3 -1.3 49 113 64 yes no no Intergenic 
8 chr6 135113039 135113532 1 10.0 -1.9 21 50 29 no no Hebp1 intron 1 
9 chr8 45770616 45771095 1 7.8 -2.0 8 35 27 no no no Intergenic 
10 chr15 48311014 48311576 3 16.4 -2.1 9 46 37 yes no Csmd3 Intron 
11 chr16 37635843 37636340 1 10.9 -2.1 9 29 20 yes no no Intergenic 
12 chr17 81577021 81577634 4 13.2 -1.3 36 95 59 yes no no intergenic 
 
Table 6h. Genomic locations and characteristics of DMR tophits.  * = Log2((sumT+1)/(sumC+1)) 
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C
as
e
s 
vs
. 
co
n
tr
o
ls
 
DMR Gene 
Genic 
region 
UCSC genomic features Gene function 
 
H
yp
e
rm
e
th
yl
at
e
d
 D
M
R
s 
1 no intergenic Nil   
2 
Ctnnbip1  
(ICAT) 
intron 4 
Repeat-rich region. 10kb downstream 
from CTCF binding site, 10kb upstream 
from 3’ UTR. 
Inhibits beta-catenin and TCF4 (a T cell transcription factor). Beta-catenin-
interacting protein. Widely expressed, including in liver.   
 
3 Npc1l1 intron 10 Dense repeat sequence 
Niemann-Pick disease, type 1.  Critical for intestinal and biliary cholesterol 
absorption.  A target for ezetimibe (J Lipid Res, 2012).  Expressed in liver.  
Regulated by PPARa in humans.  
4 Asxl2 intron 5 Repeat-rich 
Promotes fat cell differentiation, via PPARs (Park, JBC, 2011).  Also a 
regulator of bone mineral density and osteoclastogenesis (Farber, Plos Gen, 
2011).  In drosophila, it is a trithorax with a dual role in transcriptional 
repression and activation  
5 no intergenic 
adjacent (upstream) to ORegAnno and 
TFBS, overlying microsatellite repeat 
  
 
H
yp
o
m
e
th
yl
at
e
d
 D
M
R
s 
6 Nr4a3 intron 1 Adjacent to 5’UTR, minimal repeat 
Nuclear receptor subfamily 4A3 - in humans, member of steroid-thyroid 
hormone-retinoid receptor subfamily.  Multiple other metabolic functions 
including glucose and lipid metabolism (Pearen, Mol Endocrinol 2010).  
7 no 
Intergenic 
?promoter 
Adjacent to TFBS with p300, RNA pol2 and 
DNaseI peak. 15kb upstream of Dennd4c 
5’ UTR 
Dennd4c is a guanine nucleotide exchange factor required for GLUT4 
translocation in adipocytes (Sano, JBC, 2011) 
 
8 Hebp1 intron 1 
500bp downstream of ORegAnno, 4kb 
upstream of 5’ UTR 
Heme binding protein 1.  A transcription factor expressed in the liver. 
 
9 no intergenic 2kb upstream of ORegAnno.  Repeat rich    
10 Csmd3 intron Moderate p300.  Repeat rich 
CUB and Sushi multiple domains 3 – possible role in juvenile myoclonic 
epilepsy and autism  
11 no Intergenic 
Adjacent to CTCF (500bp downstream) 
and p300 (500bp upstream) sites, 4 kb 
downstream of Hgd 3’ UTR.  Repeat rich. 
Hgd is required for tyrosine catabolism.  Human mutations cause 
alkaptonuria 
 
12 no Intergenic  
2kb downstream of p300 peak.  Repeat 
rich with microsatellite repeats.  Slc8a1 
15kb downstream 
 
 
Table 6i  Genomic details of DMR tophits
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6.4 Discussion 
 
6.4.1 Mouse model 
The mouse model used in these experiments exploited a genetic tendency towards diabetes in 
pregnancy in Lepr heterozygote females, comparing these to wildtypes.  By breeding 
heterozygote (‘GDM’) and wildtype (‘control’) mothers, with standard C57BL/6 males, it was 
possible to study the effects of maternal diabetes in pregnancy on offspring.  By selecting and 
studying only the wildtype offspring from both ‘GDM’ and ‘control’ mothers, it was possible to 
isolate the effects of the maternal environment and exclude any genetic tendency towards 
diabetes in the offspring. This model has been used before to study fetal programming in 
response to maternal GDM, and showed raised fasting glucose and fat mass in 24-week old 
female offspring born to GDM mothers.  In this study, which used larger numbers, increased 
body weight, fat mass and liver weights were seen in offspring (male and female) and glucose 
intolerance was noted in male and female offspring, indicated by the differences at some (but 
not all) glucose measurements during 3 hour glucose tolerance tests.  There were some 
differences between male and female offspring in terms of their programmed phenotype, and 
the increase fat mass was more evident in females than males, however, the data does 
support the presence of a programmed phenotype in both and the variation may result from 
variability of testing and/or sample size. 
The study by Yamashita et al showed that the maternal GDM phenotype was associated with, 
and perhaps caused by, overfeeding.  Furthermore, by using taking a pair-feeding approach to 
some of the pregnant mice, it was possible to reduce the programmed phenotypic outcome in 
their offspring.  This study has also identified that the programmed offspring (at 6 months of 
age) displayed hepatic insulin resistance, as shown by decreased hepatic Akt-phosphorylation 
and increased hepatic glucose-6-phosphatase activity.  These findings were sufficient evidence 
to support the use of this model in the study of GDM-associated fetal programming, however 
they did not attempt to explain why this programming may have occurred, nor what was 
occurring on a genome-wide level. 
This study therefore adds to this evidence in support of fetal programming via the maternal 
GDM environment, and the study of DNA methylation in the livers of embryonic offspring born 
to GDM and control mothers has produced insights into the underlying mechanisms by which 
it occurs.  By studying the epigenetic consequences of maternal GDM exposure in 17.5dpc 
embryos, it is possible to conclude that this is a programmed event occurring in utero, rather 
than during post-natal life.  The only caveat to this is that the Lepr heterozygote mice were 
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slightly heavier to their wildtype counterparts pre-pregnancy, and therefore it is conceivable 
that the programmed event could have occurred prior to pregnancy through the effects of the 
different genotype on the developing germ-line.  
It is not possible to define the specific environmental factor that has induced programming, 
nor whether it results from a combination of factors.  The maternal environment in this 
experiment was known to vary according to glucose tolerance and fat mass and it can be 
assumed from other studies using this model that the GDM mothers were also 
hyperinsulinaemic, insulin and leptin resistant, and that they had different feeding behaviours.  
Within this model, it would not be possible to identify which of these factors are important, 
other than perhaps by pair-feeding.  It might be possible to use other models, such as that 
described by Gauguier et al to identify whether hyperglycaemia alone is the programmable 
influence.  However, as the Lepr mouse model of GDM is analogous to the range of aberrant 
metabolic conditions of human gestational diabetes, it is perhaps unimportant to study this 
further.  Should it be necessary to study this further, cell line experiments could also be 
designed to expose cells from specific tissues to altered environmental conditions, such as 
glucotoxicity. 
Additional areas of study using this mouse model would be to identify whether the 
programmed outcome was dependent on litter size, sex of offspring, or male characteristics.  
However, within this study, the emphasis was not put on these possible influences and the size 
of the model was probably too small to dissect out these fine details.   
 
6.4.2 Medip-seq 
The Medip-seq library preparation experiments appeared to be technically-sound, however, 
post-sequencing quality control filtering resulted in a loss of approximately 50% of sequenced 
reads.  Although some loss of reads is expected, there was a greater attrition than in the Pune 
experiments.  It is not clear as to why there were greater losses and as the other quality 
control checks, were satisfactory and even across all samples, it is hoped that the filtered data 
is of high quality.   
 
6.4.3 DMRs 
The identification of differential methylation in the Medip-seq dataset has used two different 
bioinformatic algorithms and selected a ‘shortlist’ of DMRs according to those where there is 
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overlap.  Further discussion of the limitations of this approach will be included in Chapter 8.  In 
contrast to the Pune study, in which 44 DMRs were identified, only 12 DMRs were found in this 
study.  This was an unexpected finding as it was thought that the absence of genetic variation 
between these mice would facilitate the detection of pure epigenetic difference.  However, 
the 12 samples from this study were sequenced over a single flowcell (in contrast to the two 
flowcells in the Pune experiment) and therefore it is likely that it was more difficult to detect 
differences due to the smaller dataset.  Interestingly, there were similar numbers of DMRs 
called by the Thomas Down algorithms across both studies, and it was not until USeq was used 
that the detection of DMRs fell.  This is likely to be because the Useq algorithm is more 
stringent and has filtered out those DMRs that were being driven by difference originating 
from a single sample.   
The DMRs that have been identified in this experiment are located within regions of the 
genome with a putative functional role towards the programmed phenotype.  The majority of 
DMRs are genic, and of these, 100% are intronic and overlie genes that have a function in 
adipogenesis and glucose/insulin metabolism.  Furthermore, the genes identified appear to be 
expressed in mouse liver, again supporting these being ‘true’ DMRs rather than false discovery.  
However, this study is only preliminary and does not exclude the possibility of the DMRs being 
chance events, and further experiments will need to be performed to address this important 
question.  In the first instance, technical validation of these DMRs will be performed using 
targeted assays of DNA methylation (BS-pyrosequencing) and in a larger set of embryonic 
mouse tissues.  These targeted studies will also interrogate the methylation state at Akt to see 
whether there is varied methylation that might associate with the altered expression in 
programmed offspring livers described in Yamashita et al. 
The location of the DMRs at putative regulatory features gives some suggestion that, if true, 
they could have important functional effects on gene activity and higher order chromosome 
functions.  Again, this question will require further study with experiments focused on 
transcriptional regulation and gene expression rather than DNA methylation.   
Another finding from this whole genome interrogation of DNA methylation is that the majority 
of DMRs are located at repeat-rich regions.  This was also a feature of Pune Medip-seq DMRs 
and the wider context of this finding will be discussed in more detail in Chapter 8.  However, 
the relevance of this finding to mouse experiments is significant in the light of recent 
understanding of the genomic architecture of inbred mice.  Whilst it is assumed that inbred 
mice colonies are isogenic and derived from well-characterised strains with limited haplotype 
diversity, studies of the commonly used laboratory mouse strains have shown unexpected 
diversity and uncharacterised structural variation within strains (197).  Whilst it is unlikely that 
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the mice used in this experiment, which were all purchased from one animal laboratory, vary 
significantly from each other, it is important when comparing genetic data from them to 
reference databases and genome browsers. 
The final point of consideration in regard to the DMRs identified in this study are that they are 
only from the female offspring born to this model.  It will be important to replicate the findings 
of this experiment in male offspring to see if there are any sex-specific differences. 
 
6.4.4 Other limitations 
There are other, wider limitations to this study that must be discussed in the light of the 
findings of differential methylation in programmed offspring.  The means by which mouse 
tissues were dissected and stored for DNA extraction did not allow for histological analysis of 
cell types within the tissues.  The programmed phenotype in offspring could have influenced 
the tissue directly and resulted in a different proportion of cell types within the liver.  The liver 
is composed of several different cell types, including hepatocytes, endothelial cells and Kupffer 
cells and each is likely to have its own specific DNA methylation profile.  Therefore, differential 
methylation may in fact represent a difference in cell types studied, rather than a true 
epigenetic difference consequent on programming.   
There are many studies in the field of fetal programming that make an association between 
maternal stress, glucocorticoid levels in utero, and an adverse phenotypic outcome (e.g. 
(198)).  Whilst this area of research remains contentious, it is important to consider these 
findings in the context of this animal experiment.  The environment of the laboratory mouse in 
these experiments could be considered as stressful, in particular during the time of glucose 
tolerance testing, tail snipping for genotyping and during culling.  During these procedures, the 
mice were visibly stressed and, in the case of the glucose tolerance tests and the long fast prior 
to them, this stress lasted many hours.  Theoretically, the same techniques/stresses were 
applied to all mice and therefore should not bias the results that compare the GDM vs. control-
exposed offspring, however stresses are by nature unpredictable and it is not possible to fully 
control for this in mouse experiments.  Furthermore, there are always possible means by 
which cases and controls could be differently exposed, e.g. by heavier animals being more 
difficult to pick up, and administer intraperitoneal injections.   
The final potential limitation of epigenetic studies in isogenic mouse models should be 
discussed in the light of the issue of sample contamination in the Pune study.  Sample 
processing and library preparation, especially when cases and controls are processed randomly 
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to avoid systematic bias, is prone to sample mix-ups and potential contamination.  With 
outbred mouse or human studies, it is possible to detect sample contamination during genetic 
analysis, however it is not possible to when isogenic mice are being studied.  Whilst this is not 
thought to have been a problem within this study due to very cautious laboratory processing, 
it is an important factor to consider when analysing datasets. 
 
6.4.5 Next steps 
As discussed above, the next steps will be to validate the 12 DMRs identified in this experiment 
in the larger sample set of embryonic mouse livers, to include male and females and across the 
whole spectrum of maternal glucose tolerance.  This will provide an important technical 
validation of the Medip-seq DMRs, but may also produce some insight into quantitative 
differences according to maternal glucose status and sex-specificity.  The ability to design 
appropriate primers for this analysis may be hindered by the amount of repeat sequences in 
these regions, but it is hoped that it will be possible to achieve sufficient coverage of some of 
the CpG sites within the 500bp Medip-seq windows. 
In this sample set, the possibility of inter-individual structural variation occurring must be 
considered, especially due to the observation that there are known microsatellite repeat 
sequences within some of the DMR regions, as determined by UCSC.  Should funds and DNA 
quantity permit, an Agilent CGH array will be used to assay for copy number variation and 
other structural variants within these samples.   
The next approach to understanding the mechanisms underlying fetal programming in these 
samples will be to perform gene expression studies in the embryonic livers as well as liver and 
adipose tissue from aged offspring.  The aim of these studies will be to determine the 
functional effects of the programming event in the two most relevant tissues to the 
phenotypic outcome.  The Illumina WG6 mouse expression array will be used to give genome-
wide coverage and generate an expression profile across 24 case and 24 control offspring in all 
tissues.  Liver tissue expression profiles will be compared between embryonic and 6-month old 
(aged) offspring so that developmental changes associated with the programming can be 
assessed, as well as to identify associations with phenotypic outcome.  Adipose tissue is hoped 
to provide a more homogenous tissue than liver with which to identify tissue-specific 
differences, and individual fat pads (gonadal) will be used in this analysis.  The application of 
expression analysis has been chosen over the study of more DNA methylation profiles or other 
epigenetic modifications with the understanding that expression differences between animals 
exposed and unexposed to GDM should be a good means of targeting further regions for 
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epigenetic studies.  The uncertainty over the validity and interpretation of Medip-seq has 
suggested that this approach may yield a more hypothesis-driven approach whilst still having 
the advantage of a genome-wide and unbiased approach.   It will also be possible to design 
additional targeted studies (or genome-wide studies if funds permit) in the other tissues that 
have been stored from the mice in this experiment, e.g. placenta, muscle, brain. 
Following these expression studies, an integrated approach to data analysis will be taken, 
using Ingenuity software.  The aim is to be able to associate gene expression differences with 
DNA methylation profiles from Medip-seq analysis.  Ingenuity will facilitate this understanding 
with its ability to draw together interacting genomic influences on epigenetic and functional 
levels.  It will be important to consider the influence of both cis and trans effects and their role 
in controlling gene expression.  The regions of methylation difference identified in this Medip-
seq experiment suggest that they may have a role in transcription factor binding, a finding that 
would mean that an epigenetic variant could have wide-ranging effects across the genome and 
its function.  It may be necessary to design studies that identify specific transcription factors or 
their binding sites, e.g. ChIP-chip, ChIP-seq or newer techniques that identify sequence-specific 
TF DNA binding to putative TFBS using dsDNA microarray or SELEX-seq (199).  By taking this 
integrative approach, it is hoped that regulatory networks can be identified and understood in 
the context of this model of fetal programming.   
Finally, a crucial downstream application of this study is to integrate its findings with those of 
human studies of gestational diabetes (see Chapter 7).  This mouse experiment has been used 
as a model system with which to identify the molecular mechanisms of fetal programming 
from gestational diabetes that would be difficult to elucidate in a human model.  The particular 
advantages of this animal model over a human one is the ability to study tissue-specific 
epigenetic variation, long-term outcomes in ‘aged’ animals, and to study epigenetic events 
that are independent of genetic variation.  The following chapter will discuss a human model 
of gestational diabetes and put into context the complexity of the environmental differences in 
such a study, where multiple confounding variables may co-exist with gestational diabetes due 
to converging risk factors.   
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Chapter 7.  Human Model of Gestational Diabetes 
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7. 1 Introduction 
 
7.1.1 Gestational diabetes as a model of fetal programming 
Understanding gestational diabetes as a model of fetal programming has an increasing 
importance in the context of the rising prevalence of the disorder in global populations.  The 
neonatal complications of diabetes in pregnancy (including pre-existing type 1 and 2 diabetes), 
such as macrosomia, have been recognised since Pedersen’s original 1954 study of women 
with severe, untreated hyperglycaemia in pregnancy (200).  Over the last decade, large clinical 
trials of gestational diabetes, have raised awareness of the adverse outcomes associated with 
relatively mild degrees of maternal hyperglycaemia, resulting in a significant change in clinical 
practice in both diagnosis and treatment of the condition (201).   
During these years, the role of diabetes in pregnancy in fetal programming of future chronic 
diseases has also been elucidated, but is isolated to a few specific clinical models.  These 
models, such as the Pima Indians and Mysore Parthenon Study described in Chapter 1, are 
important at defining the risk of programming but may have unique characteristics that do not 
allow wider contextualisation of their findings.  For example, the Mysore population has been 
shown to have a high prevalence of maternal vitamin B12 deficiency and is predictive of 
gestational diabetes, a finding that has not been replicated outside of India (202).  The Pima 
Indian population has provided invaluable insights into fetal programming via gestational 
diabetes and obesity, but recent studies suggest that they have unique genetic susceptibility 
underlying these diseases that may differs to other populations, thereby limiting how easily 
they can be compared (203).   Evidence from animal models does support the notion that 
gestational diabetes can induce fetal programming, but these models are sparse.  The most 
convincing evidence for the ability of maternal hyperglycaemia to induce a programmed 
offspring phenotype of hyperglycaemia and hyperinsulinaemia comes from Gauguier et al. 
(36).  The mouse model presented in Chapter 6, confirms the findings of Yamashita et al.  that 
maternal gestational diabetes programmes offspring towards diabetes (37).  Together with the 
innovative studies identifying the increased propensity towards type 2 diabetes in the 
offspring of mothers with type 1 diabetes, these models provide convincing evidence of the 
longstanding metabolic changes induced in offspring exposed to maternal hyperglycaemia, 
independent of the potential confounding genetic risks associated with human gestational 
diabetes.  The Gauguier model also suggests that the key environmental influence on 
programming in these models is hyperglycaemia rather than the other pathophysiological 
features associated with gestational diabetes.  In contrast, Lindsay et al. show that maternal 
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hyperleptinaemia in association with obesity may also have programmable effects on offspring 
(39); and important consideration as maternal diabetes and obesity commonly co-exist. 
With these limitations of the existing evidence base, the aim of this study is, first, to 
characterise maternal environmental factors that may vary in a pregnancy population and 
confound or associate with gestational diabetes exposure.  In particular, this study seeks to 
characterise the micronutrient status of women with and without gestational diabetes to 
identify prevalent deficiencies and evaluate their associations.    The second aim of this study is 
to investigate whether there are any epigenetic differences detectable in cord blood and 
placenta in offspring born to mothers with and without gestational diabetes, and whether 
these may be signatures associated with fetal programming. 
 
7.1.2 Gestational diabetes and micronutrient deficiency 
There is a body of evidence that suggests certain specific micronutrient deficiencies are more 
common in women with gestational diabetes.  Several studies, including a systematic review 
and meta-analysis of 2146 participants (of whom 433 had gestational diabetes) and a post-hoc 
analysis of HAPO participants, report an association of vitamin D deficiency (as measured by 
25(OH)D) and gestational diabetes (e,g (204)).  However, conflicting data exists and the studies 
reporting an association do not adequately control for the multiple confounders that could 
underlie their finding, e.g. ethnicity, socioeconomic status, health behaviours and uptake of 
nutritional supplements recommended in pregnancy.   For both, evidence of a true association 
needs to be obtained from larger cross-sectional studies with adequate control for 
confounders, and to identify causation, an RCT looking at whether vitamin D supplementation 
reduces the risk of gestational diabetes should be performed.    
As highlighted above, there is a reported epidemiological association between the functioning 
of the one-carbon cycle (see figure 7a) and gestational diabetes in the Mysore Parthenon 
study.  This study identified an association of B12 deficiency with gestational diabetes 
incidence (8.7 vs. 4.6% of women had GDM in those with and without B12 deficiency, OR = 2.1, 
p = 0.02) although the association seemed partly mediated through maternal BMI (202).  This 
study, performed in south India where a lacto-vegetarian diet is common, may not relate to 
other global populations.  However, a range of studies find an association of maternal 
homocysteine levels with gestational diabetes and glucose intolerance in pregnancy (205), and 
this appears to have a variable relationships with B12 and folate, although the studies 
performed have not made adequate control for trimester-specific changes in their metabolism 
nor the need for specific assays in pregnancy that are unaffected by physiological changes or 
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use of nutritional supplements.   None of these studies of micronutrient deficiencies and 
gestational diabetes explain why these associations exist, and further work to understand 
whether there is a biochemical or metabolic cause for this, or whether they are due to a 
common, e.g. socio-economic or behavioural, confounder. 
The studies described above use standard clinical assays of serum cobalamin (B12) and folate 
that are insufficient to examine the functioning of the one-carbon cycle effectively in 
pregnancy (reviewed in (206)).  The standard assay of cobalamin measures total circulating 
serum B12 and, in pregnancy, levels fall after the first trimester of pregnancy due to 
haemodilution making it difficult to interpret these accurately in the diagnosis of deficiency.  
Holo-transcobalamin is emerging as a useful marker of B12 status, and represents the fraction 
of cobalamin that is bound to the transcobalamin II molecule and is ready for tissue uptake.   
This test is not routinely available in clinical laboratories but is thought to offer a useful 
biomarker of B12 status in pregnancy.  Methylmalonic acid (MMA) is an intracellular 
metabolite that is converted to succinyl-CoA for use in the Krebs cycle and requires B12 as a 
cofactor for its conversion.  Multiple studies now show that MMA is a sensitive functional 
marker of cobalamin deficiency at a tissue level and this is now increasingly used to diagnose 
true B12 deficiency in routine clinical practice, but some uncertainty lies over whether MMA 
can diagnose deficiency in pregnancy as its concentration rises in the third trimester of 
pregnancy.  These concerns are summarised by Murphy et al. (207) and addressed in their 
study that characterises B12 status from pre-pregnancy, through gestation, and to fetal (cord 
blood) levels, using cobalamin, MMA and holoTC.  They identified that preconception MMA 
was significantly associated with MMA in pregnancy (at 8, 20 and 32 weeks) and in cord blood, 
and also had a significant inverse relationship with maternal B12 and holoTC during pregnancy 
and with cord blood holoTC.  Using regression modelling, the authors also found an association 
between low pre-pregnancy and a rising maternal MMA at the end of gestation and suggest 
that MMA is a useful biomarker of B12 status in pregnancy.  Unfortunately, this study did not 
include assays of folate status, or other intermediates of the one-carbon cycle such as 
homocysteine, both of which may be useful to determine the relevant influences on fetal 
programming. 
Folate assays also have to be chosen carefully in pregnancy as the routine serum folate assay is 
affected by recent ingestion of folate, and therefore true deficiency may be masked in women 
who are taking folic acid supplements (as is routine in early pregnancy) and have taken a dose 
prior to blood sampling.  The red cell folate assay is the optimal measure of folate status as it 
offers a marker of availability over the 90-120 day lifecycle of an erythrocyte.   
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Figure 7a.  The one-carbon cycle.  Metabolites assayed in these studies are highlighted in bold.  GNMT = 
glycine N-methyltransferase; BHMT = betaine homocysteine S-methyltransferase 
 
 
7.1.3 Generation of pilot epigenetic data 
Complementary to the aim of this study to characterise maternal micronutrient status in 
gestational diabetes is the aim to generate an initial insight into the epigenetic mechanisms 
underlying programming via human gestational diabetes.  This study, whilst small, is hoped to 
elucidate how specific variations in the maternal environment, with respect to diabetes status 
and micronutrient deficiency, may play a role in the developmental origins of disease, and also 
to act as a test of feasibility for future hypothesis-driven studies.  It was decided that 
gestational diabetes would be used as a model, rather than type 2 or type 1 diabetes, partly as 
a pragmatic decision (there are greater numbers of women with GDM pregnancy) but also so 
that there was a direct correlate with the mouse model in order to maximise their combined 
potential. 
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It was hoped that epigenetic modifications associated with GDM exposure may represent early 
markers of programming that could be followed up with longitudinal sampling and in larger 
cohorts.  The study was also designed to obtain some relevant tissue samples, i.e. placenta, 
and umbilical cord, to fetal growth and nutrient delivery, in addition to fetal cord blood.   
To date, there is no published evidence of epigenetic changes associated with this model of 
programming, and the putative link between maternal hyperglycaemia and DNA methylation is 
less clear than other models, e.g. programming mediated by one-carbon metabolism.  
However, there is a wealth of clinical and epidemiological data in support of this model of 
programming, as summarised above and in the introduction.  In addition, the work of El-Osta 
et al, summarised in Chapter 1, suggests that glucose can have lasting effects on gene 
expression via epigenetic modifications at genes (e.g. NFkappaB) that regulate transcriptional 
activity and a possible role in metabolic complications.  Data showing the epigenetic regulation 
of nutrient transfer and glucose metabolism genes in placenta according to glucose exposure 
has also been discussed in Chapter 1 and lends further support to this study in its attempt to 
elucidate whether there are epigenetic signatures of maternal glycaemia in the cord blood and 
placenta of offspring.  
 
7.1.4 Specific study aims 
The role of gestational diabetes and possible interacting nutritional influences on the neonatal 
epigenome will be studied with the following specific aims in mind: 
1. Identification of differential methylation in the offspring of mothers of South Asian 
origin with and without gestational diabetes 
2. Detailed characterisation of the maternal pregnancy environment with respect to 
metabolic and micronutrient status. 
3. Collection of cord blood and placenta to identify tissue-specific DNA methylation in the 
offspring studied. 
4. Development of standardised sample collection protocols for future epigenetic studies 
in larger clinical cohorts powered to detect associations with longitudinal offspring 
phenotype. 
5. A human correlate of the mouse model of gestational diabetes in Chapter 6.   
6. Combined analysis with related studies, including growth-restricted pregnancy, and 
the models of fetal programming described in chapters 4 and 5. 
 
 254 
7.2 Methods 
 
7.2.1 Local population – background demographics 
The study was performed in the East London borough of Tower Hamlets.  Data from the 2001 
Census (available through towerhamlets.gov.uk) describes that this borough has a young 
population, with 59 percent of its population falling between the ages of 15 and 44 years of 
age, compared to the national average of 42%.  Tower Hamlets is ethnically diverse, and its 
second largest ethnic group (after White British) are Bangladeshi, comprising 30% of the total 
population.  In 2008/9 there were 68 births per 1000 women aged 15-44 in Tower Hamlets, 
compared to 62 per 1000 in England.  During this same time period, of the 4255 births within 
the borough, 45% were to women of Bangladeshi origin. 
Gestational diabetes is estimated to affect 5% of pregnancies in the UK (NICE guidance).  
However, there is a lack of published data on GDM prevalence, in part due to the variation in 
screening practices and diagnostic cut-offs.  The current clinical guidelines at the Royal London 
Hospital use a hybrid of NICE and IADPSG diagnostic criteria for the diagnosis of gestational 
diabetes (see Chapter 1).  In an unselected audit of pregnancies (n=433) at the Royal London 
Hospital in 2010, 9% (n=39) of women had pregnancies affected by gestational diabetes, 
diagnosed by their own criteria.  Of these 39 women with gestational diabetes, 92% were of 
Asian (Bangladeshi) origin.   By comparison, estimated prevalence of GDM in a rural 
Bangladeshi population, using the less stringent WHO criteria, was 8.2% (208). 
 
7.2.2 Recruitment 
Pregnant women were recruited from the Royal London Hospital antenatal clinics, and where 
possible, male partners were also recruited.   Women were identified and invited to join the 
study after routine screening for gestational diabetes mellitus (GDM) was performed at 28 
weeks’ gestation.  The screening test used at this time, the 75g 2-hour oral glucose tolerance 
test (OGTT) is offered to all women of Asian origin at the Royal London Hospital due to their 
high risk of GDM and the glucose cutoffs are ≥5.8 and 7.8mmol/l fasting and 2 hours post-
challenge.  Women with and without a diagnosis of GDM made at this time were selected to 
join the study in equal number.  Alison Fiddler, Senior Midwife performed most recruitment to 
the study, under supervision from Sarah Finer, involving verbal discussion of the study and the 
use of written information sheets and leaflets given to all potential participants.   The study 
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was performed under standard Good Clinical Practice guidelines, with REC approval.  The 
inclusion and exclusion criteria for the study were as follows: 
Inclusion criteria: 
Women with and without GDM 
Women of Asian origin 
 
Exclusion criteria: 
Multiple pregnancy 
Pre-existing type 2 diabetes (diagnosed pre-pregnancy, or on the basis of an abnormal 
16 week OGTT)  
Type 1 diabetes 
 
Women and their partners who gave verbal consent to join the study were invited to one 
study visit, run by Sarah Finer, with assistance from Francess Fode and Margaret Mbah-Ebako, 
Research Nurses from the North-East London Diabetes Research Network.  The study visit 
comprised the following: 
1. Additional explanation of the study and requirements of participants 
2. Obtaining formal written consent from each adult.  Pregnant women were also asked to 
give consent on behalf of their offspring to join the study as well as Human Tissue Act 
consent for the use of stored tissue samples. 
3. Medical, social and dietary history taking. 
4. Brief clinical examination 
5. Venepuncture  
 
7.2.3 Clinical data collection 
7.2.3.1 Parental study visits 
Maternal study visits were performed in the 3rd trimester of pregnancy, from 28 weeks’ 
gestation onwards.   The timing of paternal study visits was not fixed and was generally 
performed at the same time as the maternal study visit, or to coincide with other routine 
antenatal care appointments.   
All participants were asked to attend study visits in the fasting state, and appointments were 
all performed during the hours of 8am and 11am each morning. 
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Structured questionnaires were used to take medical, social and dietary histories and were 
based on standardised questionnaires validated in the Bangladip study (MRC funded study of 
diabetes prevention in Bangladeshis, PI: Graham Hitman).  Brief clinical examinations of 
participants were performed and included measurement of height, weight, abdominal 
circumference (men only) and blood pressure. 
Additional clinical data collection was performed post-partum and prior to her discharge from 
hospital.  At this time, details of the pregnancy (from study visit to delivery) were recorded 
from the hospital notes, such as treatment of gestational diabetes, administration of steroids, 
onset of pre-eclampsia and use of any other medications during pregnancy.  Routine clinical 
data on the labour, mode of delivery and postnatal complications were also recorded from the 
hospital notes.  Approximate total cumulative doses of metformin and insulin during 
pregnancy were calculated from recommended prescriptions recorded in hospital notes. 
 
7.2.3.2 Offspring  
Prior to discharge from hospital, brief neonatal anthropometry was measured on all babies, 
including measurements of head and abdominal circumference, length, birth weight and 
ponderal index.  A customised birth weight centile calculator, available at www.gestation.net, 
was used to generate birth weight centiles, adjusted for maternal height and weight, ethnic 
origin, parity and sex of the offspring.  This algorithm is based on data collected from 96,830 
births from a database in the West Midlands and used in routine clinical use in some UK 
hospitals and in some research studies (209). 
Follow-up of offspring beyond the neonatal period was not performed, however mothers were 
asked to give consent to be re-contacted in the future should this become necessary. 
All biological samples obtained were stored using anonymised codes with no direct link to 
personal information, other than in a password-protected NHS computer database.  
 
7.2.4 Nutritional, hormonal and biochemical assays  
Maternal blood samples taken at the study visit were processed and analysed in 3 clinical 
laboratories in London, all with Clinical Pathology Accreditation.  Laboratories were chosen 
due to convenience, expertise in specific assays and cost.  The tests performed on study visit 
samples are summarised in table 7a.
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Blood test Sample type Method Normal range Units Lab 
Serum glucose (as part of 
oral glucose tolerance test) 
Fluoride 
oxalate 
Hexokinase assay (Roche) Dependent on context mmol/l 
Barts 
Health 
Insulin (fasting) Serum 
Electrochemilluminescent sandwich 
immunoassay (Roche) 
2.6 - 24.9 mIU/L Barts 
Health 
Fructosamine (corrected for 
serum protein) 
Serum Nitroblue tetrazolium (Roche) <300 umol/L 
Barts 
Health 
Serum B12 Serum 
Electrochemilluminescent competitive 
immunoassay (Roche) 
191-900 ng/L Barts 
Health 
Holotranscobalamin Serum Immunoassay 
<25 - Result suggests vitamin B12 deficiency 
pmol/L St Thomas’ 
Hospital 
25-50 - Vitamin B12 deficiency cannot be 
excluded. Measure MMA 
51-165 - Vitamin B12 replete  
>165 - Seen in early cobalamin treatment 
Methylmalonic acid Serum 
Gas chromatography-mass 
spectrometry 
≤280 (<65 yrs)  
nmol/L 
St Thomas’ 
Hospital ≤360 (>65 yrs) 
Serum folate Serum 
Electrochemilluminescent competitive 
immunoassay (Roche) 
3.8-20.0 ug/L Barts 
Health 
Red cell folate 
EDTA whole 
blood 
Competitive binding paramagnetic 
particle assay (Beckman Coulter) 
160-640 ug/L Barts 
Health 
5-methyltetrahydrofolate Plasma HPLC (Variant II) 7.6-42.0 nmol/L 
St Thomas’ 
Hospital 
Homocysteine Plasma HPLC (Variant II) <10 (in pregnancy) umol/L Homerton 
Vitamin D (25(OH)D) Serum 
LC-MS/MS (Acquity Quattro Premier 
XE) 
<30 deficiency 
nmol/L Barts 
Health 30 – 79 insufficiency 
Vitamin A Serum HPLC (Variant II) 1.05 - 2.45 umol/L 
Barts 
Health 
Vitamin E Serum HPLC (Variant II) 11.6 - 46.4 umol/L 
Barts 
Health 
Table 7a.  Summary of blood tests performed on maternal samples.   
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7.2.5 Sample collection for molecular studies 
 
7.2.5.1 Parental samples 
Whole blood was collected for DNA in a 5ml EDTA tubes during venepuncture at study visits.  
Samples were divided into 1ml aliquots and frozen at -80oC within 2 hours of collection.   
 
7.2.5.2 Offspring samples (at delivery) 
At delivery, fetal samples were taken from the umbilical cord and placenta.  15-20ml of cord 
blood was obtained from the umbilical cord arteries and vein using a needle and syringe as 
soon as possible after delivery, using a standard operating protocol.   EDTA and Tempus tubes 
were filled with cord blood for DNA and RNA samples, respectively.  EDTA samples were 
divided into 1ml aliquots and frozen -80oC, along with the Tempus tube, within 12 hours of 
collection.  
Placenta samples (approximately 2 x 2cm) were taken adjacent to the insertion of the 
umbilical cord on the fetal surface of the placenta.  Umbilical cord samples (also 2 x 2 cm) 
were taken from the end of the cord near to its placental insertion.  Tissue samples were 
rinsed in sterile PBS and then placed in 5ml tubes containing RNA-later solution and stored at 
4oC.  The time between delivery and sampling was documented for each collection.  SF took 
the majority of samples, and the midwifery and obstetric staff of the Labour Ward took the 
rest.  After 24-48 hours, samples were dissected into 4 pieces and divided into two cryotubes 
before being placed at -80oC for long-term storage. 
There was careful documentation of the time taken between placenta delivery and sample 
collection to ensure that external factors, such as tissue hypoxia or blood coagulation, can be 
considered in sample QC and data interpretation. 
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7.3 Results 
 
7.3.1 Samples collected 
Recruitment to the study yielded 80 maternal samples, of which 41 were paired with paternal 
samples (see figure 7b).  Samples from 65 of the 80 women recruited were obtained at 
delivery, with 15 lost due to the women delivering elsewhere or the research team being 
unaware of their labour.  3 offspring samples were excluded from analysis due to significant 
fetal problems, (prolonged neonatal hypoxia during delivery and fetal abnormality due to a 
chromosomal abnormality).  
Figure 7b.  Recruitment and sample numbers collected in the human GDM study 
 
 
7.3.2 Maternal data 
Maternal phenotype data and biochemistry on metabolic and micronutrient parameters are 
presented in table 7b.  There was a statistically significant difference in the age of women with 
and without gestational diabetes, which is expected due age being a risk factor for the 
condition.  Body mass index, parity and blood pressure parameters might have been expected 
to be different between the groups but were not, although the wide standard deviations 
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suggests that this is due to small sample size.   The mean BMI across both groups was in the 
‘overweight’ range, suggesting a population that is at risk of obesity and diabetes.  As would be 
expected, women with gestational diabetes had, on average, higher fasting and 2 hour post-
glucose challenge glucose measurements at diagnosis of gestational diabetes.  In addition, 
serum fructosamine was significantly different, reflecting an increase in a glycosylated protein 
that is measurable in serum and reflects blood glucose concentrations over the previous 2-4 
weeks.  HOMA-IR scores, based on fasting glucose and insulin computed by a standard 
algorithm (www.dtu.ox.ac.uk/homacalculator/index.php) were not significantly different 
between experimental groups, but showed a wide standard deviation across groups and 
therefore a larger sample number would have been required to detect a significant difference.  
It is important to recognise glucose tolerance in the individuals studied as being a spectrum, 
and given that the diagnosis of GDM can be made on either a fasting or 2 hour OGTT glucose 
level, there is considerable overlap in glucose levels in the GDM and non-GDM groups (see 
figure 7c).  Women with gestational diabetes were, on average, recruited one week later in 
gestation than control women.  This difference therefore affects the timing of blood sampling, 
but did not have a significant effect on the biochemical or metabolic test results presented, as 
determined by regression analysis (data not shown). 
There was a significant difference in serum holo-transcobalamin (or ‘active B12’) between 
women with and without GDM (median 50 pmol/L vs. 57.4 pmol/L, p<0.05), but in no other of 
the micronutrients measured.  These effects were independent of metformin treatment, a 
drug used to treat type 2 and gestational diabetes known to induce B12 deficiency (via unclear 
mechanisms) (210).  Serum B12 and methylmalonic acid showed differences that support the 
suspicion of B12 deficiency from the finding of lower holo-transcobalamin in GDM women, but 
these were not different at a statistically significant level themselves.
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Controls (n=36) GDM (n=39) 
t-test 
Mean (SD) Mean (SD) 
Gestation at study visit (weeks) 32 (208) 33 (3.0) * 
Age (years) 28 (5.2) 31 (4.5) ** 
Body mass index (m/kg
2
) 27 (6.4) 27 (4.6) ns 
Parity (n) 1.5 (1.5) 1.8 (1.5) ns 
Systolic blood pressure at booking (mmHg) 111 (12.6) 110 (10.3) ns 
Diastolic blood pressure at booking (mmHg) 70 (11.3) 72 (9.9) ns 
28 week GTT 0 mins (mmol/L) 5.0 (0.5) 5.3 (1.1) *** 
28 week GTT 120 mins (mmol/L) 5.8 (1.1) 9.6 (1.7) *** 
Fasting insulin 16.8 (11.1) 16.6 (12.0) ns 
HOMA-IR 0.31 (0.21) 0.31 (0.23) ns 
Corrected fructosamine 282 (18.0) 294 (28.2) * 
 Mean (SD) Median (SEM) Mean (SD) Median (SEM)  
Serum B12 (ng/L) 258 (84.4) 255 (14.3) 280 (151.6) 230 (24.0) ns 
Holotranscobalamin (pmol/L) 50 (15.6) 50 (2.6) 73.3 (52.7) 57.4 (8.5) * 
Methylmalonic acid (nmol/L) 260 (227.3) 168 (37.9) 248 (200.0) 222 (32) ns 
Serum folate (ug/L) 9.5 (5.1) 7.5 (0.9) 9.9 (5.4) 8.4 (0.9) ns 
Red cell folate (ug/L) 350 (209.6) 309 (36.5) 358 (137) 342 (22.0) ns 
5-methyltetrahydrofolate (nmol/L) 25.9 (26.3) 15.9 (4.4) 24.3 (19.8) 16.9 (3.2) ns 
Homocysteine (umol/L) 5.7 (2.2) 4.9 (0.4) 5.9 (2.0) 5.6 (0.3) ns 
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25(OH)D (nmol/L 38.8 (25.4) 32 (4.2) 45.6 (31.8) 35.5 (5.0) ns 
 Mean (SD) Mean (SD)  
Vitamin A (umol/L) 0.94 (0.26) 0.89 (0.3) ns 
Vitamin E (umol/L) 28.6 (9.3) 28.1 (7.7) ns 
Table 7b.  Maternal metabolic and micronutrient parameters.  Mean and standard deviation are presented and where means are significantly different *p<0.05, **p<0.005, 
***p<0.0005.  Where mean and median are presented, data is non-normally distributed and t-tests are performed on log-transformed data. 
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Figure 7c.  Serum glucose measurements in control (non-GDM) and GDM women at their diagnostic 
glucose tolerance test. 
 
 
Table 7c shows the prevalence of micronutrient deficiencies across both groups of women 
studied.  Overall, there were high rates of vitamin D deficiency and insufficiency across both 
groups, with almost half of all women having a 25(OH)D level of less than 30nmol/L.  The 
assays of vitamin B12 and its functional markers highlight the difficulty in diagnosing deficiency 
in pregnant women.  Serum B12 (cobalamin) suggests that a quarter of women may be 
deficient; whereas holo-transcobalamin measures indicate that up to 41% of women could be 
deficient.  Methylmalonic acid measurements suggest that this number is lower, but significant 
at 32%.  Serum and red cell folate levels are consistent and suggest a low prevalence of 
deficiency, although this is a surprising proportion nevertheless, given that all women are 
supposed to take folic acid supplementation in early pregnancy.  The measurement of 5-
methyltetrahydrofolate reveals deficiency in 15% of women in this downstream metabolite of 
dietary tetrahydrofolate formed after catalysis using the methyltetrahydrofolate enzyme.   
These biochemical measures suggest that the excess deficiency of 5-methyltetrahydrofolate, 
compared to tetrahydrofolate, could be due to the presence of the MTHFR polymorphism in 
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those individuals.  This is supported by the minor allele frequency of risk polymorphisms in the 
MTHFR gene (e.g. rs1801133) that are associated with hyperhomocysteinaemia and found in 
33% of individuals of European origin.  This high frequency of this allele has not been 
replicated in population-wide studies of South Asians, but is corroborated by some (211) but 
not all (212) smaller studies in this ethnic group.  
 
Micronutrient Proportion of deficient mothers (n=75) 
Serum B12 24% 
Holo-transcobalamin 
True deficiency 4% 
‘Deficiency not excluded’ 41% 
Methylmalonic acid (MMA) 32% 
Serum folate 5% 
Red cell folate 6% 
5-methyltetrahydrofolate (5MTHF) 15% 
Homocysteine 5% 
25(OH)D 
Deficient 49% 
Insufficient 40% 
Table 7c.  Prevalence of micronutrient deficiencies in all women 
 
Homocysteine, can be thought of as a marker of the overall functioning of the one-carbon 
cycle; it is known to vary with B12 and folate status, as well as the presence or absence of 
MTHFR polymorphisms.  Multiple linear regression modelling was performed to identify the 
predictors of homocysteine, and thus characterise what factors, in these pregnant women, 
were disruptors of the one-carbon cycle.  Regression modelling, showed that only holo-
transcobalamin concentrations were a significant (inverse) predictor of serum homocysteine 
(beta = -0.225, p = 0.012) (table 7d).  Other markers of B12 status and/or folate status did not 
contribute to homocysteine levels and nor did maternal age, gestation, BMI or parity.     
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Independent variable:  (log)homocysteine 
Covariates 
Unstandardised Coefficients 
t Sig. 
B Std. Error 
 
(Constant) 1.281 .434 2.953 .005 
Red cell folate (log) -.131 .145 -.904 .370 
Holotranscobalamin (log) -.225 .087 -2.586 .012 
Methylmalonic acid (log) .016 .052 .299 .766 
5MTHF (log) -.205 .228 -.898 .373 
HOMA-IR -.043 .084 -.506 .615 
Serum B12 (log) .055 .116 .474 .637 
Serum folate (log) .112 .317 .354 .725 
Gestational age at delivery .004 .006 .686 .495 
Maternal age .004 .003 1.043 .302 
Maternal BMI -.002 .003 -.605 .548 
Parity .002 .014 .154 .878 
 Model summary 
 R R square Adjusted R square Std Error of the estimate P value 
 0.662 0.438 0.326 0.115 0.000 
Table 7d.  Multiple regression modelling to identify independent variables of (log)homocysteine.  The 
‘log’ prefix is used to denote data that is not normally distributed and has been log transformed prior to 
inclusion in the regression model.  
 
Additional data was collected regarding treatment of gestational diabetes with metformin and 
insulin and is presented in table 7e and has been presented as cumulative dose exposures due 
to the variable timing of initiation and dosages of insulin and metformin treatment.  No 
women in the control group were given metformin or insulin.  The majority of participants 
(67%) with GDM were managed with diet-control alone.   
  
 
Table 7e.  Summary of treatment methods and dosing GDM mothers (n=39). 
 n % 
Diet control only 26 67 
Mothers treated with metformin 10  26 
Mothers treated with insulin 11 28 
% of women receiving both metformin and insulin 8 21 
Mean cumulative dose of metformin (g) 66 grams 
Mean cumulative dose of insulin (units) 592 units 
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7.3.3 Fetal data 
Data collected at delivery is presented in table 7f.  There were no significant differences in any 
of the phenotypic markers of birth weight/size between offspring born to GDM or control 
mothers and this was expected due to the small sample size.  Although there is an apparent 
difference in customised birth weight centile between control and GDM offspring, this 
difference was not significant in parametric and non-parametric tests. 
 
 
Controls (n=34) GDM (n=39) 
Chi-squared test 
n (%) n (%) 
Sex 21M, 13F 23M, 16F ns 
Macrosomia (>90
th
 centile) 5 3 ns 
Growth restriction (<10
th
 centile) 9 7 ns 
 
 
Mean (SD) Mean (SD) t-test 
Birth weight (grams) 3134 (473.9) 3156 (533.3) ns 
Gestational age at delivery (days) 274 (8.5) 271 (10.5) ns 
Ponderal index 28.9 (4.1) 29.7 (4.7) ns 
Cord blood haematocrit 0.45 (0.07) 0.46 (0.06) ns 
 Mean (SD) Median (SEM) Mean (SD) Median (SEM)  
Customised birth weight centile 39.5 (32.1) 28.2 (5.5) 45.7 (30.3) 51.5 (4.9) ns 
Table 7f.  Data collected at delivery of offspring 
 
 
Regression modelling was performed to identify any predictors of birthweight, customised 
birth weight centile and ponderal index.  There were no significant associations with 
customised birth weight centile (log transformed) after excluding the covariates already 
included in its own algorithm, nor were there any significant predictors of ponderal index.  
When birthweight was used as the independent variable, there was a significant association 
between the 0 minutes glucose level (log transformed) measured at the diagnostic glucose 
tolerance test and birthweight, as well as a positive association of parity and birth weight, both 
contributing to the overall model.  Both of these factors are well known in multiple studies to 
have a positive association with birth weight.  There was no association with any of the 
maternal nutritional parameters with birthweight and these have been excluded from the 
model in table 7g. 
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Independent variable:  Birthweight 
Covariates 
Unstandardised Coefficients 
t Sig. 
B Std. Error 
 
(Constant) 417.744 1261.002 0.331 0.742 
Corrected fructosamine 2.361 3.031 0.779 0.439 
Gestational age at delivery 15.806 23.229 0.68 0.499 
Log 0mins glucose (GTT) 2480.563 1044.72 2.374 0.021 
Log 120mins glucose (GTT) -86.313 565.987 -0.153 0.879 
Maternal HOMA-R -57.138 361.357 -0.158 0.875 
Cumulative insulin dose -0.076 0.22 -0.346 0.731 
Cumulative metformin dose -3.226 2.143 -1.506 0.138 
Maternal age -15.142 15.074 -1.005 0.32 
Maternal BMI 11.857 14.845 0.799 0.428 
Parity 128.638 54.637 2.354 0.022 
Offspring sex -98.414 123.676 -0.796 0.43 
 Model summary 
 R R square Adjusted R square Std Error of the estimate P value 
 0.551 0.304 0.165 464 0.029 
Table 7g. Multiple regression modelling to identify independent variables of birth weight.  The ‘log’ 
prefix is used to denote data that is not normally distributed and has been log transformed prior to 
inclusion in the regression model. 
 
 
7.3.4 Epigenomic data 
After DNA extraction and bisulphite conversion, paired cord blood and placenta samples were 
hybridised to the Illumina 450k array in a single batch.  Array data underwent standard QC, 
processing and normalisation.  At the present time, this analysis is incomplete but preliminary 
data is presented.  Matched cord blood and placenta samples show significant differences on a 
genome-wide scale, suggesting the presence of strong tissue-specific methylation patterns.  
Figure 7d is a multi-dimensional scaling plot shows genome-wide differences, at the 429,273 
array probes that passed the QC, between cord blood and placenta pairs.   The plot shows cord 
blood samples (in green) in a much tighter cluster than placenta samples (in orange).  This is 
likely to reflect the greater heterogeneity of cell types in placenta samples than cord blood 
leading to varied methylation patterns  
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Figure 7d.   Multi-dimensional scaling plot of normalised 450k data from cord blood (green) and 
placenta (orange) samples. 
 
 
A subsequent MVP call has confirmed the presences of widespread methylation differences at 
genome-wide significance and withstanding FDR correction, at 338,062 probes (p<0.05) and 
317,110 (p<0.01) and, at the present time, is being compared to a related study of cord blood 
and placenta sampling (described below). 
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7.4  Discussion 
 
7.4.1 Nutritional data 
This study has shown the wide variation in pregnancy phenotypes across a group of women of 
South Asian origin with and without gestational diabetes.  The traditional risk factors for 
gestational diabetes, such as maternal BMI and parity were no more common in women with 
gestational diabetes recruited to this study, although on average they were 3 years older than 
controls.  Micronutrient deficiencies were observed across control and GDM women, and of 
particular note, vitamin D deficiency was present in almost half of the women recruited.  Other 
micronutrient deficiencies were identified and have highlighted a need for further study and 
characterisation.  Folate deficiency in pregnancy is thought to be uncommon in the UK and 
peri-conceptual folate supplementation is advised to reduce the risk of neural tube defects 
across a population with mostly normal folate status.  Data from East London has previously 
reported a 1% prevalence of folate deficiency of pregnant women (from European, African, 
Caribbean and Asian backgrounds), in contrast to the 6% identified in this study.  This disparity 
may reflect a higher prevalence of folate deficiency in women of South Asian origin and 
requires further study with food frequency questionnaires to identify whether there is a clear 
dietary trigger to this deficiency, as well as understanding the adherence to folate 
supplements in early pregnancy.  The observation that 15% women are deficient of the 
downstream folate metabolite, 5-methyltetrahydrofolate, suggests that the well-known 
genetic polymorphism of MTHFR may be common in the population studied and future studies 
should include genotyping of the known SNPs that are associated with folate deficiency and 
hyperhomocysteinaemia.  The application of new assays of B12 metabolism, such as holo-
transcobalamin and methylmalonic acid, has also highlighted possible deficiencies in as many 
as 41% of the population.  The interpretation of these data in pregnancy is not well established 
and an important finding from this study is that holo-transcobalamin has an inverse 
relationship with homocysteine, suggesting the impact low B12 status on the overall 
functioning of the one-carbon cycle.  Currently, holo-TC and MMA are not measured routinely 
in pregnancy and, other than an excess risk of neural tube defects, there is a lack of data 
suggesting what the direct risks of B12 deficiency to pregnancy outcomes might be.  The 
identification of these one-carbon cycle defects in a ‘healthy’ UK population is a significant 
finding in relation to the findings of Yajnik et al showing their role in programming a childhood 
phenotype of insulin resistance and obesity.  The prevalence of B12 deficiency in this London-
based Bangladeshi population is somewhat surprising given that they do not follow lacto-
vegetarian diets and are thought to have a regular consumption of fish.  Analysis of food 
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frequency questionnaires will complement this data and provide an insight into whether B12 
deficiency has a clear dietary cause or whether it may be due to reduced GI absorption or 
genetic factors affecting its metabolism.  Future studies will also include characterisation of 
B12 status in women taking metformin in pregnancy to understand whether the excess risks of 
deficiency are increased with chronic metformin use, as has been shown in a non-pregnant 
population (213). 
 
7.4.2 Metabolic data 
Gestational diabetes represents the pathological glucose intolerance in pregnancy associated 
with excessive fetal growth and related maternal and fetal complications.  A cross-section of 
pregnant women receiving antenatal care will exhibit a spectrum of glucose tolerance ranging 
from normal to that which is abnormal and diagnosed as gestational diabetes.  The diagnostic 
criteria for gestational diabetes have raised debate due to uncertainty over the optimal 
glucose tolerance test cut-offs.  Despite large population-based studies of the complications of 
gestational diabetes, there is still no consensus due to the linear association of maternal 
glucose status and adverse pregnancy outcome.  This debate must be considered when 
designing studies of gestational diabetes, as the choice diagnostic criteria may affect the 
external validity of results.  The linear association of glucose exposure and adverse fetal 
outcome (defined by cord blood C-peptide, macrosomia and neonatal hypoglycaemia) in the 
HAPO study was observed in a blinded group of women which provides strong proof of this 
association.  However, using maternal glucose tolerance as a linear variable may not work in 
studies where women have received standard clinical care, including being managed as 
someone ‘with’ or ‘without’ gestational diabetes.  Women who fall just within the diagnostic 
cut-offs for gestational diabetes and receive intensive clinic management based around 
reducing glycaemia may improve their glucose tolerance to a level that is better than a woman 
who was just outside the diagnostic criteria for GDM who did not receive this management.  
The higher corrected fructosamine levels in GDM women recruited to this study compared to 
controls (294 vs. 282 umol/L) does not support this theory, but this blood test will have only 
measured glycaemia around the first few weeks of gestational diabetes (as it was performed at 
recruitment to the study), and future studies should include a measure of maternal glycaemia, 
at the end of gestation or in cord blood to assess the cumulative glucose exposure throughout 
gestation to the fetus.  
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7.4.3 Potential interactions between gestational diabetes and one-carbon metabolism 
As outlined in the introduction, it is important to understand the relationship between 
gestational diabetes and maternal nutrition in human fetal programming studies to elucidate 
their potential combined role.  The data collected in this study suggests that women with 
gestational diabetes have lower levels of holo-transcobalamin, the ‘active’ vitamin B12 
metabolite.  Furthermore, the inverse relationship of holo-transcobalamin with homocysteine 
levels indicates that this may have a direct role on the overall functioning of the one-carbon 
cycle and, putatively, could disrupt the provision of methyl groups for DNA methylation. 
There is little biochemical and molecular evidence to suggest a direct link between glucose (or 
diabetes) and the one-carbon cycle, apart from studies of the enzyme glycine N-
methyltransferase (GNMT), reviewed by Luka et al. (214).  GNMT is widely expressed in liver, 
pancreas and prostate and has a role in the functioning of the one-carbon cycle, in its transfer 
of a methyl group from S-adenosylmethionine to glycine to form sarcosine.  In addition, folate 
is known to directly inhibit GNMT activity.  The relevance of GNMT to diabetes is that it allows 
the utilisation of methionine for gluconeogenesis and it activated by glucagon.  A study has 
shown that Zucker diabetic rats have increased GNMT activity, abundance and mRNA 
expression in liver and this is associated with differential methylation of certain genes with 
important epigenetic roles, such as Dnmt1 (215).  Whilst this evidence does not provide 
conclusive proof of a direct link between a diabetic state and DNA methylation via the one-
carbon cycle, it does suggest a plausible mechanism where this interaction could lie.  GNMT 
knockout mice have a phenotype of hepatic steatosis secondary to failure of gluconeogenesis, 
with hypoglycaemia and increased serum cholesterol (216).  These observations suggest 
potential mechanisms whereby diabetic state, e.g. increased rate of gluconeogenesis, could 
affect epigenetic processes, or vice versa.    It could be expected that increased 
gluconeogenesis could require an increased amount or activity of GNMT, and that this may 
increase the conversion of S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH), 
increasing the SAM/SAH ratio and increasing amount of methyl groups for DNA methylation.  
However, it is important to note that these metabolic processes have only been studied in liver 
and could be tissue-specific.  However, this hypothesis is supported by data published by 
Obeid et al. that assays multiple one-carbon cycle metabolites (including SAM and SAH) in 
individuals with and without type 2 diabetes (210).  The researchers find a reduced serum 
SAM/SAH ratio in individuals with type 2 diabetes, compared to controls (8.2 vs. 9.1, p = 0.006, 
and p = 0.023 after adjustment for BMI) and described an association of this with a reduction 
in intracellular vitamin B12 concentration and increase in MMA.  Future studies trying to 
elucidate the interaction between the one-carbon cycle and diabetes in pregnancy should 
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include further assessment of these metabolites.  The advancement of metabolomic studies 
should allow assays of multiple metabolites to be performed with minimal sample quantity 
and high accuracy. 
 
7.4.4 Epigenomic data 
At the present time, the epigenomic data from this study is limited and has not yet focused on 
the identification of DNA methylation signatures associated with maternal GDM exposure.   
Sample collection and processing methods have been established as part of this study and the 
quality of samples in epigenomic studies has been high.  To date, the analysis of DNA samples 
from cord blood and placenta have been bisulphite converted and hybridised to the Illumina 
450k array with QC and normalisation of the data.  Initial analysis has identified significant DNA 
methylation differences, on a genome-wide scale, between cord blood and placenta.  These 
differences exist at the majority of probes on the 450k array and have strong statistical 
significance when examined using the analytical approach described in Chapter 2.  It is hoped 
that understanding these tissue-specific differences will give a functional perspective on the 
epigenetic consequences of fetal exposure to maternal gestational diabetes.  Regions of 
differential methylation between those exposed to GDM and those unexposed will be 
performed in cord blood primarily (chosen due to its greater homogeneity than placenta).  It 
will then be possible to identify whether the same genomic positions that are differentially 
methylated in cord blood show variation in placenta, as well as performing independent 
analysis of placenta samples.  Characterisation of any MVPs using pathway analysis will yield 
preliminary insights into the functional processes that may be affected by GDM exposure, and 
it may be possible to hypothesise how these relate to processes such as nutrient transfer in 
the placenta.  Once MVPs have been identified in this human model, a comparison will be 
made with data from the mouse model presented in Chapter 6 to look for commonality that 
may represent stable epigenetic marks associated with this model of programming.  This 
comparison will have to be between mouse livers and human cord blood/placenta, but 
additional replication can be performed in mouse placenta as this has been stored.  
Analysis of methylation variation associated with GDM will also be performed using maternal 
glucose as a continuous variable.  This may help identify whether there is a quantitative or 
threshold-based association of maternal glucose with the neonatal epigenome.  As alluded to 
earlier, this approach will not be able to take into account the potential bias from GDM women 
being ‘treated’ and the possible improvement in their glucose parameters post-diagnosis 
through clinical management.  Additional analysis will look for the effects of differences in one-
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carbon status and DNA methylation.  Whilst the numbers to do these additional analyses are 
small, it is hoped that it will yield sufficient insight to study further in new cohorts or existing 
cohorts in a more directed and hypothesis-driven manner.  
Further analysis of the epigenomic data from this cohort will be performed in combination 
with a related study (PIs Sara Hillman, David Williams, UCL) that have collected clinical samples 
of women with normal and growth-restricted pregnancy.  This study has been designed using 
the same sampling protocols as above so that direct comparisons may be made.  Additionally, 
the cord blood and placenta samples that have been taken have undergone 450k array analysis 
in the same experimental batch.  It is hoped that comparison of these datasets will be able to 
elucidate MVPs associated with ethnicity (the UCL samples come from a predominantly White 
European population), gestational age and growth restriction.  Fetal programming studies of 
growth restriction and gestational diabetes exposure suggest a common end phenotype of 
cardiometabolic disease risk, therefore identification of common MVPs across both studies 
may elucidate epigenetic signatures that have stability and confer risk of that phenotype.  It 
will not be possible to elucidate the association with phenotype in these studies, but this 
approach will guide hypothesis-driven studies of epigenotype-phenotype association using 
longitudinal sampling and detailed clinical phenotyping. 
The study of epigenetic inheritance in model systems and humans has provided a tantalising 
possibility that epigenetic marks may be carried through successive generations (217).  This 
theory suggests that a ‘memory’ of past environmental perturbations in pregnancy could be 
maintained, and may confer an adverse phenotypic outcome across these generations (218).  
This study has not been designed to study epigenetic inheritance, and indeed would require 3 
successive generations to do so, but the availability of parental DNA from the recruits will 
allow follow-up of significant MVPs in parents.  This may be of particular importance in SNP-
associated methylation differences to understand whether these could be transmitted 
transgenerationally or whether they are a feature of the environmental exposure in pregnancy 
or stochastic processes. 
 
7.4.5 Limitations of this study  
There are several specific limitations of this study with regard to the proposed objectives set 
out in section 7.1.4.  First, the identification of differential methylation in offspring born to 
mothers with and without gestational diabetes has not been completed and requires more 
analysis.  The main limitations affecting all of the study objectives are (a) the small sample size, 
and (b) the recruitment of a group of women with gestational diabetes who had relatively 
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‘mild’ fasting hyperglycaemia.  The sample size in this study was not designed to be sufficient 
to detect phenotypic outcomes associated with GDM exposure and therefore it will not be 
possible to identify epigenotype-phenotype associations.  Furthermore, the phenotyping of 
offspring was limited and did not include anthropometric measures (e.g. skinfold thickness) 
that have been shown to be early markers of adiposity (40).  Future studies should be designed 
with adequate sample sizes to detect phenotypic outcomes and longitudinal sampling from 
offspring would be a useful addition to uncover those epigenetic differences are primary 
effects of programming and which are secondary to the programmed phenotype.  The sample 
size is also insufficient to examine genetic-epigenetic interactions in gestational diabetes, and 
it is conceivable that similar interactions occur as do in type 2 diabetes.  The second main 
limitation of this study is that the women with GDM recruited to the study displayed ‘mild’ 
dysglycaemia, exemplified by the mean fasting glucose value at diagnosis of GDM (5.3 mmol/l) 
which is below the diagnostic thresholds for gestational diabetes.  The majority of women met 
diagnostic criteria for GDM because of their 120 minutes (post-glucose challenge) glucose 
concentration, a finding which is not unexpected in women of Asian origin (24), but that is 
unusual compared to large studies such as HAPO.  Further evidence for the ‘mild’ nature of the 
GDM in recruits comes from the small proportion of women who required metformin and/or 
insulin treatment.  These findings could be due to selection bias, as individuals with severe 
dysglycaemia from gestational diabetes may require more medical attention and therefore be 
less likely to participate in a study, or because of the Hawthorne effect in which individuals 
participating in a study change their behaviour due to increased supervision or surveillance.  
The latter could have a significant effect on women with gestational diabetes with 
improvements in glucose tolerance via strict adherence to dietary control and physical activity 
recommendations.  These biases could have significant effects on the expected outcomes, 
reducing the chance of finding significant differences between those with and without GDM 
with respect to micronutrient status, metabolic parameters and epigenetic outcomes.  To best 
address this concern, a larger sample size and careful consideration of potential barriers to 
recruitment are important.  In addition, the outcomes related to fetal programming may be 
better studied with additional recruitment of women with a pre-pregnancy diagnosis of type 2 
diabetes or impaired glucose tolerance.  Inclusion of these women would need careful 
consideration in terms of the expected outcomes, e.g. maternal hyperglycaemia would be a 
continuous fetal exposure rather than one limited to late gestation.  However, this approach 
could maximise the potential to identify epigenetic differences associated with fetal 
programming as well as the possible collateral influences of micronutrient deficiency and 
gestational diabetes.   Furthermore, recruitment of women with type 1 diabetes would expand 
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the possible outcomes related to maternal hyperglycaemia as a pure environmental influence, 
analogous to the approach of studies by Lindsay et al. (39). 
Data collected on micronutrient status of the women in this study, particularly in relation to 
the one-carbon cycle, provides a new perspective on maternal B12 deficiency in an otherwise 
‘healthy’ population of South Asian women in the UK.  Whilst focus has been placed on folate 
and vitamin D supplementation in pregnancy for many years, there is little recognition of the 
possibility of B12 deficiency being prevalent.  Further studies are required to evaluate this in 
larger numbers and to identify any association with adverse pregnancy outcomes or long-term 
programming risks.   The data collected also suggests that current public health strategies 
around vitamin D supplementation in pregnancy are ineffective, given that the majority of 
women recruited to the study had either vitamin D deficiency or insufficiency.   Other 
environmental factors that could play a role in programming or confound the maternal 
glucose-related effects include maternal lipids, obesity and macronutrient intake.  These 
factors have not been fully evaluated in this study and should be included in future studies to 
elucidate their potential role.   Future studies should also include people from different 
geographical areas and ethnicities to establish the role of other environmental and genetic 
factors that play a role in fetal programming. 
Wider limitations that affect this study, such as sample size and power, will be discussed in 
Chapter 8 as it has relevance to the work presented in Chapters 3,4,5 and 6.  Issues of tissue-
specificity, timing of environmental exposures and the detection of genetic-epigenetic 
interactions will also be discussed in Chapter 8. 
 
7.4.6 Next steps 
The experimental plans set out in section 7.4.4 regarding the epigenomic data from this study 
will be used to guide further studies.  It is hoped that this data, and the mouse model data in 
chapter 6, will yield sufficient insights to develop further hypothesis-driven research on the 
downstream functional consequences of such epigenetic variation and how this may 
predispose to disease onset in this programming model.  This will guide the translational 
potential of these studies, and it is hoped that this will enable targeted intervention and 
therapeutic strategies to be developed.  Future work will also focus on the possible ‘double 
burden’ of over and undernutrition (219), particularly in populations in transition where the 
prevalence of cardiometabolic disease is increasing.   This approach could address important 
questions of whether gestational diabetes interacts with specific micronutrient deficiencies to 
confer risk, and if so, what mechanisms, e.g. placental nutrient transfer, are involved.   
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Chapter 8. Discussion 
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8.1 Main objectives 
 
The main objectives of this thesis were as follows: 
 To identify epigenetic factors involved in susceptibility to Type 2 diabetes as a route to 
understand disease aetiology and pathogenesis. 
 To apply animal and human models to elucidate the role of epigenetic mechanisms in fetal 
programming of Type 2 diabetes and related cardiometabolic conditions. 
 To use ‘discovery-based’ techniques to determine interactions between genetic, epigenetic 
and environmental influences, on an epigenomic scale. 
 
 
8.2 Component studies 
 
The main objectives have been investigated in a series of component studies, set out in 
chapters 3-7, and the main outcomes of these will now be discussed.  
 
8.2.1 Type 2 diabetes study (chapter 3) 
This study focused on the identification of epigenetic variation at specific regions of genetic 
susceptibility to Type 2 diabetes to characterise putative regions of genetic-epigenetic 
interactions.  A Medip-chip approach was used to profile DNA methylation in nucleated blood 
cells on a genome-wide scale at regions determined by recent insights from type 2 diabetes 
and obesity genome-wide association studies.  In this study, a genetic-epigenetic association 
was identified within the type 2 diabetes susceptibility haplotype of the FTO gene, 
characterised by the presence of a CpG-SNP at rs8050136 that created or abrogated a site for 
DNA methylation according to the phase of the SNP; this was conformed in DNA from adult 
hypothalamus and cerebral cortex.  Our functional interpretation of this discovery suggests 
that this SNP-CpG site may have a dual role on FTO expression and in the functioning of an 
enhancer, IRX3, that has a role in development of the hypothalamus.  The creation of a CpG 
site capable of methylation when the FTO risk allele is present may reduce the activity of this 
enhancer, suggesting a potential influence on brain systems involved in energy balance and 
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appetite regulation.  The identification of this CpG-SNP has, in part, been replicated in a similar 
study performed by Toperoff (152), providing reassuring external validity of our findings.  
In a wider context, the findings of this study have provided an important insight into how 
genetic and epigenetic variants may co-exist and provide a practical focus to determine which 
of the many genetic polymorphisms identified through GWAS have a functional role.  This 
study also highlights the importance of integrating genetic and epigenetic techniques so as to 
avoid the assumption that an epigenetic variant is an independent, and perhaps stochastic 
event, when in fact it is driven purely by genetic variation.  What this study lacks, most 
importantly, is an ability to identify allele-specific methylation and gene expression differences 
driven by this genetic-epigenetic variant.  Determining allele-specific expression differences 
driven by genetic and methylation differences would require large and complex study, using 
epigenomic and transcriptomic techniques such as RNA-seq and BS-seq, and there is only a 
small body of published data taking this approach.  One such study, performed by Chen et al. 
(220) has provided an important insight into the role of DNA methylation on transcriptional 
regulation in human embryonic stem cell development at cis-regulatory elements (e.g. 
transcription factor binding sites), and another study has identified the important influence 
genetic variation on DNA methylation patterns and subsequent gene expression (221).  A 
different, and adequately powered, approach would be required to identify similar combined 
epigenomic and transcriptomic functions in studies of complex disease, such as type 2 
diabetes. 
 
8.2.2 Pune Maternal Nutrition Study (chapter 4) 
In this study, epigenomic techniques were used to identify differentially methylated regions in 
the whole blood from offspring from this seminal fetal programming cohort in which maternal 
one-carbon cycle defects have been shown to induce a programmed phenotype of insulin 
resistance and obesity in offspring. 
The aim of this study was to elucidate environmentally induced DNA methylation differences 
in the offspring epigenome with which to focus further studies of epiallelic variation and the 
relative influence on environmental and genetic factors.  Medip-seq was used to identify DNA 
methylation differences in a super-selected group of offspring from the extremes of maternal 
exposure and associated programmed phenotype. Differentially methylated regions were 
identified between the control and case groups but this data has not yet been technically 
validated.  The main limitations of this dataset are its small sample size and the difficulties of 
identifying the correct bioinformatic approach for to detect true methylation differences, itself 
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affected by sample size.  More specifically, concerns over the bioinformatic analysis of Medip-
seq datasets also include how to account for experimental biases (such as Medip enrichment) 
and false discovery.  Since this project was started, the advent of newer whole genome and 
genome-wide technologies such as BS-seq and the 450k array have largely superseded Medip-
seq experiments and offer a more robust platform with which to detect methylation without 
the experimental bias of an enrichment-based technique. 
The Illumina 450k array was also used to identify differences between offspring groups in 
PMNS and has generated 2045 methylation variable positions (MVPs) between study groups, 
but none of these differences reach genome-wide significance.  Unfortunately, the lack of 
overlaps between the 450k array and the Medip-seq DMRs meant that the former could not 
be used as technical validation of the latter.  This dataset will require further work if 
conclusions are to be drawn from it about epigenomic differences in offspring exposed vs. 
unexposed to maternal vitamin B12 deficiency.  Further experiments using the 450k array in 
additional offspring samples are planned, and a power calculation of the sample size required 
will be performed using data from the Matlab study. 
Other possible limitations of this study exist and will be addressed in future studies.  First, the 
selection of offspring enriched for the programmed phenotype as epigenetic differences 
secondary to the phenotype of insulin resistance and obesity may obscure primary epigenetic 
signatures of programming.  This limitation is common to most cross-sectional studies 
designed to detect epigenetic variation with an aetiological role, and will be overcome in 
future studies by inclusion of offspring with and without the programmed phenotype as well 
as longitudinal sampling to study developmental and dynamic epigenetic differences before 
and after emerging phenotypic differences.  The forthcoming intervention studies in PMNS, in 
which women will be randomly assigned to pre-pregnancy B12 supplementation or placebo, 
will also provide an invaluable insight into which epigenetic differences in offspring are related 
to the programming or other, perhaps stochastic, influences.  Second, the use of whole blood 
DNA may be a poor surrogate for tissues with a more direct role in the pathogenesis of 
diabetes and obesity.  Whole blood may a useful tissue for a preliminary discovery-based study 
such as this, especially as a periconceptual insult may mean that all 3 germ layers hold a 
molecular memory of it, it is not likely to inform downstream studies on gene function in 
relevant tissue.  These kind of functional studies are important to develop a deeper 
understanding of the mechanisms by which the phenotype is induced and are likely to offer a 
greater potential for clinical translation and understanding the specific risks of adiposity and 
diabetes in this Indian population.  To address these concerns, complementary studies are now 
taking place using an adipose tissue cell line (CHUB-S7) exposed to varying B12 and folate 
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environments (in collaboration with Gyan Tripathi and Sara Ponnusamy, University of 
Warwick).  These studies have already shown that an environment deficient in vitamin B12 can 
promote adipogenesis via gene expression changes within the cholesterol biosynthesis 
pathway.  Work is now underway to correlate these gene expression differences with genome-
wide DNA methylation differences, using the 450k array.  Preliminary data suggests that DNA 
methylation differences at 2 target genes (SREBF1 and LDLR) exist and correlate to gene 
expression differences (Adaikalakoteswari A, Finer S et al., submitted to Circulation Research, 
2012).  Finally, another important consideration in all programming studies, such as PMNS, is 
to understand whether there are differences in the potential for programming according to 
the timing of the environmental insult in early development.  The PMNS study is unique in its 
ability to define pre-pregnancy and early environmental factors, but is not designed to 
differentiate between these in the programmed outcome.  Furthermore, the postnatal 
differences in childhood B12 and folate status were not studied until follow-up at 6 years, 
meaning that early life nutritional differences could have existed between the offspring study 
groups (and might be expected to be associated with the maternal nutritional differences) but 
are not accounted for.   
 
8.2.3 Matlab Famine Study (chapter 5) 
This study has generated data suggesting differences in DNA methylation in offspring directly 
exposed to famine in utero and early postnatal life, compared to those unexposed.  DNA 
methylation differences, whilst not reaching genome-wide significance, were validated in a 
second sample set from the same Matlab study.  Of particular interest is the finding that DNA 
methylation variants identified in a related model of fetal programming, in Gambia, seem to 
show commonality in this study.  This finding supports the potential for there to be regions of 
the genome that are sensitive to environmental pertubation and that could play a central role 
in the development of a programmed cardiometabolic phenotype.  The findings of this Matlab 
study will be used to generate sample size calculations in future studies as it provides an 
important insight into the numbers of samples required to detect statistically significant 
methylation differences using a genome-wide platform.   
Gene ontology analysis of the MVPs identified in this study has produced findings that suggest 
that these epigenetic differences exert their effect via altered growth factor stimulation of 
cellular processes and signalling. 
These findings can be considered to support an interaction between the early life environment 
and epigenetic profile of young adults.  Interestingly, most programming models suggest that 
 281 
the time of particular environmental susceptibility is in utero, whereas this supports the 
influence of postnatal life.  The phenotypic outcome of the individuals in this study suggests 
that the strongest programmed influence is in those exposed in utero, rather than postnatally, 
but the small sample size and variation in the measurements taken may have obscured 
differences in this group.  Alternatively, the programmed phenotype may not be fully evident 
in the postnatally exposed group, and if this is the case, it suggests that the epigenetic 
differences identified in these offspring may have a causal role, rather than be secondary to 
phenotypic outcome. 
More detailed analysis of the phenotypic data from this study will be performed, and it is 
hoped that future studies will incorporate longitudinally collected samples and phenotypes 
from this cohort as well as studying the F2 offspring to look for possible transgenerational 
effects.   It may also be possible to validate our data with that from other famine-associated 
programming cohorts, e.g. the Gambian, Dutch Winter Hunger or Chinese Great Leap Forward 
studies, and at the present time collaborations are being sought to do this. 
 
8.2.4 Gestational diabetes studies (chapters 6 and 7) 
The programming influence on the offspring epigenome from gestational diabetes exposure 
has been investigated using a mouse and human model.  The mouse model, analogous to 
human gestational diabetes, was to generate tissue samples from offspring at the end of 
gestation and in adult life to study both tissue-specific and age-associated epigenomic 
differences.  This model confirmed a programmed phenotype of glucose intolerance and 
adiposity in those mice exposed to GDM, and there were epigenomic differences in the fetal 
livers of those exposed vs. unexposed at the end of gestation.  These findings have not yet 
been validated and are currently being followed up with gene expression studies in fetal liver 
and liver and adipose of aged offspring.  A human study of gestational diabetes was set up and 
has generated samples for related epigenomic studies in cord blood and placenta from 
exposed.  These samples have not yet been fully analysed, but the clinical data from this study 
has provided a useful insight into the complexity of studying human pregnancy due to the 
multiple different environmental ‘exposures’ that may occur in such a cohort.  The women 
recruited to this study were predominantly vitamin D deficient and therefore it will be difficult 
to identify whether vitamin D status has an independent or contributory influence on any 
epigenomic differences in offspring.  A focused study of one-carbon metabolism in the 
mothers recruited to this study has highlighted a prevalent deficiency of functional vitamin 
B12, using holo-transcobalamin and methylmalonic acid assays, with downstream effects on 
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homocysteine status and therefore possible influence on provision of methylation groups for 
epigenetic processes.  
By combining an isogenic mouse model and human study, it is hoped that it will be possible to 
address important questions relating to tissue- sex- and age-specificity of epigenetic changes 
and their functional role, but also provide an important translational focus to guide future 
clinical studies and prevention strategies.  Future experiments using this mouse model will 
enable a direct view of epigenetic-environment interactions, unaffected by genetic 
polymorphism, such a pure epialleles.  In contrast, the human model, performed in women of 
Asian origin with a presumed high background genetic risk of diabetes, may yield insights into 
genetic-epigenetic-environmental interactions, but to assess these fully, much larger sample 
numbers will be required.    
 
 
8.3 Discussion points relating to all studies 
 
In addition to the summarised findings above, this thesis has generated points for discussion 
that relate to all of these studies and their ability to produce insights into type 2 diabetes 
aetiology, and these will now be discussed. 
 
8.3.1 Methodology of epigenomic studies 
The epigenomic studies performed first used Medip-seq as a means to assay and quantify DNA 
methylation across the genome (human and mouse).  Two published studies have shown that 
Medip-seq, coupled with the Batman bioinformatic algorithm, is able to detect large 
methylation differences (>25%) between cancerous and non-cancerous human samples that 
technically validate using other experimental platforms including the Illumina 27k array and 
targeted BS-pyrosequencing (222).  In this study, and others (223), the large methylation 
differences identified are thought to be driven by underlying genomic variants, e.g. cytogenetic 
differences, copy number variation and repeat sequences, associated with carcinogenesis 
itself.  However, despite the large methylation differences detected in these studies, the DMRs 
identified did not withstand correction for multiple testing using the standard Benjamini and 
Hochberg FDR approach, although the statistical strength of methylation differences at 
individual DMRs identified were strong and analysis of the DMRs called showed individual 
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FDRs of <3.7%.  The majority of DMRs identified in these studies were at repeat elements and 
areas of high CpG density, and this may be a true biological representation of where 
differential methylation occurs, but may also reflect the correction of the Batman algorithm 
for CpG density.  The Medip-seq analyses presented in Chapters 3 and 6 used a different 
bioinformatic approach to call DMRs due to concerns that Batman was overcorrecting for CpG 
density and thereby biasing the DMR calling strategy.  In these experiments, an approach 
developed by Thomas Down was used first to look for significant differences across the 
epigenome using simple t-test statistics in pair-wise and group-wise comparisons, and in the 
Pune experiment, pairs of samples were matched in such a way that possible enrichment 
biases would be reduced.  This approach did not apply any correction for multiple testing and 
is prone to over-calling DMRs, and therefore an additional bioinformatic technique, USeq, was 
combined with this calling strategy.  USeq incorporates the principles of a binomial distribution 
to the detection and comparison of enrichment peaks between groups of samples, and 
assumes a non-random distribution of sequencing reads across the genome.   USeq may under 
call DMRs due to its stringent processing, and has not been validated in Medip-seq 
experiments, and therefore a combined approach of Thomas Down and USeq DMR calling 
strategies was used to generate a final ‘top hit’ list of DMRs in these experiments.   To date, 
these top hits have not been individually validated and therefore it is not clear whether the 
Medip-seq data is technically sound and these are true DMRs or false discoveries.  The FDR 
threshold in our USeq call was up to 20%, significantly higher than in the Saied and Feber 
studies, despite relatively similar sequencing depth in the former with our Pune dataset (the 
Saied study yielded 400 million reads for DMR calling from 12 cases vs. 4 controls; compared to 
393 million reads in 8 cases vs. 8 controls in the Pune Study).  The greater strength of the Saied 
and Feber DMRs that were called is likely to be due to the greater size of methylation 
difference at their DMRs due to their being driven by large genomic differences affecting 
methylation, in contrast to the smaller environmentally-determined differences expected in 
out programming studies.  The importance of the sequencing depth and types of methylation 
difference expected for DMR detection is also highlighted between the mouse GDM study and 
Pune studies.  The murine study, using inbred mice, identified a similar number of DMRs to the 
Pune study (outbred humans) with half the number of sequencing reads, suggesting that the 
CpG-SNPs identified in the Pune study may obscure the small, environmentally-induced 
methylation differences expected in these programming studies.   
 
Technical validation of the Pune and Mouse GDM studies DMRs is underway, using different 
experimental platforms, and it is hoped that this may support the Medip-seq data, as is the 
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case in the Feber and Saied studies.  Data using the Illumina 450k array suggests that where 
Medip-seq DMRs overlap 450k probes, there is a similar directionality of methylation 
difference.   However, this analysis has not been performed across the Medip-seq dataset as a 
whole and the 450k array is not sufficiently epigenomic to validate the ability of Medip-seq to 
detect DMRs in the unbiased and discovery-based way that was originally intended in this 
study.  For true validation of DMRs and the calling strategies that have been used, Medip-seq 
data should be compared to a dataset that is equivalently or more epigenomic, such as that 
derived from BS-seq.   This type of validation analysis is also required to understand the 
sample size required in future studies to detect small methylation differences at genome-wide 
significance.  It is likely that larger sample sizes and greater sequencing depth will be needed 
to overcome the issues of power, but they are unlikely to influence the possible bias from 
enrichment differences and non-random genomic coverage (i.e. bias towards highly 
methylated regions of the genome) in Medip-seq experiments.  BS-seq is now a more 
accessible platform with which to study the epigenome, and it enables the direct 
quantification of DNA methylation at CpG sites across the epigenome, unaffected by antibody 
enrichment efficiency or CpG density.  This now seems to offer a far better approach and will 
be used in future discovery-based epigenomic studies.  Where a genome-wide approach is 
sufficient to test hypotheses, the Illumina 450k array offers a cheaper and reproducible means 
of generating DNA methylation data and can be readily integrated with genomic and 
expression profiling and used in so-called epigenome-wide association studies (EWAS) (224). 
 
8.3.2 Other epigenetic signatures 
In future studies, attention must also be paid to non-CpG associated DNA methylation, e.g. 
hydroxymethylation.  This molecular event is thought to play an important role in 
developmental processes such as embryonic stem cell differentiation but cannot be detected 
in all epigenomic approaches (225).  Techniques that use bisulphite conversion, e.g. 450k array 
and BS-seq, are unable to detect hydroxymethylation due to their reliance on genetic basis of 
CpG sites to assay methylation.  The role of hydroxymethylation in fetal programming has not 
been determined, but would be an interesting molecular mechanism to study in this context 
due to its important developmental role. 
Higher order epigenetic modifications, such as histone modifications, have not been studied in 
the experiments performed and would be a useful component of any follow-up studies and 
could provide an important means to integrate epigenomic data with studies of gene 
expression.  Specific histone marks, and other post-translational modifications such as 
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transcription factor binding sites can be assayed on an epigenomic scale using chromatin 
immunoprecipitation with Next Generation Sequencing in a technique called ChIP-seq.  Such 
experiments have provided important insights into the understanding of complex disease, for 
example in understanding the widespread genomic functions of vitamin D through its receptor 
binding (226), and its interaction with genomic variation and gene expression.  Other 
regulatory features, e.g. Dnase hypersensitivity sites, can be assayed on a genomic scale using 
an enzyme-based approach coupled with sequencing, to identify their role in chromatin 
structure and its role in epigenomic regulation of transcription alongside specific histone marks 
(227).  Recently, the ENCODE project has highlighted the importance of integrating studies of 
the chromatin landscape with DNA methylation maps to understand cis- and trans-regulatory 
elements if the functions of the genome, and especially its non-coding parts, are to be fully 
understood (228).  One recent study by Sandovici et al. highlights the importance of studying 
higher order epigenetic marks to understand how fetal programming may disrupt 
transcriptional regulation of genes involved in diabetes pathogenesis (229).  The authors 
identified that the promoter-enhancer interaction in Hnf4a was altered through diet-induced 
fetal programming and ageing, and that gene expression was associated with differences in 
active and repressive histone marks at the enhancer region, and DNA methylation differences 
were not identified at the same region.  Beyond this study, the role of higher order epigenomic 
factors has not been well-studied in the context of fetal programming, but is likely to yield 
deeper insights into how DNA methylation changes exert their function and whether the 
dynamic chromatin landscape is susceptible to environmental influences and if so how by what 
processes.  DMRs identified in the Pune study are seen to over-represent regions transcription 
factor binding sites and DNase hypersensitivity sites, suggesting an important and integrated 
role for these epigenomic processes in programming.    
Studies of higher order marks are complex to perform as each histone mark requires a 
separate ChIP-seq protocol and it is therefore costly and bioinformatically complex to provide 
epigenomic data sets for integration.  Furthermore, sample collection methods for chromatin 
immunoprecipitation studies are not easily applied to clinical cohorts, requiring greater 
amounts of DNA and immediate laboratory processing to cross-link chromatin and yield it 
stable and suitable for downstream experiments.   
Another important factor in post-translational regulation of gene expression is the role of 
microRNAs in gene silencing.  These nuclear DNA-encoded small RNA molecules have been 
shown to have a functional role in disease pathogenesis and their dysregulation may be 
induced through the maternal environment with functional consequences on adipose tissue 
and possible cardiometabolic disease pathogenesis (230). 
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8.3.3 Detection of environment-epigenetic interactions 
The notion of pure epialleles, or epigenetic variants induced through environmental and/or 
stochastic factors, and their putative role in fetal programming, has been described in section 
1.5.2.  The human studies of fetal programming performed in this thesis have highlighted the 
difficulties of detecting epigenetic variants associated purely with the environment and 
uninfluenced by genetic variation.  The Pune, Matlab and human GDM studies described in 
chapters 4, 5 and 7 incorporate studies of outbred individuals who can be assumed to vary 
genetically each other, especially with regard to SNPs.  The DNA methylation studies 
performed in these experiments identify multiple regions of differential methylation located at 
SNPs where the creation or abrogation of a CpG site changes the ability to methylate, like the 
FTO SNP-CpG site described in Chapter 3.  The variation in methylation at these regions, either 
0, 50 or 100%, is large and therefore easily detected and may obscure the smaller differences 
in methylation induced through the environment.   Future studies require greater power to 
detect smaller differences and this is best achieved through increasing sample size.  Other 
options to identify pure environment-epigenome interactions would be to include assays of 
genetic variation, e.g. SNP genotyping and CNV arrays, so that these regions could be defined 
and analysed separately.  Alternatively, this problem could be improved by reducing the 
amount of inter-individual genetic variation, e.g. by using sibling controls or twin studies, or 
before and after intervention studies of the same individual.   
 
8.3.4 Detection of genetic-epigenetic interactions 
The study of genetic-epigenetic interactions in type 2 diabetes described in Chapter 3 
identified a CpG-SNP associated with the FTO risk allele for obesity with a putative functional 
role via enhancer activity.  This study has shown that integrated detection of molecular 
variants may help direct outputs of association-based studies towards functional 
understanding and a similar approach is now used in many genomic studies of complex 
diseases.  What future studies need to incorporate is the ability to detect allele-specific 
differences in DNA methylation and gene expression to understand the role of these genetic-
epigenetic variants fully.  Allele-specific methylation was studied by Li et al. (181) using high-
density BS-sequencing across the genome of one Asian individual using DNA from peripheral 
blood mononuclear cells.  This study identified multiple regions of allele-specific methylation 
associated with regions of imprinting and sequence variation, and that these were associated 
with allele-specific expression.  Our Type 2 diabetes did not detect allele-specific methylation 
associated with the FTO CpG-SNP, i.e. it was a haplotype-driven effect rather than one with 
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wider allelic differences in methylation beyond the CpG-SNP.  However, Shoemaker et al. have 
suggested that there is a concentration of highly correlated methylation patterns around some 
CpG-SNPs (and their LD blocks) in the genome, and that these tend to be represented by 
intermediate methylation (25-75%) (231).  The authors of this paper suggest that CpG-SNPs are 
an important component of cis-regulation of the genome and epigenome, and beyond this 
study these findings highlight the importance of genetic control over the epigenome and the 
need for specific experimental approaches to define this fully. 
Other genetic variants, such as repeat elements and transposons, have been shown to be 
associated with major sites of methylation variation (179).  The identification of differentially 
methylation regions at repeat-rich regions has been confirmed in the Pune Study, in which 
88% of DMRs were located at repeat-rich regions.  Furthermore, the study of methylation 
differences in Gambian offspring exposed to seasonal nutritional differences in the Gambia 
showed preponderance at hypervariable regions, suggesting that these genetic-epigenetic 
interactions may have a role in fetal programming, although the mechanisms are not clear.  
These associations may have evolutionarily significant functions, such as the development of 
genomic imprinting or genome defence via transposable elements.  It is therefore conceivable 
that the effects of methylation variation at these positions could be protective to subsequent 
generations by inducing parent-of-origin effects and/or minimising their effects via the 
accumulation of transposons, or could have the opposite effect by maladaptive influences on 
these evolutionary mechanisms.  However, other data suggests that fetal programming 
induced through maternal nutrition may not exert influence via imprinting (99), and the bias of 
enrichment-based methylation assays towards regions of high CpG density may over-represent 
these genomic features in their outputs.    
 
8.3.5 Biological relevance of epigenetic variants 
The data presented in this thesis is significantly limited by the absence of gene expression 
studies to investigate the functional role of the differential methylation identified.  Future 
studies in the mouse GDM study will be performed to look at genome-wide expression and 
integrate this with epigenomic data.  This study lends itself well to this kind of investigation, as 
sample collection was tissue-specific and performed with methods suitable for high quality 
RNA extraction.  Expression studies may also be performed in cord blood and placenta samples 
collected from the human GDM study but will be limited by the mixed cell populations in the 
samples collected.  Future approaches will need to incorporate micro-dissection of tissues 
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and/or cell sorting of blood samples if detailed biological studies of these molecular 
differences are to be performed.   
Other means by which these molecular studies may expand their biological relevance is to 
incorporate different study designs.  Longitudinal sampling from cohorts is going to be an 
important means by which cause versus consequence are disentangled in studies, using the 
temporal stability of epigenetic variants and temporal association with phenotype to do so.  
Identification of quantitative traits and exposures and their effects on epigenetic variation may 
also yield useful functional insights and this approach will be taken with the human GDM study 
which will analyses methylation differences according to maternal glycaemia as a linear 
variable.  
 
 
8.4 Wider discussion points 
 
8.4.1 Does fetal programming underlie the missing heritability of type 2 diabetes?   
Chapters 4-7 concentrate on the concept of fetal programming, a theory that is thought by 
many to provide a partial explanation of the missing heritability of complex diseases such as 
type 2 diabetes and obesity.  There are many criticisms of this theory that need to be taken 
into account when considering the wider consequences of these studies.  First and foremost 
that despite the wealth of cohort studies, there are no studies assessing the population 
attributable risk of fetal programming on complex disease, and therefore its global impact 
cannot be quantified.  This may be due to the second, and more commonly voiced criticism of 
fetal programming studies, which is that despite high quality epidemiological, clinical and now 
molecular evidence of fetal programming, fetal programming is only supported by evidence 
from specific and extreme environmental contexts and have limited external validity.  This 
second criticism, and related points, will be discussed in more detail as follows: 
 
8.4.1.1 Environmental exposures 
The environmental exposures studied in fetal programming studies are wide-ranging, and 
include nutritional, metabolic and toxic exposures before, during and after pregnancy.   The 
nutritional exposures that have been studied most commonly in human cohorts are 
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generalised nutritional deficiencies (e.g. famine exposure), single micronutrient (e.g. vitamin 
B12) deficiencies.  The major limitation of these studies is that studies of famine exposure have 
not quantified the specific nutritional insult that pregnant women are exposed to, and 
therefore it is difficult to interpret the outcome of these studies in a more general light.  In 
contrast, the studies of vitamin B12 deficiency, e.g. PMNS, are well quantified using 
biomarkers of nutritional status from pre-conception to the post-natal period, but these 
studies may have limited applicability outside of India where a lacto-vegetarian diet is rare.   
Since the PMNS studies were performed, new data on the effects of other one-carbon 
metabolites, e.g. choline and betaine, has been generated and shows a potentially important 
role in developmental processes and offspring phenotype (e.g. (232)).  The limitations of these 
human studies affect the potential to combine understanding of the pathogenic processes 
involved in these models, but are partly overcome by animal models where nutritional insults 
can be quantified and regulated.   In the future, the application of metabolomic approaches 
may improve the ability to quantify multiple nutritional makers in these cohort studies and 
their applicability to small sample volumes may enable testing at multiple time points in order 
to understand specific periods of susceptibility.   Additionally, data collected on maternal diet, 
even using the most sensitive of assays, may not fully reflect nutrient delivery to the fetus that 
may be affected by other factors such as placental function.  Studies of nutritional 
programming should incorporate cord blood assays as an additional window to characterise 
the in utero environment. 
Programming via metabolic dysregulation, e.g. diabetes in pregnancy, has been studied in 
many human contexts and the mouse model presented in Chapter 6 adds to a previously 
minimal body of literature using a murine model.  Again, these models are limited by the detail 
in which the maternal phenotype is studied, and many of the studies of diabetes in pregnancy 
(including those in Chapter 6 and 7) have a glucocentric approach that does not take into 
account the potential programming of fat mass via leptin and other processes.  Studies have 
also shown that ‘stress’ in utero may programme cardiometabolic phenotypes, with a putative 
role via cortisol, (e.g. (198)) but do not sufficiently investigate the possible confounding 
influences on glucose and insulin metabolism, altered cortisol binding globulin dynamics, nor 
the possible confounding of maternal stress with poor nutritional status, disruptions in 
circadian rhythmicity and adverse health behaviours.  Finally, the increasing prevalence of 
gestational diabetes in transitional populations may result in a dichotomy of an excessive 
glucose environment in combination with specific micronutrient deficiencies.  
Toxin exposure in pregnancy is less well studied but may have a role in programming of adult 
disease.  Studies of arsenic exposure in Bangladesh have produced variable results, but suggest 
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that this may have an impact on thymic development (189) and cognitive development (233).  
These studies have been performed in the same region as the Matlab famine study, thus 
highlighting the possible combined or confounding influences of arsenic and nutrition in the 
offspring studied, not least because arsenic has multiple influences on the one-carbon cycle. 
The overlap found between DNA methylation variants in the Matlab study and published 
Gambian study suggests possible common pathways that could underlie fetal programming via 
different environmental exposures (80).  These pathways should be studied further in future 
investigations, and will be optimised by using similar experimental platforms to allow direct 
comparison.   
 
8.4.1.2 Timing of exposure 
The Dutch Winter Hunger studies suggest that the epigenetic changes associated with their 
fetal programming model are specific to the peri-conceptual period (109).  In contrast, the 
original study that identified the diabetic phenotype in offspring exposed to famine showed 
that late gestational exposure conferred the highest risk (47).   This study also identified an 
excess risk of major affective disorder in offspring exposed to famine in the second and third 
trimester, compared to those unexposed.  The discordance of these findings suggest that the 
epigenetic memory of this late gestational exposure may be specific to tissues directly involved 
in pathogenesis, rather than the whole blood used in their epigenetic studies.  Periconceptual 
exposure may suggest that environmental factors have influenced early epigenetic 
reprogramming and/or set down epigenetic variants that are perpetuated through all 3 
developing germ layers. 
In contrast, to the Dutch Winter Hunger findings, the Matlab study in Chapter 4 identified 
whole blood DNA methylation differences in those exposed to famine in early postnatal life as 
well as in utero (the specific timing in utero was not determined) suggesting that whole blood 
may still be a useful marker of epigenetic signatures involved in fetal programming. 
 
8.4.1.3 Phenotypic outcomes 
The phenotypic outcomes measured in fetal programming studies vary in their detail and 
scope.  Many researchers have used birth weight as a window to understand the in utero 
environment, fetal growth and risk of disease in later life.  Assumptions are frequently made 
that low birth weight reflects fetal growth restriction and future cardiometabolic disease risk.  
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However, birth weight is a variable that is affected by non-pathological factors including 
parental height, weight and ethnicity, maternal parity and smoking, and gestational age at 
delivery, as well as pathological factors such as prematurity, hypoxia, nutritional deficit and 
genetic aberrations.  The inconsistent and non-linear relationship between perinatal mortality 
and birth weight has been well reported and is thought to be due to non-causal pathways such 
as maternal smoking (234).  Similar non-causal relationships may underlie the association 
between birth weight and adult disease in models of fetal programming and low birth weight 
should not be assumed to reflect and need further investigation.  The wide range of 
programming studies performed by Fall and Yajnik in India (e.g. PMNS) show the importance of 
detailed neonatal anthropometry to measure adiposity, as well as longitudinal phenotyping 
with more detailed biochemical and metabolic studies of older children.  Newer techniques to 
measure fat mass and body composition, e.g. the Peapod, could provide important insights for 
future studies.   In addition, longer-term phenotypic outcome measures relating to 
cardiovascular health, bone strength, cognitive function and physical capability are included in 
some cohort studies and will provide an invaluable insight into the outcomes of fetal 
programming and confounding influences. 
 
8.4.1.4 Postnatal influences 
Postnatal influences on fetal programming, and its molecular basis, are well studied in animal 
models but not in human studies.  The Matlab famine study presented in Chapter 4 suggests 
that postnatal life is itself a susceptible developmental stage to epigenomic change induced 
through famine exposure.  Future studies must include a postnatal phase to identify whether 
exposure to nutritional deficits are solely maternal influences in utero, or whether they 
continue during breastfeeding and post-weaning.  These factors are important given also the 
role of ‘catch-up growth’ in mediating further excess risk towards cardiometabolic risk (235) 
and are rarely studied in combination with in utero programming studies in humans.   
 
8.4.1.5 Stochastic environmental influences in later life 
Beyond developmental life, a range of stochastic influences may give rise to epigenomic 
variation in different tissues, suggested by the diverging epigenome of ageing twins 
throughout the lifecourse.   Stochastic factors are, by definition, ill defined and difficult to 
characterise.  One such stochastic environmental factor that has gained recent notoriety as a 
possible influence on diabetes risk is that of circadian rhythm disruption.  Epidemiological 
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studies have identified an increased risk of metabolic syndrome in individuals who work shifts 
(236).  Recent mechanistic studies suggest that this may be due to disruption of circadian 
rhythms and a consequent decrease in metabolic rate and pancreatic insulin secretion (237).  
Circadian control may be under epigenetic control by sirtuins, a family of proteins with 
histone-modifying potential via NAD+-dependent deacetylation.  One such sirtuin, SIRT1, has 
also been implicated in both ageing and is down regulated in insulin resistant individuals (238).  
Further insights into this area are likely to elucidate the common mechanisms behind ageing 
and diseases that become increasingly common in old age, such as type 2 diabetes, and may 
yield translational insights via agents that enhance SIRT1 expression such as resveratrol (239) 
and metformin (240) (241).  However, these studies highlight the need to characterise 
stochastic environmental exposures in clinical cohorts as well as the importance of studying 
different epigenetic modifications, including those carried by histones.  An interesting 
observation by Sandovici et al. shows that the combined effects of maternal diet-induced fetal 
programming and ageing of exposed offspring has a combined, and detrimental, effect on 
Hnf4a epigenetic regulation expression in rat islets, and hypothesise that this may have a role 
in the development of type 2 diabetes (229).  This study highlights the importance of 
examining a range of different stochastic influences in a longitudinal manner to maximise the 
understanding of how genetic, epigenetic and environmental influences interact through the 
lifecourse. 
  
 
8.4.1.6 Genetic influences 
As discussed earlier, the molecular basis of fetal programming is best studied with an 
integrated approach using epigenomic and genomic studies and functional analysis.  The role 
of the fetal genotype in modulating fetal growth has been well characterised by GWAS studies 
(e.g. (21)) but the role of these genetic variants, e.g. glucokinase polymorphisms, in 
programming long-term cardiometabolic disease risk are not known.   This angle is an 
important one to pursue in future studies and the collection of parental DNA samples will help 
understand the relative contribution of genotypic factors, and the potential conflicting 
influences of certain mother-child genetic polymorphisms. 
Comparison of epigenomic datasets to existing genomic insights is difficult in studies of people 
of Asian origin, such as those in this thesis, due to the paucity of GWAS studies in these 
populations.  At the present time, the genetic risk of type 2 diabetes in Asians is assumed but 
not characterised.  Whilst many assume that Asians have a higher genetic risk towards 
cardiometabolic disease compared to White Europeans, this is far from confirmed.  Chauhan et 
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al. have suggested that the GWAS hits derived in European studies have stronger effect sizes in 
Asians (242).  GWAS hits may also perform different functions in Asian populations, and 
studies of FTO in South Asians suggest that FTO risk alleles increase the risk of type 2 diabetes 
independent of obesity, unlike in Europeans (243).  A study of genetic variants regulating the 
one-carbon cycle was performed in Indians to understand whether the programming 
influences of B12 deficiency could have a genetic basis, but no association was found between 
these variants and risk of type 2 diabetes in the Indians studied (244).   Genetic variation 
between South Asian groups is another important consideration in these studies due to the 
differences in populations with Dravidian (indigenous) and European ancestries, and these 
differences are thought to affect SNP variation, CNVs and mitochondrial inheritance (245).  The 
Indian Genome Variation Consortium should soon characterise these differences, and the 
results of the latter will be released through HapMap.   
 
8.4.1.7 Paternal effects 
Recent evidence suggests that paternal insulin resistance and diabetes has an inverse 
relationship with newborn size and adiposity (246), but does not elucidate the molecular 
mechanism whereby this occurs.  Paternal genetic influences for this association are plausible, 
but a study by Carone et al. suggests that the paternal diet may influence offspring hepatic 
gene expression towards a cardiometabolic disease phenotype (247), and is an important 
factor to consider in future studies. 
  
8.4.2 Epigenetic reprogramming and inheritance 
The experiments designed to elucidate the epigenomic basis of fetal programming set out in 
this thesis concentrate on identifying DNA methylation differences in F1 offspring exposed and 
unexposed to an environmental insult.  This approach yields insights into the possible role of 
epigenetic variation in the programmed phenotype and suggests a direct role on the 
developing epigenome, but does provide insights into the processes of epigenetic 
reprogramming.  Understanding the mechanisms of epigenetic reprogramming is a complex 
field and was beyond the scope of this thesis, but is an important consideration in 
understanding the putative mechanisms by which disease risk may be perpetuated across 
generations.  Epigenetic reprogramming is understood as a process by which primordial germ 
cells erase their DNA methylation and histone modifications on a genomic scale and in 
complex stages that are poorly understood and is summarised in a recent paper studying its 
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relationship with the onset of pluripotency (248).   The stages in which demethylation occurs 
varies according to the epigenomic landscape, with specific certain genomic features (e.g. 
imprinted regions) that carry long-term epigenetic memory undergoing demethylation later 
than other regions.  Demethylation is thought to include both passive and active processes and 
the mediators of the latter are elusive, and poorly characterised, although recent studies have 
suggested a role for DNA deaminases (249).  Recent studies also suggest that some regions of 
the genome, e.g. retro-elements, may resist demethylation leading to only partial 
demethylation during primordial germ cell development (250).  Remethylation of the genome 
occurs at around the time of embryonic implantation and occurs with the assistance of 
methyltransferases, e.g. Dnmt3 and Dnmt3a.   
These processes of epigenetic reprogramming may have the potential to induce epigenetic 
inheritance, via the stable transmission of epigenetic marks through successive generations.  
Animal models using the Avy and AxinFu mice have identified that retro-transposon regions that 
are resistant to full demethylation during reprogramming are locations that seem to permit 
epigenetic inheritance to occur (74).   In addition to these retrotransposons, Seisenberger et al. 
have recently identified specific CpG islands that are variably erased during epigenetic 
reprogramming, and note that one of these was within a gene, Exoc4, that is involved in 
insulin-stimulated glucose transport and associated with type 2 diabetes (248).   
In contrast to these animal models, there is, there is scant evidence that true epigenetic 
inheritance occurs in humans, despite a great deal of suggestion that it may occur and underlie 
the transgenerational patterns of complex disease risk.  The paucity of evidence of the 
molecular mechanisms of epigenetic reprogramming in humans reflects the technical 
difficulties of studying these processes in primordial germ cells, gametes and developing 
embryos.  Without the opportunity to study these processes in human development, the 
question of whether environmental influences on fetal programming are mediated through 
epigenetic reprogramming will remain an unknown until molecular studies can be performed 
in multi-generational cohorts.  
 
 
8.4.3 Evolutionary perspectives 
The potential evolutionary roles of the epigenetic modifications described in these studies are 
important to consider in the wider context of changing disease susceptibility.  The 
identification of a CpG-SNP in the Type 2 diabetes study is interesting to consider in the light of 
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a recent suggestion that genetic-epigenetic variants have a role in evolutionary adaptation.   
Authors have suggested that the loss or gain of CpG dinucleotides over time can add to the 
variance at genetic features, e.g. SNPs, and allow evolutionary adaptation to the environment 
or changing disease susceptibility over time (173).    Furthermore, the deamination of 
methylated CpGs (as was seen in this study) is thought to have a potential role in the 
formation of transcription factor binding sites, itself an important evolutionary process, and 
has previously been noted in the p53 binding sites which themselves have a critical role in 
regulation of insulin resistance (175).    
The wider evolutionary context of epigenomic variation in fetal programming has already been 
discussed (section 8.3.4), and relates to the possible role of parent-of-origin effects in 
mediating adaptation to the environment. 
An interesting observation across many fetal programming studies is that famine exposure in 
utero may influence sex ratio at birth (251).  In over 300,000 people studied during and after 
the Great Leap Forward famine, there was an abrupt decline in the numbers of female births in 
the famine-exposed mothers.  This observation fits with the hypothesis that mothers in poor 
condition are likely to give birth to daughters and those in healthy condition are more likely to 
give birth to sons; this would serve an evolutionary purpose to preserve a population by 
promoting reproduction of the famine-survivors.  These evolutionarily adaptive mechanisms 
have not been studied on a molecular level but could provide a fascinating angle to future 
epigenomic studies in famine-based cohorts. 
 
 
8.5 Final conclusions and future direction 
 
The studies performed in this thesis have provided novel insights into epigenetic variants 
associated with genetic variation in type 2 diabetes and in studies of fetal programming and 
have achieved most of the original objectives set out in the introduction.  First, the 
identification of an FTO-associated CpG-SNP has elucidated a possible mechanism by which 
genetic and epigenetic variation can have combined functional consequence.  The Matlab 
study shows reproducible variation in DNA methylation in offspring exposed to famine in utero 
and in postnatal life, compared to those unexposed and sheds light on the potential molecular 
mechanisms of fetal programming of adult cardiometabolic disease.  The related study of 
offspring in the Pune Maternal Nutrition study has been hampered by difficulties in analysing 
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and reproducing a Medip-seq dataset, but it is hoped that additional studies using the Illumina 
450k array and combined cell line work will elucidate the mechanisms by which insulin 
resistance and adiposity are programmed.  A studies of gestational diabetes in mice has 
confirmed the long-term programmed phenotype in offspring exposed to maternal 
hyperglycaemia and epigenomic studies in embryonic offspring have identified DNA 
methylation differences in exposed vs. unexposed.  This study has provided a platform for 
investigations of functional pathways and the tissue- and age-specific effects of this 
programming, all of which are currently underway.  A small human cohort of women of Asian 
origin with and without gestational diabetes has provided an invaluable opportunity to identify 
whether nutritional and metabolic disturbances coexist in pregnant women and has suggested 
that an apparently ‘healthy’ UK population has a high prevalence of micronutrient deficiencies.  
This study of gestational diabetes is now being used to generate epigenomic insights into the 
effects on offspring of adverse maternal pregnancy environments and will be used to 
complement the murine model. 
The difficulties of taking an unbiased ‘discovery-based’ approach to studying the epigenome 
has been highlighted several times in this thesis and has been hindered by small sample sizes 
and technical difficulties.  Methylation array based studies have offered a robust alternative to 
Medip-seq, but do not offer the same discovery-based approach to investigate epigenomic 
variation associated with programming.  The future of these kinds of studies could take two 
directions, first to expand on the association-based approach using larger sample numbers to 
identify epigenetic variants associated with a programmed environment or outcome.  This 
approach, best served by a genome-wide or epigenomic experimental platform, would need 
careful study design and estimation of sample size to overcome the difficulties encountered in 
these studies.  Such epigenome-wide association studies could be integrated with genomic and 
gene expression studies to expand their functional relevance.  Second, this area of research 
could take a more focused and hypothesis-driven approach, perhaps following up candidate 
regions of epigenomic variation and studying these in different environments and sample 
types.  A combination of both approaches, and their application to model systems, such as cell 
lines, looks set to expand the understanding of gene-environment interactions in 
developmental life and their impact on future cardiometabolic disease risk.  This 
understanding is crucial to elucidate the mechanisms by which diabetes prevalence is 
increasing and it is hoped that these molecular insights, coupled with intervention studies, and 
advancements in –omic studies, will enable their direct translation to targeted prevention 
studies and the design of specific therapeutic interventions.   
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